{"PMC7115718": [["It is believed that changes in housing prices would influence consumer price inflation and have substantial impact on the economy, which subsequently may also affect the competitiveness of Hong Kong.", [["substantial", "OBSERVATION_MODIFIER", 96, 107], ["impact", "OBSERVATION_MODIFIER", 108, 114]]], ["As Hong Kong has adopted a free market economic system and its economy is governed under positive non-interventionism, the level of government interventions in the economy is comparatively low in the world.", [["government interventions", "TREATMENT", 132, 156]]], ["Resulted from high degree of economic freedom, the real estate market in Hong Kong is basically market-driven and dependent on demand and supply.", [["high degree of economic freedom", "PROBLEM", 14, 45], ["high degree", "OBSERVATION_MODIFIER", 14, 25], ["economic freedom", "OBSERVATION", 29, 45]]], ["The short of land and housing would lead to the rise in housing prices and rents.", [["short", "OBSERVATION_MODIFIER", 4, 9]]], ["More recently, the Hong Kong government has gradually been introducing various \u201ccooling\u201d measures to cool the overheating real estate market and stamp out short-term speculation.", [["various \u201ccooling\u201d measures", "TREATMENT", 71, 97]]], ["For instance, stamp duty was raised to 4.25% for properties worth more than HK$20 million since February 2010; My Home Purchase Plan was introduced and Special Stamp Duty (SSD) was imposed in November 2010; the Buyer\u2019s Stamp Duty (BSD) for non-permanent residents and foreign companies was introduced in October 2012; and the Double Stamp Duty (DSD), which doubles the stamp duty rate for property transactions, was announced in February 2013.", [["DSD", "DISEASE", 345, 348], ["the Double Stamp Duty (DSD", "TREATMENT", 322, 348]]], ["These measures appeared to have temporarily cooled down the real estate market to some extent.IntroductionMany studies in the literature indicated that housing prices in Hong Kong are subject to international and regional economic events.", [["temporarily", "OBSERVATION_MODIFIER", 32, 43], ["cooled", "OBSERVATION", 44, 50], ["some", "OBSERVATION_MODIFIER", 82, 86], ["extent", "OBSERVATION_MODIFIER", 87, 93]]], ["For instance, due to the Asian financial crisis began in early 1997, Hong Kong suffered an economic recession and the real estate market was badly hit with property prices dropped by more than 40% between the last quarter of 1997 and the last quarter of 1998.", [["the Asian financial crisis", "PROBLEM", 21, 47], ["an economic recession", "PROBLEM", 88, 109], ["property prices", "TEST", 156, 171], ["economic", "OBSERVATION_MODIFIER", 91, 99], ["recession", "OBSERVATION", 100, 109]]], ["Given the importance of real estate in Hong Kong economy, it is essential to study what drives the changes in Hong Kong\u2019s housing prices and how real estate market is influenced by international and regional economic events.IntroductionIn the studies on real estate market, it is well known that housing prices are influenced by many key factors such as interest rate (mortgage rate), land supply and inflation rate (see, for example, Tian and Ma, 2009, Tsatsaronis and Zhu, 2004).", [["interest rate (mortgage rate", "TREATMENT", 354, 382], ["inflation rate", "TEST", 401, 415]]], ["Jump points, sharp or abrupt changes are typically related to some regional or international events which are possibly driven by government policies and economic events, and thus, detecting and identifying these sharp changes are vital since they reveal important findings that enable policy-makers and investors to look forward.", [["Jump points", "PROBLEM", 0, 11], ["sharp or abrupt changes", "PROBLEM", 13, 36], ["some regional or international events", "PROBLEM", 62, 99], ["these sharp changes", "PROBLEM", 206, 225], ["sharp", "OBSERVATION_MODIFIER", 13, 18], ["abrupt", "OBSERVATION_MODIFIER", 22, 28], ["sharp", "OBSERVATION_MODIFIER", 212, 217]]], ["Since such sharp changes may be caused by a mixture of information and noise, it is difficult to observe them directly in the time series.", [["sharp", "OBSERVATION_MODIFIER", 11, 16]]], ["Hence the detection of these sharp changes has drawn much attention from researchers and practitioners.IntroductionMotivated by the recent researches on jump point detection, the aim of this paper is to propose an effective approach for identifying and detecting jump points in the time series of Hong Kong housing price indices.", [["these sharp changes", "PROBLEM", 23, 42], ["sharp", "OBSERVATION_MODIFIER", 29, 34]]], ["In the proposed method, we apply the empirical mode decomposition (EMD) (Rilling et al., 2003, Rilling et al., 2007, Huang and Shen, 2005) to decompose a given signal1into a set of sub-signals.", [["the empirical mode decomposition", "TREATMENT", 33, 65]]], ["First, adaptive basis functions are used in the decomposition process that leads to an effective reconstruction of the original signal, which can enhance the detection of jump points.", [["the decomposition process", "TREATMENT", 44, 69], ["an effective reconstruction", "TREATMENT", 84, 111], ["effective", "OBSERVATION_MODIFIER", 87, 96], ["reconstruction", "OBSERVATION", 97, 111], ["jump points", "OBSERVATION", 171, 182]]], ["Second, a high-level derivative detector is proposed that can improve the detection performance for a highly nonlinear and fluctuated signal.", [["a high-level derivative detector", "TREATMENT", 8, 40], ["the detection performance", "TEST", 70, 95], ["a highly nonlinear and fluctuated signal", "PROBLEM", 100, 140], ["fluctuated", "OBSERVATION_MODIFIER", 123, 133]]], ["Comparative experimental results show that our method outperforms the wavelet approach in Hui et al. (2010).IntroductionThis paper is organized as follows: we are providing a literature review in the next section, presenting the proposed jump point detection methodology in Section 3, reporting experimental results in Section 4, which is followed by the conclusion in Section 5.Applications of jump point detection ::: Literature reviewThe detection of jump points, sharp or abrupt changes (for simplicity, we shall refer all sharp or abrupt changes to as jump points hereafter) has been applied successfully in various fields such as quality control, economics and finance, signal and image processing, and engineering.", [["jump points", "PROBLEM", 454, 465], ["sharp or abrupt changes", "PROBLEM", 467, 490], ["jump points", "OBSERVATION", 454, 465], ["sharp", "OBSERVATION_MODIFIER", 467, 472], ["abrupt", "OBSERVATION_MODIFIER", 476, 482]]], ["In Willsky and Jones (1976), the authors demonstrated that jump point detection is useful in the design of failure detection and compensation systems.", [["jump point detection", "TEST", 59, 79], ["failure detection and compensation systems", "PROBLEM", 107, 149], ["Jones", "ANATOMY", 15, 20], ["failure", "OBSERVATION", 107, 114]]], ["Basseville and Nikiforov (1993) discussed the theory and applications of jump point detection in quality control, navigation system monitoring, seismic data processing, segmentation of signals and vibration monitoring of mechanical systems.", [["jump point detection in quality control", "TREATMENT", 73, 112], ["navigation system monitoring", "TEST", 114, 142], ["seismic data processing", "TEST", 144, 167], ["segmentation of signals", "TEST", 169, 192], ["vibration monitoring of mechanical systems", "TEST", 197, 239]]], ["Some studies discuss the applications to stock data, exchange and interest rate series.", [["Some studies", "TEST", 0, 12], ["interest rate series", "TEST", 66, 86]]], ["For instance, Ip et al. (2004) proposed a computing algorithm to detect jump points of the daily exchange rate of US Dollar against Deutsche Mark.", [["a computing algorithm", "TEST", 40, 61]]], ["Hillebrand and Schnabl (2006) and Ito (2003) identified jump points in the exchange rate series to study the impact of Japanese foreign exchange intervention.", [["the exchange rate series", "TEST", 71, 95], ["Japanese foreign exchange intervention", "TREATMENT", 119, 157], ["foreign exchange", "OBSERVATION", 128, 144]]], ["Lavielle and Teyssi\u00e8re (2006) detected jump points in the multivariate series of daily stock indices returns while Strikholm (2006) applied a sequential method to investigate and determine the number of breaks in the US ex-post real interest rate series.", [["a sequential method", "TREATMENT", 140, 159], ["the US ex", "TEST", 213, 222]]], ["More examples on the applications of jump point detection in stock exchange data can be found in Wang (1995) and Arago-Manzana and Fernandez-Izquierdo (2007).", [["jump point detection", "TEST", 37, 57]]], ["The jump point detection is also applicable to the study of crude oil markets (see, for example, Kang et al., 2011).", [["The jump point detection", "TEST", 0, 24], ["the study", "TEST", 47, 56], ["jump point", "OBSERVATION", 4, 14]]], ["They further investigated the effects of various economic events on four Asian office markets (Hui et al., 2013) (including Beijing, Shanghai, Hong Kong and Singapore) by detecting the jump points.Methodologies of jump point detection ::: Literature reviewVarious approaches for the detection of jump points have been extensively studied in the literature.", [["jump points", "PROBLEM", 296, 307]]], ["Muller (1992) adopted a nonparametric regression approach to obtain weakly consistent estimators for the locations of jump points and the corresponding jump sizes.", [["a nonparametric regression approach", "TREATMENT", 22, 57], ["jump points", "OBSERVATION", 118, 129], ["jump", "OBSERVATION_MODIFIER", 152, 156], ["sizes", "OBSERVATION_MODIFIER", 157, 162]]], ["Yin (1988) proposed a detection method for the number, location and magnitudes of jumps of a regression function in the presence of noise.", [["a detection method", "TEST", 20, 38], ["a regression function", "PROBLEM", 91, 112]]], ["We remark that a small kernel will lead to spurious jump point locations whereas a large kernel may not detect jump points with relatively small jump sizes.", [["a small kernel", "TREATMENT", 15, 29], ["spurious jump point locations", "PROBLEM", 43, 72], ["relatively small jump sizes", "PROBLEM", 128, 155], ["small", "OBSERVATION_MODIFIER", 17, 22], ["large kernel", "OBSERVATION", 83, 95], ["may not detect", "UNCERTAINTY", 96, 110], ["jump points", "OBSERVATION", 111, 122], ["relatively", "OBSERVATION_MODIFIER", 128, 138], ["small", "OBSERVATION_MODIFIER", 139, 144], ["jump", "OBSERVATION_MODIFIER", 145, 149], ["sizes", "OBSERVATION_MODIFIER", 150, 155]]], ["Based on the sequence of parameter constancy tests in the smooth transition regression framework, a sequential method was used in Strikholm (2006) for determining the number of breaks in a piecewise linear structural break model, which breaks the time series into a number of polynomial functions.", [["parameter constancy tests", "TEST", 25, 50], ["a sequential method", "TREATMENT", 98, 117], ["a piecewise linear structural break model", "TREATMENT", 187, 228], ["breaks", "OBSERVATION", 177, 183], ["break model", "OBSERVATION", 217, 228], ["polynomial functions", "OBSERVATION", 276, 296]]], ["In addition, Yang and Song (2014) proposed a polynomial spline approach for jump point detection and the estimation of the discontinuities of regression functions.", [["a polynomial spline approach", "TREATMENT", 43, 71], ["jump point detection", "PROBLEM", 76, 96], ["regression functions", "PROBLEM", 142, 162]]], ["Although these methods provide a sound mathematical theory that underpins the validity of the framework, we note that their methods may miss the jump points with small jump sizes.", [["small jump sizes", "PROBLEM", 162, 178], ["small", "OBSERVATION_MODIFIER", 162, 167], ["jump sizes", "OBSERVATION_MODIFIER", 168, 178]]], ["Moreover, some of the detection methods perform well only for a data set with moderate size.Methodologies of jump point detection ::: Literature reviewIn addition to the approaches mentioned above, a time-frequency transformation method is also popular in the literature.", [["the detection methods", "TEST", 18, 39], ["a data", "TEST", 62, 68], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["With the use of Fourier analysis, jump points could be detected but their locations (i.e. time) cannot be identified.", [["Fourier analysis", "TEST", 16, 32], ["jump points", "TREATMENT", 34, 45]]], ["In addition, some jump points may be missed due to the smoothness of the Fourier basis function.", [["some jump points", "PROBLEM", 13, 29]]], ["To remedy the shortcoming of Fourier transform, Hui et al. (2010) presented a wavelet method with non-smooth Haar wavelet for detecting jump points in the time series of the private domestic price indices and stock price index.", [["a wavelet method", "TEST", 76, 92]]], ["They found that jump points detected by the wavelet approach reflect the announcement of regulations/policies or some regional/international events.", [["some regional/international events", "PROBLEM", 113, 147], ["jump points", "OBSERVATION", 16, 27]]], ["With reference to the wavelet approaches in Ip et al. (2004) and Donoho and Johnstone (1994), Hui et al. (2013) employed an improved nonparametric wavelet model to detect jump points in the Asian office markets.", [["an improved nonparametric wavelet model", "PROBLEM", 121, 160]]], ["Although wavelet approaches usually achieve promising results, the major drawback is that it adopts a fixed basis function which may not approximate signals very well.Empirical mode decomposition ::: Jump point detectionEmpirical mode decomposition (EMD) aims to decompose a given signal x(t) into n elementary sub-signals (Rilling et al., 2003, Huang and Shen, 2005) as follows:x(t)=c1(t)+c1(t)+\u22c5\u22c5\u22c5+cn(t)+r(t)where c1(t), c2(t), \u2026, cn(t) are the Intrinsic Mode Functions (IMF) and r(t) is the residual.", [["Jump point detectionEmpirical mode decomposition", "PROBLEM", 200, 248], ["\u22c5", "TEST", 398, 399], ["c1", "TEST", 416, 418], ["c2", "TEST", 423, 425], ["\u2026", "TEST", 430, 431], ["c2", "ANATOMY", 423, 425], ["residual", "OBSERVATION", 494, 502]]], ["The EMD has been widely used in time-frequency analysis applications including audio engineering (Kl\u00fcgel, 2012), climate analysis (Barnhart and Eichinger, 2011), various flux, respiratory and neuromuscular signals found in medicine and biology (Assous et al., 2005, Andrade et al., 2006, Liu et al., 2008, Mostafanezhad et al., 2009), etc. Generally speaking, the EMD algorithm recursively detects local extrema in the signal followed by estimating the lower/upper envelopes based on the interpolation of these extrema.", [["neuromuscular", "ANATOMY", 192, 205], ["climate analysis", "TEST", 113, 129], ["various flux, respiratory and neuromuscular signals", "PROBLEM", 162, 213], ["local extrema in the signal", "PROBLEM", 398, 425], ["the lower/upper envelopes", "PROBLEM", 449, 474], ["upper", "ANATOMY_MODIFIER", 459, 464]]], ["The average of the envelopes, which is a low-pass centerline, is then removed from the signal and the high-frequency oscillations (i.e. IMF), which capture the oscillatory patterns of the original signal, are extracted.Empirical mode decomposition ::: Jump point detection", [["IMF", "PROTEIN", 136, 139], ["Jump point detection", "TEST", 252, 272], ["average", "OBSERVATION_MODIFIER", 4, 11], ["envelopes", "OBSERVATION_MODIFIER", 19, 28], ["low-pass centerline", "OBSERVATION_MODIFIER", 41, 60], ["signal", "OBSERVATION_MODIFIER", 87, 93], ["high", "OBSERVATION_MODIFIER", 102, 106], ["frequency oscillations", "OBSERVATION", 107, 129], ["oscillatory patterns", "OBSERVATION", 160, 180], ["original signal", "OBSERVATION", 188, 203]]]], "3e9d44668957111c5c879db82245c4206b192e9b": [["correlation between cytopathic effect (CPE) and apoptosis, and whether infected, bystander or both infected and bystander cells undergo apoptosis.", [["cells", "ANATOMY", 122, 127], ["bystander cells", "CELL", 112, 127], ["bystander cells", "CELL_TYPE", 112, 127], ["cytopathic effect", "PROBLEM", 20, 37], ["CPE", "PROBLEM", 39, 42], ["apoptosis", "PROBLEM", 48, 57], ["infected", "PROBLEM", 71, 79], ["apoptosis", "PROBLEM", 136, 145], ["cytopathic", "OBSERVATION_MODIFIER", 20, 30], ["infected", "OBSERVATION_MODIFIER", 71, 79], ["infected", "OBSERVATION_MODIFIER", 99, 107], ["apoptosis", "OBSERVATION_MODIFIER", 136, 145]]]], "56feb53034b99302ba30fa1c3e2042b2118fe6cb": [["BackgroundFour different genotypes of Hepatitis E Virus (HEV) are known to infect mammals.", [["Hepatitis E", "DISEASE", 38, 49], ["Hepatitis E Virus", "ORGANISM", 38, 55], ["HEV", "ORGANISM", 57, 60], ["Hepatitis E Virus", "SPECIES", 38, 55], ["Hepatitis E Virus", "SPECIES", 38, 55], ["HEV", "SPECIES", 57, 60], ["Hepatitis E Virus", "PROBLEM", 38, 55], ["Four different", "OBSERVATION_MODIFIER", 10, 24], ["Hepatitis", "OBSERVATION", 38, 47]]], ["The majority of HEV epidemics in Asia, Africa and Latin America (Mexico) have been caused by genotype 1 and 2 [1] .", [["HEV epidemics", "DISEASE", 16, 29], ["HEV", "ORGANISM", 16, 19], ["HEV", "SPECIES", 16, 19], ["HEV epidemics", "OBSERVATION", 16, 29]]], ["In these endemic regions the virus is usually transmitted fecal-orally and spread through contamination of drinking water often related to flood and heavy rainfall [2] .", [["fecal", "ORGANISM_SUBSTANCE", 58, 63], ["the virus", "PROBLEM", 25, 34], ["endemic", "OBSERVATION_MODIFIER", 9, 16], ["virus", "OBSERVATION", 29, 34]]], ["However HEV is also endemic to industrialized countries of Europe, Asia and the U.S., where the number of sporadic cases of hepatitis E of genotype 3 and 4 has increased in recent years [3] .", [["hepatitis E", "DISEASE", 124, 135], ["HEV", "ORGANISM", 8, 11], ["HEV", "SPECIES", 8, 11], ["hepatitis E of genotype", "PROBLEM", 124, 147], ["endemic", "OBSERVATION_MODIFIER", 20, 27], ["hepatitis", "OBSERVATION", 124, 133], ["increased", "OBSERVATION_MODIFIER", 160, 169]]], ["While genotypes 1 and 2 seem to be restricted to humans, genotypes 3 and 4 have a high prevalence in pig populations world-wide.", [["2", "GENE_OR_GENE_PRODUCT", 22, 23], ["humans", "ORGANISM", 49, 55], ["pig", "ORGANISM", 101, 104], ["humans", "SPECIES", 49, 55], ["pig", "SPECIES", 101, 104], ["humans", "SPECIES", 49, 55], ["pig", "SPECIES", 101, 104]]], ["Hepatitis E is now regarded as a zoonotic disease and pigs and most likely other animal species are reservoirs [4] .", [["Hepatitis E", "DISEASE", 0, 11], ["zoonotic disease", "DISEASE", 33, 49], ["Hepatitis E", "ORGANISM", 0, 11], ["pigs", "ORGANISM", 54, 58], ["pigs", "SPECIES", 54, 58], ["Hepatitis E", "SPECIES", 0, 11], ["pigs", "SPECIES", 54, 58], ["Hepatitis E", "PROBLEM", 0, 11], ["a zoonotic disease", "PROBLEM", 31, 49], ["most likely", "UNCERTAINTY", 63, 74]]], ["In addition to genotypes 1-4, novel genotypes have been detected in wild boars from Japan [5] and in rats from Germany [6] .BackgroundGenerally, hepatitis E is a self-limiting disease with low mortality.", [["hepatitis E", "DISEASE", 145, 156], ["rats", "ORGANISM", 101, 105], ["hepatitis E", "ORGANISM", 145, 156], ["genotypes 1-4", "DNA", 15, 28], ["boars", "SPECIES", 73, 78], ["rats", "SPECIES", 101, 105], ["hepatitis E", "SPECIES", 145, 156], ["genotypes", "TEST", 15, 24], ["novel genotypes", "PROBLEM", 30, 45], ["hepatitis E", "PROBLEM", 145, 156], ["a self-limiting disease", "PROBLEM", 160, 183], ["low mortality", "PROBLEM", 189, 202], ["hepatitis", "OBSERVATION", 145, 154], ["self-limiting", "OBSERVATION_MODIFIER", 162, 175], ["disease", "OBSERVATION", 176, 183], ["low mortality", "OBSERVATION_MODIFIER", 189, 202]]], ["However severe courses of the disease with acute liver failure have been reported during pregnancy [7] and in patients with liver cirrhosis [8] .", [["liver", "ANATOMY", 49, 54], ["liver", "ANATOMY", 124, 129], ["acute liver failure", "DISEASE", 43, 62], ["liver cirrhosis", "DISEASE", 124, 139], ["liver", "ORGAN", 49, 54], ["patients", "ORGANISM", 110, 118], ["liver", "ORGAN", 124, 129], ["patients", "SPECIES", 110, 118], ["the disease", "PROBLEM", 26, 37], ["acute liver failure", "PROBLEM", 43, 62], ["liver cirrhosis", "PROBLEM", 124, 139], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["disease", "OBSERVATION", 30, 37], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["liver", "ANATOMY", 49, 54], ["failure", "OBSERVATION", 55, 62], ["liver", "ANATOMY", 124, 129], ["cirrhosis", "OBSERVATION", 130, 139]]], ["So far prolonged courses have been registered only in organ transplant recipients [9] and patients suffering from leukemia [10] .BackgroundHEV is a non-enveloped, single stranded (+) RNA virus classified in the Hepeviridae family [11] with a 7.2 kb HEV genome encoding for three partly overlapping open reading frames (ORF) and a capped 5' and polyadenylated 3' end.", [["organ", "ANATOMY", 54, 59], ["leukemia", "ANATOMY", 114, 122], ["leukemia", "DISEASE", 114, 122], ["BackgroundHEV", "CHEMICAL", 129, 142], ["organ", "ORGAN", 54, 59], ["patients", "ORGANISM", 90, 98], ["leukemia", "CANCER", 114, 122], ["3' end", "CELLULAR_COMPONENT", 359, 365], ["BackgroundHEV", "DNA", 129, 142], ["7.2 kb HEV genome", "DNA", 242, 259], ["open reading frames", "DNA", 298, 317], ["ORF", "DNA", 319, 322], ["capped 5' and polyadenylated 3' end", "DNA", 330, 365], ["patients", "SPECIES", 90, 98], ["BackgroundHEV", "SPECIES", 129, 142], ["organ transplant recipients", "TREATMENT", 54, 81], ["leukemia", "PROBLEM", 114, 122], ["a non-enveloped", "PROBLEM", 146, 161], ["single stranded (+) RNA virus", "PROBLEM", 163, 192], ["a 7.2 kb HEV genome encoding", "TREATMENT", 240, 268], ["a capped 5' and polyadenylated 3' end", "TREATMENT", 328, 365], ["organ", "ANATOMY", 54, 59], ["transplant", "OBSERVATION", 60, 70], ["leukemia", "OBSERVATION", 114, 122], ["non-enveloped", "OBSERVATION_MODIFIER", 148, 161]]], ["ORF1 comprises several putative functional domains [12] (Figure 1 ): A methyltransferase (Met) with subsequent Y domain; a papain-like cysteine protease (Plp), which over a proline-rich variable (V) region is connected to the so-called X domain; a helicase (Hel) and a RNA-dependent RNA polymerase (RdRp).", [["proline", "CHEMICAL", 173, 180], ["cysteine", "CHEMICAL", 135, 143], ["proline", "CHEMICAL", 173, 180], ["A methyltransferase", "GENE_OR_GENE_PRODUCT", 69, 88], ["Met", "GENE_OR_GENE_PRODUCT", 90, 93], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 123, 152], ["Plp", "GENE_OR_GENE_PRODUCT", 154, 157], ["Hel", "GENE_OR_GENE_PRODUCT", 258, 261], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 269, 297], ["ORF1", "DNA", 0, 4], ["methyltransferase", "PROTEIN", 71, 88], ["Met", "PROTEIN", 90, 93], ["Y domain", "PROTEIN", 111, 119], ["papain", "PROTEIN", 123, 129], ["cysteine protease", "PROTEIN", 135, 152], ["Plp", "PROTEIN", 154, 157], ["proline-rich variable (V) region", "PROTEIN", 173, 205], ["X domain", "PROTEIN", 236, 244], ["helicase", "PROTEIN", 248, 256], ["Hel", "PROTEIN", 258, 261], ["RNA-dependent RNA polymerase", "PROTEIN", 269, 297], ["RdRp", "PROTEIN", 299, 303], ["A methyltransferase (Met)", "TREATMENT", 69, 94], ["subsequent Y domain", "TREATMENT", 100, 119], ["a papain-like cysteine protease", "TREATMENT", 121, 152], ["a helicase (Hel)", "TREATMENT", 246, 262], ["a RNA", "TEST", 267, 272]]], ["ORF2 encodes for the viral capsid protein, which contains dominant antigenic determinants [13] and neutralizing epitopes [14] .", [["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF2", "DNA", 0, 4], ["viral capsid protein", "PROTEIN", 21, 41], ["dominant antigenic determinants", "PROTEIN", 58, 89], ["neutralizing epitopes", "PROTEIN", 99, 120], ["the viral capsid protein", "PROBLEM", 17, 41], ["neutralizing epitopes", "TREATMENT", 99, 120], ["dominant", "OBSERVATION_MODIFIER", 58, 66], ["antigenic", "OBSERVATION_MODIFIER", 67, 76]]], ["ORF 3 encodes a small phosphoprotein [15] of controversially discussed function that seems to be essential for in vivo infectivity [16, 17] .BackgroundCurrently different synthetic peptides and recombinant antigens of ORF2 and 3 of genotypes 1, 2 and 3 are used for commercially available serological tests (enzyme linked immunosorbent assay (ELISA), line-immuno-assay (LIA)) and the most relevant related publications are limited to the description of these antigens.", [["ORF 3", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF2", "GENE_OR_GENE_PRODUCT", 218, 222], ["3", "GENE_OR_GENE_PRODUCT", 251, 252], ["ORF 3", "DNA", 0, 5], ["recombinant antigens", "PROTEIN", 194, 214], ["ORF2", "DNA", 218, 222], ["antigens", "PROTEIN", 459, 467], ["a small phosphoprotein", "PROBLEM", 14, 36], ["BackgroundCurrently different synthetic peptides", "PROBLEM", 141, 189], ["ORF2", "TEST", 218, 222], ["genotypes", "TEST", 232, 241], ["serological tests", "TEST", 289, 306], ["enzyme", "TEST", 308, 314], ["immunosorbent assay", "TEST", 322, 341], ["ELISA", "TEST", 343, 348], ["line-immuno", "TEST", 351, 362], ["small", "OBSERVATION_MODIFIER", 16, 21], ["synthetic peptides", "OBSERVATION", 171, 189]]], ["Studies characterizing immunogenic peptides in regions of all three ORFs of porcine [18] and human [19, 20] hepatitis E virus are limited to a non-systematic approach or have not yet transferred their results to the field of diagnostic routine testing.BackgroundIn this work we present a systematic strategy for screening of the entire proteome of HEV for the identification of serologically reactive HEV antigens based on recombinant, bacterially expressed and purified HEV proteins.", [["hepatitis E", "DISEASE", 108, 119], ["porcine [18]", "ORGANISM", 76, 88], ["human", "ORGANISM", 93, 98], ["[19, 20] hepatitis E virus", "ORGANISM", 99, 125], ["HEV", "ORGANISM", 348, 351], ["HEV", "ORGANISM", 401, 404], ["HEV", "ORGANISM", 471, 474], ["ORFs", "DNA", 68, 72], ["serologically reactive HEV antigens", "PROTEIN", 378, 413], ["recombinant, bacterially expressed and purified HEV proteins", "PROTEIN", 423, 483], ["porcine", "SPECIES", 76, 83], ["human", "SPECIES", 93, 98], ["hepatitis E virus", "SPECIES", 108, 125], ["human", "SPECIES", 93, 98], ["hepatitis E virus", "SPECIES", 108, 125], ["HEV", "SPECIES", 348, 351], ["HEV", "SPECIES", 401, 404], ["HEV", "SPECIES", 471, 474], ["Studies", "TEST", 0, 7], ["immunogenic peptides", "PROBLEM", 23, 43], ["hepatitis E virus", "PROBLEM", 108, 125], ["diagnostic routine testing", "TEST", 225, 251], ["screening", "TEST", 312, 321], ["serologically reactive HEV antigens", "PROBLEM", 378, 413], ["HEV proteins", "OBSERVATION", 471, 483]]], ["For this purpose, fifteen potentially immunogenic HEV antigens of ORFs 1, 2 and 3 were recombinatorially cloned into bacterial expression vectors of which nine were subsequently expressed and purified.", [["HEV", "ORGANISM", 50, 53], ["2", "GENE_OR_GENE_PRODUCT", 74, 75], ["3", "GENE_OR_GENE_PRODUCT", 80, 81], ["ORFs 1, 2 and 3", "DNA", 66, 81], ["bacterial expression vectors", "DNA", 117, 145], ["HEV", "SPECIES", 50, 53], ["ORFs", "TEST", 66, 70], ["bacterial expression vectors", "TREATMENT", 117, 145]]], ["Their immunogenicity was evaluated with pre-characterized blood samples on a microarray format in comparison to seven recombinant antigens already in use in a commercially available anti-HEV diagnostic test-system.", [["blood samples", "ANATOMY", 58, 71], ["blood samples", "ORGANISM_SUBSTANCE", 58, 71], ["recombinant antigens", "PROTEIN", 118, 138], ["blood samples", "TEST", 58, 71], ["a microarray format", "TEST", 75, 94], ["anti-HEV diagnostic test", "TEST", 182, 206]]], ["Analyzed data show that seven of those nine HEV proteins were putative serologic markers of HEV infections.", [["HEV infections", "DISEASE", 92, 106], ["HEV", "ORGANISM", 44, 47], ["HEV", "ORGANISM", 92, 95], ["HEV proteins", "PROTEIN", 44, 56], ["HEV", "SPECIES", 44, 47], ["HEV", "SPECIES", 92, 95], ["Analyzed data", "TEST", 0, 13], ["HEV proteins", "TEST", 44, 56], ["HEV infections", "PROBLEM", 92, 106], ["HEV infections", "OBSERVATION", 92, 106]]], ["Statistical analysis of measured signal intensities could confirm well known epitopes, identify immunogenic subdomains and characterize newly described antigens and their possible suitability in commercial assay formats.Recombinatorial cloning of a complete HEV libraryThe genotype 1 HEV genome synthesized by Geneart (Regensburg, Germany) served as template for subcloning Figure 2 ).", [["HEV", "ORGANISM", 284, 287], ["epitopes", "PROTEIN", 77, 85], ["immunogenic subdomains", "PROTEIN", 96, 118], ["antigens", "PROTEIN", 152, 160], ["HEV library", "DNA", 258, 269], ["genotype 1 HEV genome", "DNA", 273, 294], ["HEV", "SPECIES", 258, 261], ["HEV", "SPECIES", 284, 287], ["Statistical analysis", "TEST", 0, 20], ["measured signal intensities", "PROBLEM", 24, 51], ["known epitopes", "PROBLEM", 71, 85], ["immunogenic subdomains", "PROBLEM", 96, 118], ["newly described antigens", "PROBLEM", 136, 160], ["commercial assay formats", "TEST", 195, 219], ["HEV library", "OBSERVATION", 258, 269]]], ["Recombinatorial cloning of the HEV ORFs was performed as described recently [22] .Expression and purification of His-tagged HEV antigensBacterial expression vectors pETG-A-His-N-HEV-ORFs were transformed into E. coli Rosetta (DE3).", [["His", "CHEMICAL", 113, 116], ["HEV", "ORGANISM", 31, 34], ["His", "GENE_OR_GENE_PRODUCT", 113, 116], ["HEV", "ORGANISM", 124, 127], ["E. coli Rosetta", "ORGANISM", 209, 224], ["DE3", "GENE_OR_GENE_PRODUCT", 226, 229], ["HEV ORFs", "DNA", 31, 39], ["His", "PROTEIN", 113, 116], ["pETG-A-His-N-HEV-ORFs", "DNA", 165, 186], ["E. coli Rosetta", "SPECIES", 209, 224], ["HEV", "SPECIES", 31, 34], ["HEV", "SPECIES", 124, 127], ["E. coli", "SPECIES", 209, 216], ["the HEV ORFs", "TEST", 27, 39], ["HEV antigens", "TEST", 124, 136], ["pETG", "TEST", 165, 169], ["His-N", "TEST", 172, 177], ["HEV-ORFs", "TEST", 178, 186], ["HEV ORFs", "OBSERVATION", 31, 39]]], ["400 ml LBmedium main cultures supplemented with ampicillin were incubated at 30\u00b0C, inducted with 1 mM Isopropyl \u03b2-D-1-thiogalactopyranoside and grown for 3 h at 30\u00b0C. After centrifugation bacterial pellets were resuspended and incubated in ice-cold lysis buffer (10% glycerol, 20 mM Tris-HCl, 0.5 M NaCl, 5 mM Imidazole, pH 7.9, supplemented with DNAse, RNAse, proteinase inhibitors, and lysozym) and homogenized using the Magna-Lyser (Roche Applied Science, Germany) according to manufacture's instructions.", [["ampicillin", "CHEMICAL", 48, 58], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 102, 139], ["glycerol", "CHEMICAL", 267, 275], ["Tris-HCl", "CHEMICAL", 283, 291], ["NaCl", "CHEMICAL", 299, 303], ["Imidazole", "CHEMICAL", 310, 319], ["ampicillin", "CHEMICAL", 48, 58], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 102, 139], ["glycerol", "CHEMICAL", 267, 275], ["Tris-HCl", "CHEMICAL", 283, 291], ["NaCl", "CHEMICAL", 299, 303], ["Imidazole", "CHEMICAL", 310, 319], ["ampicillin", "SIMPLE_CHEMICAL", 48, 58], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 102, 139], ["glycerol", "SIMPLE_CHEMICAL", 267, 275], ["Tris-HCl", "SIMPLE_CHEMICAL", 283, 291], ["Imidazole", "SIMPLE_CHEMICAL", 310, 319], ["DNAse", "SIMPLE_CHEMICAL", 347, 352], ["RNAse", "GENE_OR_GENE_PRODUCT", 354, 359], ["proteinase", "GENE_OR_GENE_PRODUCT", 361, 371], ["lysozym", "SIMPLE_CHEMICAL", 388, 395], ["DNAse", "PROTEIN", 347, 352], ["RNAse", "PROTEIN", 354, 359], ["main cultures", "TEST", 16, 29], ["ampicillin", "TREATMENT", 48, 58], ["thiogalactopyranoside", "TREATMENT", 118, 139], ["centrifugation bacterial pellets", "TREATMENT", 173, 205], ["cold lysis buffer", "TREATMENT", 244, 261], ["glycerol", "TREATMENT", 267, 275], ["0.5 M NaCl", "TREATMENT", 293, 303], ["5 mM Imidazole", "TREATMENT", 305, 319], ["pH", "TEST", 321, 323], ["DNAse", "TREATMENT", 347, 352], ["RNAse", "TREATMENT", 354, 359], ["proteinase inhibitors", "TREATMENT", 361, 382], ["lysozym", "TREATMENT", 388, 395], ["the Magna", "TREATMENT", 419, 428], ["bacterial pellets", "OBSERVATION", 188, 205]]], ["After sonication, protein inclusion bodies were pelleted by centrifugation, resuspended, sonicated and incubated in binding buffer (0.5 M NaCl, 5 mM Imidazol, 20 mM Tris-HCl, 8 M urea, pH 7.9).", [["NaCl", "CHEMICAL", 138, 142], ["Imidazol", "CHEMICAL", 149, 157], ["Tris-HCl", "CHEMICAL", 165, 173], ["urea", "CHEMICAL", 179, 183], ["NaCl", "CHEMICAL", 138, 142], ["Imidazol", "CHEMICAL", 149, 157], ["Tris-HCl", "CHEMICAL", 165, 173], ["urea", "CHEMICAL", 179, 183], ["Imidazol", "SIMPLE_CHEMICAL", 149, 157], ["Tris-HCl", "SIMPLE_CHEMICAL", 165, 173], ["urea", "SIMPLE_CHEMICAL", 179, 183], ["protein inclusion bodies", "TREATMENT", 18, 42], ["NaCl", "TREATMENT", 138, 142], ["5 mM Imidazol", "TREATMENT", 144, 157], ["pH", "TEST", 185, 187]]], ["After centrifugation His-tagged proteins from supernatants were purified using HisBind Columns (Novagen, Germany) according to the steps described by the manufacture using buffers with an Imidazole gradient up to 250 mM for elution.", [["supernatants", "ANATOMY", 46, 58], ["Imidazole", "CHEMICAL", 188, 197], ["His", "CHEMICAL", 21, 24], ["Imidazole", "CHEMICAL", 188, 197], ["Imidazole", "SIMPLE_CHEMICAL", 188, 197], ["His-tagged proteins", "PROTEIN", 21, 40], ["centrifugation", "TEST", 6, 20], ["HisBind Columns", "TREATMENT", 79, 94], ["Novagen", "TREATMENT", 96, 103], ["an Imidazole gradient", "TREATMENT", 185, 206]]], ["Expression and degree of purification of recombinant N-terminally His-tagged HEV proteins were analyzed by SDS/PAGE followed by Coomassie staining and verified by Western blotting using monoclonal mouse anti RGS-His antibody (Qiagen, Germany) ( Figure 3 ).", [["His", "CHEMICAL", 66, 69], ["Coomassie", "CHEMICAL", 128, 137], ["HEV", "ORGANISM", 77, 80], ["Coomassie", "SIMPLE_CHEMICAL", 128, 137], ["mouse", "ORGANISM", 197, 202], ["RGS", "GENE_OR_GENE_PRODUCT", 208, 211], ["recombinant N-terminally His-tagged HEV proteins", "PROTEIN", 41, 89], ["monoclonal mouse anti RGS-His antibody", "PROTEIN", 186, 224], ["mouse", "SPECIES", 197, 202], ["HEV", "SPECIES", 77, 80], ["mouse", "SPECIES", 197, 202], ["HEV proteins", "TEST", 77, 89], ["Coomassie staining", "TEST", 128, 146], ["monoclonal mouse anti RGS", "TREATMENT", 186, 211], ["His antibody", "TEST", 212, 224]]], ["Purified proteins were stored at -20\u00b0C.Antigen-immunogenicity evaluation experiments in microarray formatFor immunogenic evaluation, nine small scale purified HEV antigens were spotted onto nitrocellulose microarrays (Max von Pettenkofer-Institute (MvP-I) antigens).", [["nitrocellulose", "CHEMICAL", 190, 204], ["HEV", "ORGANISM", 159, 162], ["MvP-I) antigens", "GENE_OR_GENE_PRODUCT", 249, 264], ["HEV antigens", "PROTEIN", 159, 171], ["Max von Pettenkofer-Institute (MvP-I) antigens", "PROTEIN", 218, 264], ["HEV", "SPECIES", 159, 162], ["Antigen", "TEST", 39, 46], ["immunogenicity evaluation", "TEST", 47, 72], ["immunogenic evaluation", "TEST", 109, 131], ["HEV antigens", "TEST", 159, 171], ["nitrocellulose microarrays", "TEST", 190, 216]]], ["Additionally incubation and conjugate control spots as well as seven purified recombinant proteins already included in a commercially available anti-HEV diagnostic test-system (recomLine HEV, Mikrogen, Germany) were spotted on the same membranes: the N-(O2NGT1, O2NGT3), C-terminal (O2CGT1, O2CGT3) (each of genotype (GT) 1 and 3) and the middle part (O2MGT1) (of genotype 1) of ORF2 as well as the complete ORF3 (each of genotype 1 and 3: O3GT1, O3GT3) ( Figure 1 ).", [["membranes", "ANATOMY", 236, 245], ["N", "CHEMICAL", 251, 252], ["O2NGT3", "CHEMICAL", 262, 268], ["C-", "CHEMICAL", 271, 273], ["membranes", "CELLULAR_COMPONENT", 236, 245], ["genotype (GT) 1", "GENE_OR_GENE_PRODUCT", 308, 323], ["ORF2", "GENE_OR_GENE_PRODUCT", 379, 383], ["ORF3", "GENE_OR_GENE_PRODUCT", 408, 412], ["recombinant proteins", "PROTEIN", 78, 98], ["O2NGT1", "PROTEIN", 254, 260], ["O2NGT3", "PROTEIN", 262, 268], ["C-terminal", "PROTEIN", 271, 281], ["O2CGT1", "PROTEIN", 283, 289], ["O2CGT3", "PROTEIN", 291, 297], ["GT", "PROTEIN", 318, 320], ["middle part", "PROTEIN", 339, 350], ["O2MGT1", "PROTEIN", 352, 358], ["ORF2", "DNA", 379, 383], ["ORF3", "DNA", 408, 412], ["HEV", "SPECIES", 187, 190], ["conjugate control spots", "PROBLEM", 28, 51], ["anti-HEV diagnostic test", "TEST", 144, 168], ["C-terminal (O2CGT1, O2CGT3", "TREATMENT", 271, 297], ["genotype (GT)", "TREATMENT", 308, 321], ["ORF2", "TREATMENT", 379, 383], ["genotype", "TEST", 422, 430], ["middle", "ANATOMY_MODIFIER", 339, 345]]], ["Publication of the exact locations and amino acid compositions of the used commercially produced antigens was not possible as this information was con- peroxidase labeled conjugates (Seramun, Germany).", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "AMINO_ACID", 39, 49], ["con- peroxidase labeled conjugates", "SIMPLE_CHEMICAL", 147, 181], ["amino acid compositions", "TREATMENT", 39, 62]]], ["Visualization of immune complexes was achieved by tetramethylbenzidine substrate (Seramun, Germany).", [["tetramethylbenzidine", "CHEMICAL", 50, 70], ["tetramethylbenzidine", "CHEMICAL", 50, 70], ["tetramethylbenzidine", "SIMPLE_CHEMICAL", 50, 70], ["immune complexes", "PROTEIN", 17, 33], ["immune complexes", "PROBLEM", 17, 33], ["tetramethylbenzidine substrate", "TREATMENT", 50, 80], ["immune complexes", "OBSERVATION", 17, 33]]], ["After automated scanning, the quantification of specific signals was performed by digitalization of grey tones with the recomDot Scan software (recomDot system, Mikrogen, Germany).Blood samples used for evaluationAll samples were pre-characterized for the presence of HEV-IgG and IgM by recomLine HEV (Mikrogen, Germany) and IgG negative sera additionally by HEV ELISA (Genelabs Diagnostics, Singapore) with consistent results.", [["Blood samples", "ANATOMY", 180, 193], ["samples", "ANATOMY", 217, 224], ["sera", "ANATOMY", 338, 342], ["Blood samples", "ORGANISM_SUBSTANCE", 180, 193], ["HEV", "ORGANISM", 268, 271], ["IgG", "GENE_OR_GENE_PRODUCT", 272, 275], ["IgM", "GENE_OR_GENE_PRODUCT", 280, 283], ["recomLine HEV", "ORGANISM", 287, 300], ["sera", "ORGANISM_SUBSTANCE", 338, 342], ["HEV", "ORGANISM", 359, 362], ["IgG", "PROTEIN", 272, 275], ["IgM", "PROTEIN", 280, 283], ["IgG", "PROTEIN", 325, 328], ["HEV", "SPECIES", 268, 271], ["HEV", "SPECIES", 297, 300], ["HEV", "SPECIES", 359, 362], ["automated scanning", "TEST", 6, 24], ["grey tones", "TEST", 100, 110], ["Dot Scan software", "TEST", 125, 142], ["Blood samples", "TEST", 180, 193], ["evaluation", "TEST", 203, 213], ["All samples", "TEST", 213, 224], ["HEV", "TEST", 268, 271], ["IgG", "TEST", 272, 275], ["IgM", "TEST", 280, 283], ["IgG", "TEST", 325, 328], ["HEV ELISA", "TEST", 359, 368]]], ["In order to identify immunogenic HEV antigens, the microarrays were probed with blood samples from clinically healthy blood donors (n = 20, defined as IgG and IgM negative) and from patients suffering from an acute HEV infection including follow up samples (N = 35).", [["blood samples", "ANATOMY", 80, 93], ["blood", "ANATOMY", 118, 123], ["samples", "ANATOMY", 249, 256], ["HEV infection", "DISEASE", 215, 228], ["HEV", "ORGANISM", 33, 36], ["blood samples", "ORGANISM_SUBSTANCE", 80, 93], ["blood donors", "ORGANISM_SUBSTANCE", 118, 130], ["IgG", "GENE_OR_GENE_PRODUCT", 151, 154], ["IgM", "GENE_OR_GENE_PRODUCT", 159, 162], ["patients", "ORGANISM", 182, 190], ["immunogenic HEV antigens", "PROTEIN", 21, 45], ["IgG", "PROTEIN", 151, 154], ["IgM", "PROTEIN", 159, 162], ["patients", "SPECIES", 182, 190], ["HEV", "SPECIES", 33, 36], ["HEV", "SPECIES", 215, 218], ["immunogenic HEV antigens", "PROBLEM", 21, 45], ["the microarrays", "TEST", 47, 62], ["blood samples", "TEST", 80, 93], ["blood donors", "TEST", 118, 130], ["IgG", "TEST", 151, 154], ["IgM", "TEST", 159, 162], ["an acute HEV infection", "PROBLEM", 206, 228], ["follow up samples", "TEST", 239, 256], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["HEV", "OBSERVATION_MODIFIER", 215, 218], ["infection", "OBSERVATION", 219, 228]]], ["In the group of Hepatitis E patients, 35 were defined as IgG positive and 28 IgM positive of which 22 had detectable HEV RNA ( Figure 4 ).", [["Hepatitis E", "DISEASE", 16, 27], ["Hepatitis E", "ORGANISM", 16, 27], ["patients", "ORGANISM", 28, 36], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["HEV", "ORGANISM", 117, 120], ["IgG", "PROTEIN", 57, 60], ["IgM", "PROTEIN", 77, 80], ["HEV RNA", "RNA", 117, 124], ["patients", "SPECIES", 28, 36], ["Hepatitis E", "SPECIES", 16, 27], ["HEV", "SPECIES", 117, 120], ["Hepatitis E patients", "TEST", 16, 36], ["IgG", "TEST", 57, 60], ["IgM", "TEST", 77, 80], ["HEV RNA", "OBSERVATION", 117, 124]]], ["To test patient samples for the presence of HEV RNA, a routine diagnostic PCR amplifying a fragment of the conserved 5' non-coding-region was used.", [["patient", "ORGANISM", 8, 15], ["HEV", "ORGANISM", 44, 47], ["HEV RNA", "RNA", 44, 51], ["5' non-coding-region", "DNA", 117, 137], ["patient", "SPECIES", 8, 15], ["HEV", "SPECIES", 44, 47], ["HEV RNA", "PROBLEM", 44, 51], ["a routine diagnostic PCR", "TEST", 53, 77], ["a fragment of the conserved 5' non-coding-region", "TREATMENT", 89, 137], ["HEV RNA", "OBSERVATION", 44, 51]]], ["A few amplicons were sequenced with a CEQ\u2122 8,800 Genetic Analysis System (Beckman Coulter Inc., Fullerton CA, USA) and sequences compared with Genebank entries, using the BLAST application [23] .", [["CEQ", "DNA", 38, 41], ["A few amplicons", "TREATMENT", 0, 15], ["the BLAST application", "TREATMENT", 167, 188], ["few", "OBSERVATION_MODIFIER", 2, 5], ["amplicons", "OBSERVATION", 6, 15]]], ["Sequence analysis of 10 sera showed three genotype 1, two genotype 3 and five genotype 4 infections, respectively.Statistic analysisAll statistical tests were performed by the SPSS 18.0.0 software for Windows.", [["sera", "ANATOMY", 24, 28], ["infections", "DISEASE", 89, 99], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["Sequence analysis", "TEST", 0, 17], ["sera", "TEST", 24, 28], ["three genotype", "TEST", 36, 50], ["five genotype 4 infections", "PROBLEM", 73, 99], ["Statistic analysis", "TEST", 114, 132], ["All statistical tests", "TEST", 132, 153], ["infections", "OBSERVATION", 89, 99]]], ["Sensitivity and specificity were calculated with binary logistic regression methods.", [["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 16, 27]]], ["Additionally performance of antigens was evaluated by comparing Receiver Operator Characteristics (ROC) curves and calculated area under the curves (AUCs).", [["antigens", "PROTEIN", 28, 36], ["ROC) curves", "TEST", 99, 110], ["the curves", "TEST", 137, 147], ["AUCs", "TEST", 149, 153]]], ["A bivariate correlation (Pearson) > 0.8 was defined as a high correlation.", [["A bivariate correlation", "TEST", 0, 23]]], ["Results were accepted as significant if the pvalue was < 0.05.", [["the pvalue", "TEST", 40, 50]]], ["For binary regression analysis inclusion and exclusion criteria for variables are based on Pearson correlation coefficients.", [["binary regression analysis", "TEST", 4, 30], ["exclusion criteria", "TEST", 45, 63]]], ["In this study this method can be explained as followed: The backward method starts with an assay consisting of all available antigens.", [["antigens", "PROTEIN", 125, 133], ["this study", "TEST", 3, 13], ["The backward method", "TREATMENT", 56, 75], ["an assay", "TEST", 88, 96]]], ["If an antigen does not have an explanatory value which is significant for the assay the antigen is removed in the next step.", [["the assay the antigen", "PROBLEM", 74, 95]]], ["This method discontinues when no further antigen can be removed from the set of antigens without significant loss of the explanatory value of the assay.", [["antigens", "PROTEIN", 80, 88], ["This method", "TREATMENT", 0, 11], ["further antigen", "PROBLEM", 33, 48]]], ["Analogously the forward method starts with a single antigen which has the highest explanatory value of all available antigens.", [["antigens", "PROTEIN", 117, 125], ["a single antigen", "PROBLEM", 43, 59]]], ["In the following step only an antigen which increases the explanatory value of the hole assay is added to the set of antigens.", [["antigens", "PROTEIN", 117, 125], ["an antigen", "TEST", 27, 37], ["the hole assay", "TEST", 79, 93]]], ["The forward method discontinues when the addition of a further antigen to the assay does not improve the explanatory value of current antigens [24] .ResultsSerum profiling experiments of pre-characterized sera in microarray format 9 out of 15 HEV proteins (60%) could be detected in bacterial lysates and purification of all 9 N-terminally Histagged proteins was verified by western blot analysis using monoclonal mouse anti RGS-His antibody, namely: Met, Y, V, X, Hel, O3N, O3C, O3, O2C ( Figure 3 ).", [["sera", "ANATOMY", 205, 209], ["lysates", "ANATOMY", 293, 300], ["N", "CHEMICAL", 327, 328], ["Met", "CHEMICAL", 451, 454], ["O3N", "CHEMICAL", 470, 473], ["O3C", "CHEMICAL", 475, 478], ["O3", "CHEMICAL", 480, 482], ["O2C", "CHEMICAL", 484, 487], ["sera", "ORGANISM_SUBSTANCE", 205, 209], ["HEV", "ORGANISM", 243, 246], ["mouse", "ORGANISM", 414, 419], ["RGS", "GENE_OR_GENE_PRODUCT", 425, 428], ["Met", "GENE_OR_GENE_PRODUCT", 451, 454], ["Y, V, X, Hel", "SIMPLE_CHEMICAL", 456, 468], ["O3N", "SIMPLE_CHEMICAL", 470, 473], ["O3C", "SIMPLE_CHEMICAL", 475, 478], ["O3", "SIMPLE_CHEMICAL", 480, 482], ["O2C", "SIMPLE_CHEMICAL", 484, 487], ["HEV proteins", "PROTEIN", 243, 255], ["N-terminally Histagged proteins", "PROTEIN", 327, 358], ["monoclonal mouse anti RGS-His antibody", "PROTEIN", 403, 441], ["mouse", "SPECIES", 414, 419], ["HEV", "SPECIES", 243, 246], ["mouse", "SPECIES", 414, 419], ["the assay", "TEST", 74, 83], ["pre-characterized sera", "TEST", 187, 209], ["microarray format", "TEST", 213, 230], ["HEV proteins", "TEST", 243, 255], ["bacterial lysates", "TEST", 283, 300], ["purification", "TEST", 305, 317], ["blot analysis", "TEST", 383, 396], ["monoclonal mouse anti RGS", "TEST", 403, 428], ["His antibody", "TEST", 429, 441], ["Hel", "TEST", 465, 468], ["O3C", "TEST", 475, 478]]], ["In microarray format the proteins Y, V, X, Hel, O3N, O3C, O3, O2C differentiated significantly between IgG positive and negative sera (p < 0.05) ( Figure 1 ).", [["sera", "ANATOMY", 129, 133], ["O3N", "CHEMICAL", 48, 51], ["O3C", "CHEMICAL", 53, 56], ["O3", "CHEMICAL", 58, 60], ["Hel", "GENE_OR_GENE_PRODUCT", 43, 46], ["O3N", "GENE_OR_GENE_PRODUCT", 48, 51], ["O3C", "SIMPLE_CHEMICAL", 53, 56], ["O3", "SIMPLE_CHEMICAL", 58, 60], ["O2C", "SIMPLE_CHEMICAL", 62, 65], ["IgG", "GENE_OR_GENE_PRODUCT", 103, 106], ["sera", "ORGANISM_SUBSTANCE", 129, 133], ["V", "PROTEIN", 37, 38], ["X", "PROTEIN", 40, 41], ["Hel", "PROTEIN", 43, 46], ["O3N", "PROTEIN", 48, 51], ["O3C", "PROTEIN", 53, 56], ["O3", "PROTEIN", 58, 60], ["O2C", "PROTEIN", 62, 65], ["IgG", "PROTEIN", 103, 106], ["the proteins Y", "TEST", 21, 35], ["Hel", "TEST", 43, 46], ["O3N", "TEST", 48, 51], ["O3C", "TEST", 53, 56], ["O2C", "TEST", 62, 65], ["IgG", "TEST", 103, 106], ["sera", "TEST", 129, 133]]], ["Met, Y, V, X, O3N, O3C, O3, O2C significantly discriminated between sera of IgM positive patients and negative control patients (p < 0.05).Combination of antigens for optimal test performanceThe best possible antigen combination for the optimal test performance was calculated using forward and backward binary regression methods comparing negative control sera with all sera positive for IgG and IgM, respectively.", [["sera", "ANATOMY", 68, 72], ["sera", "ANATOMY", 357, 361], ["sera", "ANATOMY", 371, 375], ["O3", "CHEMICAL", 24, 26], ["Met", "CHEMICAL", 0, 3], ["O3N", "CHEMICAL", 14, 17], ["O3C", "CHEMICAL", 19, 22], ["O3", "CHEMICAL", 24, 26], ["O2C", "CHEMICAL", 28, 31], ["Met", "GENE_OR_GENE_PRODUCT", 0, 3], ["O3N", "SIMPLE_CHEMICAL", 14, 17], ["O3C", "SIMPLE_CHEMICAL", 19, 22], ["O3", "SIMPLE_CHEMICAL", 24, 26], ["O2C", "SIMPLE_CHEMICAL", 28, 31], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["IgM", "GENE_OR_GENE_PRODUCT", 76, 79], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 119, 127], ["sera", "ORGANISM_SUBSTANCE", 357, 361], ["sera", "ORGANISM_SUBSTANCE", 371, 375], ["IgG", "GENE_OR_GENE_PRODUCT", 389, 392], ["IgM", "GENE_OR_GENE_PRODUCT", 397, 400], ["IgM", "PROTEIN", 76, 79], ["antigens", "PROTEIN", 154, 162], ["IgG", "PROTEIN", 389, 392], ["IgM", "PROTEIN", 397, 400], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 119, 127], ["IgM", "TEST", 76, 79], ["optimal test performance", "TEST", 167, 191], ["the optimal test performance", "TEST", 233, 261], ["forward and backward binary regression methods", "PROBLEM", 283, 329], ["all sera", "TEST", 367, 375], ["IgG", "TEST", 389, 392], ["IgM", "TEST", 397, 400]]], ["When choosing from all 16 antigens in IgG detection using the backwards method, it discontinued with Y and O2CGT3, which were left over in the last step.", [["O2CGT3", "CHEMICAL", 107, 113], ["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "PROTEIN", 38, 41], ["IgG detection", "TEST", 38, 51], ["Y and O2CGT3", "TREATMENT", 101, 113], ["left", "ANATOMY_MODIFIER", 126, 130]]], ["Consequently, the removal of one of these two antigens would change the explanatory value of the assay significantly.", [["the removal", "TREATMENT", 14, 25], ["the assay", "TEST", 93, 102]]], ["Similar, when choosing only from the seven \"Mikrogen antigens\" the same method discontinued with O2NGT1 and O2CGT3.", [["O2NGT1", "CHEMICAL", 97, 103], ["O2CGT3", "CHEMICAL", 108, 114], ["O2NGT1", "CHEMICAL", 97, 103], ["O2CGT3", "CHEMICAL", 108, 114], ["O2NGT1", "SIMPLE_CHEMICAL", 97, 103], ["O2CGT3", "SIMPLE_CHEMICAL", 108, 114], ["Mikrogen antigens", "PROTEIN", 44, 61], ["O2NGT1 and O2CGT3", "TREATMENT", 97, 114]]], ["Comparing both antigen combinations, binary regression analysis showed that there is no statistically significant difference between both combinations.", [["binary regression analysis", "TEST", 37, 63], ["no", "UNCERTAINTY", 85, 87], ["statistically", "OBSERVATION_MODIFIER", 88, 101], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["difference", "OBSERVATION", 114, 124]]], ["In IgM detection a similar result was obtained: Choosing from 16 antigens the backwards method reveals V, O2CGT3 and O3GT3 to be the best combination.", [["IgM", "GENE_OR_GENE_PRODUCT", 3, 6], ["O2CGT3", "SIMPLE_CHEMICAL", 106, 112], ["O3GT3", "SIMPLE_CHEMICAL", 117, 122], ["IgM", "PROTEIN", 3, 6], ["O3GT3", "PROTEIN", 117, 122], ["O2CGT3", "TREATMENT", 106, 112], ["O3GT3", "TREATMENT", 117, 122]]], ["If restricted to the seven \"Mikrogen antigens\" only, O2NGT3 was set instead of V, but binary regression analysis could not determine any statistically significant difference between both antigen combinations.", [["Mikrogen antigens", "GENE_OR_GENE_PRODUCT", 28, 45], ["O2NGT3", "SIMPLE_CHEMICAL", 53, 59], ["Mikrogen antigens", "PROTEIN", 28, 45], ["O2NGT3", "PROTEIN", 53, 59], ["binary regression analysis", "TEST", 86, 112]]], ["Further calculation of a forward binary regression method used to obtain the best antigen combination choosing from all 16 antigens resulted in O2CGT3 in combination with O2NGT1 for IgG detection.", [["O2CGT3", "CHEMICAL", 144, 150], ["O2NGT1", "CHEMICAL", 171, 177], ["O2CGT3", "SIMPLE_CHEMICAL", 144, 150], ["O2NGT1", "SIMPLE_CHEMICAL", 171, 177], ["IgG", "GENE_OR_GENE_PRODUCT", 182, 185], ["16 antigens", "PROTEIN", 120, 131], ["O2CGT3", "PROTEIN", 144, 150], ["O2NGT1", "PROTEIN", 171, 177], ["IgG", "PROTEIN", 182, 185], ["a forward binary regression method", "TREATMENT", 23, 57], ["O2CGT3", "TREATMENT", 144, 150], ["IgG detection", "TEST", 182, 195]]], ["This means that the addition of any other antigen would not increase the explanatory value of the assay consisting of these two antigens.", [["any other antigen", "PROBLEM", 32, 49], ["the assay", "TEST", 94, 103]]], ["O2CGT1 alone is sufficient as diagnostic marker for IgM detection, as calculated by the forward regression method.Combination of antigens for optimal test performanceCorrelation of serologic reactivities of ORF2 and ORF3 antigens (Tables 2 and 3) Analysis of bivariate correlations between ORF3 subdomains, homologous GT1 ORF3 and homologous GT1 ORF2 antigens in IgG-and IgM seroreactivities are shown in Tables 2 and 3 .", [["O2CGT1", "CHEMICAL", 0, 6], ["O2CGT1", "SIMPLE_CHEMICAL", 0, 6], ["ORF2", "GENE_OR_GENE_PRODUCT", 207, 211], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 216, 229], ["ORF3", "GENE_OR_GENE_PRODUCT", 290, 294], ["GT1 ORF3", "GENE_OR_GENE_PRODUCT", 318, 326], ["GT1 ORF2 antigens", "GENE_OR_GENE_PRODUCT", 342, 359], ["IgG", "GENE_OR_GENE_PRODUCT", 363, 366], ["IgM", "GENE_OR_GENE_PRODUCT", 371, 374], ["O2CGT1", "DNA", 0, 6], ["IgM", "PROTEIN", 52, 55], ["antigens", "PROTEIN", 129, 137], ["ORF2", "DNA", 207, 211], ["ORF3 antigens", "PROTEIN", 216, 229], ["ORF3 subdomains", "DNA", 290, 305], ["homologous GT1 ORF3", "DNA", 307, 326], ["homologous GT1 ORF2 antigens", "PROTEIN", 331, 359], ["IgG", "PROTEIN", 363, 366], ["IgM", "PROTEIN", 371, 374], ["diagnostic marker", "TEST", 30, 47], ["IgM detection", "TEST", 52, 65], ["optimal test performance", "TEST", 142, 166], ["serologic reactivities", "TEST", 181, 203], ["ORF2", "TEST", 207, 211], ["ORF3 antigens", "TEST", 216, 229], ["bivariate correlations", "TEST", 259, 281], ["ORF3 subdomains", "PROBLEM", 290, 305], ["homologous GT1 ORF3", "TEST", 307, 326], ["homologous GT1 ORF2 antigens", "TEST", 331, 359], ["IgG", "TEST", 363, 366], ["IgM seroreactivities", "TEST", 371, 391], ["IgM seroreactivities", "OBSERVATION", 371, 391]]], ["Among ORF3 antigens only low and moderate correlations of O3N with other ORF3 antigens (O3C, O3 and O3GT1) was found for IgG-and IgM-seroreactivities.", [["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 6, 19], ["O3N", "GENE_OR_GENE_PRODUCT", 58, 61], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 73, 86], ["O3C", "GENE_OR_GENE_PRODUCT", 88, 91], ["O3", "SIMPLE_CHEMICAL", 93, 95], ["IgG", "GENE_OR_GENE_PRODUCT", 121, 124], ["IgM", "GENE_OR_GENE_PRODUCT", 129, 132], ["ORF3 antigens", "PROTEIN", 6, 19], ["O3N", "PROTEIN", 58, 61], ["ORF3 antigens", "PROTEIN", 73, 86], ["O3C", "PROTEIN", 88, 91], ["O3", "PROTEIN", 93, 95], ["O3GT1", "PROTEIN", 100, 105], ["IgG", "PROTEIN", 121, 124], ["IgM", "PROTEIN", 129, 132], ["Among ORF3 antigens", "TEST", 0, 19], ["other ORF3 antigens", "TEST", 67, 86], ["O3C", "TEST", 88, 91], ["O3GT1", "TEST", 100, 105], ["IgG", "TEST", 121, 124], ["IgM", "TEST", 129, 132], ["moderate", "OBSERVATION_MODIFIER", 33, 41]]], ["In contrast O3C seroreactivities exhibited a high correlation with O3 and O3GT1 in IgG and IgM.", [["O3", "CHEMICAL", 67, 69], ["O3", "CHEMICAL", 67, 69], ["O3GT1", "CHEMICAL", 74, 79], ["O3C", "SIMPLE_CHEMICAL", 12, 15], ["O3", "SIMPLE_CHEMICAL", 67, 69], ["O3GT1", "SIMPLE_CHEMICAL", 74, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 83, 86], ["O3C", "PROTEIN", 12, 15], ["O3GT1", "PROTEIN", 74, 79], ["IgG", "PROTEIN", 83, 86], ["O3GT1", "TEST", 74, 79], ["IgG", "TEST", 83, 86]]], ["O3 and O3GT1 were also found to correlate very highly in IgG and IgM.", [["O3", "CHEMICAL", 0, 2], ["O3", "CHEMICAL", 0, 2], ["O3GT1", "CHEMICAL", 7, 12], ["O3", "SIMPLE_CHEMICAL", 0, 2], ["O3GT1", "SIMPLE_CHEMICAL", 7, 12], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["O3GT1", "PROTEIN", 7, 12], ["IgG", "PROTEIN", 57, 60], ["O3", "TREATMENT", 0, 2], ["O3GT1", "TREATMENT", 7, 12]]], ["Analogue O2C and O2CGT1 showed a high correlation of IgG and IgM seroreactivities.Combination of antigens for optimal test performanceSensitivities and specificities of HEV antigens (Table 1 ) Table 1 shows specificity and sensitivity of IgG and IgM of all tested antigens.", [["O2CGT1", "CHEMICAL", 17, 23], ["O2CGT1", "CHEMICAL", 17, 23], ["O2C", "SIMPLE_CHEMICAL", 9, 12], ["O2CGT1", "SIMPLE_CHEMICAL", 17, 23], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgM", "GENE_OR_GENE_PRODUCT", 61, 64], ["HEV", "ORGANISM", 169, 172], ["IgG", "GENE_OR_GENE_PRODUCT", 238, 241], ["IgG", "PROTEIN", 53, 56], ["IgM", "PROTEIN", 61, 64], ["antigens", "PROTEIN", 97, 105], ["HEV antigens", "PROTEIN", 169, 181], ["IgG", "PROTEIN", 238, 241], ["IgM", "PROTEIN", 246, 249], ["HEV", "SPECIES", 169, 172], ["Analogue O2C", "TEST", 0, 12], ["O2CGT1", "TEST", 17, 23], ["IgG", "PROBLEM", 53, 56], ["IgM seroreactivities", "PROBLEM", 61, 81], ["optimal test performanceSensitivities", "TEST", 110, 147], ["HEV antigens", "TEST", 169, 181], ["specificity", "TEST", 207, 218], ["sensitivity", "TEST", 223, 234], ["IgG", "TEST", 238, 241], ["IgM", "TEST", 246, 249], ["IgM seroreactivities", "OBSERVATION", 61, 81]]], ["These results were obtained by calculation of binary regression analysis and AUC of ROC.", [["binary regression analysis", "TEST", 46, 72], ["ROC", "TEST", 84, 87]]], ["Since regression analysis of Met in IgG-and Hel in IgM-testing did not generate significant (p > 0.05) results, these two antigens were not pursued in subsequent analysis.Combination of antigens for optimal test performanceAmong all antigens Y performed with the lowest specificity in both IgG and IgM detection.", [["Met", "CHEMICAL", 29, 32], ["Met", "GENE_OR_GENE_PRODUCT", 29, 32], ["IgG", "GENE_OR_GENE_PRODUCT", 36, 39], ["Hel", "SIMPLE_CHEMICAL", 44, 47], ["IgG", "GENE_OR_GENE_PRODUCT", 290, 293], ["IgM", "GENE_OR_GENE_PRODUCT", 298, 301], ["Met", "PROTEIN", 29, 32], ["IgG", "PROTEIN", 36, 39], ["IgM", "PROTEIN", 51, 54], ["antigens", "PROTEIN", 186, 194], ["antigens Y", "PROTEIN", 233, 243], ["IgG", "PROTEIN", 290, 293], ["IgM", "PROTEIN", 298, 301], ["regression analysis", "TEST", 6, 25], ["Met in IgG", "TEST", 29, 39], ["Hel in IgM", "TEST", 44, 54], ["these two antigens", "TEST", 112, 130], ["subsequent analysis", "TEST", 151, 170], ["optimal test performance", "TEST", 199, 223], ["both IgG", "TEST", 285, 293], ["IgM detection", "TEST", 298, 311]]], ["Simultaneously the Y protein achieved the highest sensitivity rates among ORF1 proteins in IgG and IgM detection.", [["ORF1", "GENE_OR_GENE_PRODUCT", 74, 78], ["IgG", "GENE_OR_GENE_PRODUCT", 91, 94], ["IgM", "GENE_OR_GENE_PRODUCT", 99, 102], ["Y protein", "PROTEIN", 19, 28], ["ORF1 proteins", "PROTEIN", 74, 87], ["IgG", "PROTEIN", 91, 94], ["IgM", "PROTEIN", 99, 102], ["the Y protein", "TEST", 15, 28], ["ORF1 proteins", "TEST", 74, 87], ["IgG", "TEST", 91, 94], ["IgM detection", "TEST", 99, 112]]], ["V performed with the lowest sensitivity rates among all 16 antigens in IgG as well as IgM detection, but simultaneously highest ORF1 specificity in IgM detection and generated the largest AUC in IgM ROC analysis among ORF1 antigens.", [["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgM", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgM", "GENE_OR_GENE_PRODUCT", 148, 151], ["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 218, 231], ["IgG", "PROTEIN", 71, 74], ["IgM", "PROTEIN", 86, 89], ["ORF1", "DNA", 128, 132], ["IgM", "PROTEIN", 148, 151], ["IgM", "PROTEIN", 195, 198], ["ORF1 antigens", "PROTEIN", 218, 231], ["the lowest sensitivity rates", "TEST", 17, 45], ["IgG", "TEST", 71, 74], ["IgM detection", "TEST", 86, 99], ["IgM detection", "TEST", 148, 161], ["the largest AUC", "TEST", 176, 191], ["IgM ROC analysis", "TEST", 195, 211], ["ORF1 antigens", "TEST", 218, 231]]], ["The largest AUC in IgG ROC analysis among ORF1 antigens was generated by X protein with a value of 0.899, which is notably higher than the AUC The best performance in IgG detection among all 16 antigens was achieved by O2CGT3 with a specificity of 100%, sensitivity of 97.1% and AUC of 0.997.", [["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 42, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 167, 170], ["O2CGT3", "SIMPLE_CHEMICAL", 219, 225], ["ORF1 antigens", "PROTEIN", 42, 55], ["X protein", "PROTEIN", 73, 82], ["IgG", "PROTEIN", 167, 170], ["The largest AUC in IgG ROC analysis", "TEST", 0, 35], ["ORF1 antigens", "TEST", 42, 55], ["a value", "TEST", 88, 95], ["IgG detection", "TEST", 167, 180], ["sensitivity", "TEST", 254, 265], ["AUC", "TEST", 279, 282], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["higher", "OBSERVATION_MODIFIER", 123, 129]]], ["The lowest results in IgG and IgM detection among ORF2 proteins were detected in O2MGT1 antigen specificities, sensitivities and AUCs.", [["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgM", "GENE_OR_GENE_PRODUCT", 30, 33], ["ORF2", "GENE_OR_GENE_PRODUCT", 50, 54], ["O2MGT1 antigen", "GENE_OR_GENE_PRODUCT", 81, 95], ["IgG", "PROTEIN", 22, 25], ["IgM", "PROTEIN", 30, 33], ["ORF2 proteins", "PROTEIN", 50, 63], ["The lowest results", "TEST", 0, 18], ["IgG", "TEST", 22, 25], ["IgM detection", "TEST", 30, 43], ["ORF2 proteins", "TEST", 50, 63], ["sensitivities", "TEST", 111, 124], ["AUCs", "TEST", 129, 133]]], ["Optimal results regarding IgM detection were accomplished by O2CGT1 and O2C with specificities and sensitivities of 100% resulting in an AUC of 1.", [["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["O2CGT1", "SIMPLE_CHEMICAL", 61, 67], ["O2C", "SIMPLE_CHEMICAL", 72, 75], ["IgM", "PROTEIN", 26, 29], ["IgM detection", "TEST", 26, 39], ["specificities", "TEST", 81, 94], ["sensitivities", "TEST", 99, 112], ["an AUC", "TEST", 134, 140]]], ["O2NGT1 had an IgM specificity of 100%.Combination of antigens for optimal test performanceO3N shows clearly the lowest diagnostic performance of all ORF3 antigens in both IgG and IgM detection.", [["O2NGT1", "CHEMICAL", 0, 6], ["O2NGT1", "SIMPLE_CHEMICAL", 0, 6], ["IgM", "GENE_OR_GENE_PRODUCT", 14, 17], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 149, 162], ["IgG", "GENE_OR_GENE_PRODUCT", 171, 174], ["IgM", "GENE_OR_GENE_PRODUCT", 179, 182], ["O2NGT1", "PROTEIN", 0, 6], ["IgM", "PROTEIN", 14, 17], ["antigens", "PROTEIN", 53, 61], ["ORF3 antigens", "PROTEIN", 149, 162], ["IgG", "PROTEIN", 171, 174], ["IgM", "PROTEIN", 179, 182], ["an IgM specificity", "TEST", 11, 29], ["optimal test performance", "TEST", 66, 90], ["all ORF3 antigens", "TEST", 145, 162], ["both IgG", "TEST", 166, 174], ["IgM detection", "TEST", 179, 192], ["IgM", "OBSERVATION_MODIFIER", 14, 17]]], ["Among ORF3 proteins best values in IgG detection were accomplished by O3GT3.", [["O3GT3", "CHEMICAL", 70, 75], ["ORF3", "GENE_OR_GENE_PRODUCT", 6, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["O3GT3", "SIMPLE_CHEMICAL", 70, 75], ["ORF3 proteins", "PROTEIN", 6, 19], ["IgG", "PROTEIN", 35, 38], ["O3GT3", "PROTEIN", 70, 75], ["ORF3 proteins", "TEST", 6, 19], ["IgG detection", "TEST", 35, 48]]], ["Only O3C showed with 95.0% a higher specificity value than O3GT1.", [["O3C", "SIMPLE_CHEMICAL", 5, 8], ["O3C", "PROTEIN", 5, 8], ["O3C", "TEST", 5, 8]]], ["In IgM detection O3GT3 scored highest in specificity, sensitivity and AUC among ORF3 antigens.Combination of antigens for optimal test performanceGenotype-specific reactivity of O2NGT1/3 and O2CGT1/3 antigens (Table 4) To assess the potential of homologous genotype 1 and 3 antigens from ORF2 and 3 to discriminate between sera from different genotypes the quotient of measured signal intensities was calculated.", [["sera", "ANATOMY", 323, 327], ["IgM", "GENE_OR_GENE_PRODUCT", 3, 6], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 80, 93], ["O2NGT1/3", "GENE_OR_GENE_PRODUCT", 178, 186], ["O2CGT1/3 antigens", "GENE_OR_GENE_PRODUCT", 191, 208], ["ORF2", "GENE_OR_GENE_PRODUCT", 288, 292], ["sera", "ORGANISM_SUBSTANCE", 323, 327], ["IgM", "PROTEIN", 3, 6], ["O3GT3", "DNA", 17, 22], ["ORF3 antigens", "PROTEIN", 80, 93], ["antigens", "PROTEIN", 109, 117], ["O2NGT1", "PROTEIN", 178, 184], ["O2CGT1", "PROTEIN", 191, 197], ["homologous genotype 1 and 3 antigens", "PROTEIN", 246, 282], ["ORF2", "DNA", 288, 292], ["IgM detection O3GT3", "TEST", 3, 22], ["specificity", "TEST", 41, 52], ["sensitivity", "TEST", 54, 65], ["AUC", "TEST", 70, 73], ["ORF3 antigens", "TEST", 80, 93], ["optimal test performance", "TEST", 122, 146], ["Genotype", "TEST", 146, 154], ["O2NGT1", "TEST", 178, 184], ["O2CGT1", "TEST", 191, 197], ["homologous genotype 1", "PROBLEM", 246, 267], ["ORF2", "TEST", 288, 292], ["sera", "TEST", 323, 327]]], ["Higher O2N and O2C IgG-as well as IgM-signal intensities were measured when genotype 1 antigen was incubated with genotype 1 sera (n = 3) and genotype 3 antigen with genotype 3 sera (n = 2).", [["sera", "ANATOMY", 125, 129], ["sera", "ANATOMY", 177, 181], ["O2N", "SIMPLE_CHEMICAL", 7, 10], ["O2C IgG", "GENE_OR_GENE_PRODUCT", 15, 22], ["IgM", "GENE_OR_GENE_PRODUCT", 34, 37], ["sera", "ORGANISM_SUBSTANCE", 125, 129], ["sera", "ORGANISM_SUBSTANCE", 177, 181], ["O2N", "PROTEIN", 7, 10], ["O2C IgG", "PROTEIN", 15, 22], ["IgM", "PROTEIN", 34, 37], ["O2C IgG", "TEST", 15, 22], ["IgM-signal intensities", "TEST", 34, 56], ["genotype 1 antigen", "TEST", 76, 94], ["genotype", "TEST", 114, 122], ["sera", "TEST", 125, 129], ["genotype", "TEST", 142, 150], ["genotype", "TEST", 166, 174]]], ["No such correlation was found for O3 genotype 1 and 3, where reactivity of genotype 1 antigen was always higher than of genotype 3 antigen.", [["O3", "CHEMICAL", 34, 36], ["genotype 1 antigen", "GENE_OR_GENE_PRODUCT", 75, 93], ["genotype 3 antigen", "GENE_OR_GENE_PRODUCT", 120, 138], ["genotype 1 antigen", "PROTEIN", 75, 93], ["genotype 3 antigen", "PROTEIN", 120, 138], ["O3 genotype", "TEST", 34, 45], ["genotype 1 antigen", "TEST", 75, 93], ["genotype 3 antigen", "PROBLEM", 120, 138]]], ["When genotype 1 and 3 antigens were incubated with genotype 4 sera (n = 5) the results were inconsistent either between O2N and O2C (3/5) or between IgG and IgM (2/5).DiscussionOver the last years increasing numbers of autochthonous cases, zoonotic spread and chronic infections has led to a better understanding of viral hepatitis E [25] .", [["sera", "ANATOMY", 62, 66], ["chronic infections", "DISEASE", 260, 278], ["hepatitis", "DISEASE", 322, 331], ["sera", "ORGANISM_SUBSTANCE", 62, 66], ["O2N", "SIMPLE_CHEMICAL", 120, 123], ["IgG", "GENE_OR_GENE_PRODUCT", 149, 152], ["IgM", "GENE_OR_GENE_PRODUCT", 157, 160], ["IgG", "PROTEIN", 149, 152], ["IgM", "PROTEIN", 157, 160], ["genotype 4 sera", "TEST", 51, 66], ["IgG", "TEST", 149, 152], ["IgM", "TEST", 157, 160], ["autochthonous cases", "PROBLEM", 219, 238], ["zoonotic spread", "PROBLEM", 240, 255], ["chronic infections", "PROBLEM", 260, 278], ["viral hepatitis E", "PROBLEM", 316, 333], ["zoonotic", "OBSERVATION_MODIFIER", 240, 248], ["spread", "OBSERVATION_MODIFIER", 249, 255], ["chronic", "OBSERVATION_MODIFIER", 260, 267], ["infections", "OBSERVATION", 268, 278]]], ["The prevalence of anti-HEV in Central Europe may reach up to 15% [26] .", [["anti-HEV", "TREATMENT", 18, 26]]], ["It is unclear whether this high prevalence is caused by a high number of undiagnosed cases of subclinical HEV infections or by a high false positive rate of unreliable serologic HEV antibody assays.", [["HEV infections", "DISEASE", 106, 120], ["HEV", "ORGANISM", 106, 109], ["HEV", "SPECIES", 106, 109], ["HEV", "SPECIES", 178, 181], ["subclinical HEV infections", "PROBLEM", 94, 120], ["a high false positive rate of unreliable serologic HEV antibody assays", "PROBLEM", 127, 197], ["subclinical", "OBSERVATION_MODIFIER", 94, 105], ["HEV infections", "OBSERVATION", 106, 120]]], ["Despite the increasing epidemiological and clinical relevance of the HEV and demanding research needs [3] , available serological tests are limited to the detection of antibodies against so-called \"traditional\" antigens ORF2 and ORF3 [1] .", [["HEV", "ORGANISM", 69, 72], ["ORF2", "GENE_OR_GENE_PRODUCT", 220, 224], ["ORF3", "GENE_OR_GENE_PRODUCT", 229, 233], ["antibodies", "PROTEIN", 168, 178], ["ORF2", "DNA", 220, 224], ["ORF3", "DNA", 229, 233], ["HEV", "SPECIES", 69, 72], ["available serological tests", "TEST", 108, 135], ["antibodies", "PROBLEM", 168, 178], ["increasing", "OBSERVATION_MODIFIER", 12, 22]]], ["In this study we describe a novel seroreactivity for ORF1 domains and extensively characterized it for their diagnostic potential in direct comparison to commercial available ORF2 and ORF3 antigens.", [["ORF2", "GENE_OR_GENE_PRODUCT", 175, 179], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 184, 197], ["ORF1 domains", "DNA", 53, 65], ["ORF2", "DNA", 175, 179], ["ORF3 antigens", "PROTEIN", 184, 197], ["this study", "TEST", 3, 13], ["ORF1 domains", "TEST", 53, 65], ["ORF3 antigens", "TEST", 184, 197]]], ["The sequence of the potential ORF1 antigen was determined by the probably most native structure namely defined functional domains.", [["ORF1 antigen", "GENE_OR_GENE_PRODUCT", 30, 42], ["ORF1 antigen", "PROTEIN", 30, 42], ["functional domains", "PROTEIN", 111, 129], ["the potential ORF1 antigen", "TEST", 16, 42], ["functional domains", "OBSERVATION", 111, 129]]], ["Other studies of putative ORF1 epitopes are based on computer analysis of hydrophobicity and secondary structure [18, 20] or overlapping decamers [19] .", [["ORF1", "GENE_OR_GENE_PRODUCT", 26, 30], ["putative ORF1 epitopes", "PROTEIN", 17, 39], ["Other studies", "TEST", 0, 13], ["putative ORF1 epitopes", "TEST", 17, 39], ["computer analysis", "TEST", 53, 70], ["hydrophobicity", "PROBLEM", 74, 88], ["secondary structure", "PROBLEM", 93, 112]]], ["A common disadvantage of these artificially predicted epitopes is the presence of only linear epitopes and therefore conformational antigens might be missed [19] .", [["linear epitopes", "PROTEIN", 87, 102], ["conformational antigens", "PROTEIN", 117, 140], ["linear epitopes", "PROBLEM", 87, 102], ["conformational antigens", "PROBLEM", 117, 140], ["linear", "OBSERVATION_MODIFIER", 87, 93], ["epitopes", "OBSERVATION", 94, 102]]], ["ORF1 epitopes found in earlier studies were within the regions of Met [18, 19] , Plp [19] , V [19] , \u00d7 [18, 19] , Hel [19] , Rdrp [18] [19] [20] .", [["Met", "CHEMICAL", 66, 69], ["V [19]", "SIMPLE_CHEMICAL", 92, 98], ["\u00d7 [18, 19]", "SIMPLE_CHEMICAL", 101, 111], ["Hel [19]", "SIMPLE_CHEMICAL", 114, 122], ["Rdrp [18] [19] [20]", "SIMPLE_CHEMICAL", 125, 144], ["ORF1 epitopes", "PROTEIN", 0, 13], ["ORF1 epitopes", "PROBLEM", 0, 13], ["earlier studies", "TEST", 23, 38], ["Plp", "TEST", 81, 84], ["Hel", "TEST", 114, 117], ["Rdrp", "TEST", 125, 129]]], ["According to Zhao et al. the major antigenic epitopes of HEV are located in the ORF2 and ORF3.", [["HEV", "ORGANISM", 57, 60], ["ORF2", "GENE_OR_GENE_PRODUCT", 80, 84], ["ORF3", "GENE_OR_GENE_PRODUCT", 89, 93], ["ORF2", "DNA", 80, 84], ["ORF3", "DNA", 89, 93], ["HEV", "SPECIES", 57, 60], ["major", "OBSERVATION_MODIFIER", 29, 34], ["antigenic", "OBSERVATION_MODIFIER", 35, 44], ["epitopes", "OBSERVATION", 45, 53], ["HEV", "OBSERVATION", 57, 60]]], ["Four ORF1 antigens were excluded early in the study after initial experiments showed inadequate immunoreactivities of ORF1 antigens [18] .", [["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 5, 18], ["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 118, 131], ["ORF1 antigens", "PROTEIN", 5, 18], ["ORF1 antigens", "PROTEIN", 118, 131], ["Four ORF1 antigens", "TEST", 0, 18], ["the study", "TEST", 42, 51], ["initial experiments", "TEST", 58, 77], ["inadequate immunoreactivities of ORF1 antigens", "PROBLEM", 85, 131]]], ["Kaur et al. used two serum pools to screen for reactive ORF1 polypeptides but did not investigate the diagnostic impact with sensitivity and specificity levels of the distinct ORF1 proteins [19] .", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["ORF1", "GENE_OR_GENE_PRODUCT", 176, 180], ["ORF1 proteins", "PROTEIN", 176, 189], ["two serum pools", "TEST", 17, 32], ["reactive ORF1 polypeptides", "PROBLEM", 47, 73], ["sensitivity", "TEST", 125, 136], ["specificity levels", "TEST", 141, 159], ["the distinct ORF1 proteins", "TEST", 163, 189]]], ["Overall these data revealed that the diagnostic impact of ORF1 antigens is low.", [["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 58, 71], ["ORF1 antigens", "PROTEIN", 58, 71], ["ORF1 antigens", "TEST", 58, 71], ["low", "OBSERVATION_MODIFIER", 75, 78]]], ["Only Qi et al. could show that the inclusion of an Rdrp epitope in a serologic assay increases the test performance for an unknown reason but did not focus on the performance of other ORF1 epitopes [19] .", [["Rdrp", "GENE_OR_GENE_PRODUCT", 51, 55], ["Rdrp epitope", "PROTEIN", 51, 63], ["ORF1 epitopes", "PROTEIN", 184, 197], ["an Rdrp epitope", "PROBLEM", 48, 63], ["a serologic assay", "TEST", 67, 84], ["the test performance", "TEST", 95, 115], ["Rdrp epitope", "OBSERVATION", 51, 63]]], ["In our study we also calculated if the additional presence of an ORF1 antigen could complement ORF2 and ORF3 antigens in a diagnostic test.", [["ORF1 antigen", "GENE_OR_GENE_PRODUCT", 65, 77], ["ORF2", "GENE_OR_GENE_PRODUCT", 95, 99], ["ORF3 antigens", "GENE_OR_GENE_PRODUCT", 104, 117], ["ORF1 antigen", "PROTEIN", 65, 77], ["ORF2", "DNA", 95, 99], ["ORF3 antigens", "PROTEIN", 104, 117], ["our study", "TEST", 3, 12], ["an ORF1 antigen", "TEST", 62, 77], ["ORF3 antigens", "TEST", 104, 117], ["a diagnostic test", "TEST", 121, 138]]], ["It became clear that the two ORF1 antigens included in the diagnostic test according to backwards regression analysis (Y in IgG detection and V in IgM detection) could be exchanged by antigens already used in commercially test without significant change of the diagnostic performance.DiscussionFor the first time we are able to describe immunogenic properties of the Y protein, a protein with homologies to non-structural proteins of the Rubella virus and beet necrotic yellow vein virus [12] .", [["Rubella virus", "DISEASE", 438, 451], ["necrotic", "DISEASE", 461, 469], ["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 29, 42], ["Y protein", "GENE_OR_GENE_PRODUCT", 367, 376], ["Rubella virus", "ORGANISM", 438, 451], ["beet necrotic yellow vein virus", "ORGANISM", 456, 487], ["ORF1 antigens", "PROTEIN", 29, 42], ["IgG", "PROTEIN", 124, 127], ["IgM", "PROTEIN", 147, 150], ["antigens", "PROTEIN", 184, 192], ["Y protein", "PROTEIN", 367, 376], ["non-structural proteins", "PROTEIN", 407, 430], ["Rubella virus", "SPECIES", 438, 451], ["yellow vein virus", "SPECIES", 470, 487], ["Rubella virus", "SPECIES", 438, 451], ["beet necrotic yellow vein virus", "SPECIES", 456, 487], ["the two ORF1 antigens", "TEST", 21, 42], ["the diagnostic test", "TEST", 55, 74], ["backwards regression analysis", "TEST", 88, 117], ["Y in IgG detection", "TEST", 119, 137], ["IgM detection", "TEST", 147, 160], ["the Rubella virus", "PROBLEM", 434, 451], ["beet necrotic yellow vein virus", "PROBLEM", 456, 487], ["Rubella virus", "OBSERVATION", 438, 451], ["necrotic", "OBSERVATION_MODIFIER", 461, 469], ["yellow vein", "ANATOMY", 470, 481]]], ["This finding is in line with results from all other ORF1 regions and completes the list now consisting of all ORF1 domains exhibiting a moderate immunogenicity.", [["ORF1 regions", "DNA", 52, 64], ["ORF1 domains", "DNA", 110, 122], ["all ORF1 domains", "PROBLEM", 106, 122], ["a moderate immunogenicity", "PROBLEM", 134, 159], ["moderate", "OBSERVATION_MODIFIER", 136, 144], ["immunogenicity", "OBSERVATION", 145, 159]]], ["This is easily explained by the fact that all parts of the ORF1 polyprotein are expressed in the same amount in the cytoplasm of infected cells, processed and presented to the immune system equally.", [["cytoplasm", "ANATOMY", 116, 125], ["cells", "ANATOMY", 138, 143], ["immune system", "ANATOMY", 176, 189], ["ORF1", "GENE_OR_GENE_PRODUCT", 59, 63], ["cytoplasm", "ORGANISM_SUBSTANCE", 116, 125], ["cells", "CELL", 138, 143], ["ORF1 polyprotein", "DNA", 59, 75], ["infected cells", "CELL_TYPE", 129, 143], ["the ORF1 polyprotein", "TREATMENT", 55, 75], ["infected cells", "PROBLEM", 129, 143], ["amount", "OBSERVATION_MODIFIER", 102, 108], ["infected cells", "OBSERVATION", 129, 143]]], ["Nevertheless, Y shows in our study the highest IgG and IgM sensitivities among all investigated ORF1 domains.DiscussionWithin the X domain we measured higher sensitivities and specificities compared to a peptide from this region detected by Zhao et al. [19] who investigated its seroreactivity exclusively in swine.", [["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["IgM", "GENE_OR_GENE_PRODUCT", 55, 58], ["swine", "ORGANISM", 309, 314], ["IgG", "PROTEIN", 47, 50], ["IgM", "PROTEIN", 55, 58], ["ORF1 domains", "DNA", 96, 108], ["X domain", "DNA", 130, 138], ["swine", "SPECIES", 309, 314], ["swine", "SPECIES", 309, 314], ["our study", "TEST", 25, 34], ["the highest IgG", "TEST", 35, 50], ["IgM sensitivities", "TEST", 55, 72], ["higher sensitivities and specificities", "PROBLEM", 151, 189]]], ["In our study values from the X-protein in human HEV diagnostics even showed a better performance than commercial O2MGT1 in detection of IgG and IgM.", [["X-protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["human", "ORGANISM", 42, 47], ["HEV", "ORGANISM", 48, 51], ["O2MGT1", "SIMPLE_CHEMICAL", 113, 119], ["IgG", "GENE_OR_GENE_PRODUCT", 136, 139], ["O2MGT1", "PROTEIN", 113, 119], ["IgG", "PROTEIN", 136, 139], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["HEV", "SPECIES", 48, 51], ["our study values", "TEST", 3, 19], ["the X-protein in human HEV diagnostics", "TEST", 25, 63], ["IgG", "TEST", 136, 139]]], ["Interestingly, it was shown, that X-protein impacts viral pathogenicity of a murine Corona Virus (MHV A59) [27, 28] .DiscussionIn contrast to the predictions of Zhao et al. [18] and Kaur et al. [19] we could not show any antigenic properties within the methyltransferase domain.", [["X-protein", "GENE_OR_GENE_PRODUCT", 34, 43], ["murine", "ORGANISM", 77, 83], ["Corona Virus", "ORGANISM", 84, 96], ["MHV A59", "ORGANISM", 98, 105], ["methyltransferase domain", "PROTEIN", 253, 277], ["murine", "SPECIES", 77, 83], ["Corona Virus (MHV A59", "SPECIES", 84, 105], ["a murine Corona Virus", "PROBLEM", 75, 96]]], ["Nevertheless, this does not necessarily exclude the possibility of a diagnostic value of ORF1 antigens under different conditions like for example investigations in endemic regions with a larger patient population.", [["ORF1 antigens", "GENE_OR_GENE_PRODUCT", 89, 102], ["patient", "ORGANISM", 195, 202], ["ORF1 antigens", "PROTEIN", 89, 102], ["patient", "SPECIES", 195, 202], ["ORF1 antigens", "PROBLEM", 89, 102], ["example investigations", "TEST", 139, 161], ["a larger patient population", "TREATMENT", 186, 213], ["larger", "OBSERVATION_MODIFIER", 188, 194]]], ["By changing the methodical approach of protein expression, further studies should investigate the seroreactivity of the remaining ORF1 domains not expressed in this study as for example the polymerase domain, which comprises several linear epitopes.DiscussionLogistic regression as well as ROC analysis confirmed that the ORF2 C-terminus has the highest diagnostic potential of all until now investigated HEV antigens.", [["HEV", "ORGANISM", 405, 408], ["ORF1 domains", "DNA", 130, 142], ["polymerase domain", "PROTEIN", 190, 207], ["linear epitopes", "PROTEIN", 233, 248], ["ORF2 C-terminus", "DNA", 322, 337], ["HEV antigens", "PROTEIN", 405, 417], ["HEV", "SPECIES", 405, 408], ["protein expression", "TREATMENT", 39, 57], ["further studies", "TEST", 59, 74], ["the seroreactivity of the remaining ORF1 domains", "PROBLEM", 94, 142], ["this study", "TEST", 160, 170], ["the polymerase domain", "PROBLEM", 186, 207], ["several linear epitopes", "PROBLEM", 225, 248], ["DiscussionLogistic regression", "PROBLEM", 249, 278], ["ROC analysis", "TEST", 290, 302], ["the ORF2 C-terminus", "PROBLEM", 318, 337], ["several", "OBSERVATION_MODIFIER", 225, 232], ["linear", "OBSERVATION_MODIFIER", 233, 239], ["epitopes", "OBSERVATION", 240, 248]]], ["It is well known that immunogenicity of ORF3 is also determined by the C-terminus [29] .", [["ORF3", "GENE_OR_GENE_PRODUCT", 40, 44], ["ORF3", "DNA", 40, 44], ["immunogenicity of ORF3", "PROBLEM", 22, 44]]], ["Our data confirm that the N-terminus of ORF3 is not suitable for detection of IgG and IgM antibodies.", [["ORF3", "GENE_OR_GENE_PRODUCT", 40, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 78, 81], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 86, 100], ["N-terminus", "PROTEIN", 26, 36], ["ORF3", "DNA", 40, 44], ["IgG", "PROTEIN", 78, 81], ["IgM antibodies", "PROTEIN", 86, 100], ["Our data", "TEST", 0, 8], ["the N-terminus of ORF3", "TEST", 22, 44], ["IgG", "TEST", 78, 81], ["IgM antibodies", "PROBLEM", 86, 100]]], ["In contrast the reactivity of the C-terminus correlates very well with the full length ORF3 protein and showed an even better AUC in ROC analysis.", [["C", "CHEMICAL", 34, 35], ["ORF3", "GENE_OR_GENE_PRODUCT", 87, 91], ["C-terminus", "PROTEIN", 34, 44], ["ORF3 protein", "PROTEIN", 87, 99], ["the full length ORF3 protein", "TEST", 71, 99], ["ROC analysis", "TEST", 133, 145]]], ["A differentiated view on N-and Cterminal parts of ORF3 seems to play an important role not only in serologic diagnostics but also in the newly postulated involvement of ORF3 in viral egress [17, 27, 30] .", [["ORF3", "GENE_OR_GENE_PRODUCT", 50, 54], ["ORF3", "GENE_OR_GENE_PRODUCT", 169, 173], ["N-and Cterminal parts", "DNA", 25, 46], ["ORF3", "DNA", 50, 54], ["ORF3", "DNA", 169, 173], ["A differentiated view", "TEST", 0, 21], ["serologic diagnostics", "TEST", 99, 120], ["viral egress", "OBSERVATION", 177, 189]]], ["For ORF3 the prediction of a transmembrane domain was included in our study to optimize mimicry of naturally occurring antigen conformations and probably explains the predominant seroreactivity of the Cterminal subdomain.", [["transmembrane", "ANATOMY", 29, 42], ["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3", "DNA", 4, 8], ["transmembrane domain", "PROTEIN", 29, 49], ["Cterminal subdomain", "PROTEIN", 201, 220], ["a transmembrane domain", "TEST", 27, 49], ["our study", "TEST", 66, 75], ["naturally occurring antigen conformations", "PROBLEM", 99, 140], ["the predominant seroreactivity of the Cterminal subdomain", "PROBLEM", 163, 220], ["predominant", "OBSERVATION_MODIFIER", 167, 178], ["seroreactivity", "OBSERVATION", 179, 193], ["Cterminal subdomain", "ANATOMY", 201, 220]]], ["Of course this hypothetic secondary structure needs to be confirmed in additional molecular studies.", [["additional molecular studies", "TEST", 71, 99], ["secondary structure", "OBSERVATION", 26, 45]]], ["In general the finding of different seroreactivities of morphologic ORF3 subdomains supports the approach to investigate functional ORF1 subdomains separately.DiscussionIn this study we followed our method for serum profiling experiments [26] achieving an even higher expression level of 60% and a purification efficiency of 100%.", [["serum", "ANATOMY", 210, 215], ["ORF3", "GENE_OR_GENE_PRODUCT", 68, 72], ["ORF1", "GENE_OR_GENE_PRODUCT", 132, 136], ["serum", "ORGANISM_SUBSTANCE", 210, 215], ["morphologic ORF3 subdomains", "PROTEIN", 56, 83], ["ORF1 subdomains", "DNA", 132, 147], ["different seroreactivities of morphologic ORF3 subdomains", "PROBLEM", 26, 83], ["this study", "TEST", 172, 182], ["serum profiling experiments", "TEST", 210, 237], ["a purification efficiency", "TEST", 296, 321]]], ["As HEV genome size is restricted to about 7,200 nt the complete sequence could be synthesized in vitro thus avoiding the necessity of handling infectious virions during test development and pre-selection of specific viral antigens.", [["HEV", "ORGANISM", 3, 6], ["7,200 nt", "DNA", 42, 50], ["viral antigens", "PROTEIN", 216, 230], ["HEV", "SPECIES", 3, 6], ["handling infectious virions", "PROBLEM", 134, 161], ["test development", "TEST", 169, 185], ["specific viral antigens", "PROBLEM", 207, 230], ["size", "OBSERVATION_MODIFIER", 14, 18], ["infectious", "OBSERVATION", 143, 153]]], ["In addition the recomDOT system applied in this study represents a different and independent assayformat as compared to the already commercially available LIA and ELISA, where the \"Mikrogen antigens\" are already in use.DiscussionOur statistical analysis of genotype 1 ORF2 (O2C vs. O2CGT1) and ORF3 (O3 vs. O3GT1) seroreactivities (IgG and IgM) showed, that respective proteins reacted in the same way with patient serum unrelated to the production method.", [["serum", "ANATOMY", 415, 420], ["Mikrogen antigens", "GENE_OR_GENE_PRODUCT", 181, 198], ["ORF3", "GENE_OR_GENE_PRODUCT", 294, 298], ["IgG", "GENE_OR_GENE_PRODUCT", 332, 335], ["IgM", "GENE_OR_GENE_PRODUCT", 340, 343], ["patient", "ORGANISM", 407, 414], ["serum", "ORGANISM_SUBSTANCE", 415, 420], ["Mikrogen antigens", "PROTEIN", 181, 198], ["genotype 1 ORF2", "DNA", 257, 272], ["O2C", "DNA", 274, 277], ["O2CGT1", "DNA", 282, 288], ["ORF3", "DNA", 294, 298], ["O3", "DNA", 300, 302], ["O3GT1", "DNA", 307, 312], ["IgG", "PROTEIN", 332, 335], ["IgM", "PROTEIN", 340, 343], ["patient", "SPECIES", 407, 414], ["the recomDOT system", "TREATMENT", 12, 31], ["this study", "TEST", 43, 53], ["ELISA", "TEST", 163, 168], ["genotype 1 ORF2", "TREATMENT", 257, 272], ["ORF3 (O3 vs. O3GT1)", "TEST", 294, 313], ["seroreactivities", "TEST", 314, 330], ["IgG", "TEST", 332, 335], ["IgM", "TEST", 340, 343], ["respective proteins", "PROBLEM", 358, 377], ["patient serum", "TEST", 407, 420], ["the production method", "TREATMENT", 434, 455]]], ["Correlation coefficients were more than 0.9 between homologous proteins and specificity as well as sensitivity levels appeared to be almost equal.", [["Correlation coefficients", "TEST", 0, 24], ["homologous proteins", "TEST", 52, 71], ["specificity", "TEST", 76, 87], ["sensitivity levels", "TEST", 99, 117]]], ["Therefore the described pipeline was proven to be an adequate method to produce proteins of proper quality and characteristics for serum profiling experiments.", [["serum", "ANATOMY", 131, 136], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["serum profiling experiments", "TEST", 131, 158]]], ["Furthermore results indicate, that existing commercial HEV assays seem to measure HEV prevalence properly [26] .DiscussionGermany is a country of low HEV endemicity.", [["HEV", "ORGANISM", 55, 58], ["HEV", "ORGANISM", 82, 85], ["HEV", "ORGANISM", 150, 153], ["HEV", "SPECIES", 55, 58], ["HEV", "SPECIES", 82, 85], ["commercial HEV assays", "TEST", 44, 65], ["low HEV endemicity", "PROBLEM", 146, 164]]], ["Studies could show that genotype 1 infections are commonly associated with traveling in endemic countries and autochthonous genotype 3 infections probably acquired from domestic livestock [31] .", [["infections", "DISEASE", 35, 45], ["infections", "DISEASE", 135, 145], ["Studies", "TEST", 0, 7], ["genotype 1 infections", "PROBLEM", 24, 45], ["autochthonous genotype 3 infections", "PROBLEM", 110, 145], ["infections", "OBSERVATION", 35, 45]]], ["As PCR results frequently remain negative and thus no sequence data are obtained genotype during HEV infections often remains unclear.", [["HEV infections", "DISEASE", 97, 111], ["HEV", "ORGANISM", 97, 100], ["HEV", "SPECIES", 97, 100], ["PCR", "TEST", 3, 6], ["sequence data", "TEST", 54, 67], ["genotype during HEV infections", "PROBLEM", 81, 111], ["infections", "OBSERVATION", 101, 111]]], ["\"Serologic genotyping\" would easily allow to answer epidemiologic questions when the source of infections is unknown or to estimate the potentially genotype dependent outcome of HEV infections during pregnancy [7] .", [["infections", "DISEASE", 95, 105], ["HEV infections", "DISEASE", 178, 192], ["HEV", "ORGANISM", 178, 181], ["HEV", "SPECIES", 178, 181], ["Serologic genotyping", "TEST", 1, 21], ["infections", "PROBLEM", 95, 105], ["HEV infections", "PROBLEM", 178, 192], ["infections", "OBSERVATION", 182, 192]]], ["Comparison of measured signal intensities of genotype 1 and genotype 3 antigens with defined patient sera indicate that there might be a genotype specific reactivity of ORF2 antigens.", [["sera", "ANATOMY", 101, 105], ["patient", "ORGANISM", 93, 100], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["ORF2 antigens", "GENE_OR_GENE_PRODUCT", 169, 182], ["ORF2 antigens", "PROTEIN", 169, 182], ["patient", "SPECIES", 93, 100], ["genotype", "TEST", 45, 53], ["patient sera", "TEST", 93, 105], ["a genotype specific reactivity of ORF2 antigens", "PROBLEM", 135, 182]]], ["Further studies with a larger population need to be performed to confirm this finding.", [["Further studies", "TEST", 0, 15], ["a larger population", "PROBLEM", 21, 40]]], ["Eventually specific sequences of ORF1 also hold the potential for \"serologic genotyping\" and therefore should be investigated addressing this question.ConclusionsThis study used epitopes defined by functional domains of all three ORFs and was able to identify novel seroreactive epitopes in each of the three ORFs.", [["ORF1", "GENE_OR_GENE_PRODUCT", 33, 37], ["ORF1", "DNA", 33, 37], ["epitopes", "PROTEIN", 178, 186], ["ORFs", "DNA", 230, 234], ["seroreactive epitopes", "PROTEIN", 266, 287], ["ORFs", "DNA", 309, 313], ["ORF1", "TREATMENT", 33, 37], ["serologic genotyping", "TEST", 67, 87], ["This study", "TEST", 162, 172], ["novel seroreactive epitopes", "PROBLEM", 260, 287]]], ["Analysis could show that the diagnostic value of identified ORF1 epitopes is not high enough to improve the overall quality of existing test systems.", [["ORF1", "GENE_OR_GENE_PRODUCT", 60, 64], ["ORF1 epitopes", "PROTEIN", 60, 73], ["Analysis", "TEST", 0, 8], ["ORF1 epitopes", "PROBLEM", 60, 73]]], ["The most potent HEV antigen of the independent systematic screen was found to be the same epitope as the in literature and commercial tests well established C-terminal ORF2 protein.", [["HEV", "ORGANISM", 16, 19], ["C-terminal ORF2", "GENE_OR_GENE_PRODUCT", 157, 172], ["HEV antigen", "PROTEIN", 16, 27], ["C-terminal ORF2 protein", "PROTEIN", 157, 180], ["HEV", "SPECIES", 16, 19], ["the independent systematic screen", "TEST", 31, 64], ["commercial tests", "TEST", 123, 139], ["-terminal ORF2 protein", "TEST", 158, 180], ["most potent", "OBSERVATION_MODIFIER", 4, 15]]], ["Additionally ORF3 C-terminus is able to compete with antigens used in a commercial test.", [["ORF3 C-terminus", "GENE_OR_GENE_PRODUCT", 13, 28], ["ORF3 C-terminus", "PROTEIN", 13, 28], ["antigens", "PROTEIN", 53, 61], ["ORF3 C-terminus", "PROBLEM", 13, 28], ["a commercial test", "TEST", 70, 87]]], ["Summarizing all results obtained from our experiments we conclude that existing commercial HEV assays seem to measure HEV prevalence properly which is based on the high correlation of seroreactivities of homologous antigens.", [["HEV", "ORGANISM", 91, 94], ["HEV", "ORGANISM", 118, 121], ["homologous antigens", "PROTEIN", 204, 223], ["HEV", "SPECIES", 91, 94], ["HEV", "SPECIES", 118, 121], ["commercial HEV assays", "TEST", 80, 101], ["seroreactivities of homologous antigens", "PROBLEM", 184, 223]]], ["Furthermore we remark that our systematic approach for serum profiling experiments can be used to screen the majority of a complete HEV library for novel antigens.", [["serum", "ANATOMY", 55, 60], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["HEV", "ORGANISM", 132, 135], ["novel antigens", "PROTEIN", 148, 162], ["HEV", "SPECIES", 132, 135], ["serum profiling experiments", "TEST", 55, 82]]], ["Finally different antigen genotypes could possibly be used to serologically differentiate between genotype 1 and genotype 3 infections and therefore serve as a useful tool to obtain insight into etiological and epidemiological questions of HEV disease.", [["infections", "DISEASE", 124, 134], ["HEV disease", "DISEASE", 240, 251], ["HEV", "ORGANISM", 240, 243], ["HEV", "SPECIES", 240, 243], ["different antigen genotypes", "PROBLEM", 8, 35], ["genotype 1", "PROBLEM", 98, 108], ["genotype 3 infections", "PROBLEM", 113, 134], ["HEV disease", "PROBLEM", 240, 251], ["HEV disease", "OBSERVATION", 240, 251]]], ["AO performed subcloning of vectors, sequence analysis, establishment and optimization of expression and purification protocols, microarray experiments and statistical analysis as well as writing the manuscript.", [["subcloning of vectors", "TREATMENT", 13, 34], ["sequence analysis", "TEST", 36, 53], ["purification protocols", "TREATMENT", 104, 126], ["microarray experiments", "TEST", 128, 150], ["statistical analysis", "TEST", 155, 175]]], ["MGVP optimized expression and purification protocols and participated in drafting the manuscript.", [["MGVP", "SIMPLE_CHEMICAL", 0, 4], ["purification protocols", "TREATMENT", 30, 52]]], ["RH participated in designing strategies and methods for vector cloning.", [["vector cloning", "TREATMENT", 56, 70]]], ["HN conceived of the study, coordinated the cooperation of both partner institutions and performed PCR analysis and sequencing.", [["the study", "TEST", 16, 25], ["PCR analysis", "TEST", 98, 110], ["sequencing", "TEST", 115, 125]]], ["SJ designed and performed microarray experiments, carried out data processing and helped to draft the manuscript.", [["microarray experiments", "TEST", 26, 48]]], ["MS coordinated and optimized microarray analysis.", [["optimized microarray analysis", "TEST", 19, 48]]], ["MM provided basic protocols for microarray analysis and critically revised the manuscript.", [["basic protocols", "TREATMENT", 12, 27], ["microarray analysis", "TEST", 32, 51]]], ["UM coordinated the cooperation of both partner institutions, designed the study, collected and pre-characterized patient sera, helped with microarray optimization and data interpretation as well as drafting the manuscript.", [["sera", "ANATOMY", 121, 125], ["patient", "ORGANISM", 113, 120], ["sera", "ORGANISM_SUBSTANCE", 121, 125], ["patient", "SPECIES", 113, 120], ["the study", "TEST", 70, 79], ["microarray optimization", "TEST", 139, 162], ["data interpretation", "TEST", 167, 186]]], ["AB conceived of the study, designed bacterial expression vectors and coordinated the cooperation of both partner institutions.", [["the study", "TEST", 16, 25], ["bacterial expression vectors", "TREATMENT", 36, 64]]], ["MM is general director of Mikrogen GmbH.", [["MM", "DISEASE", 0, 2], ["MM", "CANCER", 0, 2]]]], "PMC1831551": [["IntroductionAcute undifferentiated diarrhoea in young calves (neonatal calf diarrhoea) is a daily occurrence all over the world, and rotavirus, Cryptosporidium parvum and coronavirus are major aetiological agents.IntroductionIn the European Union, veterinary homeopathy is in common use in field practice, including for calf diarrhoea, and in some countries is increasing in popularity.", [["undifferentiated diarrhoea", "DISEASE", 18, 44], ["neonatal calf diarrhoea", "DISEASE", 62, 85], ["Cryptosporidium parvum", "DISEASE", 144, 166], ["coronavirus", "DISEASE", 171, 182], ["diarrhoea", "DISEASE", 325, 334], ["calves", "ORGANISM", 54, 60], ["calf", "ORGANISM_SUBDIVISION", 71, 75], ["rotavirus", "ORGANISM", 133, 142], ["Cryptosporidium parvum", "ORGANISM", 144, 166], ["coronavirus", "ORGANISM", 171, 182], ["calf", "ORGANISM_SUBDIVISION", 320, 324], ["calves", "SPECIES", 54, 60], ["calf", "SPECIES", 71, 75], ["Cryptosporidium parvum", "SPECIES", 144, 166], ["calf", "SPECIES", 320, 324], ["rotavirus", "SPECIES", 133, 142], ["Cryptosporidium parvum", "SPECIES", 144, 166], ["IntroductionAcute undifferentiated diarrhoea in young calves (neonatal calf diarrhoea", "PROBLEM", 0, 85], ["rotavirus", "PROBLEM", 133, 142], ["Cryptosporidium parvum", "PROBLEM", 144, 166], ["coronavirus", "PROBLEM", 171, 182], ["calf diarrhoea", "PROBLEM", 320, 334], ["undifferentiated", "OBSERVATION_MODIFIER", 18, 34], ["diarrhoea", "OBSERVATION", 35, 44], ["calf", "ANATOMY", 71, 75], ["veterinary homeopathy", "OBSERVATION", 248, 269], ["calf", "ANATOMY", 320, 324], ["diarrhoea", "OBSERVATION", 325, 334], ["increasing", "OBSERVATION_MODIFIER", 361, 371]]], ["Homeopathy may be defined as the treatment of animals that have signs of disease with a diluted and specially prepared substance that, in sufficient quantity in a healthy animal, would cause the same clinical signs.", [["Homeopathy", "DISEASE", 0, 10], ["animals", "ORGANISM", 46, 53], ["Homeopathy", "PROBLEM", 0, 10], ["disease", "PROBLEM", 73, 80]]], ["The existing literature on the subject comprises studies on various diseases and, although it is claimed that experimental and clinical evidence supports the use of homeopathy in some situations (see, for example [11]), more than 200 years in practice have not rendered convincing proof of its efficacy.IntroductionIn cattle, there is limited literature on the use of homeopathy.", [["cattle", "ORGANISM", 318, 324], ["cattle", "SPECIES", 318, 324], ["cattle", "SPECIES", 318, 324], ["various diseases", "PROBLEM", 60, 76], ["homeopathy", "PROBLEM", 368, 378], ["diseases", "OBSERVATION", 68, 76], ["homeopathy", "OBSERVATION", 368, 378]]], ["The study design in the trials is a matter of debate, e.g. in the reviews of clinical trials on homeopathic treatment of mastitis by [3] and [9].", [["mastitis", "DISEASE", 121, 129], ["[9]", "SIMPLE_CHEMICAL", 141, 144], ["The study", "TEST", 0, 9], ["clinical trials", "TREATMENT", 77, 92], ["homeopathic treatment", "TREATMENT", 96, 117], ["mastitis", "PROBLEM", 121, 129], ["mastitis", "OBSERVATION", 121, 129]]], ["Clinical trials on calves have been reported, e.g. by [8], who found no discernible differences between the treated and control groups in their manifestation of resistance to bovine lungworm or their clinical responses to the disease produced, by [10], who found no effect on calf health after homeopathic treatment of their dams with periparturient diseases, and by [4], who claimed effect on calf diarrhoea by Arsenicum album C30, although the results were not statistically valid.", [["lungworm", "ANATOMY", 182, 190], ["periparturient diseases", "DISEASE", 335, 358], ["diarrhoea", "DISEASE", 399, 408], ["calves", "ORGANISM", 19, 25], ["bovine", "ORGANISM", 175, 181], ["lungworm", "CANCER", 182, 190], ["calf", "ORGANISM_SUBDIVISION", 276, 280], ["dams", "ORGANISM", 325, 329], ["calf", "ORGANISM_SUBDIVISION", 394, 398], ["calves", "SPECIES", 19, 25], ["bovine", "SPECIES", 175, 181], ["calf", "SPECIES", 276, 280], ["calf", "SPECIES", 394, 398], ["bovine", "SPECIES", 175, 181], ["bovine lungworm", "PROBLEM", 175, 190], ["homeopathic treatment", "TREATMENT", 294, 315], ["periparturient diseases", "PROBLEM", 335, 358], ["calf diarrhoea", "PROBLEM", 394, 408], ["Arsenicum album C30", "TEST", 412, 431], ["calf", "ANATOMY", 394, 398]]], ["To make interpretation of results possible, trials need to be double-blind and placebo-controlled, and the use of relevant statistical analyses should be made.", [["blind", "PROBLEM", 69, 74]]], ["Currently it is difficult to assess the efficacy of homeopathy from the present literature [6], and therefore scientific evaluation of the effect of homeopathic treatment is required as a matter of urgency.IntroductionThe aim of the present study was to evaluate the effect of the homeopathic remedy Podophyllum on the duration and clinical course of neonatal calf diarrhoea.Materials and methodsThe trial was performed during 1999 and 2000 in 12 dairy herds using a randomised double-blind, placebo-controlled study design.", [["Podophyllum", "CHEMICAL", 300, 311], ["calf diarrhoea", "DISEASE", 360, 374], ["calf", "ORGANISM_SUBDIVISION", 360, 364], ["calf", "SPECIES", 360, 364], ["homeopathy", "PROBLEM", 52, 62], ["scientific evaluation", "TEST", 110, 131], ["homeopathic treatment", "TREATMENT", 149, 170], ["urgency", "PROBLEM", 198, 205], ["the present study", "TEST", 229, 246], ["the homeopathic remedy Podophyllum", "TREATMENT", 277, 311], ["neonatal calf diarrhoea", "PROBLEM", 351, 374], ["a randomised double-blind", "TREATMENT", 465, 490], ["placebo", "TREATMENT", 492, 499], ["calf", "ANATOMY", 360, 364], ["diarrhoea", "OBSERVATION", 365, 374]]], ["All of the herds were tested free from bovine viral diarrhoea virus (BVDV) in accordance with the Swedish voluntary control programme [5], and no Salmonella spp. had been detected.", [["bovine viral diarrhoea", "DISEASE", 39, 61], ["herds", "ORGANISM", 11, 16], ["bovine viral diarrhoea virus", "ORGANISM", 39, 67], ["BVDV", "ORGANISM", 69, 73], ["Salmonella spp", "ORGANISM", 146, 160], ["bovine viral diarrhoea virus", "SPECIES", 39, 67], ["bovine viral diarrhoea virus", "SPECIES", 39, 67], ["BVDV", "SPECIES", 69, 73], ["bovine viral diarrhoea virus", "PROBLEM", 39, 67], ["Salmonella spp", "PROBLEM", 146, 160]]], ["In total, 48 calves that contracted neonatal diarrhoea spontaneously were included in the trial; however, 4 calves were excluded from the analyses (missing data n = 1, concurrent therapy n = 3).", [["diarrhoea", "DISEASE", 45, 54], ["calves", "ORGANISM", 13, 19], ["calves", "ORGANISM", 108, 114], ["calves", "SPECIES", 13, 19], ["calves", "SPECIES", 108, 114], ["neonatal diarrhoea", "PROBLEM", 36, 54], ["the analyses", "TEST", 134, 146], ["concurrent therapy n", "TREATMENT", 168, 188]]], ["All calves were housed in single pens.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["All calves", "TREATMENT", 0, 10], ["calves", "ANATOMY", 4, 10]]], ["The calves were given a homeopathic preparation or placebo.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["a homeopathic preparation", "TREATMENT", 22, 47], ["placebo", "TREATMENT", 51, 58], ["calves", "ANATOMY", 4, 10]]], ["Antibiotic treatment was considered not relevant to include [1].Materials and methodsThe homeopathically prepared remedy Podophyllum (D30) and the placebo were obtained from DCG Farmaceutiska AB, G\u00f6teborg, Sweden.", [["Podophyllum", "CHEMICAL", 121, 132], ["D30", "CHEMICAL", 134, 137], ["Antibiotic treatment", "TREATMENT", 0, 20], ["The homeopathically prepared remedy Podophyllum (D30)", "TREATMENT", 85, 138], ["the placebo", "TREATMENT", 143, 154]]], ["Each of the farms received packages with randomised dosages of Podophyllum and the placebo in coded bottles.", [["Podophyllum", "CHEMICAL", 63, 74], ["Podophyllum", "SIMPLE_CHEMICAL", 63, 74], ["packages", "TREATMENT", 27, 35], ["randomised dosages", "TREATMENT", 41, 59], ["Podophyllum", "TREATMENT", 63, 74], ["the placebo in coded bottles", "TREATMENT", 79, 107]]], ["Diarrhoeic calves were treated by the farmers, to whom the contents of the bottles were unknown.Materials and methodsTreatment was initiated at the onset of diarrhoea and given orally for 3 consecutive days.", [["diarrhoea", "DISEASE", 157, 166], ["calves", "ORGANISM", 11, 17], ["calves", "SPECIES", 11, 17], ["Diarrhoeic calves", "PROBLEM", 0, 17], ["Treatment", "TREATMENT", 117, 126], ["diarrhoea", "PROBLEM", 157, 166]]], ["During the course of the illness, calf health (i.e. general condition, body temperature, feed intake and faecal consistency) was monitored, rated on a 0\u20133 scale and recorded daily by the farmers.", [["body", "ANATOMY", 71, 75], ["calf", "ORGANISM_SUBDIVISION", 34, 38], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["faecal", "ORGANISM_SUBDIVISION", 105, 111], ["calf", "SPECIES", 34, 38], ["body temperature", "TEST", 71, 87], ["faecal consistency", "TEST", 105, 123], ["a 0\u20133 scale", "TREATMENT", 149, 160]]], ["Score 0 referred to a clinically healthy calf, whereas score 3 signified severe depression, anorexia, a body temperature >40.5\u00b0C and/or watery faeces.", [["body", "ANATOMY", 104, 108], ["watery faeces", "ANATOMY", 136, 149], ["depression", "DISEASE", 80, 90], ["anorexia", "DISEASE", 92, 100], ["calf", "ORGANISM_SUBDIVISION", 41, 45], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["calf", "SPECIES", 41, 45], ["severe depression", "PROBLEM", 73, 90], ["anorexia", "PROBLEM", 92, 100], ["a body temperature", "TEST", 102, 120], ["watery faeces", "PROBLEM", 136, 149], ["calf", "ANATOMY", 41, 45], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["depression", "OBSERVATION", 80, 90], ["anorexia", "OBSERVATION", 92, 100]]], ["For practical reasons, farmers were not able to monitor dehydration, acidosis and electrolyte imbalance in calves.Materials and methodsOn average calves in the Podophyllum group were 29.0 days old and in the placebo group, 26.3 days.", [["dehydration", "DISEASE", 56, 67], ["acidosis", "DISEASE", 69, 77], ["Podophyllum", "CHEMICAL", 160, 171], ["electrolyte", "SIMPLE_CHEMICAL", 82, 93], ["calves", "ORGANISM", 107, 113], ["calves", "ORGANISM", 146, 152], ["calves", "SPECIES", 107, 113], ["calves", "SPECIES", 146, 152], ["dehydration", "PROBLEM", 56, 67], ["acidosis", "PROBLEM", 69, 77], ["electrolyte imbalance in calves", "PROBLEM", 82, 113], ["acidosis", "OBSERVATION", 69, 77], ["electrolyte imbalance", "OBSERVATION", 82, 103], ["average", "OBSERVATION_MODIFIER", 138, 145], ["calves", "OBSERVATION", 146, 152]]], ["Altogether 46% of the calves in the Podophyllum group and 45% in the placebo group were heifer calves, and the mean age of the dams was 2.5 and 2.4 lactations, respectively.", [["Podophyllum", "CHEMICAL", 36, 47], ["calves", "ORGANISM", 22, 28], ["calves", "ORGANISM", 95, 101], ["dams", "ORGANISM", 127, 131], ["calves", "SPECIES", 22, 28], ["calves", "SPECIES", 95, 101]]], ["The clinical signs on the first day of treatment were equivalent in the 2 groups (mean scores 2.8 and 3.2, respectively).Materials and methodsFaecal samples from each calf were collected daily by the farmers, placed in plastic tubes and transported by mail to the National Veterinary Institute (NVI), Uppsala, Sweden.", [["Faecal samples", "ANATOMY", 142, 156], ["Faecal samples", "CANCER", 142, 156], ["calf", "ORGANISM", 167, 171], ["calf", "SPECIES", 167, 171], ["The clinical signs", "TEST", 0, 18], ["treatment", "TREATMENT", 39, 48], ["mean scores", "TEST", 82, 93], ["methodsFaecal samples", "TEST", 135, 156], ["plastic tubes", "TREATMENT", 219, 232], ["calf", "ANATOMY", 167, 171], ["plastic tubes", "OBSERVATION", 219, 232]]], ["The samples were searched by ELISA for rotavirus (Svensson et al 1983, [7]), Cryptosporidium parvum (Prospect Cryptosporidium microplate assay, Alexon-Trend, Ramsey, MN, USA) and coronavirus (in-house ELISA, NVI).", [["samples", "ANATOMY", 4, 11], ["Cryptosporidium parvum", "DISEASE", 77, 99], ["rotavirus", "ORGANISM", 39, 48], ["Cryptosporidium parvum", "ORGANISM", 77, 99], ["Cryptosporidium parvum", "SPECIES", 77, 99], ["rotavirus", "SPECIES", 39, 48], ["Cryptosporidium parvum", "SPECIES", 77, 99], ["The samples", "TEST", 0, 11], ["ELISA", "TEST", 29, 34], ["rotavirus", "PROBLEM", 39, 48], ["Cryptosporidium parvum", "PROBLEM", 77, 99], ["Prospect Cryptosporidium microplate assay", "TEST", 101, 142], ["Alexon", "TEST", 144, 150], ["coronavirus", "PROBLEM", 179, 190]]], ["Analyses were performed blind.Materials and methodsDuration of diarrhoea was chosen as the primary variable in the analyses.", [["diarrhoea", "DISEASE", 63, 72], ["Analyses", "TEST", 0, 8], ["diarrhoea", "PROBLEM", 63, 72], ["diarrhoea", "OBSERVATION", 63, 72]]], ["The groups were compared using Poisson regression.Materials and methodsThe study design was approved by the Ethics Committee for Animal Experiments, Uppsala, Sweden (C133/98), and the Swedish Board of Agriculture, J\u00f6nk\u00f6ping, Sweden (35\u20134272/98).ResultsNo statistically significant difference between the calves treated with Podophyllum and calves treated with the placebo was demonstrated.ResultsCalves treated with Podophyllum (n = 24) had an average of 3.1 days' duration of diarrhoea (range 1\u20138 days), while calves treated with a placebo (n = 20) had an average of 2.9 days' duration of diarrhoea (range 1\u20137 days).", [["Podophyllum", "CHEMICAL", 324, 335], ["Podophyllum", "CHEMICAL", 416, 427], ["diarrhoea", "DISEASE", 477, 486], ["diarrhoea", "DISEASE", 590, 599], ["calves", "ORGANISM", 304, 310], ["calves", "ORGANISM", 340, 346], ["calves", "ORGANISM", 511, 517], ["calves", "SPECIES", 304, 310], ["calves", "SPECIES", 340, 346], ["calves", "SPECIES", 511, 517], ["The study", "TEST", 71, 80], ["Podophyllum and calves", "TREATMENT", 324, 346], ["the placebo", "TREATMENT", 360, 371], ["Podophyllum (n", "TREATMENT", 416, 430], ["diarrhoea", "PROBLEM", 477, 486], ["a placebo (n", "TREATMENT", 531, 543], ["diarrhoea", "PROBLEM", 590, 599], ["No", "UNCERTAINTY", 252, 254], ["statistically", "OBSERVATION_MODIFIER", 255, 268], ["significant", "OBSERVATION_MODIFIER", 269, 280], ["difference", "OBSERVATION", 281, 291], ["calves", "ANATOMY", 304, 310], ["calves", "ANATOMY", 340, 346]]], ["The confidence interval for the difference between the groups with regard to mean duration was [-0.6; 1.5].", [["mean duration", "TEST", 77, 90]]], ["The percentage of clinical signs in the calves in each group is shown in Fig. 1.", [["calves", "ORGANISM", 40, 46], ["calves", "SPECIES", 40, 46], ["clinical signs in the calves", "PROBLEM", 18, 46], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["calves", "ANATOMY", 40, 46], ["Fig", "OBSERVATION", 73, 76]]], ["No deaths of calves occurred during the study period.ResultsDuring the diarrhoeic period, 9/24 calves treated with Podophyllum and 3/20 treated with a placebo excreted rotavirus in the faeces.", [["faeces", "ANATOMY", 185, 191], ["deaths", "DISEASE", 3, 9], ["Podophyllum", "CHEMICAL", 115, 126], ["rotavirus", "DISEASE", 168, 177], ["calves", "ORGANISM", 13, 19], ["calves", "ORGANISM", 95, 101], ["rotavirus", "ORGANISM", 168, 177], ["faeces", "ORGANISM_SUBDIVISION", 185, 191], ["calves", "SPECIES", 13, 19], ["calves", "SPECIES", 95, 101], ["rotavirus", "SPECIES", 168, 177], ["deaths of calves", "PROBLEM", 3, 19], ["the study", "TEST", 36, 45], ["Podophyllum", "TREATMENT", 115, 126], ["a placebo excreted rotavirus", "TREATMENT", 149, 177], ["deaths", "OBSERVATION", 3, 9], ["calves", "OBSERVATION", 13, 19], ["diarrhoeic period", "OBSERVATION", 71, 88]]], ["On average, rotavirus-excreting calves were 19.5 days old at the onset of diarrhoea.", [["diarrhoea", "DISEASE", 74, 83], ["rotavirus", "ORGANISM", 12, 21], ["calves", "ORGANISM", 32, 38], ["calves", "SPECIES", 32, 38], ["rotavirus", "TREATMENT", 12, 21], ["diarrhoea", "PROBLEM", 74, 83], ["diarrhoea", "OBSERVATION", 74, 83]]], ["Adjusting for rotavirus in the statistical analysis did not alter the results.", [["rotavirus", "SPECIES", 14, 23], ["rotavirus", "TREATMENT", 14, 23]]], ["In samples from 2 calves in total, Cryptosporidium parvum and coronavirus were detected.DiscussionA 50% reduction in the duration of diarrhoea was considered a clinically significant effect but there was no clinically or statistically significant effect of treatment with Podophyllum, as compared with the placebo.", [["samples", "ANATOMY", 3, 10], ["Cryptosporidium parvum", "DISEASE", 35, 57], ["diarrhoea", "DISEASE", 133, 142], ["Podophyllum", "CHEMICAL", 272, 283], ["calves", "ORGANISM", 18, 24], ["Cryptosporidium parvum", "ORGANISM", 35, 57], ["coronavirus", "ORGANISM", 62, 73], ["Podophyllum", "SIMPLE_CHEMICAL", 272, 283], ["calves", "SPECIES", 18, 24], ["Cryptosporidium parvum", "SPECIES", 35, 57], ["coronavirus", "SPECIES", 62, 73], ["Cryptosporidium parvum", "SPECIES", 35, 57], ["Cryptosporidium parvum", "PROBLEM", 35, 57], ["coronavirus", "PROBLEM", 62, 73], ["diarrhoea", "PROBLEM", 133, 142], ["Podophyllum", "TREATMENT", 272, 283], ["the placebo", "TREATMENT", 302, 313], ["Cryptosporidium parvum", "OBSERVATION", 35, 57], ["coronavirus", "OBSERVATION", 62, 73]]], ["The general condition, feed intake and body temperature of the calves were not affected by the treatment.DiscussionIn the light of these results, we do not consider Podophyllum relevant for treatment of neonatal calf diarrhoea.", [["body", "ANATOMY", 39, 43], ["Podophyllum", "CHEMICAL", 165, 176], ["calf diarrhoea", "DISEASE", 212, 226], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["calves", "ORGANISM", 63, 69], ["calf", "ORGANISM_SUBDIVISION", 212, 216], ["calves", "SPECIES", 63, 69], ["calf", "SPECIES", 212, 216], ["the treatment", "TREATMENT", 91, 104], ["Podophyllum", "TREATMENT", 165, 176], ["treatment", "TREATMENT", 190, 199], ["neonatal calf diarrhoea", "PROBLEM", 203, 226], ["calves", "ANATOMY", 63, 69], ["calf", "ANATOMY", 212, 216], ["diarrhoea", "OBSERVATION", 217, 226]]], ["Any medical treatment should have an effect that is visible in practice.", [["Any medical treatment", "TREATMENT", 0, 21]]], ["Neonatal calf diarrhoea therapy should consist of oral rehydration and milk feeding, but preventive measures and good management practices are still fundamental in calf diarrhoea control.", [["oral", "ANATOMY", 50, 54], ["milk", "ANATOMY", 71, 75], ["diarrhoea", "DISEASE", 14, 23], ["diarrhoea", "DISEASE", 169, 178], ["calf", "ORGANISM", 9, 13], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["calf", "ORGANISM_SUBDIVISION", 164, 168], ["calf", "SPECIES", 9, 13], ["calf", "SPECIES", 164, 168], ["Neonatal calf diarrhoea therapy", "TREATMENT", 0, 31], ["oral rehydration", "TREATMENT", 50, 66], ["milk feeding", "TREATMENT", 71, 83], ["preventive measures", "TREATMENT", 89, 108], ["good management practices", "TREATMENT", 113, 138], ["calf diarrhoea control", "PROBLEM", 164, 186], ["calf", "ANATOMY", 9, 13], ["diarrhoea", "OBSERVATION", 14, 23], ["calf", "ANATOMY", 164, 168], ["diarrhoea", "OBSERVATION", 169, 178]]], ["Antibiotics are not an appropriate treatment of choice and should be reserved for treating conditions such as pneumonia.", [["pneumonia", "DISEASE", 110, 119], ["Antibiotics", "TREATMENT", 0, 11], ["an appropriate treatment of choice", "TREATMENT", 20, 54], ["treating conditions", "PROBLEM", 82, 101], ["pneumonia", "PROBLEM", 110, 119], ["pneumonia", "OBSERVATION", 110, 119]]], ["In countries where Salmonella and BVDV are prevalent in cattle herds, special attention must be paid to controlling these infections.DiscussionNeonatal calf diarrhoea may be considered relatively harmless to some farmers, but it is noteworthy that 70.5% of the calves in this study showed additional signs of illness, such as fever, depression and/or inappetence.", [["infections", "DISEASE", 122, 132], ["calf diarrhoea", "DISEASE", 152, 166], ["illness", "DISEASE", 309, 316], ["fever", "DISEASE", 326, 331], ["depression", "DISEASE", 333, 343], ["inappetence", "DISEASE", 351, 362], ["BVDV", "ORGANISM", 34, 38], ["calf", "ORGANISM", 152, 156], ["calves", "ORGANISM", 261, 267], ["BVDV", "SPECIES", 34, 38], ["cattle", "SPECIES", 56, 62], ["calf", "SPECIES", 152, 156], ["calves", "SPECIES", 261, 267], ["Salmonella", "SPECIES", 19, 29], ["BVDV", "SPECIES", 34, 38], ["cattle", "SPECIES", 56, 62], ["Salmonella", "PROBLEM", 19, 29], ["BVDV", "PROBLEM", 34, 38], ["these infections", "PROBLEM", 116, 132], ["Neonatal calf diarrhoea", "PROBLEM", 143, 166], ["this study", "TEST", 271, 281], ["illness", "PROBLEM", 309, 316], ["fever", "PROBLEM", 326, 331], ["depression", "PROBLEM", 333, 343], ["inappetence", "PROBLEM", 351, 362], ["infections", "OBSERVATION", 122, 132], ["calf", "ANATOMY", 152, 156], ["diarrhoea", "OBSERVATION", 157, 166], ["illness", "OBSERVATION", 309, 316]]], ["In 13.6% of the calves, all 3 additional signs were recorded concurrently.", [["calves", "ORGANISM", 16, 22], ["calves", "SPECIES", 16, 22], ["13.6%", "OBSERVATION_MODIFIER", 3, 8], ["calves", "ANATOMY", 16, 22]]], ["Younger calves were more frequently ill than were older calves.", [["calves", "ORGANISM", 8, 14], ["calves", "ORGANISM", 56, 62], ["calves", "SPECIES", 8, 14], ["calves", "SPECIES", 56, 62]]], ["A comparison between calves up to 2 weeks of age and calves older than 6 weeks showed that depression, inappetence and fever were present more frequently in the youngest animals.", [["depression", "DISEASE", 91, 101], ["inappetence", "DISEASE", 103, 114], ["fever", "DISEASE", 119, 124], ["calves", "ORGANISM", 21, 27], ["calves", "ORGANISM", 53, 59], ["calves", "SPECIES", 21, 27], ["calves", "SPECIES", 53, 59], ["depression", "PROBLEM", 91, 101], ["inappetence", "PROBLEM", 103, 114], ["fever", "PROBLEM", 119, 124], ["depression", "OBSERVATION", 91, 101]]], ["Rotavirus infection, which is likely to affect clinical signs, was more commonly diagnosed in younger calves than in the older animals.", [["Rotavirus infection", "DISEASE", 0, 19], ["Rotavirus", "ORGANISM", 0, 9], ["calves", "ORGANISM", 102, 108], ["calves", "SPECIES", 102, 108], ["Rotavirus infection", "PROBLEM", 0, 19], ["infection", "OBSERVATION", 10, 19], ["likely to", "UNCERTAINTY", 30, 39]]], ["The more severe clinical picture seen in young calves seems only to emphazise the importance of careful handling of neonatal calves.DiscussionTo our knowledge, this is the only report of a double-blind, placebo-controlled clinical trial evaluating the effect of homeopathy in neonatal calf diarrhoea.", [["calf diarrhoea", "DISEASE", 285, 299], ["calves", "ORGANISM", 47, 53], ["calves", "ORGANISM", 125, 131], ["calf", "ORGANISM_SUBDIVISION", 285, 289], ["calves", "SPECIES", 47, 53], ["calves", "SPECIES", 125, 131], ["calf", "SPECIES", 285, 289], ["The more severe clinical picture", "PROBLEM", 0, 32], ["a double-blind", "TREATMENT", 187, 201], ["placebo", "TREATMENT", 203, 210], ["homeopathy", "PROBLEM", 262, 272], ["neonatal calf diarrhoea", "PROBLEM", 276, 299], ["more", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["neonatal calves", "ANATOMY", 116, 131], ["calf", "ANATOMY", 285, 289], ["diarrhoea", "OBSERVATION", 290, 299]]], ["In our opinion, studies such as this are invaluable in the evaluation of the clinical effect of homeopathic or any other drugs.", [["studies", "TEST", 16, 23], ["the evaluation", "TEST", 55, 69], ["homeopathic", "TREATMENT", 96, 107]]], ["The homeopathic view was considered, as homeopathy experts were involved in the planning of the study and a majority of the farmers had experience in homeopathic treatment of calves.DiscussionThe study was performed on Swedish dairy farms and thus based on local conditions, e.g. are veterinarians not allowed to use homeopatic preparations in practice.", [["calves", "ORGANISM", 175, 181], ["calves", "SPECIES", 175, 181], ["The homeopathic view", "TEST", 0, 20], ["the study", "TEST", 92, 101], ["homeopathic treatment of calves", "TREATMENT", 150, 181], ["The study", "TEST", 192, 201], ["homeopatic preparations", "TREATMENT", 317, 340], ["calves", "ANATOMY", 175, 181]]], ["Homeopathic treatment of the calves in the study were done by the farmers.", [["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["Homeopathic treatment", "TREATMENT", 0, 21], ["the study", "TEST", 39, 48], ["calves", "ANATOMY", 29, 35]]], ["Swedish farms traditionally rear calves in single pens which likely has impact on the age when calves encounter infectious agents, compared with other countries.", [["calves", "ORGANISM", 33, 39], ["calves", "ORGANISM", 95, 101], ["calves", "SPECIES", 33, 39], ["calves", "SPECIES", 95, 101]]], ["Salmonella spp and BVDV are rare in cattle herds in Sweden.DiscussionAny medical treatment without a clinical effect poses a risk, as it may delay recovery or deprive the animal of adequate therapy.", [["Salmonella spp", "ORGANISM", 0, 14], ["BVDV", "ORGANISM", 19, 23], ["BVDV", "SPECIES", 19, 23], ["cattle", "SPECIES", 36, 42], ["BVDV", "SPECIES", 19, 23], ["cattle", "SPECIES", 36, 42], ["Salmonella spp", "PROBLEM", 0, 14], ["BVDV", "PROBLEM", 19, 23], ["Any medical treatment", "TREATMENT", 69, 90], ["adequate therapy", "TREATMENT", 181, 197], ["spp", "OBSERVATION_MODIFIER", 11, 14], ["BVDV", "OBSERVATION", 19, 23], ["rare", "OBSERVATION_MODIFIER", 28, 32]]], ["This is especially crucial in the case of serious infectious diseases or any other illness which may prove fatal.", [["infectious diseases", "DISEASE", 50, 69], ["serious infectious diseases", "PROBLEM", 42, 69], ["any other illness", "PROBLEM", 73, 90], ["serious", "OBSERVATION_MODIFIER", 42, 49], ["infectious", "OBSERVATION", 50, 60]]], ["Possible neglect of animal welfare must always be a concern.DiscussionDuring the past decade, there has been a considerable development of organic farming in the European Union, and in adopting EC Regulation No. 1804/1999 rules for organic livestock production are being set up.", [["EC", "ANATOMY", 194, 196], ["EC", "CELL", 194, 196], ["EC", "CELL_TYPE", 194, 196], ["neglect of animal welfare", "PROBLEM", 9, 34], ["organic livestock production", "PROBLEM", 232, 260], ["neglect", "OBSERVATION", 9, 16], ["considerable", "OBSERVATION_MODIFIER", 111, 123], ["organic farming", "OBSERVATION", 139, 154]]], ["Priority is often given to homeopathic treatment rather than allopathic veterinary medicine on organic farms, and in our view this involves a considerable risk for animal welfare as scientific proof of the efficacy of homeopathy is lacking.", [["homeopathic treatment", "TREATMENT", 27, 48], ["allopathic veterinary medicine", "TREATMENT", 61, 91], ["organic farms", "TREATMENT", 95, 108], ["animal welfare", "TREATMENT", 164, 178], ["homeopathy", "PROBLEM", 218, 228], ["homeopathy", "OBSERVATION", 218, 228]]]], "PMC7300780": [["Reports from ChinaAlthough criticism has been levelled concerning the transparency of the early coronavirus epidemic experience in China, several preliminary clinical and epidemiological papers, summarised in a recent Practical Diabetes editorial,4have achieved rapid publication5,6,7primarily listing diabetes simply as an adverse comorbidity, more prevalent in severe cases and with non\u2010survivors.", [["coronavirus", "DISEASE", 96, 107], ["Diabetes", "DISEASE", 228, 236], ["diabetes", "DISEASE", 302, 310], ["an adverse comorbidity", "PROBLEM", 321, 343], ["non\u2010survivors", "TREATMENT", 385, 398], ["early", "OBSERVATION_MODIFIER", 90, 95], ["coronavirus", "OBSERVATION", 96, 107]]], ["These early reports of COVID\u201019 infection included observations of 52 critically ill adult patients with coronavirus pneumonia admitted to the ICU at the Wuhan Jin Yin\u2010tan hospital, where diabetes was found in twice the number of individuals who died compared to those who survived (22% vs 10%).5", [["infection", "DISEASE", 32, 41], ["critically ill", "DISEASE", 70, 84], ["coronavirus pneumonia", "DISEASE", 105, 126], ["diabetes", "DISEASE", 188, 196], ["patients", "ORGANISM", 91, 99], ["coronavirus", "ORGANISM", 105, 116], ["patients", "SPECIES", 91, 99], ["coronavirus", "SPECIES", 105, 116], ["COVID\u201019 infection", "PROBLEM", 23, 41], ["coronavirus pneumonia", "PROBLEM", 105, 126], ["diabetes", "PROBLEM", 188, 196], ["coronavirus", "OBSERVATION_MODIFIER", 105, 116], ["pneumonia", "OBSERVATION", 117, 126]]]], "PMC7123455": [["IntroductionThe patient\u2019s occupation, activity level, and expectations determine mostly the decision for anterior cruciate ligament (ACL) reconstruction.", [["anterior cruciate ligament", "ANATOMY", 105, 131], ["ACL", "ANATOMY", 133, 136], ["patient", "ORGANISM", 16, 23], ["anterior cruciate ligament", "MULTI-TISSUE_STRUCTURE", 105, 131], ["ACL", "MULTI-TISSUE_STRUCTURE", 133, 136], ["patient", "SPECIES", 16, 23], ["anterior cruciate ligament (ACL) reconstruction", "TREATMENT", 105, 152], ["anterior", "ANATOMY_MODIFIER", 105, 113], ["cruciate ligament", "ANATOMY", 114, 131], ["ACL", "ANATOMY", 133, 136]]], ["Even if sedentary patients and those willing to modify their activities can consider nonoperative treatment, this injury results in increased risk for meniscal and chondral lesions and, subsequently, high possibility for early cartilage degeneration [11].", [["meniscal", "ANATOMY", 151, 159], ["chondral lesions", "ANATOMY", 164, 180], ["cartilage", "ANATOMY", 227, 236], ["cartilage degeneration", "DISEASE", 227, 249], ["patients", "ORGANISM", 18, 26], ["meniscal", "TISSUE", 151, 159], ["chondral lesions", "PATHOLOGICAL_FORMATION", 164, 180], ["cartilage", "TISSUE", 227, 236], ["patients", "SPECIES", 18, 26], ["nonoperative treatment", "TREATMENT", 85, 107], ["this injury", "PROBLEM", 109, 120], ["meniscal and chondral lesions", "PROBLEM", 151, 180], ["early cartilage degeneration", "PROBLEM", 221, 249], ["meniscal", "ANATOMY", 151, 159], ["chondral", "ANATOMY", 164, 172], ["lesions", "OBSERVATION", 173, 180], ["high possibility for", "UNCERTAINTY", 200, 220], ["cartilage", "ANATOMY", 227, 236], ["degeneration", "OBSERVATION", 237, 249]]], ["Consequently, ACL reconstruction is the method of choice, with no specific chronologic age as contraindication [42] and with numerous proce\u00addures annually performed all over the world.IntroductionFor most active patients, ACL reconstruction provides an excellent chance to return to their preinjury activities.", [["ACL", "ANATOMY", 222, 225], ["ACL", "PATHOLOGICAL_FORMATION", 14, 17], ["patients", "ORGANISM", 212, 220], ["ACL", "MULTI-TISSUE_STRUCTURE", 222, 225], ["patients", "SPECIES", 212, 220], ["ACL reconstruction", "TREATMENT", 14, 32], ["numerous proce\u00addures", "TREATMENT", 125, 145], ["ACL reconstruction", "TREATMENT", 222, 240]]], ["The use of autologous grafts is very popular and there are many clinical studies reporting good results [13, 25, 26].", [["grafts", "ANATOMY", 22, 28], ["grafts", "TISSUE", 22, 28], ["autologous grafts", "TREATMENT", 11, 28], ["many clinical studies", "TEST", 59, 80], ["autologous grafts", "OBSERVATION", 11, 28]]], ["However, there are many second thoughts such as how to avoid autogenous tissue sacrifice and reduce donor-site morbidity [60].", [["tissue", "ANATOMY", 72, 78], ["tissue", "TISSUE", 72, 78], ["autogenous tissue sacrifice", "TREATMENT", 61, 88], ["donor-site morbidity", "PROBLEM", 100, 120]]], ["Although patellar tendon has become the most common graft source for ACL reconstruction (bone-patellar tendon-bone/BPTB autograft) [19, 41, 60], there are significant complications from the donor site, such as quadriceps weakness, patellofemoral pain, loss of range of motion (ROM), patella fracture, patellar tendonitis, patella infera syndrome, early cartilage degenerative changes, and arthrofibrosis [2, 28, 37].", [["patellar tendon", "ANATOMY", 9, 24], ["graft", "ANATOMY", 52, 57], ["ACL", "ANATOMY", 69, 72], ["bone", "ANATOMY", 89, 93], ["tendon", "ANATOMY", 103, 109], ["bone", "ANATOMY", 110, 114], ["donor site", "ANATOMY", 190, 200], ["quadriceps", "ANATOMY", 210, 220], ["patellofemoral", "ANATOMY", 231, 245], ["patella", "ANATOMY", 283, 290], ["patellar", "ANATOMY", 301, 309], ["patella", "ANATOMY", 322, 329], ["cartilage", "ANATOMY", 353, 362], ["quadriceps weakness", "DISEASE", 210, 229], ["patellofemoral pain", "DISEASE", 231, 250], ["loss of range of motion", "DISEASE", 252, 275], ["patella fracture", "DISEASE", 283, 299], ["tendonitis", "DISEASE", 310, 320], ["patella infera syndrome", "DISEASE", 322, 345], ["arthrofibrosis", "DISEASE", 389, 403], ["patellar tendon", "MULTI-TISSUE_STRUCTURE", 9, 24], ["graft", "TISSUE", 52, 57], ["ACL", "TISSUE", 69, 72], ["bone", "TISSUE", 89, 93], ["bone", "TISSUE", 110, 114], ["quadriceps", "ORGANISM_SUBDIVISION", 210, 220], ["patella", "ORGANISM_SUBDIVISION", 283, 290], ["cartilage", "TISSUE", 353, 362], ["patellar tendon", "PROBLEM", 9, 24], ["ACL reconstruction (bone-patellar tendon-bone/BPTB autograft", "TREATMENT", 69, 129], ["significant complications from the donor site", "PROBLEM", 155, 200], ["quadriceps weakness", "PROBLEM", 210, 229], ["patellofemoral pain", "PROBLEM", 231, 250], ["loss of range of motion (ROM)", "PROBLEM", 252, 281], ["patella fracture", "PROBLEM", 283, 299], ["patellar tendonitis", "PROBLEM", 301, 320], ["patella infera syndrome", "PROBLEM", 322, 345], ["early cartilage degenerative changes", "PROBLEM", 347, 383], ["arthrofibrosis", "PROBLEM", 389, 403], ["patellar tendon", "ANATOMY", 9, 24], ["bone", "ANATOMY", 89, 93], ["patellar tendon", "ANATOMY", 94, 109], ["bone", "ANATOMY", 110, 114], ["BPTB autograft", "OBSERVATION", 115, 129], ["significant", "OBSERVATION_MODIFIER", 155, 166], ["complications", "OBSERVATION", 167, 180], ["donor site", "OBSERVATION", 190, 200], ["quadriceps", "ANATOMY", 210, 220], ["weakness", "OBSERVATION", 221, 229], ["patellofemoral", "ANATOMY", 231, 245], ["pain", "OBSERVATION", 246, 250], ["patella", "ANATOMY", 283, 290], ["fracture", "OBSERVATION", 291, 299], ["patellar", "ANATOMY", 301, 309], ["tendonitis", "OBSERVATION", 310, 320], ["patella", "ANATOMY", 322, 329], ["infera syndrome", "OBSERVATION", 330, 345], ["early", "OBSERVATION_MODIFIER", 347, 352], ["cartilage", "ANATOMY", 353, 362], ["degenerative", "OBSERVATION", 363, 375], ["arthrofibrosis", "OBSERVATION", 389, 403]]], ["On the other hand, hamstrings autografts (semitendinosus and gracilis) have also been popular as graft option, with functional results similar to BPTB but without the extensor mechanism deficit.", [["hamstrings autografts", "ANATOMY", 19, 40], ["semitendinosus", "ANATOMY", 42, 56], ["gracilis", "ANATOMY", 61, 69], ["graft", "ANATOMY", 97, 102], ["BPTB", "DISEASE", 146, 150], ["hamstrings autografts", "TISSUE", 19, 40], ["semitendinosus", "TISSUE", 42, 56], ["gracilis", "ORGANISM_SUBDIVISION", 61, 69], ["graft", "TISSUE", 97, 102], ["extensor", "ORGANISM_SUBDIVISION", 167, 175], ["hamstrings autografts (semitendinosus and gracilis", "TREATMENT", 19, 69], ["graft option", "TREATMENT", 97, 109], ["BPTB", "TEST", 146, 150], ["the extensor mechanism deficit", "PROBLEM", 163, 193], ["hamstrings", "ANATOMY", 19, 29], ["autografts", "OBSERVATION", 30, 40], ["semitendinosus", "ANATOMY", 42, 56], ["gracilis", "ANATOMY", 61, 69], ["graft", "OBSERVATION", 97, 102]]], ["However, it has been reported that there are some disadvantages including knee flexor strength, variability in hamstring size, fixation limitations, and delayed incorporation [1, 52, 62].", [["knee flexor", "ANATOMY", 74, 85], ["hamstring", "ANATOMY", 111, 120], ["knee flexor", "TISSUE", 74, 85], ["hamstring", "ORGANISM_SUBDIVISION", 111, 120], ["fixation limitations", "TEST", 127, 147], ["knee flexor", "ANATOMY", 74, 85], ["variability", "OBSERVATION_MODIFIER", 96, 107], ["hamstring", "ANATOMY", 111, 120], ["size", "OBSERVATION_MODIFIER", 121, 125], ["fixation", "OBSERVATION", 127, 135]]], ["For these reasons, as surgeons try to limit the significant morbidity associated with autograft harvesting, the use of allogenic tissue from a cadaver has emerged as an excellent option [45].", [["tissue", "ANATOMY", 129, 135], ["cadaver", "ANATOMY", 143, 150], ["tissue", "TISSUE", 129, 135], ["cadaver", "ORGAN", 143, 150], ["the significant morbidity", "PROBLEM", 44, 69], ["autograft harvesting", "TREATMENT", 86, 106], ["allogenic tissue", "PROBLEM", 119, 135], ["autograft harvesting", "OBSERVATION", 86, 106], ["allogenic tissue", "OBSERVATION", 119, 135]]], ["However, ACL reconstruction with allografts carries specific problems and, therefore, there is a dilemma when deciding graft type.IntroductionThe advantage of no donor-site morbidity is the most important for allograft use.", [["allografts", "ANATOMY", 33, 43], ["graft", "ANATOMY", 119, 124], ["allograft", "ANATOMY", 209, 218], ["ACL", "PATHOLOGICAL_FORMATION", 9, 12], ["allografts", "TISSUE", 33, 43], ["graft", "TISSUE", 119, 124], ["allograft", "TISSUE", 209, 218], ["ACL reconstruction", "TREATMENT", 9, 27], ["allografts", "TREATMENT", 33, 43], ["donor-site morbidity", "PROBLEM", 162, 182], ["allografts", "OBSERVATION", 33, 43], ["allograft", "OBSERVATION", 209, 218]]], ["In addition, allografts offer larger graft sizes, which could be ordered, low incidence of arth\u00adrofibrosis, shorter operative time, and improved overall \u00adhealth-related quality of life.", [["allografts", "ANATOMY", 13, 23], ["graft", "ANATOMY", 37, 42], ["arth\u00adrofibrosis", "DISEASE", 91, 106], ["allografts", "TISSUE", 13, 23], ["graft", "TISSUE", 37, 42], ["allografts", "TREATMENT", 13, 23], ["larger graft sizes", "TREATMENT", 30, 48], ["arth\u00adrofibrosis", "PROBLEM", 91, 106], ["allografts", "OBSERVATION", 13, 23], ["larger", "OBSERVATION_MODIFIER", 30, 36], ["graft", "OBSERVATION", 37, 42], ["sizes", "OBSERVATION_MODIFIER", 43, 48], ["arth\u00adrofibrosis", "OBSERVATION", 91, 106]]], ["However, there are considerable disadvantages including cost, slower graft embodiment, and potential disease transmission (bacterial, viral, and prion) [19].", [["graft", "ANATOMY", 69, 74], ["bacterial, viral, and prion)", "DISEASE", 123, 151], ["graft", "TISSUE", 69, 74], ["considerable disadvantages", "PROBLEM", 19, 45], ["cost, slower graft embodiment", "TREATMENT", 56, 85], ["potential disease transmission (bacterial, viral, and prion)", "PROBLEM", 91, 151], ["considerable", "OBSERVATION_MODIFIER", 19, 31], ["disadvantages", "OBSERVATION", 32, 45], ["slower", "OBSERVATION_MODIFIER", 62, 68], ["graft embodiment", "OBSERVATION", 69, 85]]], ["Thus, the optimal graft choice is still a matter of debate.", [["graft", "ANATOMY", 18, 23], ["graft", "TISSUE", 18, 23], ["the optimal graft choice", "TREATMENT", 6, 30], ["graft", "OBSERVATION", 18, 23]]], ["One can say that the optimal graft should be able to reproduce the anatomy and biomechanics of the native ACL, be incorporated rapidly, provide strong initial fixation, and cause low donor-site morbidity.", [["ACL", "ANATOMY", 106, 109], ["graft", "TISSUE", 29, 34], ["ACL", "ORGAN", 106, 109], ["the optimal graft", "TREATMENT", 17, 34], ["strong initial fixation", "TREATMENT", 144, 167], ["low donor-site morbidity", "PROBLEM", 179, 203], ["graft", "OBSERVATION", 29, 34], ["native ACL", "ANATOMY", 99, 109], ["fixation", "OBSERVATION", 159, 167]]], ["This chapter reviews the literature about the use of allografts in ACL reconstruction, reporting experimental, clinical, and comparison studies.Allograft SourcesUsual allografts for ACL reconstruction are patellar ligament, Achilles tendon, tibialis anterior, and posterior.", [["allografts", "ANATOMY", 53, 63], ["ACL", "ANATOMY", 67, 70], ["ACL", "ANATOMY", 182, 185], ["patellar ligament", "ANATOMY", 205, 222], ["Achilles tendon", "ANATOMY", 224, 239], ["tibialis anterior", "ANATOMY", 241, 258], ["allografts", "TISSUE", 53, 63], ["ACL", "MULTI-TISSUE_STRUCTURE", 67, 70], ["allografts", "TISSUE", 167, 177], ["ACL", "TISSUE", 182, 185], ["patellar ligament", "TISSUE", 205, 222], ["Achilles tendon", "TISSUE", 224, 239], ["tibialis anterior", "MULTI-TISSUE_STRUCTURE", 241, 258], ["allografts in ACL reconstruction", "TREATMENT", 53, 85], ["comparison studies", "TEST", 125, 143], ["Allograft SourcesUsual allografts", "TREATMENT", 144, 177], ["ACL reconstruction", "TREATMENT", 182, 200], ["allografts", "OBSERVATION", 53, 63], ["allografts", "OBSERVATION", 167, 177], ["ACL reconstruction", "OBSERVATION", 182, 200], ["patellar ligament", "ANATOMY", 205, 222], ["Achilles tendon", "ANATOMY", 224, 239], ["tibialis", "ANATOMY", 241, 249], ["anterior", "ANATOMY_MODIFIER", 250, 258], ["posterior", "ANATOMY_MODIFIER", 264, 273]]], ["The use of peroneus longus, hamstrings, and fascia latae has also been reported [36].", [["peroneus longus", "ANATOMY", 11, 26], ["hamstrings", "ANATOMY", 28, 38], ["fascia latae", "ANATOMY", 44, 56], ["peroneus longus", "ORGANISM", 11, 26], ["hamstrings", "ORGANISM_SUBDIVISION", 28, 38], ["fascia latae", "ORGANISM", 44, 56], ["peroneus longus", "SPECIES", 11, 26], ["peroneus longus, hamstrings, and fascia latae", "PROBLEM", 11, 56], ["peroneus longus", "ANATOMY", 11, 26], ["hamstrings", "ANATOMY", 28, 38], ["fascia latae", "ANATOMY", 44, 56]]], ["One study reported that the ultimate failure load for doubled tibialis anterior, tibialis posterior, and peroneus longus were 3,412, 3,391, and 2,483 N, respectively.", [["tibialis anterior", "ANATOMY", 62, 79], ["tibialis posterior", "ANATOMY", 81, 99], ["peroneus longus", "ANATOMY", 105, 120], ["tibialis anterior", "MULTI-TISSUE_STRUCTURE", 62, 79], ["tibialis posterior", "MULTI-TISSUE_STRUCTURE", 81, 99], ["peroneus longus", "ORGAN", 105, 120], ["One study", "TEST", 0, 9], ["the ultimate failure load", "PROBLEM", 24, 49], ["doubled tibialis anterior, tibialis posterior, and peroneus longus", "PROBLEM", 54, 120], ["failure", "OBSERVATION", 37, 44], ["tibialis", "ANATOMY", 62, 70], ["anterior", "ANATOMY_MODIFIER", 71, 79], ["tibialis", "ANATOMY", 81, 89], ["posterior", "ANATOMY_MODIFIER", 90, 99], ["peroneus longus", "ANATOMY", 105, 120]]], ["These values are almost the same or higher than the usual failure loads of all the currently described ACL graft sources [5].", [["ACL", "TISSUE", 103, 106], ["graft", "TISSUE", 107, 112], ["These values", "TEST", 0, 12], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["failure", "OBSERVATION", 58, 65], ["ACL graft", "OBSERVATION", 103, 112]]], ["Another study recommended the use of soft tissue allografts such as tibialis anterior tendon or doubled STG rather than allografts with bone plugs such as BPTB and Achilles tendon.", [["soft tissue allografts", "ANATOMY", 37, 59], ["tibialis anterior tendon", "ANATOMY", 68, 92], ["STG", "ANATOMY", 104, 107], ["allografts", "ANATOMY", 120, 130], ["bone", "ANATOMY", 136, 140], ["BPTB", "ANATOMY", 155, 159], ["Achilles tendon", "ANATOMY", 164, 179], ["soft tissue allografts", "TISSUE", 37, 59], ["tibialis anterior tendon", "TISSUE", 68, 92], ["STG", "MULTI-TISSUE_STRUCTURE", 104, 107], ["allografts", "TISSUE", 120, 130], ["bone", "TISSUE", 136, 140], ["Achilles tendon", "TISSUE", 164, 179], ["Another study", "TEST", 0, 13], ["soft tissue allografts", "TREATMENT", 37, 59], ["tibialis anterior tendon", "PROBLEM", 68, 92], ["doubled STG", "PROBLEM", 96, 107], ["allografts", "TREATMENT", 120, 130], ["bone plugs such as BPTB and Achilles tendon", "PROBLEM", 136, 179], ["soft tissue", "ANATOMY", 37, 48], ["allografts", "OBSERVATION", 49, 59], ["tibialis", "ANATOMY", 68, 76], ["anterior", "ANATOMY_MODIFIER", 77, 85], ["tendon", "ANATOMY", 86, 92], ["bone", "ANATOMY", 136, 140], ["plugs", "OBSERVATION", 141, 146], ["Achilles tendon", "ANATOMY", 164, 179]]], ["This is attributed to the slow incorporation of the allograft bone plug, the greater cross-sectional area available with the soft tissue allograft, and the fact that soft tissue grafts are more readily available since each donor provides six soft tissues but only four bone plug grafts [32].Allograft SourcesAnother issue that the surgeon should take into account is the possible graft-construct mismatch when ordering an allo\u00adgraft.", [["bone", "ANATOMY", 62, 66], ["cross-sectional area", "ANATOMY", 85, 105], ["soft tissue allograft", "ANATOMY", 125, 146], ["soft tissue grafts", "ANATOMY", 166, 184], ["soft tissues", "ANATOMY", 242, 254], ["bone plug grafts", "ANATOMY", 269, 285], ["graft", "ANATOMY", 380, 385], ["allograft", "TISSUE", 52, 61], ["bone", "TISSUE", 62, 66], ["soft tissue allograft", "TISSUE", 125, 146], ["soft tissue grafts", "TISSUE", 166, 184], ["soft tissues", "TISSUE", 242, 254], ["bone", "TISSUE", 269, 273], ["grafts", "TISSUE", 279, 285], ["graft", "TISSUE", 380, 385], ["the slow incorporation of the allograft bone plug", "PROBLEM", 22, 71], ["the soft tissue allograft", "TREATMENT", 121, 146], ["soft tissue grafts", "TREATMENT", 166, 184], ["four bone plug grafts", "TREATMENT", 264, 285], ["graft-construct mismatch", "TREATMENT", 380, 404], ["an allo\u00adgraft", "TREATMENT", 419, 432], ["attributed to", "UNCERTAINTY", 8, 21], ["slow", "OBSERVATION_MODIFIER", 26, 30], ["incorporation", "OBSERVATION_MODIFIER", 31, 44], ["allograft bone plug", "OBSERVATION", 52, 71], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["soft tissue", "ANATOMY", 125, 136], ["allograft", "OBSERVATION", 137, 146], ["soft tissue", "OBSERVATION_MODIFIER", 166, 177], ["grafts", "OBSERVATION", 178, 184], ["soft tissues", "ANATOMY", 242, 254], ["bone", "ANATOMY", 269, 273], ["plug grafts", "OBSERVATION", 274, 285], ["possible", "UNCERTAINTY", 371, 379], ["graft", "OBSERVATION", 380, 385]]], ["This obviously relates to BPTB allografts, for example, when a graft from a tall donor is used for a shorter patient.", [["BPTB allografts", "ANATOMY", 26, 41], ["graft", "ANATOMY", 63, 68], ["BPTB allografts", "TISSUE", 26, 41], ["graft", "TISSUE", 63, 68], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["BPTB allografts", "TREATMENT", 26, 41], ["a graft", "TREATMENT", 61, 68], ["a tall donor", "TREATMENT", 74, 86], ["BPTB allografts", "OBSERVATION", 26, 41], ["graft", "OBSERVATION", 63, 68]]], ["For this reason, it is better to provide the bone bank all the information about the recipient\u2019s height and length parameters of the graft in order to avoid any possibility of a significant graft-construct mismatch.Disease Transmission with AllograftsThe main concern for patients, families, and physicians in cases of allograft ACL reconstruction is the possibility of viral or bacterial infection.", [["bone", "ANATOMY", 45, 49], ["graft", "ANATOMY", 190, 195], ["allograft", "ANATOMY", 319, 328], ["viral or bacterial infection", "DISEASE", 370, 398], ["bone", "TISSUE", 45, 49], ["graft", "TISSUE", 133, 138], ["graft", "TISSUE", 190, 195], ["patients", "ORGANISM", 272, 280], ["allograft ACL", "MULTI-TISSUE_STRUCTURE", 319, 332], ["patients", "SPECIES", 272, 280], ["the graft", "TREATMENT", 129, 138], ["a significant graft-construct mismatch", "PROBLEM", 176, 214], ["Allografts", "TREATMENT", 241, 251], ["allograft ACL reconstruction", "TREATMENT", 319, 347], ["viral or bacterial infection", "PROBLEM", 370, 398], ["graft", "OBSERVATION", 133, 138], ["significant", "OBSERVATION_MODIFIER", 178, 189], ["graft", "OBSERVATION", 190, 195], ["construct mismatch", "OBSERVATION", 196, 214], ["Allografts", "OBSERVATION", 241, 251], ["main", "OBSERVATION_MODIFIER", 255, 259], ["possibility of", "UNCERTAINTY", 355, 369], ["viral", "OBSERVATION", 370, 375], ["bacterial", "OBSERVATION_MODIFIER", 379, 388], ["infection", "OBSERVATION", 389, 398]]], ["Human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV) viruses, human T-cell leukemia virus (HTLV), syphilis, aerobic, and anaerobic bacteria are the main pathogens implicated in allograft infection.", [["allograft", "ANATOMY", 190, 199], ["Human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV) viruses", "DISEASE", 0, 73], ["T-cell leukemia virus (HTLV), syphilis", "DISEASE", 81, 119], ["infection", "DISEASE", 200, 209], ["Human immunodeficiency virus", "ORGANISM", 0, 28], ["HIV", "ORGANISM", 30, 33], ["hepatitis B (HBV) and C (HCV) viruses", "ORGANISM", 36, 73], ["human T-cell leukemia virus", "ORGANISM", 75, 102], ["HTLV", "ORGANISM", 104, 108], ["allograft", "TISSUE", 190, 199], ["Human immunodeficiency virus (HIV", "SPECIES", 0, 33], ["hepatitis B (HBV", "SPECIES", 36, 52], ["human", "SPECIES", 75, 80], ["T-cell leukemia virus", "SPECIES", 81, 102], ["Human immunodeficiency virus", "SPECIES", 0, 28], ["HIV", "SPECIES", 30, 33], ["hepatitis B", "SPECIES", 36, 47], ["HBV", "SPECIES", 49, 52], ["HCV", "SPECIES", 61, 64], ["human T-cell leukemia virus", "SPECIES", 75, 102], ["HTLV", "SPECIES", 104, 108], ["Human immunodeficiency virus (HIV)", "PROBLEM", 0, 34], ["hepatitis B (HBV)", "PROBLEM", 36, 53], ["C (HCV) viruses", "PROBLEM", 58, 73], ["human T-cell leukemia virus (HTLV)", "PROBLEM", 75, 109], ["syphilis", "PROBLEM", 111, 119], ["aerobic", "PROBLEM", 121, 128], ["anaerobic bacteria", "PROBLEM", 134, 152], ["the main pathogens", "PROBLEM", 157, 175], ["allograft infection", "PROBLEM", 190, 209], ["immunodeficiency virus", "OBSERVATION", 6, 28], ["cell leukemia virus", "OBSERVATION", 83, 102], ["anaerobic bacteria", "OBSERVATION", 134, 152], ["allograft", "OBSERVATION_MODIFIER", 190, 199], ["infection", "OBSERVATION", 200, 209]]], ["Recently, additional concerns have been raised about newly emerging pathogens, such as the West Nile virus, the severe acute respiratory syndrome (SARS) coronavirus, and prions, which are associated with transmissible spongiform encephalopathies, such as the Creutzfeldt\u2013Jacob disease.", [["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 119, 164], ["transmissible spongiform encephalopathies", "DISEASE", 204, 245], ["Creutzfeldt\u2013Jacob disease", "DISEASE", 259, 284], ["West Nile virus", "ORGANISM", 91, 106], ["West Nile virus", "SPECIES", 91, 106], ["West Nile virus", "SPECIES", 91, 106], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 112, 164], ["newly emerging pathogens", "PROBLEM", 53, 77], ["the West Nile virus", "PROBLEM", 87, 106], ["the severe acute respiratory syndrome", "PROBLEM", 108, 145], ["SARS", "PROBLEM", 147, 151], ["coronavirus", "PROBLEM", 153, 164], ["prions", "PROBLEM", 170, 176], ["transmissible spongiform encephalopathies", "PROBLEM", 204, 245], ["Jacob disease", "PROBLEM", 271, 284], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory syndrome", "OBSERVATION", 125, 145], ["associated with", "UNCERTAINTY", 188, 203], ["transmissible", "OBSERVATION_MODIFIER", 204, 217], ["spongiform encephalopathies", "OBSERVATION", 218, 245], ["Jacob disease", "OBSERVATION", 271, 284]]], ["The Centers for Disease Control and Prevention (CDC) defines allograft-associated infections as the ones that occur during the first year after implantation in patients with no known risk factors who are otherwise healthy.", [["allograft", "ANATOMY", 61, 70], ["infections", "DISEASE", 82, 92], ["allograft", "TISSUE", 61, 70], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["Disease Control", "TREATMENT", 16, 31], ["allograft-associated infections", "PROBLEM", 61, 92], ["implantation", "TREATMENT", 144, 156], ["known risk factors", "PROBLEM", 177, 195], ["allograft", "OBSERVATION", 61, 70], ["infections", "OBSERVATION", 82, 92]]], ["Bacterial or fungal infections commonly emerge with signs of inflammation or infection in or near the operative site.", [["fungal infections", "DISEASE", 13, 30], ["inflammation", "DISEASE", 61, 73], ["infection", "DISEASE", 77, 86], ["Bacterial or fungal infections", "PROBLEM", 0, 30], ["inflammation", "PROBLEM", 61, 73], ["infection", "PROBLEM", 77, 86], ["fungal", "OBSERVATION_MODIFIER", 13, 19], ["infections", "OBSERVATION", 20, 30], ["inflammation", "OBSERVATION", 61, 73], ["infection", "OBSERVATION", 77, 86], ["operative", "OBSERVATION", 102, 111]]], ["Positive wound or blood cultures are necessary to confirm the diagnosis.", [["wound", "ANATOMY", 9, 14], ["blood cultures", "ANATOMY", 18, 32], ["wound", "PATHOLOGICAL_FORMATION", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["Positive wound", "PROBLEM", 0, 14], ["blood cultures", "TEST", 18, 32], ["wound", "OBSERVATION", 9, 14]]], ["Viral or parasitic infections are followed by symptoms and signs characteristic of the infectious agent (e.g., fever, lymphadenopathy, weakness) and by positive serological or molecular test results.Disease Transmission with AllograftsDisease transmission during allograft transplantation can occur through two different ways.", [["allograft", "ANATOMY", 263, 272], ["Viral or parasitic infections", "DISEASE", 0, 29], ["fever", "DISEASE", 111, 116], ["lymphadenopathy", "DISEASE", 118, 133], ["weakness", "DISEASE", 135, 143], ["allograft", "TISSUE", 263, 272], ["Viral or parasitic infections", "PROBLEM", 0, 29], ["symptoms", "PROBLEM", 46, 54], ["the infectious agent", "PROBLEM", 83, 103], ["fever", "PROBLEM", 111, 116], ["lymphadenopathy", "PROBLEM", 118, 133], ["weakness", "PROBLEM", 135, 143], ["molecular test results", "TEST", 176, 198], ["Disease Transmission", "PROBLEM", 199, 219], ["AllograftsDisease transmission", "TREATMENT", 225, 255], ["allograft transplantation", "TREATMENT", 263, 288], ["parasitic", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["infectious", "OBSERVATION", 87, 97], ["lymphadenopathy", "OBSERVATION", 118, 133], ["Allografts", "OBSERVATION", 225, 235], ["allograft transplantation", "OBSERVATION", 263, 288]]], ["The first way is by transmission from an infected donor as a result of an occult perimortem infection, prolonged tissue recovery time, or a donor screening failure.", [["perimortem", "ANATOMY", 81, 91], ["tissue", "ANATOMY", 113, 119], ["infection", "DISEASE", 92, 101], ["tissue", "TISSUE", 113, 119], ["an infected donor", "PROBLEM", 38, 55], ["an occult perimortem infection", "PROBLEM", 71, 101], ["a donor screening failure", "PROBLEM", 138, 163], ["infected", "OBSERVATION", 41, 49], ["occult", "OBSERVATION_MODIFIER", 74, 80], ["perimortem", "OBSERVATION_MODIFIER", 81, 91], ["infection", "OBSERVATION", 92, 101], ["prolonged tissue", "OBSERVATION_MODIFIER", 103, 119]]], ["Infectious agents may also come from the breakdown of the donor\u2019s gastrointestinal or respiratory system.", [["gastrointestinal", "ANATOMY", 66, 82], ["gastrointestinal", "ORGAN", 66, 82], ["Infectious agents", "TREATMENT", 0, 17], ["gastrointestinal", "ANATOMY", 66, 82], ["respiratory system", "ANATOMY", 86, 104]]], ["The second way is by contamination by the healthcare provider during the tissue procurement, sterilization, and preservation procedure.", [["tissue", "ANATOMY", 73, 79], ["tissue", "TISSUE", 73, 79], ["the tissue procurement", "TREATMENT", 69, 91], ["sterilization", "TREATMENT", 93, 106], ["preservation procedure", "TREATMENT", 112, 134], ["contamination", "OBSERVATION", 21, 34]]], ["In general, the risk of disease transmission depends mainly on tissue type and preparation method.Disease Transmission with AllograftsThere are no definite data available regarding the risk of disease transmission from allograft tissue transplantation.", [["tissue", "ANATOMY", 63, 69], ["allograft tissue", "ANATOMY", 219, 235], ["tissue", "TISSUE", 63, 69], ["allograft tissue", "TISSUE", 219, 235], ["disease transmission", "PROBLEM", 24, 44], ["preparation method", "TREATMENT", 79, 97], ["Allografts", "TREATMENT", 124, 134], ["disease transmission", "PROBLEM", 193, 213], ["allograft tissue transplantation", "TREATMENT", 219, 251], ["disease", "OBSERVATION", 24, 31], ["Allografts", "OBSERVATION", 124, 134], ["no definite", "UNCERTAINTY", 144, 155], ["disease", "OBSERVATION", 193, 200], ["allograft tissue transplantation", "OBSERVATION", 219, 251]]], ["Surveillance of adverse effects or disease transmission incidents after allograft implantation occurs, in most countries, in a voluntary basis.", [["allograft", "ANATOMY", 72, 81], ["allograft", "TISSUE", 72, 81], ["adverse effects", "PROBLEM", 16, 31], ["disease transmission", "PROBLEM", 35, 55], ["allograft implantation", "TREATMENT", 72, 94], ["adverse effects", "OBSERVATION", 16, 31], ["allograft implantation", "OBSERVATION", 72, 94]]], ["Buck et al. estimated that the risk of HIV transmission from an infected donor through transplanted tissue is approximately 1 in 1,667,000 [8].", [["tissue", "ANATOMY", 100, 106], ["HIV transmission", "DISEASE", 39, 55], ["HIV", "ORGANISM", 39, 42], ["tissue", "TISSUE", 100, 106], ["HIV", "SPECIES", 39, 42], ["HIV transmission", "PROBLEM", 39, 55], ["an infected donor through transplanted tissue", "TREATMENT", 61, 106], ["infected", "OBSERVATION", 64, 72]]], ["The risk of contracting hepatitis B or C is estimated to be much higher due to the greater prevalence of hepatitis in the general population.", [["hepatitis B", "DISEASE", 24, 35], ["hepatitis", "DISEASE", 105, 114], ["hepatitis B", "ORGANISM", 24, 35], ["contracting hepatitis B", "PROBLEM", 12, 35], ["hepatitis", "PROBLEM", 105, 114], ["contracting", "OBSERVATION_MODIFIER", 12, 23], ["hepatitis", "OBSERVATION", 24, 33], ["hepatitis", "OBSERVATION", 105, 114]]], ["Current donor screening, sterilization and preservation techniques have diminished the possibility of distributing allograft material from donors with active viral infection.", [["allograft", "ANATOMY", 115, 124], ["viral infection", "DISEASE", 158, 173], ["allograft material", "TISSUE", 115, 133], ["donors", "ORGANISM", 139, 145], ["Current donor screening", "TEST", 0, 23], ["sterilization", "TREATMENT", 25, 38], ["preservation techniques", "TREATMENT", 43, 66], ["distributing allograft material", "PROBLEM", 102, 133], ["active viral infection", "PROBLEM", 151, 173], ["possibility of", "UNCERTAINTY", 87, 101], ["distributing", "OBSERVATION_MODIFIER", 102, 114], ["allograft", "OBSERVATION", 115, 124], ["active", "OBSERVATION_MODIFIER", 151, 157], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 164, 173]]], ["Concerns remain, however, regarding the initial \u201cwindow period,\u201d during which viral antigen or antibody levels may not be detectable despite infection.", [["infection", "DISEASE", 141, 150], ["viral antigen", "PROTEIN", 78, 91], ["viral antigen", "TEST", 78, 91], ["antibody levels", "TEST", 95, 110], ["infection", "PROBLEM", 141, 150], ["infection", "OBSERVATION", 141, 150]]], ["The application of advanced serological testing, such as nucleic acid tests, has managed to decrease this \u201cwindow period\u201d to approximately 7 days for HIV and HCV and 8 days for HBV infection.", [["nucleic acid", "CHEMICAL", 57, 69], ["HCV", "DISEASE", 158, 161], ["HBV infection", "DISEASE", 177, 190], ["HIV", "ORGANISM", 150, 153], ["HBV", "ORGANISM", 177, 180], ["HIV", "SPECIES", 150, 153], ["HIV", "SPECIES", 150, 153], ["HCV", "SPECIES", 158, 161], ["HBV", "SPECIES", 177, 180], ["advanced serological testing", "TEST", 19, 47], ["nucleic acid tests", "TEST", 57, 75], ["HIV", "PROBLEM", 150, 153], ["HCV", "TREATMENT", 158, 161], ["HBV infection", "PROBLEM", 177, 190], ["infection", "OBSERVATION", 181, 190]]], ["The risk of implanting tissue from an HIV-positive donor is currently estimated at one in 173,000 to one in one million.", [["tissue", "ANATOMY", 23, 29], ["tissue", "TISSUE", 23, 29], ["HIV", "ORGANISM", 38, 41], ["HIV", "SPECIES", 38, 41], ["implanting tissue", "PROBLEM", 12, 29], ["an HIV-positive donor", "PROBLEM", 35, 56], ["implanting tissue", "OBSERVATION", 12, 29], ["HIV", "OBSERVATION", 38, 41]]], ["The risk of implanting HCV-infected tissue is estimated at 1 in 421,000 [69].Disease Transmission with AllograftsBacterial infection following ACL reconstruction is another important concern.", [["tissue", "ANATOMY", 36, 42], ["ACL", "ANATOMY", 143, 146], ["HCV-infected", "DISEASE", 23, 35], ["Bacterial infection", "DISEASE", 113, 132], ["HCV", "ORGANISM", 23, 26], ["tissue", "TISSUE", 36, 42], ["ACL", "MULTI-TISSUE_STRUCTURE", 143, 146], ["HCV", "SPECIES", 23, 26], ["implanting HCV", "PROBLEM", 12, 26], ["infected tissue", "PROBLEM", 27, 42], ["Disease Transmission", "PROBLEM", 77, 97], ["AllograftsBacterial infection", "PROBLEM", 103, 132], ["ACL reconstruction", "TREATMENT", 143, 161], ["implanting", "OBSERVATION_MODIFIER", 12, 22], ["HCV", "OBSERVATION", 23, 26], ["infected tissue", "OBSERVATION", 27, 42], ["Allografts", "OBSERVATION_MODIFIER", 103, 113], ["Bacterial", "OBSERVATION_MODIFIER", 113, 122], ["infection", "OBSERVATION", 123, 132]]], ["There have been several such reports of infections following allograft transplantation.", [["allograft", "ANATOMY", 61, 70], ["infections", "DISEASE", 40, 50], ["allograft", "TISSUE", 61, 70], ["infections", "PROBLEM", 40, 50], ["allograft transplantation", "TREATMENT", 61, 86], ["infections", "OBSERVATION", 40, 50], ["allograft transplantation", "OBSERVATION", 61, 86]]], ["The CDC reported in 2002 a total of 26 cases of bacterial infections associated with musculoskeletal allografts.", [["musculoskeletal allografts", "ANATOMY", 85, 111], ["bacterial infections", "DISEASE", 48, 68], ["allografts", "TISSUE", 101, 111], ["The CDC", "TEST", 0, 7], ["bacterial infections", "PROBLEM", 48, 68], ["musculoskeletal allografts", "TREATMENT", 85, 111], ["bacterial", "OBSERVATION_MODIFIER", 48, 57], ["infections", "OBSERVATION", 58, 68], ["musculoskeletal", "ANATOMY", 85, 100], ["allografts", "OBSERVATION", 101, 111]]], ["Half of these cases involved contamination with Clostridium species [9].", [["Clostridium species", "PROBLEM", 48, 67]]], ["Eight of the reported infections occurred after ACL reconstruction using tendon allografts.", [["ACL", "ANATOMY", 48, 51], ["tendon allografts", "ANATOMY", 73, 90], ["infections", "DISEASE", 22, 32], ["ACL", "TISSUE", 48, 51], ["tendon allografts", "TISSUE", 73, 90], ["the reported infections", "PROBLEM", 9, 32], ["ACL reconstruction", "TREATMENT", 48, 66], ["tendon allografts", "TREATMENT", 73, 90], ["infections", "OBSERVATION", 22, 32], ["tendon", "ANATOMY", 73, 79], ["allografts", "OBSERVATION", 80, 90]]], ["Barbour et al. reported four additional cases of Clostridium septicum infection after ACL reconstruction [6].", [["ACL", "ANATOMY", 86, 89], ["Clostridium septicum infection", "DISEASE", 49, 79], ["Clostridium septicum", "ORGANISM", 49, 69], ["Clostridium septicum", "SPECIES", 49, 69], ["Clostridium septicum", "SPECIES", 49, 69], ["Clostridium septicum infection", "PROBLEM", 49, 79], ["ACL reconstruction", "TREATMENT", 86, 104], ["Clostridium", "OBSERVATION_MODIFIER", 49, 60], ["septicum", "OBSERVATION_MODIFIER", 61, 69], ["infection", "OBSERVATION", 70, 79]]], ["In all of the above cases, disease transmission was attributed to the tissue processing conditions.", [["tissue", "ANATOMY", 70, 76], ["tissue", "TISSUE", 70, 76], ["disease transmission", "PROBLEM", 27, 47], ["the tissue processing conditions", "PROBLEM", 66, 98]]], ["The postoperative infection rate following autograft and allograft ACL reconstruction was investigated by two large retrospective studies.", [["allograft", "ANATOMY", 57, 66], ["postoperative infection", "DISEASE", 4, 27], ["The postoperative infection rate", "PROBLEM", 0, 32], ["autograft and allograft ACL reconstruction", "TREATMENT", 43, 85], ["two large retrospective studies", "TEST", 106, 137], ["postoperative", "OBSERVATION_MODIFIER", 4, 17], ["infection", "OBSERVATION", 18, 27], ["allograft ACL reconstruction", "OBSERVATION", 57, 85]]], ["The infection rates found were 0.3% and 0.14%, respectively.", [["infection", "DISEASE", 4, 13], ["The infection rates", "TEST", 0, 19], ["infection", "OBSERVATION", 4, 13]]], ["There was no significant difference in infection rates between autograft and allograft reconstructions.", [["allograft", "ANATOMY", 77, 86], ["infection", "DISEASE", 39, 48], ["autograft", "TISSUE", 63, 72], ["allograft", "TISSUE", 77, 86], ["significant difference in infection rates", "PROBLEM", 13, 54], ["autograft and allograft reconstructions", "TREATMENT", 63, 102], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["infection", "OBSERVATION", 39, 48], ["allograft", "OBSERVATION", 77, 86]]], ["In a more recent study, Katz et al. also failed to find a higher deep infection rate in allograft compared to autograft ACL reconstruction [27].", [["allograft", "ANATOMY", 88, 97], ["infection", "DISEASE", 70, 79], ["allograft", "TISSUE", 88, 97], ["a more recent study", "TEST", 3, 22], ["a higher deep infection rate in allograft", "PROBLEM", 56, 97], ["autograft ACL reconstruction", "TREATMENT", 110, 138], ["higher", "OBSERVATION_MODIFIER", 58, 64], ["deep", "OBSERVATION_MODIFIER", 65, 69], ["infection", "OBSERVATION", 70, 79], ["allograft", "OBSERVATION", 88, 97]]], ["With the advent of more advanced sterilization methods, disinfection of musculoskeletal allografts from bacteria can be practically ensured.Preparation of AllograftsThe tissue preparation procedure can be divided into several successive steps.", [["tissue", "ANATOMY", 169, 175], ["allografts", "TISSUE", 88, 98], ["tissue", "TISSUE", 169, 175], ["more advanced sterilization methods", "TREATMENT", 19, 54], ["disinfection of musculoskeletal allografts", "TREATMENT", 56, 98], ["bacteria", "PROBLEM", 104, 112], ["AllograftsThe tissue preparation procedure", "TREATMENT", 155, 197], ["musculoskeletal", "ANATOMY", 72, 87], ["allografts", "OBSERVATION", 88, 98], ["Allografts", "OBSERVATION", 155, 165]]], ["The first step is to prevent infected tissue from entering the donation pool through careful donor selection.", [["tissue", "ANATOMY", 38, 44], ["tissue", "TISSUE", 38, 44], ["infected tissue", "PROBLEM", 29, 44], ["careful donor selection", "TREATMENT", 85, 108], ["infected", "OBSERVATION", 29, 37]]], ["The second step is to prevent contamination by ensuring an aseptic graft procurement process.", [["graft", "TISSUE", 67, 72], ["contamination", "PROBLEM", 30, 43], ["an aseptic graft procurement process", "TREATMENT", 56, 92], ["aseptic graft", "OBSERVATION", 59, 72]]], ["The third step is to eliminate any residual infectious agents.", [["any residual infectious agents", "PROBLEM", 31, 61], ["infectious", "OBSERVATION", 44, 54]]], ["This is accomplished during tissue processing and final sterilization.Preparation of AllograftsAppropriate donor selection is one of the primary ways to prevent disease transmission by allografts [17].", [["tissue", "ANATOMY", 28, 34], ["tissue", "TISSUE", 28, 34], ["allografts", "TISSUE", 185, 195], ["final sterilization", "TREATMENT", 50, 69], ["AllograftsAppropriate donor selection", "TREATMENT", 85, 122], ["disease transmission", "PROBLEM", 161, 181], ["final sterilization", "OBSERVATION", 50, 69], ["Allografts", "OBSERVATION", 85, 95]]], ["Most tissue banks accept donors from 15 to 50 years of age.", [["tissue banks", "ANATOMY", 5, 17], ["tissue", "TISSUE", 5, 11], ["donors", "ORGANISM", 25, 31]]], ["The most important step is a careful history and identification of risk factors.", [["risk factors", "PROTEIN", 67, 79], ["risk factors", "PROBLEM", 67, 79]]], ["Data concerning any communicable disease history or high risk behavior (intravenous drug use or traveling history to areas with high infection rate) are obtained by surviving family members, medical or blood donation records, physical examination, or even autopsy reports.", [["intravenous", "ANATOMY", 72, 83], ["blood", "ANATOMY", 202, 207], ["infection", "DISEASE", 133, 142], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 83], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["any communicable disease history", "PROBLEM", 16, 48], ["high risk behavior", "PROBLEM", 52, 70], ["intravenous drug use", "TREATMENT", 72, 92], ["high infection rate", "PROBLEM", 128, 147], ["physical examination", "TEST", 226, 246]]], ["The next step is testing for active infection.", [["infection", "DISEASE", 36, 45], ["active infection", "PROBLEM", 29, 45], ["active", "OBSERVATION_MODIFIER", 29, 35], ["infection", "OBSERVATION", 36, 45]]], ["However, the \u201cwindow period\u201d for the detection of antibodies or viral antigens still limits the effectiveness of serologic tests, even with modern Nucleic Acid Tests used.Preparation of AllograftsTissue from accredited donors is procured in an aseptic environment.", [["Tissue", "ANATOMY", 196, 202], ["Tissue", "TISSUE", 196, 202], ["donors", "ORGANISM", 219, 225], ["antibodies", "PROTEIN", 50, 60], ["viral antigens", "PROTEIN", 64, 78], ["the detection", "TEST", 33, 46], ["antibodies", "PROBLEM", 50, 60], ["viral antigens", "PROBLEM", 64, 78], ["serologic tests", "TEST", 113, 128], ["modern Nucleic Acid Tests", "TEST", 140, 165], ["AllograftsTissue from accredited donors", "TREATMENT", 186, 225], ["AllograftsTissue", "OBSERVATION", 186, 202], ["aseptic environment", "OBSERVATION", 244, 263]]], ["Standard operating room techniques are used, including prepping and draping.", [["prepping and draping", "TREATMENT", 55, 75]]], ["Time to harvest is also important to reduce the risk of infection.", [["infection", "DISEASE", 56, 65], ["infection", "PROBLEM", 56, 65], ["infection", "OBSERVATION", 56, 65]]], ["The time limit for most tissue banks is 12 h if the body is kept in room temperature and 24 h if the body is refrigerated [64].", [["tissue banks", "ANATOMY", 24, 36], ["body", "ANATOMY", 52, 56], ["body", "ANATOMY", 101, 105], ["tissue", "TISSUE", 24, 30], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["body", "ORGANISM_SUBDIVISION", 101, 105]]], ["However, aseptically recovered tissues should not be considered sterile.", [["tissues", "ANATOMY", 31, 38], ["tissues", "TISSUE", 31, 38]]], ["Therefore, the recovered tissues usually undergo chemical soaking with biologic detergents and antibiotic or antiseptic solutions to reduce their bio-burden.", [["tissues", "ANATOMY", 25, 32], ["tissues", "TISSUE", 25, 32], ["chemical soaking", "TREATMENT", 49, 65], ["biologic detergents", "TREATMENT", 71, 90], ["antibiotic", "TREATMENT", 95, 105], ["antiseptic solutions", "TREATMENT", 109, 129], ["their bio-burden", "PROBLEM", 140, 156]]], ["These solutions are mostly effective against surface contaminants since they lack tissue penetration.", [["surface", "ANATOMY", 45, 52], ["tissue", "ANATOMY", 82, 88], ["tissue", "TISSUE", 82, 88], ["These solutions", "TREATMENT", 0, 15], ["surface contaminants", "PROBLEM", 45, 65], ["lack tissue", "OBSERVATION_MODIFIER", 77, 88], ["penetration", "OBSERVATION_MODIFIER", 89, 100]]], ["Surface swab cultures are also commonly performed to examine the presence of bacteria and fungi.", [["swab cultures", "ANATOMY", 8, 21], ["Surface swab cultures", "TEST", 0, 21], ["bacteria", "PROBLEM", 77, 85], ["fungi", "PROBLEM", 90, 95], ["bacteria", "OBSERVATION", 77, 85]]], ["The sensitivity of swab cultures has been found to range at best between 78% and 92% [65].", [["swab cultures", "ANATOMY", 19, 32], ["swab cultures", "TEST", 19, 32]]], ["Consequently, it was suggested that cultures should not be used as evidence of sterilization but only to monitor previously validated sterilizing procedures.Preparation of AllograftsHuman tissue grafts cannot be sterilized using methods applied to other implantable medical devices.", [["tissue grafts", "ANATOMY", 188, 201], ["Human", "ORGANISM", 182, 187], ["tissue grafts", "TISSUE", 188, 201], ["Human", "SPECIES", 182, 187], ["cultures", "TEST", 36, 44], ["sterilization", "TREATMENT", 79, 92], ["sterilizing procedures", "TREATMENT", 134, 156], ["AllograftsHuman tissue grafts", "TREATMENT", 172, 201], ["methods", "TREATMENT", 229, 236], ["other implantable medical devices", "TREATMENT", 248, 281], ["sterilization", "OBSERVATION", 79, 92], ["AllograftsHuman tissue grafts", "OBSERVATION", 172, 201]]], ["In particular, the complex three-dimensional structure and the increased tissue density of musculoskeletal grafts make it difficult for reagents to penetrate tissue and to eliminate pathogens.", [["tissue", "ANATOMY", 73, 79], ["musculoskeletal grafts", "ANATOMY", 91, 113], ["tissue", "ANATOMY", 158, 164], ["tissue", "TISSUE", 73, 79], ["musculoskeletal grafts", "TISSUE", 91, 113], ["tissue", "TISSUE", 158, 164], ["the increased tissue density of musculoskeletal grafts", "TREATMENT", 59, 113], ["pathogens", "PROBLEM", 182, 191], ["complex", "OBSERVATION_MODIFIER", 19, 26], ["three", "OBSERVATION_MODIFIER", 27, 32], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["tissue", "OBSERVATION_MODIFIER", 73, 79], ["density", "OBSERVATION_MODIFIER", 80, 87], ["musculoskeletal grafts", "OBSERVATION", 91, 113]]], ["Ideally, a sterilization process should provide a disease-free graft while preserving the mechanical properties and the incorporation characteristics of the graft.", [["graft", "ANATOMY", 157, 162], ["graft", "TISSUE", 63, 68], ["graft", "TISSUE", 157, 162], ["a sterilization process", "TREATMENT", 9, 32], ["a disease-free graft", "TREATMENT", 48, 68], ["the mechanical properties", "TREATMENT", 86, 111], ["the graft", "TREATMENT", 153, 162], ["free graft", "OBSERVATION", 58, 68], ["graft", "OBSERVATION", 157, 162]]], ["Additionally, the reagents used should penetrate adequately the tissue and should be safely removed from tissue without residue.", [["tissue", "ANATOMY", 64, 70], ["tissue", "ANATOMY", 105, 111], ["tissue", "TISSUE", 64, 70], ["tissue", "TISSUE", 105, 111], ["the reagents", "TREATMENT", 14, 26]]], ["Tissue banks currently use many different proprietary processes and protocols to achieve successful disinfection and sterilization of allografts.", [["Tissue", "ANATOMY", 0, 6], ["allografts", "ANATOMY", 134, 144], ["Tissue", "TISSUE", 0, 6], ["allografts", "TISSUE", 134, 144], ["Tissue banks", "TREATMENT", 0, 12], ["many different proprietary processes", "TREATMENT", 27, 63], ["protocols", "TREATMENT", 68, 77], ["successful disinfection", "TREATMENT", 89, 112], ["sterilization of allografts", "TREATMENT", 117, 144], ["allografts", "OBSERVATION", 134, 144]]], ["The FDA, however, requires that each tissue bank is in a position to prove the efficacy of the sterilization process used with validated data.Preparation of AllograftsThe process of removing contamination from allograft tissue is called disinfection.", [["tissue", "ANATOMY", 37, 43], ["allograft tissue", "ANATOMY", 210, 226], ["tissue", "TISSUE", 37, 43], ["allograft tissue", "TISSUE", 210, 226], ["each tissue bank", "TREATMENT", 32, 48], ["the sterilization process", "TREATMENT", 91, 116], ["validated data", "TEST", 127, 141], ["Allografts", "TREATMENT", 157, 167], ["removing contamination", "PROBLEM", 182, 204], ["allograft tissue", "PROBLEM", 210, 226], ["disinfection", "PROBLEM", 237, 249], ["Allografts", "OBSERVATION", 157, 167], ["allograft tissue", "OBSERVATION", 210, 226]]], ["Sterility is defined as the process of killing all forms of life, including microorganisms.", [["Sterility", "DISEASE", 0, 9], ["microorganisms", "PROBLEM", 76, 90]]], ["The effectiveness of the sterilization procedure is expressed by the sterility assurance level (SAL), which measures the likelihood that a viable pathogen exists in or on the allograft tissue.", [["allograft tissue", "ANATOMY", 175, 191], ["allograft tissue", "TISSUE", 175, 191], ["the sterilization procedure", "TREATMENT", 21, 48], ["a viable pathogen", "PROBLEM", 137, 154], ["viable", "OBSERVATION_MODIFIER", 139, 145], ["pathogen", "OBSERVATION", 146, 154], ["allograft", "OBSERVATION", 175, 184]]], ["Currently, most tissue banks attempt to reach a SAL of 10?6, according to the standards set by the American Asso\u00adciation of Tissue Banks (AATB).Preparation of AllograftsThe two main processes for sterilization are irradiation and proprietary chemical processing.", [["tissue", "ANATOMY", 16, 22], ["tissue", "TISSUE", 16, 22], ["Tissue", "TISSUE", 124, 130], ["a SAL", "TREATMENT", 46, 51], ["Allografts", "TREATMENT", 159, 169], ["sterilization", "TREATMENT", 196, 209], ["irradiation", "TREATMENT", 214, 225], ["proprietary chemical processing", "TREATMENT", 230, 261], ["most tissue", "OBSERVATION_MODIFIER", 11, 22], ["banks", "OBSERVATION", 23, 28], ["Allografts", "OBSERVATION", 159, 169], ["main", "OBSERVATION_MODIFIER", 177, 181], ["sterilization", "OBSERVATION", 196, 209]]], ["Ethylene Oxide (EO) is an industrial fumigant originally used for sterilizing medical devices which was introduced into musculoskeletal allograft processing.", [["musculoskeletal allograft", "ANATOMY", 120, 145], ["Ethylene Oxide", "CHEMICAL", 0, 14], ["EO", "CHEMICAL", 16, 18], ["Ethylene Oxide", "CHEMICAL", 0, 14], ["Ethylene Oxide", "SIMPLE_CHEMICAL", 0, 14], ["EO", "SIMPLE_CHEMICAL", 16, 18], ["allograft", "ORGAN", 136, 145], ["Ethylene Oxide (EO)", "TREATMENT", 0, 19], ["an industrial fumigant", "TREATMENT", 23, 45], ["sterilizing medical devices", "TREATMENT", 66, 93], ["musculoskeletal allograft processing", "TREATMENT", 120, 156], ["musculoskeletal", "ANATOMY", 120, 135], ["allograft", "OBSERVATION", 136, 145]]], ["EO has excellent external sterilization properties but does not penetrate tissue adequately.", [["tissue", "ANATOMY", 74, 80], ["EO", "CHEMICAL", 0, 2], ["EO", "SIMPLE_CHEMICAL", 0, 2], ["tissue", "TISSUE", 74, 80], ["excellent external sterilization properties", "TREATMENT", 7, 50], ["excellent", "OBSERVATION_MODIFIER", 7, 16], ["external sterilization", "OBSERVATION", 17, 39]]], ["However, studies with ACL allografts processed with EO have shown poor results.", [["EO", "CHEMICAL", 52, 54], ["ACL allografts", "TISSUE", 22, 36], ["studies", "TEST", 9, 16], ["ACL allografts", "TREATMENT", 22, 36]]], ["A high rate of intra-articular reactions was recorded, including persistent effusion, chronic synovitis, bone dissolution, and ultimately graft failure [48].", [["intra-articular", "ANATOMY", 15, 30], ["bone", "ANATOMY", 105, 109], ["graft", "ANATOMY", 138, 143], ["effusion", "DISEASE", 76, 84], ["synovitis", "DISEASE", 94, 103], ["intra-articular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 30], ["bone", "TISSUE", 105, 109], ["graft", "TISSUE", 138, 143], ["A high rate of intra-articular reactions", "PROBLEM", 0, 40], ["persistent effusion", "PROBLEM", 65, 84], ["chronic synovitis", "PROBLEM", 86, 103], ["bone dissolution", "PROBLEM", 105, 121], ["ultimately graft failure", "PROBLEM", 127, 151], ["high", "OBSERVATION_MODIFIER", 2, 6], ["intra-articular", "OBSERVATION", 15, 30], ["persistent", "OBSERVATION_MODIFIER", 65, 75], ["effusion", "OBSERVATION", 76, 84], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["synovitis", "OBSERVATION", 94, 103], ["bone", "ANATOMY", 105, 109], ["graft failure", "OBSERVATION", 138, 151]]], ["Host tissue reactions caused by chemical residues left in moist tissue were considered responsible for these findings.", [["tissue", "ANATOMY", 5, 11], ["tissue", "ANATOMY", 64, 70], ["tissue", "TISSUE", 5, 11], ["tissue", "TISSUE", 64, 70], ["Host tissue reactions", "PROBLEM", 0, 21], ["chemical residues left in moist tissue", "PROBLEM", 32, 70], ["chemical residues", "OBSERVATION", 32, 49], ["left", "ANATOMY_MODIFIER", 50, 54], ["moist tissue", "ANATOMY", 58, 70]]], ["It was also suggested that this agent is carcinogenic [57], although there is no evidence that EO processed allografts have induced cancer.", [["allografts", "ANATOMY", 108, 118], ["cancer", "ANATOMY", 132, 138], ["EO", "CHEMICAL", 95, 97], ["cancer", "DISEASE", 132, 138], ["EO", "SIMPLE_CHEMICAL", 95, 97], ["allografts", "TISSUE", 108, 118], ["cancer", "CANCER", 132, 138], ["cancer", "PROBLEM", 132, 138], ["no evidence that", "UNCERTAINTY", 78, 94], ["allografts", "OBSERVATION", 108, 118], ["cancer", "OBSERVATION", 132, 138]]], ["The use of EO treated allografts is currently not recommended for ACL reconstruction [45].Preparation of AllograftsGamma-irradiation has been proven effective for sterilization through two different mechanisms: the generation of free radicals and the direct destruction of the organism\u2019s genome.", [["ACL", "ANATOMY", 66, 69], ["EO", "CHEMICAL", 11, 13], ["Gamma-irradiation", "CHEMICAL", 115, 132], ["allografts", "TISSUE", 22, 32], ["ACL", "PATHOLOGICAL_FORMATION", 66, 69], ["EO treated allografts", "TREATMENT", 11, 32], ["ACL reconstruction", "TREATMENT", 66, 84], ["AllograftsGamma-irradiation", "TREATMENT", 105, 132], ["sterilization", "TREATMENT", 163, 176], ["free radicals", "PROBLEM", 229, 242], ["allografts", "OBSERVATION", 22, 32], ["AllograftsGamma-irradiation", "OBSERVATION", 105, 132], ["free radicals", "OBSERVATION", 229, 242]]], ["Doses of 40 kGy are required to neutralize HIV from BPTB allografts [15].", [["HIV", "ORGANISM", 43, 46], ["HIV", "SPECIES", 43, 46], ["HIV", "SPECIES", 43, 46], ["BPTB allografts", "TREATMENT", 52, 67]]], ["Bacteria can be eliminated at lower doses.", [["Bacteria", "PROBLEM", 0, 8]]], ["Studies, however, have indicated that there is a dose-dependent effect of irradiation on the biomechanical properties of the graft [50].", [["graft", "TISSUE", 125, 130], ["Studies", "TEST", 0, 7], ["irradiation on the biomechanical properties of the graft", "TREATMENT", 74, 130], ["graft", "OBSERVATION", 125, 130]]], ["Doses as low as 25 and 40 kGy have been shown to alter significantly the tensile strength of ACL reconstruction allografts [35].", [["ACL reconstruction allografts", "TREATMENT", 93, 122]]], ["It is possible that the collagen structure is affected by free radical production.", [["collagen", "GENE_OR_GENE_PRODUCT", 24, 32], ["free radical", "SIMPLE_CHEMICAL", 58, 70], ["the collagen structure", "PROBLEM", 20, 42], ["free radical production", "PROBLEM", 58, 81], ["collagen", "OBSERVATION", 24, 32], ["free", "OBSERVATION_MODIFIER", 58, 62], ["radical production", "OBSERVATION", 63, 81]]], ["Other studies have suggested that doses less than 25 kGy have no effect on ACL reconstruction outcomes [47].", [["ACL", "ANATOMY", 75, 78], ["ACL", "ORGANISM_SUBDIVISION", 75, 78], ["Other studies", "TEST", 0, 13], ["ACL reconstruction outcomes", "TREATMENT", 75, 102]]], ["The gamma-irradiation dose that most tissue banks currently use ranges from 1 to 35 kGy.Preparation of AllograftsIn vivo studies comparing irradiated and nonirradiated allografts have shown disappointing results.", [["tissue", "ANATOMY", 37, 43], ["tissue", "TISSUE", 37, 43], ["allografts", "TISSUE", 168, 178], ["The gamma-irradiation dose", "TREATMENT", 0, 26], ["Allografts", "TREATMENT", 103, 113], ["vivo studies", "TEST", 116, 128], ["nonirradiated allografts", "TREATMENT", 154, 178], ["most tissue", "OBSERVATION_MODIFIER", 32, 43], ["Allografts", "OBSERVATION", 103, 113]]], ["A study of pati\u00adents who underwent Achilles tendon allograft ACL reconstruction found a significantly higher failure rate in the irradiated (dose 20\u201325 kGy) compared to the nonirradiated group (33% and 2.4%, respectively) [46].", [["Achilles tendon allograft", "ANATOMY", 35, 60], ["A study", "TEST", 0, 7], ["Achilles tendon allograft ACL reconstruction", "TREATMENT", 35, 79], ["a significantly higher failure rate", "PROBLEM", 86, 121], ["Achilles tendon", "ANATOMY", 35, 50], ["allograft", "OBSERVATION", 51, 60], ["significantly", "OBSERVATION_MODIFIER", 88, 101], ["higher", "OBSERVATION_MODIFIER", 102, 108], ["failure", "OBSERVATION", 109, 116]]], ["A similar trend was confirmed in a goat model study of patellar tendon ACL reconstruction with irradiated (40 kGy) and nonirradiated allografts.", [["patellar tendon ACL", "ANATOMY", 55, 74], ["allografts", "ANATOMY", 133, 143], ["patellar tendon ACL", "MULTI-TISSUE_STRUCTURE", 55, 74], ["allografts", "TISSUE", 133, 143], ["goat", "SPECIES", 35, 39], ["goat", "SPECIES", 35, 39], ["a goat model study", "TEST", 33, 51], ["patellar tendon ACL reconstruction", "TREATMENT", 55, 89], ["nonirradiated allografts", "TREATMENT", 119, 143], ["patellar tendon", "ANATOMY", 55, 70], ["ACL reconstruction", "OBSERVATION", 71, 89], ["nonirradiated allografts", "OBSERVATION", 119, 143]]], ["Recently, the pretreatment of allo\u00adgraft tissue with radioprotectant scavengers was introduced in an attempt to block the activity of free radicals and to mini\u00admize the structural damage caused by irradiation [53].", [["allo\u00adgraft tissue", "ANATOMY", 30, 47], ["structural damage", "DISEASE", 169, 186], ["allo\u00adgraft tissue", "TISSUE", 30, 47], ["radioprotectant", "SIMPLE_CHEMICAL", 53, 68], ["allo\u00adgraft tissue", "PROBLEM", 30, 47], ["radioprotectant scavengers", "TREATMENT", 53, 79], ["free radicals", "TREATMENT", 134, 147], ["the structural damage", "PROBLEM", 165, 186], ["damage", "OBSERVATION", 180, 186]]], ["Studies have shown that bone and tendon allografts irradiated at high doses (50 kGy) after pretreatment with radioprotectants demonstrated preimplantation properties similar to conventionally irradiated and nonirradiated allografts [18].Preparation of AllograftsAllograft tissue can be preserved by three different methods: deep fresh-freezing, freeze-drying, and cryopreservation.", [["bone", "ANATOMY", 24, 28], ["tendon allografts", "ANATOMY", 33, 50], ["tissue", "ANATOMY", 272, 278], ["bone", "TISSUE", 24, 28], ["tendon allografts", "TISSUE", 33, 50], ["Allograft tissue", "TISSUE", 262, 278], ["Studies", "TEST", 0, 7], ["bone and tendon allografts", "TREATMENT", 24, 50], ["pretreatment with radioprotectants", "TREATMENT", 91, 125], ["preimplantation properties", "PROBLEM", 139, 165], ["AllograftsAllograft tissue", "TREATMENT", 252, 278], ["cryopreservation", "TREATMENT", 364, 380], ["bone", "ANATOMY", 24, 28], ["tendon", "ANATOMY", 33, 39], ["allografts", "OBSERVATION", 40, 50], ["Allografts", "OBSERVATION", 252, 262], ["Allograft tissue", "OBSERVATION", 262, 278], ["deep fresh", "OBSERVATION_MODIFIER", 324, 334]]], ["Deep freezing is the simplest and most widely used technique.", [["Deep freezing", "PROBLEM", 0, 13], ["freezing", "OBSERVATION", 5, 13]]], ["Tissues are stored after controlled freezing, at temperatures of at least ?70\u00b0C to ?80\u00b0C, which allows their preservation for 3\u20135 years [55].", [["Tissues", "ANATOMY", 0, 7], ["Tissues", "CANCER", 0, 7]]], ["This method has no effect on the strength of the graft [22] and it has been shown to reduce graft antigenicity by destroying class II major histocompatibility proteins [3].", [["graft", "ANATOMY", 92, 97], ["graft", "TISSUE", 49, 54], ["graft", "TISSUE", 92, 97], ["class II major histocompatibility proteins", "GENE_OR_GENE_PRODUCT", 125, 167], ["class II major histocompatibility proteins", "PROTEIN", 125, 167], ["the graft", "TREATMENT", 45, 54], ["graft antigenicity", "TREATMENT", 92, 110], ["no", "UNCERTAINTY", 16, 18], ["effect", "OBSERVATION_MODIFIER", 19, 25], ["graft", "OBSERVATION", 49, 54], ["graft", "OBSERVATION", 92, 97]]], ["Freeze-drying is also commonly used.", [["Freeze-drying", "TREATMENT", 0, 13]]], ["It involves dehydration of the grafts during freezing in a vacuum to a residual water content level of less than 5%.", [["grafts", "ANATOMY", 31, 37], ["dehydration", "DISEASE", 12, 23], ["grafts", "TISSUE", 31, 37], ["dehydration", "PROBLEM", 12, 23], ["the grafts", "TREATMENT", 27, 37], ["a vacuum", "TREATMENT", 57, 65], ["a residual water content level", "TEST", 69, 99], ["dehydration", "OBSERVATION", 12, 23], ["grafts", "OBSERVATION", 31, 37], ["vacuum", "OBSERVATION", 59, 65], ["residual", "OBSERVATION_MODIFIER", 71, 79], ["water content", "OBSERVATION", 80, 93]]], ["Therefore, the grafts need to be rehydrated for at least 30 min before implantation, especially if they contain bone blocks along with the soft tissue.", [["grafts", "ANATOMY", 15, 21], ["bone", "ANATOMY", 112, 116], ["soft tissue", "ANATOMY", 139, 150], ["grafts", "TISSUE", 15, 21], ["bone", "TISSUE", 112, 116], ["soft tissue", "TISSUE", 139, 150], ["the grafts", "TREATMENT", 11, 21], ["implantation", "TREATMENT", 71, 83], ["bone blocks", "PROBLEM", 112, 123], ["grafts", "OBSERVATION", 15, 21], ["bone", "ANATOMY", 112, 116], ["soft tissue", "ANATOMY", 139, 150]]], ["Viral load of infected tissue can be decreased to sub-infectious levels with this method [4], although this has been argued by other reports [12].", [["tissue", "ANATOMY", 23, 29], ["Viral", "ORGANISM", 0, 5], ["tissue", "TISSUE", 23, 29], ["Viral load of infected tissue", "PROBLEM", 0, 29], ["infected tissue", "OBSERVATION", 14, 29], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["infectious", "OBSERVATION", 54, 64]]], ["Graft antigenicity is also reduced with freeze-drying.", [["Graft", "ANATOMY", 0, 5], ["Graft", "TISSUE", 0, 5], ["Graft antigenicity", "TREATMENT", 0, 18], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["freeze", "OBSERVATION_MODIFIER", 40, 46], ["drying", "OBSERVATION_MODIFIER", 47, 53]]], ["However, the time interval between procurement and implantation has been positively correlated with allograft failure rates in ACL reconstruction, thus questioning the shelf life of freeze-dried tissues [58].", [["allograft", "ANATOMY", 100, 109], ["ACL", "ANATOMY", 127, 130], ["tissues", "ANATOMY", 195, 202], ["allograft", "TISSUE", 100, 109], ["ACL", "PATHOLOGICAL_FORMATION", 127, 130], ["tissues", "TISSUE", 195, 202], ["procurement and implantation", "TREATMENT", 35, 63], ["allograft failure rates", "PROBLEM", 100, 123], ["ACL reconstruction", "TREATMENT", 127, 145], ["allograft failure", "OBSERVATION", 100, 117], ["ACL reconstruction", "OBSERVATION", 127, 145]]], ["Clinical results of freeze-dried allografts have been successful overall [34], although slightly better results have been reported for fresh-frozen allografts [20].", [["allografts", "ANATOMY", 148, 158], ["allografts", "TISSUE", 33, 43], ["freeze-dried allografts", "TREATMENT", 20, 43], ["fresh-frozen allografts", "TREATMENT", 135, 158]]], ["The third method of tissue preservation is cryopreservation, which employs a controlled rate of freezing with a cryoprotectant media but it has shown no known advantages over fresh-freezing while incurring a considerably higher cost.Surgical TechniqueThere are no significant differences in surgical technique when using allografts.", [["tissue", "ANATOMY", 20, 26], ["allografts", "ANATOMY", 321, 331], ["tissue", "TISSUE", 20, 26], ["allografts", "TISSUE", 321, 331], ["cryopreservation", "TREATMENT", 43, 59], ["a cryoprotectant media", "TREATMENT", 110, 132], ["Surgical Technique", "TREATMENT", 233, 251], ["surgical technique", "TREATMENT", 291, 309], ["allografts", "TREATMENT", 321, 331], ["no", "UNCERTAINTY", 150, 152], ["no", "UNCERTAINTY", 261, 263], ["significant", "OBSERVATION_MODIFIER", 264, 275], ["differences", "OBSERVATION_MODIFIER", 276, 287], ["surgical", "OBSERVATION", 291, 299]]], ["The most popular type of allografts, fresh-frozen, do not require rehydration and have good results in clinical and basic science research [20].", [["allografts", "ANATOMY", 25, 35], ["allografts", "TISSUE", 25, 35], ["fresh-frozen", "TREATMENT", 37, 49], ["rehydration", "TREATMENT", 66, 77], ["most popular", "OBSERVATION_MODIFIER", 4, 16], ["allografts", "OBSERVATION", 25, 35]]], ["They also allow the use of identical instrumentation for autograft or allograft procedures and if there are bone-blocks, like BPTB grafts, there is excellent bone-to-bone healing and rigid interference fixation.Surgical TechniqueThe graft is thawed when the evaluation under anesthesia confirms the ACL deficiency.", [["allograft", "ANATOMY", 70, 79], ["bone", "ANATOMY", 108, 112], ["BPTB grafts", "ANATOMY", 126, 137], ["bone", "ANATOMY", 158, 162], ["bone", "ANATOMY", 166, 170], ["graft", "ANATOMY", 233, 238], ["ACL deficiency", "DISEASE", 299, 313], ["bone", "TISSUE", 108, 112], ["BPTB grafts", "TISSUE", 126, 137], ["bone", "TISSUE", 158, 162], ["bone", "TISSUE", 166, 170], ["graft", "TISSUE", 233, 238], ["ACL", "GENE_OR_GENE_PRODUCT", 299, 302], ["identical instrumentation", "TREATMENT", 27, 52], ["autograft", "TREATMENT", 57, 66], ["allograft procedures", "TREATMENT", 70, 90], ["bone-blocks", "PROBLEM", 108, 119], ["BPTB grafts", "TREATMENT", 126, 137], ["bone healing", "PROBLEM", 166, 178], ["rigid interference fixation", "TREATMENT", 183, 210], ["Surgical Technique", "TREATMENT", 211, 229], ["The graft", "TREATMENT", 229, 238], ["the evaluation", "TEST", 254, 268], ["anesthesia", "TREATMENT", 275, 285], ["the ACL deficiency", "PROBLEM", 295, 313], ["allograft", "OBSERVATION", 70, 79], ["bone", "ANATOMY", 108, 112], ["BPTB grafts", "OBSERVATION", 126, 137], ["excellent", "OBSERVATION_MODIFIER", 148, 157], ["bone", "ANATOMY", 158, 162], ["bone", "ANATOMY", 166, 170], ["healing", "OBSERVATION", 171, 178], ["rigid", "OBSERVATION", 183, 188], ["interference fixation", "OBSERVATION", 189, 210], ["graft", "OBSERVATION", 233, 238], ["ACL deficiency", "OBSERVATION", 299, 313]]], ["It should not be placed directly into warm saline solution, because it can become edematous and hypertrophy.", [["hypertrophy", "DISEASE", 96, 107], ["saline", "SIMPLE_CHEMICAL", 43, 49], ["warm saline solution", "TREATMENT", 38, 58], ["edematous", "PROBLEM", 82, 91], ["hypertrophy", "PROBLEM", 96, 107], ["edematous", "OBSERVATION", 82, 91], ["hypertrophy", "OBSERVATION", 96, 107]]], ["It is best thawed by keeping the tendon in the plastic bag while in the solution.", [["tendon", "ANATOMY", 33, 39], ["tendon", "TISSUE", 33, 39], ["the plastic bag", "TREATMENT", 43, 58], ["tendon", "ANATOMY", 33, 39], ["plastic bag", "OBSERVATION", 47, 58]]], ["Alternatively, thawing the graft can begin once diagnostic arthroscopy confirms the ACL rupture.", [["graft", "ANATOMY", 27, 32], ["ACL", "ANATOMY", 84, 87], ["ACL rupture", "DISEASE", 84, 95], ["graft", "TISSUE", 27, 32], ["ACL", "PATHOLOGICAL_FORMATION", 84, 87], ["the graft", "TREATMENT", 23, 32], ["diagnostic arthroscopy", "TEST", 48, 70], ["the ACL rupture", "PROBLEM", 80, 95], ["graft", "OBSERVATION", 27, 32], ["ACL rupture", "OBSERVATION", 84, 95]]], ["The thawed allograft is evaluated to confirm tissue integrity and quality.", [["allograft", "ANATOMY", 11, 20], ["tissue", "ANATOMY", 45, 51], ["allograft", "TISSUE", 11, 20], ["tissue", "TISSUE", 45, 51], ["The thawed allograft", "TREATMENT", 0, 20], ["allograft", "OBSERVATION", 11, 20]]], ["Soft tissue size (length and diameter) is measured and recorded.", [["Soft tissue", "ANATOMY", 0, 11], ["Soft tissue", "TISSUE", 0, 11], ["tissue", "OBSERVATION", 5, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["length", "OBSERVATION_MODIFIER", 18, 24], ["diameter", "OBSERVATION_MODIFIER", 29, 37]]], ["If we have a patella tendon, its central third is harvested similarly to autograft harvest.", [["patella tendon", "ANATOMY", 13, 27], ["patella tendon", "MULTI-TISSUE_STRUCTURE", 13, 27], ["autograft", "TISSUE", 73, 82], ["autograft harvest", "TREATMENT", 73, 90], ["patella tendon", "ANATOMY", 13, 27], ["central", "OBSERVATION_MODIFIER", 33, 40], ["harvested", "OBSERVATION", 50, 59], ["autograft harvest", "OBSERVATION", 73, 90]]], ["To avoid splintering, care should be taken to avoid forcible levering of the bone plugs from their beds.", [["bone", "ANATOMY", 77, 81], ["bone", "TISSUE", 77, 81], ["care", "TREATMENT", 22, 26], ["the bone plugs", "PROBLEM", 73, 87], ["bone", "ANATOMY", 77, 81], ["plugs", "OBSERVATION", 82, 87]]], ["If a soft tissue graft is used, the thawing process is the same.", [["soft tissue", "ANATOMY", 5, 16], ["soft tissue graft", "TISSUE", 5, 22], ["a soft tissue graft", "TREATMENT", 3, 22], ["the thawing process", "TREATMENT", 32, 51], ["soft tissue", "OBSERVATION_MODIFIER", 5, 16], ["graft", "OBSERVATION", 17, 22]]], ["The rest of ACL reconstruction technique steps are almost the same when using autografts.", [["ACL", "MULTI-TISSUE_STRUCTURE", 12, 15], ["autografts", "TISSUE", 78, 88], ["ACL reconstruction technique steps", "TREATMENT", 12, 46], ["autografts", "TREATMENT", 78, 88]]], ["For the double-bundle technique, soft tissue allografts (most popular tibialis anterior or posterior) provide an excellent graft source for both surgical process and final functional result [63].Biomechanics and Biology of Allograft HealingThe major factors that contribute to a successful allograft implantation are sterility, reduction of antigenicity, and preservation of the biomechanical and biologic properties of the graft [61].Biomechanics and Biology of Allograft HealingAllograft antigenicity is based on class I and II antigens encoded by genes of the major histocompatibility complex.", [["soft tissue allografts", "ANATOMY", 33, 55], ["tibialis anterior", "ANATOMY", 70, 87], ["graft", "ANATOMY", 123, 128], ["allograft", "ANATOMY", 290, 299], ["soft tissue allografts", "TISSUE", 33, 55], ["tibialis anterior", "MULTI-TISSUE_STRUCTURE", 70, 87], ["posterior", "MULTI-TISSUE_STRUCTURE", 91, 100], ["graft", "TISSUE", 123, 128], ["allograft", "TISSUE", 290, 299], ["graft", "TISSUE", 424, 429], ["class I and II antigens", "GENE_OR_GENE_PRODUCT", 515, 538], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 563, 595], ["class I and II antigens", "PROTEIN", 515, 538], ["major histocompatibility complex", "PROTEIN", 563, 595], ["the double-bundle technique", "TREATMENT", 4, 31], ["soft tissue allografts", "TREATMENT", 33, 55], ["Allograft Healing", "TREATMENT", 223, 240], ["a successful allograft implantation", "TREATMENT", 277, 312], ["sterility", "PROBLEM", 317, 326], ["antigenicity", "PROBLEM", 341, 353], ["the graft", "TREATMENT", 420, 429], ["Allograft HealingAllograft antigenicity", "TREATMENT", 463, 502], ["soft tissue", "ANATOMY", 33, 44], ["allografts", "OBSERVATION", 45, 55], ["posterior", "ANATOMY_MODIFIER", 91, 100], ["excellent", "OBSERVATION_MODIFIER", 113, 122], ["graft", "OBSERVATION", 123, 128], ["Allograft", "OBSERVATION", 223, 232], ["successful", "OBSERVATION_MODIFIER", 279, 289], ["allograft", "OBSERVATION", 290, 299], ["reduction", "OBSERVATION_MODIFIER", 328, 337], ["antigenicity", "OBSERVATION_MODIFIER", 341, 353], ["biomechanical", "OBSERVATION_MODIFIER", 379, 392], ["graft", "OBSERVATION", 424, 429], ["Allograft", "OBSERVATION", 463, 472], ["Healing", "OBSERVATION_MODIFIER", 473, 480], ["Allograft", "OBSERVATION", 480, 489]]], ["Antigenic epitopes may be present on donor cells in the ligamentous or bone components and also inside the matrix of the allograft.", [["donor cells", "ANATOMY", 37, 48], ["ligamentous", "ANATOMY", 56, 67], ["bone components", "ANATOMY", 71, 86], ["matrix", "ANATOMY", 107, 113], ["allograft", "ANATOMY", 121, 130], ["donor cells", "CELL", 37, 48], ["ligamentous", "TISSUE", 56, 67], ["bone components", "MULTI-TISSUE_STRUCTURE", 71, 86], ["matrix", "CELLULAR_COMPONENT", 107, 113], ["allograft", "TISSUE", 121, 130], ["Antigenic epitopes", "PROTEIN", 0, 18], ["donor cells", "CELL_TYPE", 37, 48], ["Antigenic epitopes", "PROBLEM", 0, 18], ["epitopes", "OBSERVATION", 10, 18], ["may be", "UNCERTAINTY", 19, 25], ["donor cells", "OBSERVATION", 37, 48], ["ligamentous", "ANATOMY", 56, 67], ["bone", "ANATOMY", 71, 75], ["matrix", "OBSERVATION_MODIFIER", 107, 113], ["allograft", "OBSERVATION", 121, 130]]], ["Fresh and cryopreserved allografts contain viable donor cells and are most likely to elicit a host immune response.", [["allografts", "ANATOMY", 24, 34], ["cells", "ANATOMY", 56, 61], ["allografts", "TISSUE", 24, 34], ["donor cells", "CELL", 50, 61], ["donor cells", "CELL_TYPE", 50, 61], ["Fresh and cryopreserved allografts", "TREATMENT", 0, 34], ["viable donor cells", "TREATMENT", 43, 61], ["cryopreserved allografts", "OBSERVATION", 10, 34], ["viable donor cells", "OBSERVATION", 43, 61], ["most likely", "UNCERTAINTY", 70, 81]]], ["Deep-frozen and freeze-dried allografts are relatively hypocellular.", [["allografts", "ANATOMY", 29, 39], ["allografts", "TISSUE", 29, 39], ["Deep-frozen and freeze-dried allografts", "TREATMENT", 0, 39], ["relatively hypocellular", "PROBLEM", 44, 67], ["frozen", "OBSERVATION", 5, 11], ["freeze", "OBSERVATION_MODIFIER", 16, 22], ["dried allografts", "OBSERVATION", 23, 39], ["relatively", "OBSERVATION_MODIFIER", 44, 54], ["hypocellular", "OBSERVATION", 55, 67]]], ["A T-lymphocyte cell-mediated response is the principal mechanism of host rejection, which may often mimic infection or mechanical failure [59].", [["T-lymphocyte cell", "ANATOMY", 2, 19], ["infection", "DISEASE", 106, 115], ["T-lymphocyte cell", "CELL", 2, 19], ["A T-lymphocyte cell", "TEST", 0, 19], ["host rejection", "PROBLEM", 68, 82], ["mechanical failure", "PROBLEM", 119, 137], ["lymphocyte cell", "OBSERVATION", 4, 19], ["host rejection", "OBSERVATION", 68, 82], ["infection", "OBSERVATION", 106, 115], ["mechanical failure", "OBSERVATION", 119, 137]]], ["The clinical consequences of such a response are currently unknown.Biomechanics and Biology of Allograft HealingAllografts, in general, heal in the same manner as autografts: donor cell death is followed by inflammation, revascularization-repopulation, and finally remodeling of the graft.", [["cell", "ANATOMY", 181, 185], ["graft", "ANATOMY", 283, 288], ["death", "DISEASE", 186, 191], ["inflammation", "DISEASE", 207, 219], ["cell", "CELL", 181, 185], ["graft", "TISSUE", 283, 288], ["Allograft HealingAllografts", "TREATMENT", 95, 122], ["cell death", "PROBLEM", 181, 191], ["inflammation", "PROBLEM", 207, 219], ["revascularization", "TREATMENT", 221, 238], ["repopulation", "TREATMENT", 239, 251], ["the graft", "TREATMENT", 279, 288], ["Allograft", "OBSERVATION", 95, 104], ["Healing", "OBSERVATION_MODIFIER", 105, 112], ["Allografts", "OBSERVATION", 112, 122], ["inflammation", "OBSERVATION", 207, 219], ["graft", "OBSERVATION", 283, 288]]], ["In the case of deep-frozen or freeze-dried allografts, donor cell death has already occurred before implantation.", [["allografts", "ANATOMY", 43, 53], ["cell", "ANATOMY", 61, 65], ["death", "DISEASE", 66, 71], ["allografts", "TISSUE", 43, 53], ["cell", "CELL", 61, 65], ["deep-frozen or freeze-dried allografts", "TREATMENT", 15, 53], ["donor cell death", "PROBLEM", 55, 71], ["implantation", "TREATMENT", 100, 112], ["deep", "ANATOMY_MODIFIER", 15, 19], ["dried allografts", "OBSERVATION", 37, 53], ["donor cell death", "OBSERVATION", 55, 71]]], ["Tendon allografts heal through the formation of fibrovascular scar tissue at the graft-tunnel interface followed by the formation of Sharpey\u2019s fibers and new bone production.", [["Tendon allografts", "ANATOMY", 0, 17], ["fibrovascular scar tissue", "ANATOMY", 48, 73], ["graft", "ANATOMY", 81, 86], ["Sharpey\u2019s fibers", "ANATOMY", 133, 149], ["bone", "ANATOMY", 158, 162], ["Tendon allografts", "TISSUE", 0, 17], ["fibrovascular scar tissue", "TISSUE", 48, 73], ["graft", "TISSUE", 81, 86], ["bone", "TISSUE", 158, 162], ["Tendon allografts heal", "TREATMENT", 0, 22], ["fibrovascular scar tissue", "PROBLEM", 48, 73], ["the graft-tunnel interface", "TREATMENT", 77, 103], ["Sharpey\u2019s fibers", "TREATMENT", 133, 149], ["new bone production", "PROBLEM", 154, 173], ["allografts", "OBSERVATION", 7, 17], ["fibrovascular", "OBSERVATION_MODIFIER", 48, 61], ["scar", "OBSERVATION", 62, 66], ["graft", "OBSERVATION", 81, 86], ["tunnel interface", "OBSERVATION", 87, 103], ["new", "OBSERVATION_MODIFIER", 154, 157], ["bone production", "OBSERVATION", 158, 173]]], ["Bone blocks contained in allografts first undergo osteonecrosis followed by incorporation of the graft by the surrounding host can\u00adcellous bone.", [["Bone", "ANATOMY", 0, 4], ["allografts", "ANATOMY", 25, 35], ["graft", "ANATOMY", 97, 102], ["can\u00adcellous bone", "ANATOMY", 127, 143], ["osteonecrosis", "DISEASE", 50, 63], ["Bone", "MULTI-TISSUE_STRUCTURE", 0, 4], ["allografts", "TISSUE", 25, 35], ["graft", "TISSUE", 97, 102], ["can\u00adcellous", "TISSUE", 127, 138], ["bone", "TISSUE", 139, 143], ["Bone blocks", "PROBLEM", 0, 11], ["allografts", "TREATMENT", 25, 35], ["osteonecrosis", "PROBLEM", 50, 63], ["the graft", "TREATMENT", 93, 102], ["allografts", "OBSERVATION", 25, 35], ["osteonecrosis", "OBSERVATION", 50, 63], ["graft", "OBSERVATION", 97, 102], ["host", "ANATOMY_MODIFIER", 122, 126], ["can\u00adcellous", "ANATOMY_MODIFIER", 127, 138], ["bone", "ANATOMY", 139, 143]]], ["The intra-articular part of the graft acts as a \u00adcollagen scaffold for host cells to repopulate.", [["intra-articular", "ANATOMY", 4, 19], ["graft", "ANATOMY", 32, 37], ["cells", "ANATOMY", 76, 81], ["graft", "TISSUE", 32, 37], ["host cells", "CELL", 71, 81], ["host cells", "CELL_TYPE", 71, 81], ["the graft", "TREATMENT", 28, 37], ["a \u00adcollagen scaffold", "TREATMENT", 46, 66], ["host cells", "TREATMENT", 71, 81], ["intra-articular", "OBSERVATION_MODIFIER", 4, 19], ["graft", "OBSERVATION", 32, 37]]], ["Graft revascu\u00adlarization occurs from the infrapatellar fat pad distally and the posterior synovial tissues proximally [39].", [["Graft", "ANATOMY", 0, 5], ["infrapatellar fat pad distally", "ANATOMY", 41, 71], ["posterior synovial tissues", "ANATOMY", 80, 106], ["Graft", "TISSUE", 0, 5], ["infrapatellar fat pad distally", "TISSUE", 41, 71], ["posterior synovial tissues", "TISSUE", 80, 106], ["Graft revascu\u00adlarization", "TREATMENT", 0, 24], ["infrapatellar fat", "ANATOMY", 41, 58], ["pad", "ANATOMY_MODIFIER", 59, 62], ["distally", "ANATOMY_MODIFIER", 63, 71], ["posterior", "ANATOMY_MODIFIER", 80, 89], ["synovial tissues", "ANATOMY", 90, 106], ["proximally", "ANATOMY_MODIFIER", 107, 117]]], ["Finally, collagen remodeling involves the replacement of the original large-diameter fibrils with smaller-diameter ones.Biomechanics and Biology of Allograft HealingThe incorporation rate of graft tissue may be an important consideration when determining graft choice, rehabilitation protocol, or time to return to play.", [["fibrils", "ANATOMY", 85, 92], ["graft tissue", "ANATOMY", 191, 203], ["graft", "ANATOMY", 255, 260], ["collagen", "GENE_OR_GENE_PRODUCT", 9, 17], ["graft tissue", "TISSUE", 191, 203], ["graft", "TISSUE", 255, 260], ["collagen", "PROTEIN", 9, 17], ["collagen remodeling", "PROBLEM", 9, 28], ["the replacement", "TREATMENT", 38, 53], ["the original large-diameter fibrils", "TREATMENT", 57, 92], ["smaller-diameter ones", "PROBLEM", 98, 119], ["Allograft Healing", "TREATMENT", 148, 165], ["The incorporation rate of graft tissue", "TREATMENT", 165, 203], ["rehabilitation protocol", "TREATMENT", 269, 292], ["collagen remodeling", "OBSERVATION", 9, 28], ["replacement", "OBSERVATION_MODIFIER", 42, 53], ["large", "OBSERVATION_MODIFIER", 70, 75], ["-diameter", "OBSERVATION_MODIFIER", 75, 84], ["fibrils", "OBSERVATION_MODIFIER", 85, 92], ["smaller", "OBSERVATION_MODIFIER", 98, 105], ["-diameter", "OBSERVATION_MODIFIER", 105, 114], ["Allograft", "OBSERVATION", 148, 157], ["graft tissue", "OBSERVATION", 191, 203]]], ["Compared to autografts, allografts were found to demonstrate a prolonged inflammatory response, a greater decrease in structural and mechanical properties and a slower rate of biologic incorporation after implantation [23].", [["autografts", "ANATOMY", 12, 22], ["allografts", "ANATOMY", 24, 34], ["autografts", "TISSUE", 12, 22], ["allografts", "TISSUE", 24, 34], ["autografts", "TREATMENT", 12, 22], ["allografts", "TREATMENT", 24, 34], ["a prolonged inflammatory response", "PROBLEM", 61, 94], ["a greater decrease in structural and mechanical properties", "PROBLEM", 96, 154], ["biologic incorporation after implantation", "TREATMENT", 176, 217], ["allografts", "OBSERVATION", 24, 34], ["prolonged", "OBSERVATION_MODIFIER", 63, 72], ["inflammatory", "OBSERVATION", 73, 85], ["greater", "OBSERVATION_MODIFIER", 98, 105], ["decrease", "OBSERVATION_MODIFIER", 106, 114], ["mechanical properties", "OBSERVATION_MODIFIER", 133, 154]]], ["Allogenic tendons also demonstrated a slower onset and rate of revascularization [38].", [["tendons", "ANATOMY", 10, 17], ["tendons", "MULTI-TISSUE_STRUCTURE", 10, 17], ["a slower onset", "PROBLEM", 36, 50], ["revascularization", "TREATMENT", 63, 80], ["tendons", "ANATOMY", 10, 17], ["slower", "OBSERVATION_MODIFIER", 38, 44]]], ["Greater bone tunnel enlargement observed after allograft ACL reconstruction may also suggest suboptimal healing of allograft tissue [14].", [["bone", "ANATOMY", 8, 12], ["allograft", "ANATOMY", 47, 56], ["allograft tissue", "ANATOMY", 115, 131], ["bone tunnel", "MULTI-TISSUE_STRUCTURE", 8, 19], ["allograft tissue", "TISSUE", 115, 131], ["Greater bone tunnel enlargement", "PROBLEM", 0, 31], ["allograft ACL reconstruction", "TREATMENT", 47, 75], ["suboptimal healing of allograft tissue", "PROBLEM", 93, 131], ["bone", "ANATOMY", 8, 12], ["tunnel enlargement", "OBSERVATION", 13, 31], ["allograft ACL reconstruction", "OBSERVATION", 47, 75], ["may also suggest", "UNCERTAINTY", 76, 92], ["suboptimal", "OBSERVATION_MODIFIER", 93, 103], ["healing", "OBSERVATION_MODIFIER", 104, 111], ["allograft tissue", "OBSERVATION", 115, 131]]], ["Although allografts seem to lose more of their time-zero strength during remodeling, this has not been associated with a poorer prognosis [24].", [["allografts", "ANATOMY", 9, 19], ["allografts", "TISSUE", 9, 19], ["allografts", "TREATMENT", 9, 19], ["allografts", "OBSERVATION", 9, 19]]], ["The general conclusion is that allografts seem to heal in the same pattern but at a slower rate than autografts.Clinical Studies Comparing Allograft and Autograft Use in ACL ReconstructionA true prospective, randomized clinical trial of autograft versus allograft ACL reconstruction is difficult because graft choice is influenced by patient age, activity level, comorbidities, and preoperative evaluation, as well as by surgeon preference and experience.", [["allografts", "ANATOMY", 31, 41], ["allograft", "ANATOMY", 254, 263], ["graft", "ANATOMY", 304, 309], ["allografts", "TISSUE", 31, 41], ["autografts", "TISSUE", 101, 111], ["allograft ACL", "MULTI-TISSUE_STRUCTURE", 254, 267], ["graft", "TISSUE", 304, 309], ["patient", "ORGANISM", 334, 341], ["patient", "SPECIES", 334, 341], ["allografts", "TREATMENT", 31, 41], ["autografts", "TREATMENT", 101, 111], ["Clinical Studies", "TEST", 112, 128], ["Allograft and Autograft Use", "TREATMENT", 139, 166], ["ACL ReconstructionA true prospective", "TREATMENT", 170, 206], ["randomized clinical trial of autograft", "TREATMENT", 208, 246], ["allograft ACL reconstruction", "TREATMENT", 254, 282], ["graft choice", "TREATMENT", 304, 316], ["comorbidities", "PROBLEM", 363, 376], ["preoperative evaluation", "TEST", 382, 405], ["allografts", "OBSERVATION", 31, 41], ["Allograft", "OBSERVATION", 139, 148], ["Autograft", "OBSERVATION", 153, 162], ["autograft", "OBSERVATION", 237, 246]]], ["Patients should be informed about all the possible risks and benefits of each option.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["each option", "TREATMENT", 73, 84]]], ["In addition, there are specific limitations including the several different scoring scales, the different kinds of patients with different prognoses, and different surgeons or rehabilitation regi\u00admes [16].", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["rehabilitation regi\u00admes", "TREATMENT", 176, 199], ["different kinds", "OBSERVATION_MODIFIER", 96, 111]]], ["During the last years, the international literature \u00adpresented 14 published clinical comparative studies about allograft and autograft use in ACL reconstruction (Table 1).", [["allograft", "ANATOMY", 111, 120], ["ACL", "ANATOMY", 142, 145], ["allograft", "TISSUE", 111, 120], ["autograft", "TISSUE", 125, 134], ["ACL", "TISSUE", 142, 145], ["clinical comparative studies", "TEST", 76, 104], ["allograft and autograft use in ACL reconstruction", "TREATMENT", 111, 160], ["autograft", "OBSERVATION", 125, 134]]], ["Most of them reported little differences in a long-term basis [19, 31, 33, 41, 43, 49, 54, 56].", [["little", "OBSERVATION_MODIFIER", 22, 28], ["differences", "OBSERVATION_MODIFIER", 29, 40]]], ["However, some studies have reported high rupture rates postoperatively with allografts [10, 60] and others have suggested that use of allograft should be reduced due to increased laxity over time [66].", [["allograft", "ANATOMY", 134, 143], ["rupture", "DISEASE", 41, 48], ["allograft", "TISSUE", 134, 143], ["some studies", "TEST", 9, 21], ["high rupture rates", "PROBLEM", 36, 54], ["allografts", "TREATMENT", 76, 86], ["allograft", "TREATMENT", 134, 143], ["increased laxity", "PROBLEM", 169, 185], ["high", "OBSERVATION_MODIFIER", 36, 40], ["rupture", "OBSERVATION", 41, 48], ["allograft", "OBSERVATION", 134, 143]]], ["It is also important to say that all the comparative studies used allografts with bone-blocks (mostly BPTB) and there is a significant lack of comparisons between soft tissue allo- and autografts, which would be extremely useful for evaluating the double-bundle technique.", [["allografts", "ANATOMY", 66, 76], ["bone", "ANATOMY", 82, 86], ["soft tissue", "ANATOMY", 163, 174], ["allografts", "TISSUE", 66, 76], ["bone", "TISSUE", 82, 86], ["soft tissue", "TISSUE", 163, 174], ["autografts", "TISSUE", 185, 195], ["allografts", "TREATMENT", 66, 76], ["bone-blocks (mostly BPTB", "TREATMENT", 82, 106], ["soft tissue allo- and autografts", "TREATMENT", 163, 195], ["the double-bundle technique", "TREATMENT", 244, 271], ["bone", "ANATOMY", 82, 86]]], ["In specific reviews and meta-analyses, the literature moves from accepting the use of allograft tissue to be much more favorable than unfavorable [36], into presenting the autografts as graft of choice for routine ACL reconstruction with allografts better reserved for multiple ligament-injured knees where extra tissue may be required [44].", [["allograft tissue", "ANATOMY", 86, 102], ["graft", "ANATOMY", 186, 191], ["ACL", "ANATOMY", 214, 217], ["allografts", "ANATOMY", 238, 248], ["ligament", "ANATOMY", 278, 286], ["knees", "ANATOMY", 295, 300], ["tissue", "ANATOMY", 313, 319], ["allograft tissue", "TISSUE", 86, 102], ["autografts", "TISSUE", 172, 182], ["graft", "TISSUE", 186, 191], ["ACL", "MULTI-TISSUE_STRUCTURE", 214, 217], ["allografts", "TISSUE", 238, 248], ["ligament", "TISSUE", 278, 286], ["knees", "TISSUE", 295, 300], ["tissue", "TISSUE", 313, 319], ["meta-analyses", "TEST", 24, 37], ["allograft tissue", "TREATMENT", 86, 102], ["the autografts", "TREATMENT", 168, 182], ["graft of choice", "TREATMENT", 186, 201], ["routine ACL reconstruction", "TREATMENT", 206, 232], ["allografts", "TREATMENT", 238, 248], ["multiple ligament-injured knees", "TREATMENT", 269, 300], ["graft", "OBSERVATION", 186, 191], ["allografts", "OBSERVATION", 238, 248], ["ligament", "ANATOMY", 278, 286], ["injured", "OBSERVATION", 287, 294], ["knees", "ANATOMY", 295, 300]]], ["In another review, ACL reconstruction with BPTB autograft was favored over BPTB allograft for graft rupture and hop test parameters.", [["graft", "ANATOMY", 94, 99], ["ACL", "PATHOLOGICAL_FORMATION", 19, 22], ["graft", "TISSUE", 94, 99], ["ACL reconstruction", "TREATMENT", 19, 37], ["BPTB autograft", "TREATMENT", 43, 57], ["BPTB allograft", "TREATMENT", 75, 89], ["graft rupture", "PROBLEM", 94, 107], ["hop test parameters", "TEST", 112, 131], ["BPTB autograft", "OBSERVATION", 43, 57], ["graft rupture", "OBSERVATION", 94, 107]]], ["However, in the latter study, the irradiated and chemically processed allografts were excluded and the results were not significantly different between the two graft types [30].", [["allografts", "ANATOMY", 70, 80], ["graft", "ANATOMY", 160, 165], ["allografts", "TISSUE", 70, 80], ["graft", "TISSUE", 160, 165], ["the latter study", "TEST", 12, 28], ["the irradiated and chemically processed allografts", "TREATMENT", 30, 80], ["allografts", "OBSERVATION", 70, 80], ["graft", "OBSERVATION", 160, 165]]]], "159a48b3ad4c914ae902222a208be9db596befc4": [["IntroductionSince being declared a pandemic by the World Health Organization on March 11, 2020 coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly causing significant suffering worldwide.", [["coronavirus disease", "DISEASE", 95, 114], ["COVID-19", "CHEMICAL", 116, 124], ["acute respiratory syndrome coronavirus", "DISEASE", 144, 182], ["coronavirus", "ORGANISM", 95, 106], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 137, 184], ["SARS-CoV-2", "ORGANISM", 186, 196], ["severe acute respiratory syndrome coronavirus", "SPECIES", 137, 182], ["SARS-CoV-2", "SPECIES", 186, 196], ["coronavirus disease", "PROBLEM", 95, 114], ["COVID", "TEST", 116, 121], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 137, 182], ["coronavirus disease", "OBSERVATION", 95, 114], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory syndrome", "OBSERVATION", 150, 170], ["significant", "OBSERVATION_MODIFIER", 226, 237]]], ["1 In the United States (US) alone there were 895,766 reported cases and 50,439 reported deaths as of April 26, 2020.", [["deaths", "DISEASE", 88, 94]]], ["2 In addition to the physical effects of COVID-19, the disease has also challenged the psychological resilience of many individuals and altered behavioral patterns.", [["COVID-19", "CHEMICAL", 41, 49], ["COVID-19", "CHEMICAL", 41, 49], ["COVID", "TEST", 41, 46], ["the disease", "PROBLEM", 51, 62], ["altered behavioral patterns", "PROBLEM", 136, 163], ["disease", "OBSERVATION", 55, 62]]], ["For instance, a study, which surveyed the Chinese public (from January 31, 2020 to February 2, 2020), found that 54% of respondents rated the psychological impact of the COVID-19 pandemic as moderate or severe.", [["a study", "TEST", 14, 21], ["the COVID", "TEST", 166, 175], ["pandemic", "PROBLEM", 179, 187], ["moderate", "OBSERVATION_MODIFIER", 191, 199], ["severe", "OBSERVATION_MODIFIER", 203, 209]]], ["Another study which surveyed the German public (from March 19, 2020 March 23, 2020) found that 28.2% of respondents were afraid of being infected by COVID-19.", [["Another study", "TEST", 0, 13], ["COVID", "TEST", 149, 154], ["infected", "OBSERVATION", 137, 145]]], ["3, 4 The fear that the public is experiencing due to COVID-19 is likely exacerbated by measures causing social isolation including quarantines, stay-at-home orders, travel restrictions and closures of non-essential businesses.", [["COVID", "TEST", 53, 58]]], ["5, 6 As people practice social distancing, self-isolation, and begin J o u r n a l P r e -p r o o f 3 working remotely, the potential for injuries such as trauma due to motor vehicle collisions (MVCs) may decline considerably. and EDs in Massachusetts were found to treat 44-45% fewer cases of depression or anxiety during March 2020.", [["injuries", "DISEASE", 138, 146], ["trauma", "DISEASE", 155, 161], ["motor vehicle collisions", "DISEASE", 169, 193], ["MVCs", "DISEASE", 195, 199], ["depression", "DISEASE", 294, 304], ["anxiety", "DISEASE", 308, 315], ["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["injuries", "PROBLEM", 138, 146], ["trauma", "PROBLEM", 155, 161], ["depression", "PROBLEM", 294, 304], ["anxiety", "PROBLEM", 308, 315]]], ["7,8 Thus, the primary objective of this study is to investigate the impact that COVID-19 may have had on ED visits nationwide.", [["this study", "TEST", 35, 45]]], ["Additionally, this study aims to discuss potential reasons for any changes in the number of ED visits during the COVID-19 pandemic.Data Source and PopulationThis retrospective analysis was performed utilizing data collected from the National Center for Immunization and Respiratory Diseases (NCIRD) division of the Centers for Disease Control and Prevention (CDC).", [["Immunization and Respiratory Diseases", "DISEASE", 253, 290], ["this study", "TEST", 14, 24], ["any changes", "PROBLEM", 63, 74], ["the COVID", "TEST", 109, 118], ["pandemic", "PROBLEM", 122, 130], ["This retrospective analysis", "TEST", 157, 184], ["Immunization", "TREATMENT", 253, 265], ["Respiratory Diseases (NCIRD)", "TREATMENT", 270, 298], ["Disease Control", "TREATMENT", 327, 342], ["Respiratory Diseases", "OBSERVATION", 270, 290]]], ["Data was gathered from NCIRD regarding total ED visits,Data Analysis and Statistical MethodsDescriptive statistical analysis was performed to evaluate the temporal relationship between the total number of ED visits and the percent of total visits for CLI or ILI from the week of September 29, 2019 to the week of April 5, 2020.", [["CLI", "DISEASE", 251, 254], ["ILI", "DISEASE", 258, 261], ["Data Analysis", "TEST", 55, 68], ["Statistical MethodsDescriptive statistical analysis", "TEST", 73, 124], ["CLI", "TREATMENT", 251, 254]]], ["A two-sample t-test was then used to assess if any significant differences existed between the mean number of ED visits for a four week period prior to increased COVID-19 awareness (week of December 15, 2019 to the week of January 5, 2020) to after increased awareness (the week of March 15, 2020 to the week of April 5, 2020).", [["A two-sample t-test", "TEST", 0, 19]]], ["COVID-19 awareness was derived from Google search trends in the US, PR and GU.Data Analysis and Statistical MethodsThe percentage decrease in ED visits was calculated by region using the mean number of ED visits from the same four-week period prior to increased COVID-19 awareness and the mean number of ED visits for the same four weeks after increased awareness.", [["the US", "TEST", 60, 66], ["Data Analysis", "TEST", 78, 91], ["Statistical Methods", "TEST", 96, 115], ["increased awareness", "PROBLEM", 344, 363], ["GU", "ANATOMY", 75, 77], ["percentage", "OBSERVATION_MODIFIER", 119, 129], ["decrease", "OBSERVATION_MODIFIER", 130, 138]]], ["Descriptive analysis of MVC data was conducted to assess if COVID-19 has impacted MVC rates.", [["MVC data", "TEST", 24, 32], ["COVID", "TEST", 60, 65], ["impacted MVC rates", "PROBLEM", 73, 91]]], ["Finally, the percentage decrease in MVCs was calculated using data from each city during the weeks of March 15, 2020 to April 5, 2020 and data for the same time J o u r n a l P r e -p r o o f period one year prior.", [["the percentage decrease in MVCs", "PROBLEM", 9, 40], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["Minitab statistical software version 19.2020.1 was utilized for all statistical analysis.", [["all statistical analysis", "TEST", 64, 88]]], ["Statistical significance was defined a p<0.05.ED Visit TrendsThe total number of ED visits per week was found be relatively stable from the week ofChange in ED Visits in Response to COVID-19TheDiscussionThe total number of ED visits per week across all study regions began to decline precipitously during the week of March 8, 2020 following months of relative stability.", [["COVID", "TEST", 182, 187], ["relatively", "OBSERVATION_MODIFIER", 113, 123], ["stable", "OBSERVATION", 124, 130], ["stability", "OBSERVATION_MODIFIER", 360, 369]]], ["This drop in the total number of ED visits per week was also preceded by an increased percentage of visits for ILI and CLI beginning around the week of February 23, 2020, which correlated with increased public awareness of COVID-19 as indicated by Google search interest.", [["ILI", "DISEASE", 111, 114], ["CLI", "DISEASE", 119, 122], ["This drop", "PROBLEM", 0, 9], ["ILI", "PROBLEM", 111, 114], ["CLI", "TREATMENT", 119, 122]]], ["The increased percentage of visits for ILI and CLI can likely be explained by a number of factors including a substantial increase in actual COVID-19 cases in the US during March 2020, revisions made to COVID-19 testing criteria allowing for wider testing starting on March 4, 2020, and increased public concern regarding COVID-19 like symptoms.", [["ILI", "DISEASE", 39, 42], ["CLI", "DISEASE", 47, 50], ["ILI", "PROBLEM", 39, 42], ["CLI", "TREATMENT", 47, 50], ["COVID", "TEST", 203, 208], ["testing criteria", "TEST", 212, 228], ["wider testing", "TEST", 242, 255], ["COVID", "TEST", 322, 327], ["like symptoms", "PROBLEM", 331, 344], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["percentage", "OBSERVATION_MODIFIER", 14, 24], ["substantial", "OBSERVATION_MODIFIER", 110, 121], ["increase", "OBSERVATION_MODIFIER", 122, 130]]], ["30th, 2020 identified that 57% of respondents were concerned about being exposed to COVID-19 due to an inability to stay home and miss work.", [["COVID", "TEST", 84, 89]]], ["11 The results of the poll also demonstrated that 82% of respondents were concerned that they will be unable to obtain needed medical care due to the health care system being overrun.", [["medical care", "TREATMENT", 126, 138]]], ["11 Thus, it appears that the current COVID-19 pandemic may have created a climate of fear similar to what has been observed in other countries like Germany and China.", [["the current COVID", "TEST", 25, 42]]], ["3, 4 The study also demonstrated regional variation in the percentage decrease in mean ED visits per week across all regions studied.", [["The study", "TEST", 5, 14], ["regional variation", "PROBLEM", 33, 51], ["regional variation", "OBSERVATION", 33, 51], ["percentage", "OBSERVATION_MODIFIER", 59, 69], ["decrease", "OBSERVATION_MODIFIER", 70, 78]]], ["Region 1 had the greatest decrease (45%) and region 8 had the smallest decrease (31%).", [["greatest", "OBSERVATION_MODIFIER", 17, 25], ["decrease", "OBSERVATION_MODIFIER", 26, 34], ["smallest", "OBSERVATION_MODIFIER", 62, 70], ["decrease", "OBSERVATION_MODIFIER", 71, 79]]], ["This variation could be due to regional cultural differences affecting levels of compliance with health guidelines, level of concern regarding infection, differences in socioeconomic status, and varying remote work opportunities.", [["infection", "DISEASE", 143, 152], ["regional cultural differences", "PROBLEM", 31, 60], ["infection", "PROBLEM", 143, 152], ["could be due to", "UNCERTAINTY", 15, 30], ["infection", "OBSERVATION", 143, 152]]], ["Finally, a steep decline in MVCs was noted across all cities studied, with the greatest decrease seen in NYC and Baton Rouge (66%).", [["a steep decline in MVCs", "PROBLEM", 9, 32], ["steep", "OBSERVATION_MODIFIER", 11, 16], ["decline", "OBSERVATION_MODIFIER", 17, 24], ["MVCs", "OBSERVATION", 28, 32], ["greatest", "OBSERVATION_MODIFIER", 79, 87], ["decrease", "OBSERVATION_MODIFIER", 88, 96]]], ["This finding is not surprising given the rise of remote work, curfews, stay at home orders, closure of nonessential businesses, COVID-19 fears, and social distancing.", [["closure", "TREATMENT", 92, 99]]], ["This decrease in MVCs has likely also substantially contributed to reduced ED visits.DiscussionThis study has several limitations.", [["MVCs", "PROBLEM", 17, 21], ["This study", "TEST", 95, 105], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["MVCs", "OBSERVATION", 17, 21], ["reduced", "OBSERVATION_MODIFIER", 67, 74]]], ["First, inconsistency in reporting and lack of centralized resources for up to date MVC data reduced the sample size and hindered the extrapolation of results to all regions studied.", [["MVC data", "TEST", 83, 91], ["size", "OBSERVATION_MODIFIER", 111, 115]]], ["Next, a lack of current fatality data due to medical conditions of J o u r n a l P r e -p r o o f 8 almost any kind prevented an analysis of the association between reduced ED visits and current fatality trends.ConclusionsThe mean number of ED visits per week for the last four weeks of available data during the pandemic was significantly less than the four weeks prior to COVID-19 pandemic.", [["COVID", "TEST", 374, 379], ["pandemic", "PROBLEM", 383, 391]]], ["A number of factors including the current climate of fear regarding COVID-19 infection and decreased opportunity for injury due to MVCs has likely contributed to the substantial decrease in ED visits.", [["infection", "DISEASE", 77, 86], ["MVCs", "DISEASE", 131, 135], ["COVID-19 infection", "PROBLEM", 68, 86], ["injury", "PROBLEM", 117, 123], ["MVCs", "PROBLEM", 131, 135], ["infection", "OBSERVATION", 77, 86], ["substantial", "OBSERVATION_MODIFIER", 166, 177], ["decrease", "OBSERVATION_MODIFIER", 178, 186]]], ["In light of these findings, it is important to raise patient awareness regarding acute conditions (e.g., STEMI and stroke) that are deadlier than COVID-19 and require immediate medical intervention to ensure recovery.", [["STEMI", "DISEASE", 105, 110], ["stroke", "DISEASE", 115, 121], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["acute conditions", "PROBLEM", 81, 97], ["STEMI", "PROBLEM", 105, 110], ["stroke", "PROBLEM", 115, 121], ["COVID", "TEST", 146, 151], ["immediate medical intervention", "TREATMENT", 167, 197]]], ["Patients should also be made aware of the strict COVID-19 guidelines imposed by organizations such as the CDC, the American College of Emergency Physicians, the American College of Surgeons and others to increase patient confidence.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 213, 220], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 213, 220]]], ["In contrast, patients should also be made aware of telehealth options for non-acute conditions but need to be encouraged to utilize ED services during an emergency.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["telehealth options", "TREATMENT", 51, 69], ["non-acute conditions", "PROBLEM", 74, 94]]]], "030a53517e43dbf6b4ac2737d8c200cf66d9b205": [["INTRODUCTION:The implementation of mandatory BCG vaccination policy by countries in the past and the BCG immunization coverage of the populations have been associated with the lower COVID-19 cases and mortality.", [["mandatory BCG vaccination policy", "TREATMENT", 35, 67], ["the BCG immunization coverage", "TREATMENT", 97, 126]]], ["However, the confounding variables among countries such as the stage of the outbreak, population age distribution, health infrastructure, management practices, the testing/screening, and reporting guidelines, etc. make the comparisons tenuous [1, 2] .", [["management practices", "TREATMENT", 138, 158], ["the testing/screening", "TEST", 160, 181], ["outbreak", "OBSERVATION_MODIFIER", 76, 84]]], ["Since the 'trained immunity' status conferred by BCG vaccination in childhood wanes rapidly within years in the absence of 'booster' Mycobacterium spp. exposures [3] , the prevalent actual 'trained immunity' of the population could be a better evaluable predictive parameter of populations' response to COVID-19 infections, if any, rather than relying on BCG vaccination in the childhood or the national policy as recently reported in JAMA by Hamiel and colleagues [4] .INTRODUCTION:Tuberculin Sensitivity Test (TST) combined with Interferon Gamma Release Assay (IGRA) is generally used to assess the presence of immune response against Mycobacteria spp.INTRODUCTION:(environmental or BCG vaccine).", [["infections", "DISEASE", 312, 322], ["Mycobacterium spp", "ORGANISM", 133, 150], ["COVID-19", "ORGANISM", 303, 311], ["Interferon Gamma", "GENE_OR_GENE_PRODUCT", 531, 547], ["Mycobacteria spp", "ORGANISM", 637, 653], ["Interferon Gamma", "PROTEIN", 531, 547], ["Mycobacterium spp", "PROBLEM", 133, 150], ["COVID", "TEST", 303, 308], ["19 infections", "PROBLEM", 309, 322], ["BCG vaccination", "TREATMENT", 355, 370], ["Tuberculin Sensitivity Test", "TEST", 483, 510], ["Interferon Gamma Release Assay", "TREATMENT", 531, 561], ["immune response", "PROBLEM", 613, 628], ["Mycobacteria spp", "PROBLEM", 637, 653], ["BCG vaccine", "TREATMENT", 685, 696]]], ["In the absence of IGRA positivity, it is referred to as 'Latent Tuberculosis Infection' (LTBI) broadly signifying the absence of tuberculosis disease but the presence of active immunity against the pathogen.", [["Latent Tuberculosis Infection", "DISEASE", 57, 86], ["LTBI", "DISEASE", 89, 93], ["tuberculosis", "DISEASE", 129, 141], ["IGRA", "GENE_OR_GENE_PRODUCT", 18, 22], ["IGRA", "PROTEIN", 18, 22], ["IGRA positivity", "PROBLEM", 18, 33], ["Latent Tuberculosis Infection' (LTBI)", "PROBLEM", 57, 94], ["tuberculosis disease", "PROBLEM", 129, 149], ["the pathogen", "PROBLEM", 194, 206], ["IGRA positivity", "OBSERVATION", 18, 33], ["Latent", "OBSERVATION_MODIFIER", 57, 63], ["Tuberculosis", "OBSERVATION", 64, 76], ["tuberculosis", "OBSERVATION", 129, 141], ["active", "OBSERVATION_MODIFIER", 170, 176]]], ["As about 1-5% of the LTBI positive individuals could develop Tuberculosis in their lifetime due to either subsequent infection after the 'trained immunity' wanes or when the immunity is compromised for any reason (e.g., HIV infection, cancer, immunosuppressant therapy) this 'LTBI' nomenclature has been retained though not without causing confusion and general aversion of its use as a measure of 'trained immunity'.", [["cancer", "ANATOMY", 235, 241], ["LTBI", "DISEASE", 21, 25], ["Tuberculosis", "DISEASE", 61, 73], ["infection", "DISEASE", 117, 126], ["HIV infection", "DISEASE", 220, 233], ["cancer", "DISEASE", 235, 241], ["LTBI", "DISEASE", 276, 280], ["confusion", "DISEASE", 340, 349], ["individuals", "ORGANISM", 35, 46], ["HIV", "ORGANISM", 220, 223], ["cancer", "CANCER", 235, 241], ["HIV", "SPECIES", 220, 223], ["HIV", "SPECIES", 220, 223], ["the LTBI positive individuals", "PROBLEM", 17, 46], ["Tuberculosis", "PROBLEM", 61, 73], ["subsequent infection", "PROBLEM", 106, 126], ["the 'trained immunity' wanes", "TREATMENT", 133, 161], ["HIV infection", "PROBLEM", 220, 233], ["cancer", "PROBLEM", 235, 241], ["immunosuppressant therapy", "TREATMENT", 243, 268], ["confusion", "PROBLEM", 340, 349], ["Tuberculosis", "OBSERVATION", 61, 73], ["infection", "OBSERVATION", 117, 126], ["not without", "UNCERTAINTY", 320, 331]]], ["We reason, if indeed 'trained immunity' status could help reduce infections in a population, the estimated prevalence of Latent Tuberculosis Infection (%LTBI) of resident populations would more closely correlate with COVID-19 infection and mortality rates.", [["infections", "DISEASE", 65, 75], ["Latent Tuberculosis Infection", "DISEASE", 121, 150], ["LTBI", "DISEASE", 153, 157], ["infection", "DISEASE", 226, 235], ["infections", "PROBLEM", 65, 75], ["Latent Tuberculosis Infection", "PROBLEM", 121, 150], ["COVID-19 infection", "PROBLEM", 217, 235], ["mortality rates", "TEST", 240, 255], ["Latent", "OBSERVATION_MODIFIER", 121, 127], ["Tuberculosis", "OBSERVATION_MODIFIER", 128, 140], ["Infection", "OBSERVATION", 141, 150], ["infection", "OBSERVATION", 226, 235]]], ["The European countries with no mandatory BCG vaccination policy, comparable medical infrastructure, mobility, exposure to SARS-CoV-2, and other confounding variables, currently at a similar stage of epidemic-curve but differential 'trained immunity' status as reflected in %LTBI offer an excellent opportunity to evaluate such assertion.METHODS:The populations from 20 European countries with a differential prevalence of %LTBI [5] (published by the 'Institute for Health Metrics and Evaluation (IHME)' 2018) and comparable confounding variables, including the stage of the pandemic (infections peak) ( Table 1) are assessed for any correlation with COVID-19 cases and mortality data without any exclusion criterion (e.g., age, sex, ethnicity) at different stages, i.e., 8 April, 12 May, and 26 May 2020 from https://www.worldometers.info/coronavirus/ [6] of the ongoing pandemic, as done previously for Vitamin D [7] .METHODS:.", [["SARS", "DISEASE", 122, 126], ["LTBI", "DISEASE", 274, 278], ["LTBI", "DISEASE", 423, 427], ["infections", "DISEASE", 584, 594], ["Vitamin D", "CHEMICAL", 904, 913], ["Vitamin D", "CHEMICAL", 904, 913], ["Vitamin D", "SIMPLE_CHEMICAL", 904, 913], ["SARS-CoV", "SPECIES", 122, 130], ["mandatory BCG vaccination policy", "TREATMENT", 31, 63], ["SARS", "TEST", 122, 126], ["CoV", "TEST", 127, 130], ["other confounding variables", "PROBLEM", 138, 165], ["epidemic-curve", "PROBLEM", 199, 213], ["Evaluation", "TEST", 484, 494], ["the pandemic (infections peak", "PROBLEM", 570, 599], ["COVID", "TEST", 650, 655], ["mortality data", "TEST", 669, 683], ["pandemic", "PROBLEM", 871, 879], ["Vitamin D", "TREATMENT", 904, 913]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprintRESULTS:The 'trained immunity' prevalence correlates of the populations (i.e., %LTBI) indicates a strong correlation with COVID-19 infections ( Table 1) Table 1) , similar to previously observed by us [1] .", [["CC", "CHEMICAL", 0, 2], ["LTBI", "DISEASE", 419, 423], ["infections", "DISEASE", 470, 480], ["COVID", "TEST", 461, 466], ["med", "ANATOMY", 102, 105]]], ["See Figure 1 for the potential predictive correlative inference of the data on May 26, 2020.DISCUSSION:In the differentially 'trained immunity' populations of European countries, the COVID-19 cases per million population negatively correlate with the %LTBI prevalence of the population at each analyzed stage of the pandemic.", [["LTBI", "DISEASE", 252, 256], ["the COVID", "TEST", 179, 188], ["the pandemic", "PROBLEM", 312, 324], ["pandemic", "OBSERVATION", 316, 324]]], ["However, an insignificant negative correlation is observed with deaths per million populations as would be expected with individuals/populations without sufficient 'trained immunity' being vulnerable to getting infected.DISCUSSION:The strength of the assertion lies in the large affected study population, i.e., 1,413,367 COVID-19 patients (about 25% of total worldwide on 26.05.2020) [6] ; representing 20 different 'trained immunity' level (%LTBI prevalence) groups/populations from countries without a mandatory BCG vaccination policy; comparable health infrastructure, screening and reporting guidelines along with similar age and sex distribution and other confounding variables.", [["deaths", "DISEASE", 64, 70], ["LTBI", "DISEASE", 444, 448], ["patients", "ORGANISM", 331, 339], ["patients", "SPECIES", 331, 339], ["infected", "PROBLEM", 211, 219], ["COVID", "TEST", 322, 327], ["a mandatory BCG vaccination policy", "TREATMENT", 503, 537], ["insignificant", "OBSERVATION_MODIFIER", 12, 25], ["negative", "OBSERVATION", 26, 34]]], ["The correlation analysis consistently indicates the same association at all 3 different time points of the epidemic curve evaluated.", [["The correlation analysis", "TEST", 0, 24], ["the epidemic curve", "TEST", 103, 121]]], ["In the light of observation presented, it may be suggested that ongoing trials/studies evaluating the effect of BCG vaccination on COVID-19 infections [2] , including the one recently concluded in Israel and reported in JAMA [4] could provide more objective conclusions on inclusions of the estimates about the 'trained immunity' of study participants/ populations.", [["infections", "DISEASE", 140, 150], ["COVID-19", "ORGANISM", 131, 139], ["participants", "SPECIES", 339, 351], ["ongoing trials/studies", "TEST", 64, 86], ["BCG vaccination", "TREATMENT", 112, 127]]], ["Dedicated studies using the available patient records or epidemiological surveys backed by followup clinical trials with suitable controls for the 'trained immunity' correlates are advisable to assess the biological significance of the observed correlation and arrive at a more meaningful conclusion about BCG vaccination conferred 'trained immunity' and COVID-19 control.DISCUSSION:.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["Dedicated studies", "TEST", 0, 17], ["epidemiological surveys", "TEST", 57, 80], ["BCG vaccination", "TREATMENT", 306, 321], ["COVID", "TEST", 355, 360]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 640, 647], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 378, 381]]]], "afbcf0a870287e32fe1e3874a44412d8fd08a163": [["Computer-Based Blood Donor Screening: A Status ReportLouis M. Katz, Paul D. Cumming, and Edward L. WallaceComputer-Based Blood Donor Screening: A Status ReportThere is a substantial literature suggesting that computer-assisted interviewing has advantages over face-to-face and written self-administration of interviews in venues eliciting sensitive information similar to that sought in blood donor history screening.", [["Blood", "ANATOMY", 15, 20], ["blood", "ANATOMY", 387, 392], ["blood", "ORGANISM_SUBSTANCE", 387, 392], ["blood donor history screening", "TEST", 387, 416]]], ["We review some of the recent developments in blood donor history screening, the evidence suggesting that automated interviews should be useful, and the experience to date using computer interviews for blood donation.", [["blood", "ANATOMY", 45, 50], ["blood", "ANATOMY", 201, 206], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["blood donor history screening", "TEST", 45, 74], ["blood donation", "TREATMENT", 201, 215]]], ["These data suggest that automated computer-assisted interviewing increases the elicitation of behaviors associated with the risk of transfusion-transmissible infection in donors, improves donor and staff satisfaction, and reduces errors and omissions that frequently accompany traditional interviewing methods.", [["transfusion-transmissible infection", "DISEASE", 132, 167], ["donors", "ORGANISM", 171, 177], ["transfusion", "TREATMENT", 132, 143], ["transmissible infection", "PROBLEM", 144, 167], ["infection", "OBSERVATION", 158, 167]]], ["Food and Drug Administration-cleared systems for computer-assisted self-interview of blood donors are briefly described.Computer-Based Blood Donor Screening: A Status ReportA 2007 Elsevier Inc. All rights reserved.Computer-Based Blood Donor Screening: A Status ReportA SSURANCE OF A safe supply of allogeneic blood and blood products is the primary driver of activity in blood services.", [["blood", "ANATOMY", 85, 90], ["Blood", "ANATOMY", 135, 140], ["Blood", "ANATOMY", 229, 234], ["blood", "ANATOMY", 309, 314], ["blood", "ANATOMY", 319, 324], ["blood", "ANATOMY", 371, 376], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["donors", "ORGANISM", 91, 97], ["blood", "ORGANISM_SUBSTANCE", 309, 314], ["blood", "ORGANISM_SUBSTANCE", 319, 324], ["blood", "ORGANISM_SUBSTANCE", 371, 376], ["blood donors", "TREATMENT", 85, 97], ["allogeneic blood and blood products", "TREATMENT", 298, 333]]], ["Interventions with extremely high cost-benefit ratios are now common.", [["Interventions", "TREATMENT", 0, 13], ["extremely high cost-benefit ratios", "PROBLEM", 19, 53]]], ["For example, introduction of nucleic acid testing in minipools for HIV and HCV in the late 1990s reduced the risks of transmission of these pathogens in transfused, tested allogeneic blood to 1:1.8 million and 1:1.6 million, respectively, leaving only small test-negative window period risks for these agents.", [["blood", "ANATOMY", 183, 188], ["nucleic acid", "CHEMICAL", 29, 41], ["HIV and HCV", "DISEASE", 67, 78], ["nucleic acid", "SIMPLE_CHEMICAL", 29, 41], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 67, 70], ["HCV", "SPECIES", 75, 78], ["nucleic acid testing", "TEST", 29, 49], ["minipools", "TREATMENT", 53, 62], ["HIV", "PROBLEM", 67, 70], ["HCV", "PROBLEM", 75, 78], ["these pathogens", "TREATMENT", 134, 149], ["tested allogeneic blood", "TREATMENT", 165, 188], ["small test", "TEST", 252, 262], ["these agents", "TREATMENT", 296, 308]]], ["1 Small infectious risks remain, as evidenced by 2 blood recipients recently infected with HIV from a nucleic acid-tested whole blood donation.", [["blood", "ANATOMY", 51, 56], ["blood", "ANATOMY", 128, 133], ["HIV", "DISEASE", 91, 94], ["nucleic acid", "CHEMICAL", 102, 114], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["HIV", "ORGANISM", 91, 94], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 91, 94], ["Small infectious risks", "PROBLEM", 2, 24], ["HIV", "PROBLEM", 91, 94], ["a nucleic acid", "TEST", 100, 114], ["whole blood donation", "TREATMENT", 122, 142], ["Small", "OBSERVATION_MODIFIER", 2, 7], ["infectious", "OBSERVATION", 8, 18]]], ["2 There are, in addition, a host of other infections-protozoan, bacterial, viral, and prion-which are transfusion-transmissible for which no tests are currently available.", [["infections", "DISEASE", 42, 52], ["transfusion-transmissible", "DISEASE", 102, 127], ["other infections", "PROBLEM", 36, 52], ["protozoan", "PROBLEM", 53, 62], ["bacterial", "PROBLEM", 64, 73], ["viral", "PROBLEM", 75, 80], ["transfusion", "TREATMENT", 102, 113], ["tests", "TEST", 141, 146], ["infections", "OBSERVATION", 42, 52], ["protozoan", "OBSERVATION_MODIFIER", 53, 62]]], ["3 Protection of the allogeneic blood supply from traditional transfusion-transmissible diseases (TTD); from emerging or reemerging TTDs; and particularly from the window period residual risks for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) depends on the effectiveness not only of laboratory screening of volunteer blood donors but also on efforts to minimize the recruitment and phlebotomy of high-risk donors.Computer-Based Blood Donor Screening: A Status ReportHigh-risk volunteer donors are persons who (i) have a history of TTDs or have engaged in behaviors, especially sexual practices or parenteral drug use, known to be associated with TTDs and/or have close contact with others with TTDs; (ii) have traveled to or resided in locations where TTDs are prevalent: or (iii) have risky health histories, for example, prior infection, recent transfusion, or receipt of plasma derivatives associated with an appreciable incidence of infection.", [["blood", "ANATOMY", 31, 36], ["blood", "ANATOMY", 329, 334], ["Blood", "ANATOMY", 440, 445], ["plasma", "ANATOMY", 886, 892], ["transfusion-transmissible diseases", "DISEASE", 61, 95], ["TTD", "DISEASE", 97, 100], ["TTDs", "DISEASE", 131, 135], ["HIV, hepatitis B virus (HBV), and hepatitis C", "DISEASE", 196, 241], ["TTDs", "DISEASE", 543, 547], ["TTDs", "DISEASE", 706, 710], ["TTDs", "DISEASE", 764, 768], ["infection", "DISEASE", 841, 850], ["infection", "DISEASE", 949, 958], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["HIV", "ORGANISM", 196, 199], ["hepatitis B virus", "ORGANISM", 201, 218], ["HBV", "ORGANISM", 220, 223], ["hepatitis C virus", "ORGANISM", 230, 247], ["HCV", "ORGANISM", 249, 252], ["blood", "ORGANISM_SUBSTANCE", 329, 334], ["donors", "ORGANISM", 418, 424], ["donors", "ORGANISM", 498, 504], ["persons", "ORGANISM", 509, 516], ["plasma", "ORGANISM_SUBSTANCE", 886, 892], ["HIV", "SPECIES", 196, 199], ["hepatitis B virus", "SPECIES", 201, 218], ["hepatitis C virus", "SPECIES", 230, 247], ["persons", "SPECIES", 509, 516], ["HIV", "SPECIES", 196, 199], ["hepatitis B virus", "SPECIES", 201, 218], ["HBV", "SPECIES", 220, 223], ["hepatitis C virus", "SPECIES", 230, 247], ["HCV", "SPECIES", 249, 252], ["the allogeneic blood supply", "TREATMENT", 16, 43], ["traditional transfusion", "TREATMENT", 49, 72], ["transmissible diseases", "PROBLEM", 73, 95], ["HIV", "PROBLEM", 196, 199], ["hepatitis B virus", "PROBLEM", 201, 218], ["HBV", "PROBLEM", 220, 223], ["hepatitis C virus (HCV)", "PROBLEM", 230, 253], ["laboratory screening", "TEST", 295, 315], ["volunteer blood donors", "TREATMENT", 319, 341], ["the recruitment", "TREATMENT", 374, 389], ["phlebotomy", "TREATMENT", 394, 404], ["high-risk donors", "PROBLEM", 408, 424], ["TTDs", "PROBLEM", 543, 547], ["prior infection", "PROBLEM", 835, 850], ["recent transfusion", "TREATMENT", 852, 870], ["plasma derivatives", "TREATMENT", 886, 904], ["infection", "PROBLEM", 949, 958], ["infection", "OBSERVATION", 841, 850], ["appreciable", "OBSERVATION_MODIFIER", 924, 935], ["infection", "OBSERVATION", 949, 958]]], ["Screening is the process by which blood collecting organizations identify and defer high-risk donors to avoid introducing TTDs into the allogeneic blood supply.", [["blood", "ANATOMY", 34, 39], ["blood", "ANATOMY", 147, 152], ["TTDs", "DISEASE", 122, 126], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["donors", "ORGANISM", 94, 100], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["introducing TTDs", "TREATMENT", 110, 126], ["the allogeneic blood supply", "TREATMENT", 132, 159]]], ["It is a multistep process involving recruitment of safe donors, provision of up-to-date donor education materials, checking for in-force prior deferrals, a mini-physical examination with elements focused on stigmata of parenteral drug use, and a health history interview preceding phlebotomy.", [["donors", "ORGANISM", 56, 62], ["a mini-physical examination", "TEST", 154, 181], ["phlebotomy", "TREATMENT", 281, 291]]], ["Like laboratory testing, donor history screening has improved substantially in recent years because of efforts by the blood community to recruit, identify, and retain lowrisk donors and by more active federal involvement and regulation of the whole blood and blood products collection and distribution process.", [["blood", "ANATOMY", 118, 123], ["blood", "ANATOMY", 249, 254], ["blood", "ANATOMY", 259, 264], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["donors", "ORGANISM", 175, 181], ["blood", "ORGANISM_SUBSTANCE", 249, 254], ["blood", "ORGANISM_SUBSTANCE", 259, 264], ["laboratory testing", "TEST", 5, 23], ["the whole blood and blood products collection and distribution process", "PROBLEM", 239, 309], ["active", "OBSERVATION_MODIFIER", 194, 200], ["federal involvement", "OBSERVATION", 201, 220], ["blood", "ANATOMY", 259, 264]]], ["As a result, the prevalence of HIV, HBV, and HCV infections among first-time blood donors are 3%, 14% and 13%, respectively, of those in the US population.", [["blood", "ANATOMY", 77, 82], ["HIV, HBV, and HCV infections", "DISEASE", 31, 59], ["HIV", "ORGANISM", 31, 34], ["HBV", "ORGANISM", 36, 39], ["HCV", "ORGANISM", 45, 48], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["donors", "ORGANISM", 83, 89], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 31, 34], ["HBV", "SPECIES", 36, 39], ["HCV", "SPECIES", 45, 48], ["HIV", "PROBLEM", 31, 34], ["HBV", "PROBLEM", 36, 39], ["HCV infections", "PROBLEM", 45, 59], ["blood donors", "TEST", 77, 89], ["HBV", "OBSERVATION", 36, 39]]], ["4 There remains room for improvement, as evidenced by the finding that 2% of volunteer whole blood donors reported deferrable high-risk behaviors on an anonymous postdonation survey.", [["blood", "ANATOMY", 93, 98], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["donors", "ORGANISM", 99, 105], ["volunteer whole blood donors", "TEST", 77, 105]]], ["5BRIEF HISTORY OF BLOOD TESTING AND DONOR SCREENINGForty years ago as many as 1 in 4 transfused patients developed viral hepatitis.", [["viral hepatitis", "DISEASE", 115, 130], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["BLOOD TESTING", "TEST", 18, 31], ["viral hepatitis", "PROBLEM", 115, 130], ["viral hepatitis", "OBSERVATION", 115, 130]]], ["In the late 1960s, some 69% of all open heart surgery patients at the National Institutes of Health Clinical Center acquired hepatitis from transfused blood.", [["heart", "ANATOMY", 40, 45], ["blood", "ANATOMY", 151, 156], ["hepatitis", "DISEASE", 125, 134], ["heart", "ORGAN", 40, 45], ["patients", "ORGANISM", 54, 62], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["patients", "SPECIES", 54, 62], ["all open heart surgery", "TREATMENT", 31, 53], ["acquired hepatitis", "PROBLEM", 116, 134], ["transfused blood", "PROBLEM", 140, 156], ["heart", "ANATOMY", 40, 45], ["surgery", "OBSERVATION", 46, 53], ["hepatitis", "OBSERVATION", 125, 134]]], ["6 Introduction of the first generation hepatitis B surface antigen (HBsAg) test in 1970 reduced the rate to 7%.", [["hepatitis B surface antigen", "CHEMICAL", 39, 66], ["HBsAg", "CHEMICAL", 68, 73], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 39, 66], ["HBsAg", "GENE_OR_GENE_PRODUCT", 68, 73], ["hepatitis B surface antigen", "PROTEIN", 39, 66], ["HBsAg", "PROTEIN", 68, 73], ["the first generation hepatitis B surface antigen", "TEST", 18, 66], ["HBsAg) test", "TEST", 68, 79], ["the rate", "TEST", 96, 104]]], ["6 Movement toward an all-volunteer whole blood supply in the 1970s further increased public confidence in the safety of allogeneic transfusion.", [["blood", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["allogeneic transfusion", "TREATMENT", 120, 142]]], ["7 The transfusion-AIDS crisis in the early and mid 1980s, however, destroyed that public trust.", [["AIDS", "DISEASE", 18, 22], ["The transfusion", "TREATMENT", 2, 17], ["AIDS crisis", "PROBLEM", 18, 29], ["transfusion", "OBSERVATION", 6, 17], ["AIDS crisis", "OBSERVATION", 18, 29]]], ["Although new or additional blood tests for HIV, HBV, and HCV introduced in the mid to late 1980s and early 1990s constituted major advances in protection of the allogeneic supply, all were traditional serologic tests with substantial seronegative window periods associated with residual risk of transfusionassociated infection (~1:225 000; 1:50 000, and 1:3 300 for HIV, HBV, and HCV, respectively).", [["blood", "ANATOMY", 27, 32], ["HIV, HBV, and HCV", "DISEASE", 43, 60], ["transfusionassociated infection", "DISEASE", 295, 326], ["HIV, HBV, and HCV", "DISEASE", 366, 383], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["HIV", "ORGANISM", 43, 46], ["HBV", "ORGANISM", 48, 51], ["HIV", "ORGANISM", 366, 369], ["HBV", "ORGANISM", 371, 374], ["HIV", "SPECIES", 43, 46], ["HIV", "SPECIES", 43, 46], ["HBV", "SPECIES", 48, 51], ["HCV", "SPECIES", 57, 60], ["HIV", "SPECIES", 366, 369], ["HBV", "SPECIES", 371, 374], ["HCV", "SPECIES", 380, 383], ["additional blood tests", "TEST", 16, 38], ["HIV", "PROBLEM", 43, 46], ["HBV", "PROBLEM", 48, 51], ["HCV", "PROBLEM", 57, 60], ["the allogeneic supply", "TREATMENT", 157, 178], ["traditional serologic tests", "TEST", 189, 216], ["substantial seronegative window periods", "PROBLEM", 222, 261], ["transfusionassociated infection", "PROBLEM", 295, 326], ["HIV", "PROBLEM", 366, 369], ["HBV", "PROBLEM", 371, 374], ["HCV", "PROBLEM", 380, 383], ["new", "OBSERVATION_MODIFIER", 9, 12], ["transfusionassociated", "OBSERVATION_MODIFIER", 295, 316], ["infection", "OBSERVATION", 317, 326]]], ["8 As public confidence in the safety of the allogeneic blood supply fell in the early 1980s, in the absence of effective laboratory screening for HIV and posttransfusion non-A and non-B hepatitis, the transfusion medicine community began serious efforts to recruit and screen low-risk donors using nonlaboratory methods.", [["blood", "ANATOMY", 55, 60], ["non-B hepatitis", "DISEASE", 180, 195], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["HIV", "ORGANISM", 146, 149], ["posttransfusion non-A", "CANCER", 154, 175], ["donors", "ORGANISM", 285, 291], ["HIV", "SPECIES", 146, 149], ["HIV", "SPECIES", 146, 149], ["the allogeneic blood supply", "TREATMENT", 40, 67], ["effective laboratory screening", "TEST", 111, 141], ["HIV", "PROBLEM", 146, 149], ["posttransfusion non-A and non-B hepatitis", "PROBLEM", 154, 195], ["the transfusion medicine", "TREATMENT", 197, 221], ["nonlaboratory methods", "TREATMENT", 298, 319], ["hepatitis", "OBSERVATION", 186, 195]]], ["By 1983, evidence from the Centers for Disease Control that HIV was a TTD convinced the American Association of Blood Banks (AABB), American Red Cross, and the Council of Community Blood Centers (now America's Blood Centers) to initiate education and questioning of blood donors about their behaviors and experiences that were epidemiologically associated with HIV infection.", [["Blood", "ANATOMY", 112, 117], ["blood", "ANATOMY", 266, 271], ["TTD", "DISEASE", 70, 73], ["HIV infection", "DISEASE", 361, 374], ["HIV", "ORGANISM", 60, 63], ["Blood", "ORGANISM_SUBSTANCE", 112, 117], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["donors", "ORGANISM", 272, 278], ["HIV", "ORGANISM", 361, 364], ["HIV", "SPECIES", 361, 364], ["HIV", "SPECIES", 60, 63], ["HIV", "SPECIES", 361, 364], ["Disease", "PROBLEM", 39, 46], ["HIV", "PROBLEM", 60, 63], ["HIV infection", "PROBLEM", 361, 374], ["infection", "OBSERVATION", 365, 374]]], ["Donors were given information about recognized risks and asked to self-defer if they self-identified as having risk 9 (men having sexual contact with multiple male partners, IV drug use, Haitian origin, hemophilia treatment with factor concentrates manufactured from large paid donor pools, and sexual contact with persons with these characteristics).", [["hemophilia", "DISEASE", 203, 213], ["Donors", "ORGANISM", 0, 6], ["men", "ORGANISM", 119, 122], ["men", "SPECIES", 119, 122], ["persons", "SPECIES", 315, 322], ["hemophilia treatment", "TREATMENT", 203, 223], ["factor concentrates", "TREATMENT", 229, 248]]], ["For reasons of assumed donor sensitivity and uncertainty about the magnitude of the AIDS threat, the 3 organizations initially did not recommend using direct questions regarding donors' sexual practices.", [["AIDS", "DISEASE", 84, 88], ["donors", "ORGANISM", 178, 184], ["assumed donor sensitivity", "PROBLEM", 15, 40]]], ["9 In 1985, after introduction of the first serologic test for HIV, some blood service organizations began direct questioning of male donors for male-to-male sexual activity, whereas other blood-collecting organizations introduced the test without amending their health history screening.", [["blood", "ANATOMY", 72, 77], ["blood", "ANATOMY", 188, 193], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["donors", "ORGANISM", 133, 139], ["blood", "ORGANISM_SUBSTANCE", 188, 193], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["the first serologic test", "TEST", 33, 57], ["HIV", "PROBLEM", 62, 65], ["the test", "TEST", 230, 238]]], ["9 Direct questioning of donors for HIV risk was not formally required in the United States until February 1991.BRIEF HISTORY OF BLOOD TESTING AND DONOR SCREENINGThroughout the early AIDS era, the US Food and Drug Administration (FDA) worked cooperatively with the principal organizations and professional associations of the whole blood and blood products sector to regulate the transfusion medicine community through consensus.", [["blood", "ANATOMY", 331, 336], ["blood", "ANATOMY", 341, 346], ["AIDS", "DISEASE", 182, 186], ["donors", "ORGANISM", 24, 30], ["HIV", "ORGANISM", 35, 38], ["blood", "ORGANISM_SUBSTANCE", 331, 336], ["blood", "ORGANISM_SUBSTANCE", 341, 346], ["HIV", "SPECIES", 35, 38], ["HIV risk", "PROBLEM", 35, 43], ["BLOOD TESTING", "TEST", 128, 141], ["the whole blood and blood products sector", "TREATMENT", 321, 362], ["the transfusion medicine", "TREATMENT", 375, 399]]], ["This changed abruptly in 1992 when the FDA imposed strict regulations (current good manufacturing practices [cGMP]), similar to those required of pharmaceutical manufacturers, on the blood collecting community.", [["blood", "ANATOMY", 183, 188], ["cGMP", "CHEMICAL", 109, 113], ["cGMP", "SIMPLE_CHEMICAL", 109, 113], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["pharmaceutical manufacturers", "TREATMENT", 146, 174]]], ["Among cGMPs was development of health history questionnaires including FDA-mandated questions on high-risk behaviors to be asked of every donor at every donation.HEALTH HISTORY QUESTIONNAIREA primary goal of appropriate donor recruitment and screening is to select and retain donors whose characteristics predict a low incidence and prevalence of TTDs.", [["TTDs", "DISEASE", 347, 351], ["donors", "ORGANISM", 276, 282], ["TTDs", "PATHOLOGICAL_FORMATION", 347, 351], ["appropriate donor recruitment", "TREATMENT", 208, 237], ["TTDs", "PROBLEM", 347, 351]]], ["Retrospective studies of blood donors infected with HIV or hepatitis viruses have repeatedly shown many to have recognizable behavioral risks, which, when disclosed, justify their deferral.", [["blood", "ANATOMY", 25, 30], ["HIV or hepatitis viruses", "DISEASE", 52, 76], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["donors", "ORGANISM", 31, 37], ["HIV", "ORGANISM", 52, 55], ["hepatitis viruses", "ORGANISM", 59, 76], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 52, 55], ["hepatitis viruses", "SPECIES", 59, 76], ["Retrospective studies", "TEST", 0, 21], ["blood donors infected", "PROBLEM", 25, 46], ["HIV", "PROBLEM", 52, 55], ["hepatitis viruses", "PROBLEM", 59, 76]]], ["American Association of Blood Banks, which authored the first uniform DHQ (UDHQ) in 1993 developed, through its Interorganizational UDHQ Task Force, new long and short form UDHQs and submitted them to the FDA for approval.", [["Blood", "ANATOMY", 24, 29], ["Blood", "ORGANISM_SUBSTANCE", 24, 29], ["new long and short form UDHQs", "PROBLEM", 149, 178]]], ["13 To date, however, the FDA has withheld approval for the new short form UDHQ, intended for frequent repeat donors, pending review of findings from ongoing studies of its performance.HEALTH HISTORY QUESTIONNAIRECurrent health history questionnaires used in the blood community include facility-specific DHQs and a mix of AABB's old and new UDHQ.", [["blood", "ANATOMY", 262, 267], ["donors", "ORGANISM", 109, 115], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["frequent repeat donors", "TREATMENT", 93, 115], ["ongoing studies", "TEST", 149, 164]]], ["All, as a condition of facility licensure, are approved by the FDA and supported by standard operating procedures (SOPs) that describe how each step in the donor interview is to be conducted and how various responses by donors to each question are to be treated, including criteria for acceptance or temporary and indefinite (ie, permanent) deferrals.HEALTH HISTORY QUESTIONNAIREIn recent years, the blood community has used donor education materials and the health history questionnaire as the initial means of protecting the blood supply from emerging and potential TTDs, for which tests are not available.", [["blood community", "ANATOMY", 400, 415], ["blood", "ANATOMY", 527, 532], ["donors", "ORGANISM", 220, 226], ["blood", "ORGANISM_SUBSTANCE", 400, 405], ["blood", "ORGANISM_SUBSTANCE", 527, 532], ["donor education materials", "TREATMENT", 425, 450], ["potential TTDs", "PROBLEM", 558, 572], ["tests", "TEST", 584, 589]]], ["For example, in 2002, the FDA mandated inclusion of additional questions intended to identify donors with past activities, residence, or travel suggesting the possibility of exposure to variant Creutzfeldt-Jakob Disease.", [["Creutzfeldt-Jakob Disease", "DISEASE", 194, 219], ["donors", "ORGANISM", 94, 100], ["Jakob Disease", "PROBLEM", 206, 219]]], ["In 2003, more questions were added about exposure to smallpox vaccine (vaccinia), severe acute respiratory syndrome, and West Nile Virus.", [["smallpox", "DISEASE", 53, 61], ["acute respiratory syndrome", "DISEASE", 89, 115], ["West Nile Virus", "DISEASE", 121, 136], ["vaccinia", "ORGANISM", 71, 79], ["West Nile Virus", "ORGANISM", 121, 136], ["West Nile Virus", "SPECIES", 121, 136], ["smallpox vaccine", "TREATMENT", 53, 69], ["severe acute respiratory syndrome", "PROBLEM", 82, 115], ["West Nile Virus", "PROBLEM", 121, 136], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115]]], ["The new long form UDHQ consists of 49 questions that were redesigned with input from cognitive scientists, using focus groups and cognitive interviews, to improve the ability to elicit the targeted information.MODES OF ADMINISTERING THE DHQHistorically blood-collecting organizations have administered the DHQ by having their staff ask each donor the questions in a face-to-face interview (FTFI) or using written donor self-administered questionnaires (WSAQ).", [["blood", "ANATOMY", 253, 258], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["THE DHQHistorically blood", "TREATMENT", 233, 258]]], ["When selecting a mode, blood-collecting organizations have the task of evaluating 3 considerations: safety, efficiency, and costs.", [["blood", "ANATOMY", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 23, 28]]], ["Each screening approach has certain advantages and disadvantages in each of the 3 dimensions.MODES OF ADMINISTERING THE DHQOf the 3 modes, FTFI, WSAQ, and CASI, the latter varies the most.", [["Each screening approach", "TREATMENT", 0, 23], ["THE DHQOf the 3 modes", "TREATMENT", 116, 137], ["FTFI", "TREATMENT", 139, 143], ["WSAQ", "TREATMENT", 145, 149], ["CASI", "TREATMENT", 155, 159]]], ["In its simplest form, CASI is conducted on a stand-alone computer with text questions displayed for reading on the monitor and answers entered by the respondent using a keyboard, keypad, or mouse.", [["mouse", "ORGANISM", 190, 195], ["mouse", "SPECIES", 190, 195], ["mouse", "SPECIES", 190, 195]]], ["Further enhancements of the basic CASI system include pictures illustrative of the content of the question; response inputs via touch screen; inclusion of back, help, and skip commands to improve accuracy and completeness of responses, staff review modules for assessment of completed DHQs, direct printing of the DHQ with provision for signatures, and electronic transfer of final interview data to other associated computer systems.EFFECTIVENESS OF THE 3 MAIN INTERVIEWING MODESSurvey interviewing is a common technique in behavioral research.", [["touch screen", "TEST", 128, 140], ["accuracy", "TEST", 196, 204], ["assessment", "TEST", 261, 271], ["back", "ANATOMY", 155, 159]]], ["Since the late 1960s, survey researchers have investigated the relative effectiveness of various forms of computerassisted interviewing, primarily CASI or audio CASI (A-CASI), as alternatives to FTFI and WSAQ for eliciting accurate responses to interview questions.", [["FTFI", "TREATMENT", 195, 199]]], ["In 1996, Weisband and Kiesler 15 reported a meta-analysis of 39 comparative studies from the social sciences, computer sciences, and medical literature between 1969 and 1994.", [["comparative studies", "TEST", 64, 83]]], ["In 1998, Turner et al, 16 studying adolescent high-risk sexual, drug use, and violent behaviors, reported them to be admitted up to 17 times more frequently when subjects were interviewed via A-CASI than by WSAQ.", [["violent behaviors", "DISEASE", 78, 95]]], ["The following year, Richman et al 17 reported a metaanalysis of 61 comparative studies conducted between 1967 and 1997.", [["a metaanalysis", "TEST", 46, 60], ["comparative studies", "TEST", 67, 86]]], ["A key finding of this study was that bcomputer instruments reduced social desirability distortion (ie, increased frank, accurate responses) when. . .used as a substitute for face-toface interviewing, particularly when. . .asking respondents to reveal highly sensitive behavior, such as whether they used illegal drugs or engaged in risky sexual behavior.Q Computer-assisted interviewing was significantly more effective than WSAQ when computer respondents were (i) assured anonymity, (ii) alone, and (iii) allowed to skip and backtrack on the computer.", [["this study", "TEST", 17, 27]]], ["Cooley et al 18 reports that using touch-screen A-CASI (AT-CASI) to obtain sensitive information on sexual and illicit drug behavior from patients 15 to 39 years of age at a sexually transmitted disease clinic was more effective than traditional interview techniques.", [["sexually transmitted disease", "DISEASE", 174, 202], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146]]], ["Johnson et al, 19 in a recent study comparing the effectiveness of CASI with WSAQ to elicit information on highrisk sexual behavior in a general population, reported similar findings.EFFECTIVENESS OF THE 3 MAIN INTERVIEWING MODESA few studies have actually involved blood donors.", [["blood", "ANATOMY", 266, 271], ["highrisk sexual behavior", "DISEASE", 107, 131], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["donors", "ORGANISM", 272, 278], ["a recent study", "TEST", 21, 35], ["few studies", "TEST", 231, 242], ["blood donors", "PROBLEM", 266, 278]]], ["In 1992, Locke et al 20 reported a crossover study that compared the effectiveness of the traditional written questionnaire plus FTFI with a CASI system using the standard American Red Cross health history questionnaire.", [["a crossover study", "TEST", 33, 50]]], ["Among 272 donors, the CASI system identified 12 reporting behaviors associated with HIV risk or symptoms compatible with AIDS, none of whom were identified when interviewed first by written questionnaire and FTFI.", [["AIDS", "DISEASE", 121, 125], ["donors", "ORGANISM", 10, 16], ["HIV", "SPECIES", 84, 87], ["HIV", "SPECIES", 84, 87], ["the CASI system", "TEST", 18, 33], ["HIV risk", "PROBLEM", 84, 92], ["symptoms", "PROBLEM", 96, 104], ["AIDS", "PROBLEM", 121, 125]]], ["In 1993, the American Institutes for Research (AIR) conducted an extensive, complex cross-over study, contracted for by the FDA, comparing the effectiveness of existing WSAQ and/or FTFI interviewing with an AT-CASI system developed by AIR for donor interviewing.", [["complex cross-over study", "TEST", 76, 100], ["AIR", "OBSERVATION", 235, 238]]], ["21 Of 7015 donors in the study, 27 (1.09%) of 2468 donors interviewed via computer were deferred for risky behavior, whereas only 23 of 4547 interviewed traditionally (0.51%) were rejected for similar reasons ( P = .00553).", [["donors", "ORGANISM", 11, 17], ["donors", "ORGANISM", 51, 57], ["the study", "TEST", 21, 30]]], ["FDA officials deemed the study inconclusive because study procedures did not permit determination of whether the observed outcome was the result of greater sensitivity of AT-CASI to identify high-risk behavior or lower specificity.", [["the study", "TEST", 21, 30], ["study procedures", "TEST", 52, 68], ["high-risk behavior", "PROBLEM", 191, 209]]], ["More recently, Sellors, 22 in a randomized cross-over study of donor deferral rates conducted at 133 blood clinics in Canada, compared a handheld computerized health history questionnaire with a written questionnaire.", [["blood", "ANATOMY", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 101, 106]]], ["They found that 43.7% of deferrable donors were identified by the CASI but not by the written questionnaire.", [["donors", "ORGANISM", 36, 42], ["deferrable donors", "PROBLEM", 25, 42]]], ["In 2005, Katz et al 23 reported results of a before-and-after study of donor deferrals for high-risk behaviors among 2739 first-time blood donors at the Mississippi Valley Regional Blood Center.", [["blood", "ANATOMY", 133, 138], ["Blood", "ANATOMY", 181, 186], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["donors", "ORGANISM", 139, 145], ["donor deferrals", "TREATMENT", 71, 86], ["high-risk behaviors", "PROBLEM", 91, 110]]], ["They found that only 1 of 890 (1.12 per 1000) such donors interviewed by FTFI between 2000 and 2001 was deferred, whereas 19 of 1849 (10.28 per 1000) donors interviewed using an audiovisual touch-screen CASI (AVT-CASI) between 2001 and 2002 were deferred, a significant difference ( P = .017; odds ratio, 9.15; 95% confidence interval, 1.3-183.8).", [["donors", "ORGANISM", 51, 57], ["donors", "ORGANISM", 150, 156], ["FTFI", "TEST", 73, 77], ["an audiovisual touch", "TEST", 175, 195], ["CASI", "TEST", 203, 207], ["P", "TEST", 283, 284], ["odds ratio", "TEST", 293, 303], ["interval", "TEST", 326, 334]]], ["In a similar study using essentially the same system at another regional blood center, Cumming et al 24 found that with a combination of FTFI and WSAQ, the rate of deferrals of first-time donors for high-risk behavior was 5.8 per 1000, whereas after installation of an AVT-CASI system the rate increased to 11.2 per 1000, a 93% increase.EFFECTIVENESS OF THE 3 MAIN INTERVIEWING MODESThese data demonstrate that CASI is more effective than FTFI in eliciting positive responses to sensitive questions.", [["blood", "ANATOMY", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["donors", "ORGANISM", 188, 194], ["a similar study", "TEST", 3, 18], ["FTFI", "TREATMENT", 137, 141], ["WSAQ", "TREATMENT", 146, 150], ["high-risk behavior", "PROBLEM", 199, 217], ["an AVT", "TEST", 266, 272], ["the rate", "TEST", 285, 293], ["MODESThese data", "TEST", 378, 393], ["CASI", "PROBLEM", 411, 415]]], ["It also appears CASI is more effective than WSAQ in this respect, although less so than when compared with FTFI.", [["CASI", "OBSERVATION", 16, 20], ["more", "OBSERVATION_MODIFIER", 24, 28], ["effective", "OBSERVATION_MODIFIER", 29, 38], ["less", "OBSERVATION_MODIFIER", 75, 79]]], ["Behavioral researchers and others infer that the difference between FTFI and the other 2 modes of interviewing arises in part from privacy differences and from reduction of social desirability distortion (the tendency of respondents to provide information biased toward what they perceive as the socially accepted or desirable answer).", [["social desirability distortion", "PROBLEM", 173, 203]]], ["15,17 Because CASI and WSAQ are quite similar in the privacy provided each interview subject, these researchers offered the following possible reasons why people disclose more when using a computer: computer interfaces create in respondents an inattention to audience; they provide for immersion in the immediate task along with invulnerability to criticism; they foster an impression that responses bdisappearQ into the computer; they give a sense of comfort leading to a less wary attitude; and there are other misattributions that cause respondents to be careless about their responses.", [["inattention", "DISEASE", 244, 255], ["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161]]], ["Whatever the underlying mechanism(s), the weight of available evidence indicates that CASI is more effective than WSAQ in eliciting accurate answers to sensitive questions.EFFECTIVENESS OF THE 3 MAIN INTERVIEWING MODESTo what extent does the observed increased deferral of donors admitting to high-risk behavior by CASI actually protect blood safety?", [["blood", "ANATOMY", 337, 342], ["donors", "ORGANISM", 273, 279], ["blood", "ORGANISM_SUBSTANCE", 337, 342], ["CASI", "PROBLEM", 86, 90], ["donors", "TREATMENT", 273, 279], ["blood safety", "TEST", 337, 349]]], ["This depends mainly on the incidence (early, test-negative infections) of TTDs among donors admitting such behavior to the computer but withholding the information when using other interview formats.", [["infections", "DISEASE", 59, 69], ["TTDs", "DISEASE", 74, 78], ["TTDs", "PATHOLOGICAL_FORMATION", 74, 78], ["donors", "ORGANISM", 85, 91], ["test", "TEST", 45, 49], ["infections", "PROBLEM", 59, 69]]], ["From studies by Petersen and Doll, 10 Conry-Cantilena et al, 11 and Murphy et al, 12 we can conclude that the elicited behaviors are useful indices of TTD risk, so the donors should be deferred.", [["TTD", "DISEASE", 151, 154], ["donors", "ORGANISM", 168, 174], ["Cantilena et al", "TREATMENT", 44, 59], ["Murphy et al", "TREATMENT", 68, 80], ["TTD risk", "PROBLEM", 151, 159]]], ["The studies that would be required to actually demonstrate a decrease in risk to transfusion recipients are too large to accomplish and unlikely to be undertaken.OTHER CONSIDERATIONSCASI systems have other characteristics that enhance their appeal for blood donor screening: (i) increased donor and staff satisfaction, (ii) potentially improved understanding by less literate donors when audio and/or visual prompts are incorporated, (iii) reduced donor and staff errors, and (iv) reduced staff time.Donor and Staff SatisfactionBlood bankers are acutely concerned with donor reactions to the screening interview.", [["blood", "ANATOMY", 252, 257], ["Blood", "ANATOMY", 528, 533], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["Blood", "ORGANISM_SUBSTANCE", 528, 533], ["The studies", "TEST", 0, 11], ["transfusion recipients", "TREATMENT", 81, 103], ["blood donor screening", "TEST", 252, 273], ["decrease", "OBSERVATION_MODIFIER", 61, 69]]], ["When interviewing of blood donors on their sexual, drug, and other socially sensitive behaviors was introduced, the intrusive nature and complexity of information sought during the interview provoked one blood banker to label the interview a bdonor interrogation.Q 25 To date, all studies of CASI systems for donor screening have included surveys assessing donor reactions to the interview format.", [["blood", "ANATOMY", 21, 26], ["blood", "ANATOMY", 204, 209], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["a bdonor interrogation", "TEST", 240, 262], ["CASI systems", "TEST", 292, 304], ["donor screening", "TEST", 309, 324]]], ["Locke et al, 20 in their early study, reported that although donors believed CASI interviewing was as effective as FTFI for screening, they found it more private (39% vs 7%) and more likely (61%) to elicit honest responses.", [["donors", "ORGANISM", 61, 67], ["screening", "TEST", 124, 133]]], ["The AIR study reported that 53.5% of the donors preferred CASI for interviewing, whereas 64.4% felt it would yield more honest answers.", [["donors", "ORGANISM", 41, 47], ["The AIR study", "TEST", 0, 13], ["AIR", "OBSERVATION", 4, 7]]], ["21 More recently, Zuck et al 26 reported that 40% of the donors participating in a pilot study of an early version of an AVT-CASI system found the computer preferable, whereas 36% preferred the FTFI mode.", [["donors", "ORGANISM", 57, 63], ["a pilot study", "TEST", 81, 94], ["the FTFI mode", "TREATMENT", 190, 203]]], ["Sixty-seven percent of donors believed donors would be more truthful when interviewed via AVT-CASI, although only 7% thought FTFI would yield more truthful information.", [["donors", "ORGANISM", 23, 29], ["donors", "ORGANISM", 39, 45]]], ["Katz et al 23 reported that 68% of donors preferred the CASI system, whereas only 10% preferred the FTFI.", [["donors", "ORGANISM", 35, 41], ["the FTFI", "TREATMENT", 96, 104]]], ["In addition, 92% of donors were very satisfied with the privacy provided by the system, and 68% felt it would elicit more truthful answers.", [["donors", "ORGANISM", 20, 26]]], ["One study, Sanchez et al, 27 has questioned increased donor satisfaction with and preference for CASI interviewing.", [["One study", "TEST", 0, 9]]], ["Thirteen percent of the blood donors they surveyed about their hypothetical reaction to CASI screening stated such a system would either discourage them from donating (5.2%) or that they were unsure (8.0%).", [["blood", "ANATOMY", 24, 29], ["CASI", "DISEASE", 88, 92], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["donors", "ORGANISM", 30, 36], ["the blood donors", "TREATMENT", 20, 36], ["CASI screening", "TEST", 88, 102]]], ["None of the donors in the study had actually used CASI screening, prompting Gillespie, 28 in an editorial commenting on the studies of Sanchez et al and Katz et al, to emphasize the importance of differentiating real and projected behavior and the importance of studying actual behavior in any scientific field.", [["donors", "ORGANISM", 12, 18], ["the study", "TEST", 22, 31], ["CASI screening", "TEST", 50, 64], ["the studies", "TEST", 120, 131]]], ["From these and similar studies, 29-31 it is reasonable to conclude that most donors and interviewees are more satisfied with CASI than FTFI.", [["donors", "ORGANISM", 77, 83], ["similar studies", "TEST", 15, 30], ["FTFI", "TREATMENT", 135, 139]]], ["Moreover, as Katz et al 23 demonstrated, blood center staffs believe AVT-CASI is faster, personally more satisfying, and less likely to induce staff errors.Donor UnderstandingComprehension of questions on the screening interview is essential.", [["blood", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["AVT", "PROBLEM", 69, 72]]], ["When donors fail to understand a question and answer it erroneously, the interview has failed.", [["donors", "ORGANISM", 5, 11]]], ["The ability of donors to understand medical and health-related questions is of particular importance for WSAQ and CASI because both assume donor literacy.", [["donors", "ORGANISM", 15, 21]]], ["There is substantial evidence that this assumption is overly optimistic.", [["substantial", "OBSERVATION_MODIFIER", 9, 20]]], ["Wilson, 32 in a summary of findings from 10 studies on literacy and health, concluded that most adults with poor literacy are adept at disguising their inability and disinclined to ask for help.", [["adults", "ORGANISM", 96, 102]]], ["In an analysis of medical literacy among a randomly selected sample of 18 to 45 old-year-old adults in Baltimore, Al-Tayib 33 found that 28% had a literacy level of grade 8 or less and 12% of grade 6 or less.", [["adults", "ORGANISM", 93, 99], ["a literacy level", "TEST", 145, 161]]], ["Eighteen percent of the study's participants with some college or a 2-year degree (sometimes cited as the prototypic blood donor) were reading at an eighth grade level when responding to a WSAQ on drug use, sexual behavior, and sexually transmitted diseases, which are topics also queried among donors.", [["blood", "ANATOMY", 117, 122], ["WSAQ", "CHEMICAL", 189, 193], ["sexual behavior", "DISEASE", 207, 222], ["sexually transmitted diseases", "DISEASE", 228, 257], ["participants", "ORGANISM", 32, 44], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["donors", "ORGANISM", 295, 301], ["participants", "SPECIES", 32, 44], ["the study", "TEST", 20, 29], ["the prototypic blood donor", "TREATMENT", 102, 128], ["sexually transmitted diseases", "PROBLEM", 228, 257]]], ["Thanks to Paul Sullivan at MVRBC, Judith Woll at Community Blood CenterDayton, and Susan Rossman at Gulf Coast Regional Blood Center for their bin-useQ system descriptions.Donor UnderstandingThe recent revision of AABB's UDHQ is the prime example of effort by the blood services community to adapt donor screening to reasonable levels of adult literacy.", [["Blood", "ANATOMY", 120, 125], ["blood", "ANATOMY", 264, 269], ["Blood", "ORGANISM_SUBSTANCE", 120, 125], ["blood", "ORGANISM_SUBSTANCE", 264, 269], ["donor screening", "TEST", 298, 313], ["revision", "OBSERVATION", 202, 210]]], ["After focus groups and cognitive interviews, many medical terms in the original UDHQ were eliminated or modified in the new questionnaire to improve donor comprehension.", [["UDHQ", "DNA", 80, 84]]], ["CASI systems can include audio to mitigate literacy issues and/or bHelpQ and bSkipQ alternative responses along with the usual bYesQ and bNoQ choices for each question providing donors with assistance when needed.", [["donors", "ORGANISM", 178, 184], ["bHelpQ", "TREATMENT", 66, 72], ["the usual bYesQ and bNoQ choices", "TREATMENT", 117, 149]]], ["Some CASI systems include visual prompts illustrating the activity or subject matter to improve donor comprehension (Table 1) .Error ReductionDonor and staff errors and omissions on screening interviews result in the collection, distribution, and transfusion of unacceptable donations.", [["Some CASI systems", "PROBLEM", 0, 17], ["visual prompts", "TREATMENT", 26, 40], ["screening interviews", "TEST", 182, 202]]], ["Donor errors, particularly donor failure to admit to high-risk behaviors, are thought to endanger the blood supply.", [["blood", "ANATOMY", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["Donor errors", "PROBLEM", 0, 12], ["donor failure", "PROBLEM", 27, 40]]], ["Also troublesome are errors and omissions recognized and reported to the collecting organization after donation (postdonation information [PDI]).", [["troublesome", "OBSERVATION_MODIFIER", 5, 16]]], ["Errors resulting in labeling and making available for distribution nonconforming blood products are transmitted to FDA as blood product deviation reports (BPDRs), and summarized annually by the agency.", [["blood", "ANATOMY", 81, 86], ["blood", "ANATOMY", 122, 127], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["distribution nonconforming blood products", "PROBLEM", 54, 95]]], ["34 The donor interview process is responsible for 75% of all BPDRs, occurring at a rate 11 times that of the next largest category.", [["BPDRs", "DISEASE", 61, 66], ["BPDRs", "PATHOLOGICAL_FORMATION", 61, 66], ["all BPDRs", "PROBLEM", 57, 66]]], ["The frequency of such errors may be, in part, a function of the screening method used by the collecting organization.", [["such errors", "PROBLEM", 17, 28], ["the screening method", "TEST", 60, 80]]], ["Cumming et al, 24 in their recent study at a regional blood center, found that in the first year after implementing an AVT-CASI system, the elicitation of information resulting in donor deferrals increased substantially.", [["blood", "ANATOMY", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["donor deferrals", "TREATMENT", 180, 195]]], ["First-time donor PDI reports to FDA increased by 269%, compared with those during the previous FTFI-WSAQ interview, whereas repeat donor PDIs increased by 79% and then declined substantially.", [["PDI", "GENE_OR_GENE_PRODUCT", 17, 20], ["repeat donor PDIs", "TEST", 124, 141], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["increased", "OBSERVATION_MODIFIER", 142, 151]]], ["The hypothesis is that AVT-CASI may have more effectively prompted donors' subsequent recall of information requested during the interview.", [["AVT", "CHEMICAL", 23, 26], ["AVT-CASI", "GENE_OR_GENE_PRODUCT", 23, 31], ["donors", "ORGANISM", 67, 73]]], ["Goldman et al, 35 in a 2005 study of 870 Canadian donors (94% repeat) found that (i) blood donors' ability to recall questions immediately after completing their paper DHQ was poor, (ii) recall was particularly poor when items were part of a list, and (iii) recall was improved when using the AABB UDHQ and further improved by using AVT-CASI.Error ReductionCASI systems have an advantage over FTFI and WSAQ for error reduction.", [["blood", "ANATOMY", 85, 90], ["donors", "ORGANISM", 50, 56], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["Error ReductionCASI systems", "PROBLEM", 342, 369], ["FTFI", "TREATMENT", 393, 397], ["error reduction", "TREATMENT", 411, 426]]], ["Properly designed CASI systems include programed quality checks and staff alerts for aberrant or incomplete donor responses, incomplete staff reviews, omission of donor and staff signatures (when done electronically), and failure to properly file donor health history records when transferred to electronic data repositories.", [["programed quality checks", "TEST", 39, 63], ["staff signatures", "TEST", 173, 189]]], ["By automating the screening process wherever possible and embedding programed checks on human error, CASI systems substantially reduce staff errors in the screening process.Error ReductionThree recent studies indicate the extent to which CASI systems are effective in this respect.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["embedding programed checks", "TEST", 58, 84], ["CASI systems", "TREATMENT", 101, 113], ["Error Reduction", "TREATMENT", 173, 188], ["recent studies", "TEST", 194, 208]]], ["Cumming et al 24 reported staff errors and omissions decreased by 69% after AVT-CASI introduction at another regional blood center.", [["blood", "ANATOMY", 118, 123], ["AVT-CASI", "CHEMICAL", 76, 84], ["AVT-CASI", "SIMPLE_CHEMICAL", 76, 84], ["blood", "ORGANISM_SUBSTANCE", 118, 123]]], ["However, data processing procedures for donor screening via WSAQ are essentially the same as those for FTFI, so it is reasonable to expect that error reduction would be similar when CASI is substituted for WSAQ.Staff Time RequiredCASI donor screening requires less staff time than FTFI.", [["donor screening", "TEST", 40, 55], ["WSAQ", "TREATMENT", 60, 64], ["FTFI", "TREATMENT", 103, 107], ["error reduction", "PROBLEM", 144, 159], ["WSAQ", "PROBLEM", 206, 210], ["donor screening", "TEST", 235, 250]]], ["In their study, based on an AVT-CASI version of the original UDHQ, Katz et al, 23 reported a decrease in staff time per interview of 5 minutes (68%), whereas total interview time for donors increased from 7.4 to 11.2 minutes, compared with the previous FTFI.", [["donors", "ORGANISM", 183, 189], ["their study", "TEST", 3, 14], ["donors", "TEST", 183, 189], ["the previous FTFI", "TEST", 240, 257], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["increased", "OBSERVATION_MODIFIER", 190, 199]]], ["Interestingly, despite the increased total time, 87% of donors perceived that the time needed for CASI was favorable, compared with FTFI.", [["donors", "ORGANISM", 56, 62], ["CASI", "TEST", 98, 102], ["FTFI", "TREATMENT", 132, 136], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["37Cost of QualityThere is a dearth of literature addressing the tradeoff between system costs and the value of quality improvements in donor screening realized when CASI reduces staff errors and omissions.", [["donor screening", "TEST", 135, 150]]], ["Cunningham 38 has estimated the costs of staff errors that occurred during donor screening at the Indiana Blood Center in 2003.", [["donor screening", "TEST", 75, 90]]], ["This study evaluated bhidden costs (of errors) to the blood center, including costs associated with documentation of the error upon discovery; initial evaluation and investigation of an error; lost product costs; labor expenses; and quarantine and resolution of quarantine of the involved products.Q The estimated annual cost of such errors was $87 280, and the study bprovided compelling evidence that automated donor screening processes should be considered.QAVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGFour vendors presently offer proprietary CASI systems for blood donor screening in the United States: Talisman Medical Systems Ltd, Vienna, VA (Quality Donor System) referred to hereafter as bQDSQ; Healthcare ID Inc, Buffalo Grove, IL, (DONOR-ID), referred to hereafter as bHCIDQ; Information Data Management, Rosemont, IL (Prelude), referred to hereafter as bIDMQ; and Haemonetics' 5D Information Management Division, Edmonton, Alberta, Canada (eQue), referred to hereafter as b5D.Q Characteristics of the 4 systems, as described by vendors and, where installed and in use, verified by customers, are summarized in Table 1 .", [["blood", "ANATOMY", 54, 59], ["blood", "ANATOMY", 567, 572], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 567, 572], ["This study", "TEST", 0, 10], ["initial evaluation", "TEST", 143, 161], ["an error", "PROBLEM", 183, 191], ["labor expenses", "PROBLEM", 213, 227], ["quarantine", "TREATMENT", 233, 243], ["the study", "TEST", 358, 367], ["automated donor screening processes", "PROBLEM", 403, 438], ["blood donor screening", "TEST", 567, 588]]], ["Of the 4 systems, 2 are operational (QDS and HCID) in blood centers; the third, IDM, is being installed at present; and the fourth, 5D, is scheduled for first installation in fall 2006.", [["blood", "ANATOMY", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 54, 59]]], ["All systems can use the new AABB long form UDHQ with English and Spanish versions available.", [["AABB long form UDHQ", "PROTEIN", 28, 47]]], ["QDS is a standardized system with the vendor responsible for installation and maintenance of all screening questions, all audio and visual prompts, and all additions and changes thereto.", [["all screening", "TEST", 93, 106]]], ["Described generically, QDS uses finger touch-screen tablet computers with Windows (Microsoft) printers for all fixed sites and mobiles; HCID uses touch-screen laptop computers for mobiles and standard desktops for fixed sites; IDM uses standard desktop computers with personal digital assistant (PDA)/handhelds planned for early 2007, touch-screen monitors, stylus-only tablet computers, wireless scanners, and electronic signature pad; and 5D uses standard desktop computers with touch-screen monitors, fingerprint scanners, and signature pads for fixed sites.", [["QDS", "DNA", 23, 26], ["finger touch", "TEST", 32, 44], ["all fixed sites", "TREATMENT", 107, 122], ["mobiles", "TREATMENT", 180, 187], ["standard desktops", "TREATMENT", 192, 209], ["fixed sites", "PROBLEM", 214, 225], ["stylus", "TEST", 358, 364], ["electronic signature pad", "TEST", 411, 435], ["touch", "TEST", 481, 486], ["fingerprint scanners", "TEST", 504, 524], ["signature pads", "TREATMENT", 530, 544], ["fixed sites", "PROBLEM", 549, 560]]], ["Typically, installation, validation, and implementation require weeks or months before center screening is fully automated.", [["center screening", "TEST", 87, 103]]], ["In general, implementations have been sequential with fixed donation sites preceding mobile operations.AVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGAll systems permit the donor the alternative of answering, skipping, or requesting help on each question.", [["fixed donation sites", "TREATMENT", 54, 74], ["mobile operations", "TREATMENT", 85, 102], ["BLOOD DONOR SCREENINGAll systems", "TREATMENT", 130, 162]]], ["When the interview is completed, each system shifts to its staff review mode, highlighting those questions that require further staff interaction with the donor.", [["the donor", "TREATMENT", 151, 160]]], ["QDS and HCID produce printed output for signature, whereas IDM and 5D display the final interview on the monitor, to be signed electronically on a signature pad.", [["pad", "TISSUE", 157, 160], ["QDS", "DNA", 0, 3], ["HCID", "DNA", 8, 12], ["printed output", "TEST", 21, 35], ["a signature pad", "TEST", 145, 160], ["output", "OBSERVATION_MODIFIER", 29, 35]]], ["An imminent release of QDS provides for touch-screen input of donor and staff signatures.AVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGNo formal donor training time is required with any of the systems because operation of each system is self-evident.", [["QDS", "PROTEIN", 23, 26], ["An imminent release of QDS", "TREATMENT", 0, 26], ["touch", "TEST", 40, 45], ["donor training", "TREATMENT", 147, 161], ["operation of each system", "TREATMENT", 211, 235]]], ["QDS, for which the vendor retains responsibility for system maintenance, requires 2 to 3 hours for center staff familiarization with system setup and the staff review procedure.", [["system maintenance", "TREATMENT", 53, 71], ["procedure", "TREATMENT", 167, 176]]], ["HCID, IDM, and 5D, because each assigns responsibility for software maintenance and process changes to center staffs, vary the requirement with HCID using 2 to 3 days of staff training.", [["staff training", "TREATMENT", 170, 184]]], ["IDM uses 5 sessions of 4 hours each together with a short refresher course, and 5D allots 1 day for reviewers and up to 3 days for system administrators.AVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGThe means by which data are communicated among stations of the screening systems and from the screening system to the blood bank computer system or other data repository is important in minimizing staff time to update system records and avoid errors in communication between systems.", [["blood", "ANATOMY", 319, 324], ["blood", "ORGANISM_SUBSTANCE", 319, 324], ["the screening system", "TEST", 291, 311], ["errors in communication between systems", "PROBLEM", 444, 483]]], ["All systems can operate on a local area network (LAN), whereby a single server holds all system software and services multiple clients on the network.", [["area network", "MULTI-TISSUE_STRUCTURE", 35, 47]]], ["At present, one center using QDS operates its fixed and mobile sites on wireless LANs.", [["LANs", "CANCER", 81, 85], ["QDS", "DNA", 29, 32], ["QDS", "TREATMENT", 29, 32], ["wireless LANs", "TEST", 72, 85], ["fixed", "OBSERVATION_MODIFIER", 46, 51]]], ["Although the QDS 510(k) covers electronic data transfer, at present, centers using the system prefer manual entry of selected interview data into the main blood bank computer system.", [["blood", "ANATOMY", 155, 160], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["QDS 510", "DNA", 13, 20], ["the QDS", "TEST", 9, 16], ["electronic data", "TEST", 31, 46]]], ["IDM, HCID, and 5D, on the other hand, produce electronic donor records that can then be transferred directly to the main system.", [["main system", "ANATOMY", 116, 127]]], ["The main difference between the 2 is that with web-based software, only the computer servers need be updated and validated for system changes, whereas with client-server software, both servers and stations must be updated and validated.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["A wide area network (WAN) using a single server to service multiple geographically dispersed stations has advantages over standalone or LAN software (see section below on system extensions).AVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGAll center system installations in the United States, whether consisting of standalone stations, LANs, or WANs must be submitted to the FDA for review and clearance.", [["area network", "MULTI-TISSUE_STRUCTURE", 7, 19], ["WANs", "TREATMENT", 344, 348], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Centers are permitted to install them using a changes being effected-30 days (CBE-30) license supplement that allows FDA 30 days to object before implementation.AVAILABLE CASI SYSTEMS FOR BLOOD DONOR SCREENINGAdditions or changes in QDS interview questions are the responsibility of the vendor staff who develop required revisions or those requested by users and transmit them to center staff for installation and validation.", [["BLOOD DONOR SCREENINGAdditions", "TREATMENT", 188, 218], ["revisions", "TREATMENT", 321, 330]]], ["This change process requires 1 week, based on experience with smallpox vaccination, severe acute respiratory syndrome, West Nile symptoms, and variant Creutzfeldt-Jacob disease guidances.", [["smallpox", "DISEASE", 62, 70], ["acute respiratory syndrome", "DISEASE", 91, 117], ["West Nile symptoms", "DISEASE", 119, 137], ["Creutzfeldt-Jacob disease", "DISEASE", 151, 176], ["This change process", "PROBLEM", 0, 19], ["smallpox vaccination", "TREATMENT", 62, 82], ["severe acute respiratory syndrome", "PROBLEM", 84, 117], ["West Nile symptoms", "PROBLEM", 119, 137], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117]]], ["Gerber et al, 39 using a QDS system, describe making such a change in 10 standalone stations within 3 days.", [["a QDS system", "TREATMENT", 23, 35]]], ["HCID, IDM, and 5D leave center staff responsible for changes for which there is no reported experience to date.EXTENSIONS OF PRESENT CASI SYSTEMSAvailable technology offers several opportunities for improvement in present AVT-CASI screening systems.", [["HCID", "DISEASE", 0, 4], ["AVT", "SIMPLE_CHEMICAL", 222, 225]]], ["Chief among these are (i) Internet donor interviewing, (ii) WAN and wireless communications, (iii) archival databases, and (iv) staff decision aids.Internet InterviewingUse of the Internet for e-mail communication is commonplace in the United States and already in use by blood centers for donor recruitment.", [["blood", "ANATOMY", 272, 277], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["donor recruitment", "TREATMENT", 290, 307]]], ["An obvious next step for blood centers, strongly supported by sponsoring organizations interested in minimizing employee donation time, is to screen donors at home or work via the Internet.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["donors", "ORGANISM", 149, 155]]], ["40 A system for Internet interviewing has been developed for QDS and pilot-tested at the Mississippi Valley Regional Blood Center.", [["Blood", "ANATOMY", 117, 122], ["Blood", "ORGANISM_SUBSTANCE", 117, 122], ["QDS", "PROBLEM", 61, 64]]], ["An encoded bar code printout with a unique identifier is produced for donors to present to the donation site.", [["donors", "ORGANISM", 70, 76], ["bar", "OBSERVATION_MODIFIER", 11, 14]]], ["The staff then scans the bar code to decode the interview, insert the donor identification, complete the staff review, and print the donor card for signatures.", [["the donor identification", "TEST", 66, 90]]], ["Most donors participating in the pilot study reported the system allowed for adequate privacy, felt the Web site was easy to access, that instructions were easy to follow, and audio and video quality was very good.", [["donors", "ORGANISM", 5, 11], ["the pilot study", "TEST", 29, 44], ["the Web site", "PROBLEM", 100, 112], ["audio and video quality", "TEST", 176, 199]]], ["A prior approval supplement for implementation has been submitted to FDA.", [["A prior approval supplement", "TREATMENT", 0, 27]]], ["In addition to assisting organizations sponsoring blood drives by decreasing donor time at the blood drive, the system is expected to increase donor satisfaction.", [["blood", "ANATOMY", 50, 55], ["blood", "ANATOMY", 95, 100], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 95, 100]]], ["Furthermore, because Internet donor interviewing is anonymous until staff review, the interview site remote, and the interview totally private and under donor control at all times, it may increase the accuracy of elicited information.", [["donor control", "TREATMENT", 153, 166]]], ["As Fielding et al 42 discovered in a recent test of postdonation telephone interviewing of blood donors, traditional onsite WSAQ for donor screening can lead to underreporting of high-risk behavior, probably because of social desirability bias and embarrassment considerations, factors that may be minimized when donors are interviewed remotely.Wide Area NetworksTypical blood center organization includes a headquarters containing the blood bank computer system and principal collection site, multiple widely dispersed satellite collection sites, and mobile collection operations used to service donors at workplaces, schools, churches, and other convenient locations.", [["blood", "ANATOMY", 91, 96], ["blood", "ANATOMY", 371, 376], ["blood", "ANATOMY", 436, 441], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["donors", "ORGANISM", 313, 319], ["blood", "ORGANISM_SUBSTANCE", 371, 376], ["blood", "ORGANISM_SUBSTANCE", 436, 441], ["donors", "ORGANISM", 597, 603], ["blood donors", "TREATMENT", 91, 103], ["donor screening", "TEST", 133, 148], ["high-risk behavior", "PROBLEM", 179, 197], ["Typical blood center organization", "PROBLEM", 363, 396], ["principal collection site", "PROBLEM", 467, 492], ["multiple widely dispersed satellite collection sites", "PROBLEM", 494, 546], ["mobile collection operations", "TREATMENT", 552, 580], ["blood center", "OBSERVATION", 371, 383], ["principal", "OBSERVATION_MODIFIER", 467, 476], ["collection", "OBSERVATION", 477, 487], ["multiple", "OBSERVATION_MODIFIER", 494, 502], ["widely", "OBSERVATION_MODIFIER", 503, 509], ["dispersed", "OBSERVATION_MODIFIER", 510, 519], ["satellite", "OBSERVATION_MODIFIER", 520, 529], ["collection", "OBSERVATION_MODIFIER", 530, 540], ["sites", "OBSERVATION_MODIFIER", 541, 546], ["mobile", "OBSERVATION_MODIFIER", 552, 558], ["collection", "OBSERVATION_MODIFIER", 559, 569]]], ["A CASI system for such a center typically consists of several interviewing stations at each fixed and mobile collection site, either standalone or on a LAN, each of which contains the full complement of screening software including a database capable of storing donor interview data.", [["A CASI system", "TEST", 0, 13], ["screening software", "TEST", 203, 221]]], ["This process is inefficient.", [["inefficient", "OBSERVATION_MODIFIER", 16, 27]]], ["Construction of a WAN simplifies all this as each site station becomes part of the center-wide electronic network.", [["electronic network", "MULTI-TISSUE_STRUCTURE", 95, 113], ["WAN", "DNA", 18, 21], ["a WAN simplifies", "TREATMENT", 16, 32]]], ["WANs allow transmission of encrypted data to and from the headquarters' central server, site servers, and each station and mobile unit.", [["headquarters' central server", "DNA", 58, 86]]], ["Because much US blood is collected on mobile operations in suburban and rural areas where no wired WANs are available, QDS, IDM, and 5D have WAN capability including data encryption.", [["blood", "ANATOMY", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["WANs", "MULTI-TISSUE_STRUCTURE", 99, 103], ["much US blood", "TEST", 8, 21], ["mobile operations", "TREATMENT", 38, 55], ["wired WANs", "TREATMENT", 93, 103], ["data encryption", "TEST", 166, 181]]], ["At present, QDS is testing a WAN system using satellite communication between headquarters and mobile units as part of its system now installed at West Tennessee Regional Blood Center.", [["Blood", "ANATOMY", 171, 176], ["Blood", "ORGANISM_SUBSTANCE", 171, 176], ["mobile units", "TREATMENT", 95, 107]]], ["A WAN configuration on a CASI system will permit staff at any collection location to access a donor's travel history during the staff review for comparison with the current information, allowing resolution of any discrepancies.", [["any discrepancies", "PROBLEM", 209, 226]]], ["Real-time access to historical data can prevent inappropriate collections, facilitate timely discovery and action on postdonation information, and prevent unnecessary deferrals when complicated donor histories have been previously evaluated and found acceptable.Decision AidsDecision aids consist of a variety of supplementary tables, flow charts, and instructions, detailing for staff how to evaluate aberrant or unclear responses to interview questions.", [["historical data", "TEST", 20, 35], ["inappropriate collections", "PROBLEM", 48, 73], ["collections", "OBSERVATION", 62, 73]]], ["American Association of Blood Banks, as part of development of the new long form UDHQ, has produced a set of decision aids consisting of flow charts and tables to assist screening staff in their response to aberrant answers.", [["Blood", "ANATOMY", 24, 29], ["Blood", "ORGANISM_SUBSTANCE", 24, 29]]], ["These lists and flow charts can be incorporated into CASI systems for use by staff when consultation or guidance is needed during review, as has been done with QDS and IDM.CONCLUSIONSComputerized health histories and donor screening increase the accuracy and efficiency of the blood donation process.", [["blood", "ANATOMY", 277, 282], ["blood", "ORGANISM_SUBSTANCE", 277, 282], ["QDS", "TREATMENT", 160, 163], ["donor screening", "TEST", 217, 232], ["the accuracy", "TEST", 242, 254], ["the blood donation process", "TREATMENT", 273, 299], ["blood", "ANATOMY", 277, 282]]], ["Presumably this translates into transfusion safety, although direct measurement is difficult, given low rates of donor infection.", [["infection", "DISEASE", 119, 128], ["transfusion safety", "TREATMENT", 32, 50], ["direct measurement", "TEST", 61, 79], ["donor infection", "PROBLEM", 113, 128], ["infection", "OBSERVATION", 119, 128]]], ["Given that 75% of BPDRs reported to FDA involve the donor interview, decrements in errors and omissions by themselves justify broader implementation of CASI systems and are consonant with the blood community's adoption of cGMPs.", [["blood", "ANATOMY", 192, 197], ["BPDRs", "DISEASE", 18, 23], ["BPDRs", "CANCER", 18, 23], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["cGMPs", "GENE_OR_GENE_PRODUCT", 222, 227], ["cGMPs", "PROTEIN", 222, 227], ["cGMPs", "TREATMENT", 222, 227]]], ["The enhancements being developed for present systems will provide further process improvements that mesh nicely with the emphasis on current good manufacturing practices in blood banking and the use of electronic health records more broadly.", [["blood", "ANATOMY", 173, 178], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["mesh", "TREATMENT", 100, 104], ["blood banking", "TREATMENT", 173, 186], ["mesh", "OBSERVATION", 100, 104]]]], "e62db9e60ff1920aad62f9d4f6cc3f419160c676": [["IntroductionThe occurrence of multiple heterogeneous complications associated with Coronavirus disease 2019, SARS-CoV-2 infection, a global pandemic [1, 2] , has led to several scientific reports and news headlines.", [["Coronavirus disease", "DISEASE", 83, 102], ["SARS-CoV-2 infection", "DISEASE", 109, 129], ["SARS-CoV-2", "ORGANISM", 109, 119], ["CoV-", "SPECIES", 114, 118], ["SARS-CoV-2", "SPECIES", 109, 119], ["multiple heterogeneous complications", "PROBLEM", 30, 66], ["Coronavirus disease", "PROBLEM", 83, 102], ["SARS", "PROBLEM", 109, 113], ["infection", "PROBLEM", 120, 129], ["multiple", "OBSERVATION_MODIFIER", 30, 38], ["heterogeneous", "OBSERVATION_MODIFIER", 39, 52], ["complications", "OBSERVATION", 53, 66], ["Coronavirus disease", "OBSERVATION", 83, 102]]], ["Li et al. published one of the first studies describing the risk of stroke among SARS-CoV-2 hospitalized patients [3] .", [["Li", "CHEMICAL", 0, 2], ["stroke", "DISEASE", 68, 74], ["SARS", "DISEASE", 81, 85], ["SARS-CoV", "ORGANISM", 81, 89], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 81, 89], ["stroke", "PROBLEM", 68, 74], ["SARS", "PROBLEM", 81, 85], ["stroke", "OBSERVATION", 68, 74]]], ["They observed a 5% risk of ischaemic stroke, 0.5% cerebral venous sinus thrombosis, and 0.5% cerebral hemorrhage.", [["cerebral venous sinus", "ANATOMY", 50, 71], ["cerebral", "ANATOMY", 93, 101], ["ischaemic stroke", "DISEASE", 27, 43], ["cerebral venous sinus thrombosis", "DISEASE", 50, 82], ["cerebral hemorrhage", "DISEASE", 93, 112], ["cerebral venous sinus", "MULTI-TISSUE_STRUCTURE", 50, 71], ["cerebral", "ORGAN", 93, 101], ["ischaemic stroke", "PROBLEM", 27, 43], ["0.5% cerebral venous sinus thrombosis", "PROBLEM", 45, 82], ["0.5% cerebral hemorrhage", "PROBLEM", 88, 112], ["ischaemic", "OBSERVATION_MODIFIER", 27, 36], ["stroke", "OBSERVATION", 37, 43], ["cerebral", "ANATOMY", 50, 58], ["venous sinus", "ANATOMY", 59, 71], ["thrombosis", "OBSERVATION", 72, 82], ["cerebral", "ANATOMY", 93, 101], ["hemorrhage", "OBSERVATION", 102, 112]]], ["However, the study was a single-center report of a limited number of patients (N: 221).", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["the study", "TEST", 9, 18]]], ["Since then, there have been several other case reports and series describing the risk of stroke among SARS-CoV-2 patients [4\u00c06].IntroductionSeveral studies have described different mechanisms in which SARS-CoV-2 can induce neurological disorders and stroke [7, 8] .", [["neurological", "ANATOMY", 223, 235], ["stroke", "DISEASE", 89, 95], ["SARS", "DISEASE", 102, 106], ["SARS", "DISEASE", 201, 205], ["neurological disorders", "DISEASE", 223, 245], ["stroke", "DISEASE", 250, 256], ["SARS-CoV", "ORGANISM", 102, 110], ["patients", "ORGANISM", 113, 121], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 211], ["patients", "SPECIES", 113, 121], ["SARS-CoV", "SPECIES", 102, 110], ["stroke", "PROBLEM", 89, 95], ["IntroductionSeveral studies", "TEST", 128, 155], ["neurological disorders", "PROBLEM", 223, 245], ["stroke", "PROBLEM", 250, 256], ["stroke", "OBSERVATION", 89, 95]]], ["Many of these mechanisms focus on Angiotensin-Converting Enzyme-2 (ACE-2), the binding site for SARS-CoV-2, and the imbalance of its function as a trigger of a cascade of events resulting in vasoconstriction, high blood pressure, or thrombus formation [9, 10] .", [["blood", "ANATOMY", 214, 219], ["thrombus", "ANATOMY", 233, 241], ["Angiotensin", "CHEMICAL", 34, 45], ["thrombus", "DISEASE", 233, 241], ["Angiotensin-Converting Enzyme-2", "GENE_OR_GENE_PRODUCT", 34, 65], ["ACE-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["thrombus", "PATHOLOGICAL_FORMATION", 233, 241], ["Angiotensin-Converting Enzyme-2 (ACE-2", "PROTEIN", 34, 72], ["binding site", "DNA", 79, 91], ["Angiotensin", "TEST", 34, 45], ["Converting Enzyme", "TEST", 46, 63], ["ACE", "TEST", 67, 70], ["the binding site", "PROBLEM", 75, 91], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104], ["vasoconstriction", "PROBLEM", 191, 207], ["high blood pressure", "PROBLEM", 209, 228], ["thrombus formation", "PROBLEM", 233, 251], ["vasoconstriction", "OBSERVATION", 191, 207], ["pressure", "OBSERVATION_MODIFIER", 220, 228], ["thrombus", "OBSERVATION", 233, 241]]], ["Other studies propose immune-mediated mechanisms and overexpression of cytokines [11] , hypercoagulability state, and thromboembolism as potential stroke etiologies [12\u00c014] .IntroductionHowever, the increased risk of stroke is not exclusive to SARS-CoV-2 and it has been reported in association with other viral respiratory infections [15\u00c023] .", [["respiratory", "ANATOMY", 312, 323], ["hypercoagulability", "DISEASE", 88, 106], ["thromboembolism", "DISEASE", 118, 133], ["stroke", "DISEASE", 147, 153], ["stroke", "DISEASE", 217, 223], ["SARS", "DISEASE", 244, 248], ["viral respiratory infections", "DISEASE", 306, 334], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 244, 254], ["cytokines", "PROTEIN", 71, 80], ["SARS-CoV", "SPECIES", 244, 252], ["Other studies", "TEST", 0, 13], ["overexpression of cytokines", "PROBLEM", 53, 80], ["hypercoagulability state", "PROBLEM", 88, 112], ["thromboembolism", "PROBLEM", 118, 133], ["potential stroke etiologies", "PROBLEM", 137, 164], ["stroke", "PROBLEM", 217, 223], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252], ["other viral respiratory infections", "PROBLEM", 300, 334], ["thromboembolism", "OBSERVATION", 118, 133], ["increased", "OBSERVATION_MODIFIER", 199, 208], ["stroke", "OBSERVATION", 217, 223], ["viral", "OBSERVATION_MODIFIER", 306, 311], ["respiratory infections", "OBSERVATION", 312, 334]]], ["A slight increase in the risk of stroke incidence was reported following influenza infection [18, 19] , or other b-coronaviruses such as Middle East respiratory syndrome coronavirus (MERS-CoV) [20\u00c023] , and severe acute respiratory syndrome (SARS) [20\u00c023] .", [["stroke", "DISEASE", 33, 39], ["influenza infection", "DISEASE", 73, 92], ["Middle East respiratory syndrome coronavirus", "DISEASE", 137, 181], ["acute respiratory syndrome", "DISEASE", 214, 240], ["SARS", "DISEASE", 242, 246], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 137, 181], ["MERS-CoV", "ORGANISM", 183, 191], ["Middle East respiratory syndrome coronavirus", "SPECIES", 137, 181], ["MERS-CoV", "SPECIES", 183, 191], ["severe acute respiratory syndrome (SARS)", "SPECIES", 207, 247], ["A slight increase", "PROBLEM", 0, 17], ["stroke incidence", "PROBLEM", 33, 49], ["influenza infection", "PROBLEM", 73, 92], ["other b-coronaviruses", "PROBLEM", 107, 128], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 137, 181], ["severe acute respiratory syndrome", "PROBLEM", 207, 240], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["stroke", "OBSERVATION", 33, 39], ["Middle", "ANATOMY_MODIFIER", 137, 143], ["respiratory syndrome", "OBSERVATION", 149, 169], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory syndrome", "OBSERVATION", 220, 240]]], ["In addition, severe sepsis and critical condition may impose an additional risk for coagulopathy or new-onset of atrial fibrillation, which can increase the risk of stroke [24\u00c027] .", [["atrial", "ANATOMY", 113, 119], ["sepsis", "DISEASE", 20, 26], ["coagulopathy", "DISEASE", 84, 96], ["atrial fibrillation", "DISEASE", 113, 132], ["stroke", "DISEASE", 165, 171], ["atrial", "MULTI-TISSUE_STRUCTURE", 113, 119], ["severe sepsis", "PROBLEM", 13, 26], ["critical condition", "PROBLEM", 31, 49], ["coagulopathy", "PROBLEM", 84, 96], ["atrial fibrillation", "PROBLEM", 113, 132], ["stroke", "PROBLEM", 165, 171], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["sepsis", "OBSERVATION", 20, 26], ["coagulopathy", "OBSERVATION", 84, 96], ["new", "OBSERVATION_MODIFIER", 100, 103], ["atrial", "ANATOMY", 113, 119], ["fibrillation", "OBSERVATION", 120, 132], ["stroke", "OBSERVATION", 165, 171]]], ["Considering the burden of stroke and its association with worse prognosis, compared with non-stroke, among hospitalized patients [28] , we designed a multi-national observational study to better depict the short-term risk of stroke and its associated factors among SARS-CoV-2 hospitalized patients.Study designSupplemental Material Document 1 (page 6) includes the details of the study design.", [["stroke", "DISEASE", 26, 32], ["stroke", "DISEASE", 225, 231], ["SARS", "DISEASE", 265, 269], ["patients", "ORGANISM", 120, 128], ["SARS-CoV-2", "ORGANISM", 265, 275], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 289, 297], ["SARS-CoV", "SPECIES", 265, 273], ["stroke", "PROBLEM", 26, 32], ["a multi-national observational study", "TEST", 148, 184], ["stroke", "PROBLEM", 225, 231], ["the study", "TEST", 376, 385], ["stroke", "OBSERVATION", 26, 32], ["stroke", "OBSERVATION", 225, 231]]], ["The study was conducted and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) [29] , Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [30] , Preferred Reporting Items for Meta-analysis Of Observational Studies in Epidemiology (MOOSE) [31] , and Enhancing the QUAlity and Transparency Of health Research (EQUATOR) guidelines [32] .", [["The study", "TEST", 0, 9], ["Observational Studies", "TEST", 85, 106], ["Systematic Reviews", "TEST", 169, 187], ["Observational Studies", "TEST", 269, 290]]], ["This multicentre, multinational observational study was designed by the investigators at the Neuroscience Institute of Geisinger Health System, Pennsylvania, the United States.", [["multinational observational study", "TEST", 18, 51]]], ["The study included patients from North America (Canada and the United States), South America (Brazil), Europe (Greece, Italy, Finland, and Turkey), Asia (Lebanon, Iran, and India), and Oceania (New Zealand).", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["The study", "TEST", 0, 9]]], ["Data were recruited up to May 1st, 2020; the beginning date of the study period was defined as the earliest date that each participating center admitted SARS-CoV-2 patients.", [["SARS", "DISEASE", 153, 157], ["SARS-CoV", "ORGANISM", 153, 161], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["the study", "TEST", 63, 72]]], ["For this study, stroke was defined as ischaemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral venous thrombosis [33] .", [["intracerebral", "ANATOMY", 56, 69], ["subarachnoid", "ANATOMY", 82, 94], ["cerebral venous", "ANATOMY", 111, 126], ["stroke", "DISEASE", 16, 22], ["ischaemic stroke", "DISEASE", 38, 54], ["intracerebral hemorrhage", "DISEASE", 56, 80], ["subarachnoid hemorrhage", "DISEASE", 82, 105], ["cerebral venous thrombosis", "DISEASE", 111, 137], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 111, 126], ["this study", "TEST", 4, 14], ["stroke", "PROBLEM", 16, 22], ["ischaemic stroke", "PROBLEM", 38, 54], ["intracerebral hemorrhage", "PROBLEM", 56, 80], ["subarachnoid hemorrhage", "PROBLEM", 82, 105], ["cerebral venous thrombosis", "PROBLEM", 111, 137], ["ischaemic", "OBSERVATION_MODIFIER", 38, 47], ["stroke", "OBSERVATION", 48, 54], ["intracerebral", "ANATOMY", 56, 69], ["hemorrhage", "OBSERVATION", 70, 80], ["subarachnoid", "OBSERVATION_MODIFIER", 82, 94], ["hemorrhage", "OBSERVATION", 95, 105], ["cerebral", "ANATOMY_MODIFIER", 111, 119], ["venous", "ANATOMY", 120, 126], ["thrombosis", "OBSERVATION", 127, 137]]], ["Ischaemic or haemorrhagic stroke was defined as the rapid onset of a neurological deficit when there was evidence of an acute ischaemic or haemorrhagic lesion on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) consistent with the symptoms.", [["neurological", "ANATOMY", 69, 81], ["Ischaemic or haemorrhagic stroke", "DISEASE", 0, 32], ["neurological deficit", "DISEASE", 69, 89], ["Ischaemic", "PROBLEM", 0, 9], ["haemorrhagic stroke", "PROBLEM", 13, 32], ["a neurological deficit", "PROBLEM", 67, 89], ["an acute ischaemic or haemorrhagic lesion", "PROBLEM", 117, 158], ["Computed Tomography", "TEST", 162, 181], ["CT", "TEST", 183, 185], ["Magnetic Resonance Imaging", "TEST", 190, 216], ["MRI", "TEST", 218, 221], ["the symptoms", "PROBLEM", 239, 251], ["haemorrhagic", "OBSERVATION_MODIFIER", 13, 25], ["stroke", "OBSERVATION", 26, 32], ["rapid", "OBSERVATION_MODIFIER", 52, 57], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["ischaemic", "OBSERVATION_MODIFIER", 126, 135], ["haemorrhagic", "OBSERVATION_MODIFIER", 139, 151], ["lesion", "OBSERVATION", 152, 158], ["consistent with", "UNCERTAINTY", 223, 238]]], ["Cerebral venous or sinus thrombosis was defined as a hyperintense signal in the involved vein or sinus as evidenced by CT scan or MRI corresponding to other imaging findings and patients' symptoms.", [["Cerebral venous", "ANATOMY", 0, 15], ["sinus", "ANATOMY", 19, 24], ["vein", "ANATOMY", 89, 93], ["sinus", "ANATOMY", 97, 102], ["Cerebral venous or sinus thrombosis", "DISEASE", 0, 35], ["Cerebral venous", "MULTI-TISSUE_STRUCTURE", 0, 15], ["sinus", "MULTI-TISSUE_STRUCTURE", 19, 24], ["vein", "MULTI-TISSUE_STRUCTURE", 89, 93], ["sinus", "MULTI-TISSUE_STRUCTURE", 97, 102], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["Cerebral venous or sinus thrombosis", "PROBLEM", 0, 35], ["a hyperintense signal in the involved vein", "PROBLEM", 51, 93], ["sinus", "PROBLEM", 97, 102], ["CT scan", "TEST", 119, 126], ["MRI", "TEST", 130, 133], ["other imaging findings", "TEST", 151, 173], ["patients' symptoms", "PROBLEM", 178, 196], ["venous", "ANATOMY", 9, 15], ["sinus", "ANATOMY", 19, 24], ["thrombosis", "OBSERVATION", 25, 35], ["hyperintense", "OBSERVATION", 53, 65], ["vein", "ANATOMY", 89, 93], ["sinus", "ANATOMY", 97, 102]]], ["Patients who did not have neuroimaging confirmation of an acute stroke were not included in this study.", [["acute stroke", "DISEASE", 58, 70], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["neuroimaging confirmation", "TEST", 26, 51], ["an acute stroke", "PROBLEM", 55, 70], ["this study", "TEST", 92, 102], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["stroke", "OBSERVATION", 64, 70]]], ["We further subclassified the ischaemic stroke lesions based on the pattern of the lesion on diffusion-weighted imaging (DWI) or CT to lacunar [34] , embolic/ large vessel athero-thromboembolism [35, 36] , and other phenotypes (borderzone or equivocal lesions).", [["lesions", "ANATOMY", 46, 53], ["lesion", "ANATOMY", 82, 88], ["vessel", "ANATOMY", 164, 170], ["lesions", "ANATOMY", 251, 258], ["ischaemic stroke", "DISEASE", 29, 45], ["lacunar", "DISEASE", 134, 141], ["athero-thromboembolism", "DISEASE", 171, 193], ["lesions", "PATHOLOGICAL_FORMATION", 46, 53], ["vessel", "MULTI-TISSUE_STRUCTURE", 164, 170], ["lesions", "PATHOLOGICAL_FORMATION", 251, 258], ["the ischaemic stroke lesions", "PROBLEM", 25, 53], ["the lesion", "PROBLEM", 78, 88], ["diffusion-weighted imaging", "TEST", 92, 118], ["DWI", "TEST", 120, 123], ["CT to lacunar", "TEST", 128, 141], ["embolic/ large vessel athero-thromboembolism", "PROBLEM", 149, 193], ["other phenotypes (borderzone or equivocal lesions", "PROBLEM", 209, 258], ["ischaemic", "OBSERVATION_MODIFIER", 29, 38], ["stroke", "OBSERVATION_MODIFIER", 39, 45], ["lesions", "OBSERVATION", 46, 53], ["lesion", "OBSERVATION", 82, 88], ["embolic", "OBSERVATION_MODIFIER", 149, 156], ["large", "OBSERVATION_MODIFIER", 158, 163], ["vessel", "ANATOMY", 164, 170], ["athero", "OBSERVATION", 171, 177], ["thromboembolism", "OBSERVATION", 178, 193], ["equivocal", "OBSERVATION_MODIFIER", 241, 250], ["lesions", "OBSERVATION", 251, 258]]], ["TOAST (the Trial of Org 10,172 in Acute Stroke Treatment) [37] was not assessed in this study since many of the patients had not completed their stroke workup (echocardiogram, long-term cardiac monitoring, etc.) at the time of data acquisition.ParticipantsWe included consecutive hospitalized SARS-CoV-2 patients and recorded patients who had a subsequent and confirmed strokeischaemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral venous thrombosis.", [["cardiac", "ANATOMY", 186, 193], ["intracerebral", "ANATOMY", 394, 407], ["subarachnoid", "ANATOMY", 420, 432], ["cerebral venous", "ANATOMY", 449, 464], ["Org 10,172", "CHEMICAL", 20, 30], ["Stroke", "DISEASE", 40, 46], ["stroke", "DISEASE", 145, 151], ["SARS", "DISEASE", 293, 297], ["strokeischaemic stroke", "DISEASE", 370, 392], ["intracerebral hemorrhage", "DISEASE", 394, 418], ["subarachnoid hemorrhage", "DISEASE", 420, 443], ["cerebral venous thrombosis", "DISEASE", 449, 475], ["Org 10,172", "CHEMICAL", 20, 30], ["patients", "ORGANISM", 112, 120], ["cardiac", "MULTI-TISSUE_STRUCTURE", 186, 193], ["patients", "ORGANISM", 304, 312], ["patients", "ORGANISM", 326, 334], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 394, 407], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 449, 464], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 304, 312], ["patients", "SPECIES", 326, 334], ["SARS-CoV", "SPECIES", 293, 301], ["Org", "TREATMENT", 20, 23], ["Acute Stroke Treatment", "TREATMENT", 34, 56], ["this study", "TEST", 83, 93], ["their stroke workup", "TEST", 139, 158], ["echocardiogram", "TEST", 160, 174], ["cardiac monitoring", "TEST", 186, 204], ["data acquisition", "TEST", 227, 243], ["strokeischaemic stroke", "PROBLEM", 370, 392], ["intracerebral hemorrhage", "PROBLEM", 394, 418], ["subarachnoid hemorrhage", "PROBLEM", 420, 443], ["cerebral venous thrombosis", "PROBLEM", 449, 475], ["stroke", "OBSERVATION", 386, 392], ["intracerebral", "ANATOMY", 394, 407], ["hemorrhage", "OBSERVATION", 408, 418], ["subarachnoid", "ANATOMY", 420, 432], ["hemorrhage", "OBSERVATION", 433, 443], ["cerebral", "ANATOMY_MODIFIER", 449, 457], ["venous", "ANATOMY", 458, 464], ["thrombosis", "OBSERVATION", 465, 475]]], ["The study cohort in all centres was defined as the total population of patients who were hospitalized with a confirmed diagnosis of SARS-CoV-2, with or without a subsequent stroke.", [["SARS", "DISEASE", 132, 136], ["stroke", "DISEASE", 173, 179], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["a subsequent stroke", "PROBLEM", 160, 179], ["stroke", "OBSERVATION", 173, 179]]], ["We also included patients who initially presented to the hospital with a stroke-related chief complaint and were found to have an imaging-confirmed acute stroke, but also had positive screening results for SARS2-CoV-2.", [["stroke", "DISEASE", 73, 79], ["acute stroke", "DISEASE", 148, 160], ["patients", "ORGANISM", 17, 25], ["SARS2-CoV-2", "GENE_OR_GENE_PRODUCT", 206, 217], ["SARS2", "PROTEIN", 206, 211], ["patients", "SPECIES", 17, 25], ["a stroke", "PROBLEM", 71, 79], ["an imaging", "TEST", 127, 137], ["acute stroke", "PROBLEM", 148, 160], ["SARS2", "TEST", 206, 211], ["stroke", "OBSERVATION", 73, 79], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["stroke", "OBSERVATION", 154, 160]]], ["Many tertiary centres especially in hot spots had routine polymerase chain reaction (PCR) or chest CT scan screening for all admitted patients or for patients who had any symptoms of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 183, 203], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 150, 158], ["SARS-CoV-2", "ORGANISM", 183, 193], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 150, 158], ["SARS-CoV-2", "SPECIES", 183, 193], ["Many tertiary centres", "PROBLEM", 0, 21], ["hot spots", "PROBLEM", 36, 45], ["routine polymerase chain reaction", "PROBLEM", 50, 83], ["PCR", "TEST", 85, 88], ["chest CT scan screening", "TEST", 93, 116], ["any symptoms", "PROBLEM", 167, 179], ["SARS", "PROBLEM", 183, 187], ["CoV", "PROBLEM", 188, 191], ["2 infection", "PROBLEM", 192, 203], ["tertiary", "OBSERVATION_MODIFIER", 5, 13], ["chest", "ANATOMY", 93, 98], ["infection", "OBSERVATION", 194, 203]]], ["In addition, we made attempts to capture SARS-CoV-2 patients who had stroke-related readmission by regular follow-ups.", [["SARS", "DISEASE", 41, 45], ["stroke", "DISEASE", 69, 75], ["SARS-CoV", "ORGANISM", 41, 49], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["stroke", "PROBLEM", 69, 75]]], ["Patients with 24 h of hospitalization were eligible for this study, regardless of their length of stay.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["this study", "TEST", 56, 66]]], ["The post-discharge follow-up protocol for SARS-CoV-2 patients varied in different countries and different centres.", [["SARS", "DISEASE", 42, 46], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50]]], ["However, every center reported uniform and non-selective follow-ups for the study population.", [["the study population", "TEST", 72, 92]]], ["In addition, attempts were made to consider all centres providing neurological services in the captured areas to maximize the chance of recording early post-discharge stroke.", [["stroke", "DISEASE", 167, 173], ["neurological services", "TREATMENT", 66, 87], ["discharge stroke", "PROBLEM", 157, 173], ["stroke", "OBSERVATION", 167, 173]]], ["In case there was a closed-loop referral system between the different tertiary centres for patients with neurological complications, we considered the total number of hospitalized SARS-CoV-2 patients (whether they had a stroke or not) in the whole referral system to estimate the frequency of stroke.ParticipantsTo minimize the heterogeneity between different regions regarding the population screening protocols, only patients who were hospitalized for more than 24 h were included in this study.", [["neurological", "ANATOMY", 105, 117], ["neurological complications", "DISEASE", 105, 131], ["SARS", "DISEASE", 180, 184], ["stroke", "DISEASE", 220, 226], ["stroke", "DISEASE", 293, 299], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 191, 199], ["Participants", "SPECIES", 300, 312], ["patients", "SPECIES", 419, 427], ["neurological complications", "PROBLEM", 105, 131], ["a stroke", "PROBLEM", 218, 226], ["stroke", "PROBLEM", 293, 299], ["this study", "TEST", 486, 496], ["stroke", "OBSERVATION", 293, 299]]], ["The preferred diagnostic criteria for SARS-CoV-2 was defined according to the World Health Organization (WHO) interim guidance [38] .", [["SARS", "DISEASE", 38, 42], ["SARS-CoV", "SPECIES", 38, 46], ["SARS", "PROBLEM", 38, 42]]], ["Due to the limited availability of PCR testing or concerns about its low predictive value, several centres used a combination of the history of exposure, symptomatology, and chest CT with or without PCR methods for diagnosis confirmation (Supplemental Table 1 , page 9).", [["PCR testing", "TEST", 35, 46], ["its low predictive value", "PROBLEM", 65, 89], ["symptomatology", "PROBLEM", 154, 168], ["chest CT", "TEST", 174, 182], ["PCR methods", "TEST", 199, 210], ["diagnosis confirmation", "TEST", 215, 237], ["chest", "ANATOMY", 174, 179]]], ["The onset of SARS-CoV-2 was considered as either the symptoms onset or positive test, whichever was first.", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["the symptoms", "PROBLEM", 49, 61], ["positive test", "PROBLEM", 71, 84]]], ["There were no age or gender exclusion criteria.", [["no", "UNCERTAINTY", 11, 13]]], ["Given the high diagnostic error associated with a transient ischaemic attack (TIA) [39\u00c041], patients who had transient stroke-like symptoms and no acute lesion on CT or MRI were not included in this study.ParticipantsCollaborators were asked to provide three sets of data: (1) number and clinical details of patients with a stroke, (2) total number and high-level summary (age and sex proportion, the severity of SARS-CoV-2 infection, mechanical ventilation, prognosis, and vital status) on the study population, and (3) clinical and laboratory findings of the study population (or at least a randomly generated subset).", [["lesion", "ANATOMY", 153, 159], ["transient ischaemic attack", "DISEASE", 50, 76], ["TIA", "DISEASE", 78, 81], ["stroke", "DISEASE", 119, 125], ["stroke", "DISEASE", 324, 330], ["SARS", "DISEASE", 413, 417], ["infection", "DISEASE", 424, 433], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 92, 100], ["Participants", "SPECIES", 205, 217], ["patients", "SPECIES", 308, 316], ["a transient ischaemic attack (TIA)", "PROBLEM", 48, 82], ["transient stroke", "PROBLEM", 109, 125], ["like symptoms", "PROBLEM", 126, 139], ["acute lesion", "PROBLEM", 147, 159], ["CT", "TEST", 163, 165], ["MRI", "TEST", 169, 172], ["this study", "TEST", 194, 204], ["a stroke", "PROBLEM", 322, 330], ["SARS", "PROBLEM", 413, 417], ["CoV", "PROBLEM", 418, 421], ["2 infection", "PROBLEM", 422, 433], ["mechanical ventilation", "TREATMENT", 435, 457], ["the study population", "TEST", 491, 511], ["the study population", "TEST", 557, 577], ["transient", "OBSERVATION_MODIFIER", 50, 59], ["ischaemic attack", "OBSERVATION", 60, 76], ["stroke", "OBSERVATION", 119, 125], ["no", "UNCERTAINTY", 144, 146], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["lesion", "OBSERVATION", 153, 159], ["stroke", "OBSERVATION", 324, 330]]], ["Data were collected by a predefined common core protocol and detailed documents for stroke cases and study population.", [["stroke", "DISEASE", 84, 90], ["stroke cases", "PROBLEM", 84, 96], ["study population", "TEST", 101, 117]]], ["Each center had the option of sending either patient-or summary-level data per their internal board approval.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["We only accepted patient-level data for ourResearch in contextEvidence before this studyResearch in contextThe authors have searched Medline, Embase, Google Scholar, MedRxiv, and all popular journals in the field of cerebrovascular diseases, in addition to forward and backward citation tracking of the related articles by April 25, 2020 , and updated to the submission date, with no restriction on publication type or language.", [["cerebrovascular", "ANATOMY", 216, 231], ["cerebrovascular diseases", "DISEASE", 216, 240], ["patient", "ORGANISM", 17, 24], ["cerebrovascular", "ANATOMICAL_SYSTEM", 216, 231], ["patient", "SPECIES", 17, 24], ["this study", "TEST", 78, 88], ["MedRxiv", "TREATMENT", 166, 173], ["cerebrovascular diseases", "PROBLEM", 216, 240], ["cerebrovascular", "ANATOMY", 216, 231], ["diseases", "OBSERVATION", 232, 240]]], ["SARS-CoV-2, SARS-CoV, MERS-CoV, COVID-19, coronavirus, neurological manifestations, cerebrovascular diseases, stroke, thrombosis, intracranial hemorrhage, intracerebral hemorrhage, and related Mesh Terms and Emtree vocabulary were used with different Boolean operations.", [["neurological", "ANATOMY", 55, 67], ["cerebrovascular", "ANATOMY", 84, 99], ["intracranial", "ANATOMY", 130, 142], ["intracerebral", "ANATOMY", 155, 168], ["SARS", "DISEASE", 0, 4], ["neurological manifestations", "DISEASE", 55, 82], ["cerebrovascular diseases", "DISEASE", 84, 108], ["stroke", "DISEASE", 110, 116], ["thrombosis", "DISEASE", 118, 128], ["intracranial hemorrhage", "DISEASE", 130, 153], ["intracerebral hemorrhage", "DISEASE", 155, 179], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "ORGANISM", 22, 30], ["COVID-19", "ORGANISM", 32, 40], ["coronavirus", "ORGANISM", 42, 53], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 84, 99], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 155, 168], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 12, 20], ["MERS-CoV", "SPECIES", 22, 30], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "PROBLEM", 12, 16], ["COVID", "TEST", 32, 37], ["coronavirus", "PROBLEM", 42, 53], ["neurological manifestations", "PROBLEM", 55, 82], ["cerebrovascular diseases", "PROBLEM", 84, 108], ["stroke", "PROBLEM", 110, 116], ["thrombosis", "PROBLEM", 118, 128], ["intracranial hemorrhage", "PROBLEM", 130, 153], ["intracerebral hemorrhage", "PROBLEM", 155, 179], ["related Mesh Terms", "PROBLEM", 185, 203], ["Emtree vocabulary", "PROBLEM", 208, 225], ["different Boolean operations", "TREATMENT", 241, 269], ["cerebrovascular", "ANATOMY", 84, 99], ["diseases", "OBSERVATION", 100, 108], ["stroke", "OBSERVATION", 110, 116], ["thrombosis", "OBSERVATION", 118, 128], ["intracranial", "ANATOMY", 130, 142], ["hemorrhage", "OBSERVATION", 143, 153], ["intracerebral", "ANATOMY", 155, 168], ["hemorrhage", "OBSERVATION", 169, 179], ["Mesh Terms", "OBSERVATION", 193, 203]]], ["Our study is not limited to a systematic review of previously reported cases; therefore, we did not provide details of the search strategy in this paper.", [["Our study", "TEST", 0, 9]]], ["Our team has reported the search results of neurological complications of SARS-CoV-2 in a separate review paper (currently in Press).", [["neurological", "ANATOMY", 44, 56], ["SARS", "DISEASE", 74, 78], ["neurological complications", "PROBLEM", 44, 70], ["SARS", "PROBLEM", 74, 78]]], ["The relevant evidence before this study was reviewed in the introduction and discussion section of the manuscript.", [["this study", "TEST", 29, 39]]], ["Briefly, there are several case reports of cerebrovascular disease among patients with SARS-CoV-2.", [["cerebrovascular", "ANATOMY", 43, 58], ["cerebrovascular disease", "DISEASE", 43, 66], ["SARS", "DISEASE", 87, 91], ["cerebrovascular", "ANATOMICAL_SYSTEM", 43, 58], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["cerebrovascular disease", "PROBLEM", 43, 66], ["SARS", "PROBLEM", 87, 91], ["cerebrovascular", "ANATOMY", 43, 58], ["disease", "OBSERVATION", 59, 66]]], ["The results of a single-center, retrospective, observational analysis of consecutive SARS-CoV-2 patients admitted to Union Hospital, Wuhan, China from 16 January 2020 to 29 February 2020 indicates that out of 221 patients, 5% developed acute ischemic stroke, and 0.5% (1 patient) developed intracerebral hemorrhage.", [["intracerebral", "ANATOMY", 290, 303], ["SARS", "DISEASE", 85, 89], ["ischemic stroke", "DISEASE", 242, 257], ["intracerebral hemorrhage", "DISEASE", 290, 314], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 213, 221], ["patient", "ORGANISM", 271, 278], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 290, 303], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 213, 221], ["patient", "SPECIES", 271, 278], ["observational analysis", "TEST", 47, 69], ["consecutive SARS", "PROBLEM", 73, 89], ["acute ischemic stroke", "PROBLEM", 236, 257], ["intracerebral hemorrhage", "PROBLEM", 290, 314], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["ischemic", "OBSERVATION_MODIFIER", 242, 250], ["stroke", "OBSERVATION", 251, 257], ["intracerebral", "ANATOMY", 290, 303], ["hemorrhage", "OBSERVATION", 304, 314]]], ["However, the study had several limitations.", [["the study", "TEST", 9, 18]]], ["It was a single-center report and no data about the outcome was available.Added-value of this studyThere are increasing concerns regarding the neurological and specifically cerebrovascular complications of SARS-CoV-2.", [["cerebrovascular", "ANATOMY", 173, 188], ["SARS", "DISEASE", 206, 210], ["cerebrovascular", "ANATOMICAL_SYSTEM", 173, 188], ["SARS-CoV", "SPECIES", 206, 214], ["this study", "TEST", 89, 99], ["the neurological and specifically cerebrovascular complications", "PROBLEM", 139, 202], ["SARS", "PROBLEM", 206, 210], ["increasing", "OBSERVATION_MODIFIER", 109, 119], ["cerebrovascular", "ANATOMY", 173, 188], ["complications", "OBSERVATION", 189, 202]]], ["Articles defining the higher risk of strokes among SARS-CoV-2 patients were published in the New York Times, CNN health, the Washington Post, and several other news outlets as early as April 1st.", [["strokes", "DISEASE", 37, 44], ["SARS", "DISEASE", 51, 55], ["SARS-CoV", "ORGANISM", 51, 59], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 51, 59], ["strokes", "PROBLEM", 37, 44], ["strokes", "OBSERVATION", 37, 44]]], ["Understanding the risk and characteristics of cerebrovascular events is critically important given their burden and prognosis.", [["cerebrovascular", "ANATOMY", 46, 61], ["cerebrovascular events", "DISEASE", 46, 68], ["cerebrovascular", "ANATOMICAL_SYSTEM", 46, 61], ["cerebrovascular events", "PROBLEM", 46, 68], ["cerebrovascular", "ANATOMY", 46, 61]]], ["Therefore, the goal of this study was to investigate the risk and associated factors of acute cerebrovascular diseases (ischemic stroke, intracranial hemorrhage including subarachnoid hemorrhage, and cerebral venous thrombosis) among patients with SARS-CoV-2 in a large population.Implications of all the available evidenceThe result of the current study suggests that although there is an increased risk of cerebrovascular events in patients infected with SARS-CoV-2, the risk is comparable to other viral infections and critical conditions.", [["cerebrovascular", "ANATOMY", 94, 109], ["intracranial", "ANATOMY", 137, 149], ["subarachnoid", "ANATOMY", 171, 183], ["cerebral venous", "ANATOMY", 200, 215], ["cerebrovascular", "ANATOMY", 408, 423], ["cerebrovascular diseases", "DISEASE", 94, 118], ["ischemic stroke", "DISEASE", 120, 135], ["intracranial hemorrhage", "DISEASE", 137, 160], ["subarachnoid hemorrhage", "DISEASE", 171, 194], ["cerebral venous thrombosis", "DISEASE", 200, 226], ["SARS", "DISEASE", 248, 252], ["cerebrovascular events", "DISEASE", 408, 430], ["SARS", "DISEASE", 457, 461], ["viral infections", "DISEASE", 501, 517], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 94, 109], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 200, 215], ["patients", "ORGANISM", 234, 242], ["cerebrovascular", "ANATOMICAL_SYSTEM", 408, 423], ["patients", "ORGANISM", 434, 442], ["SARS-CoV-2", "ORGANISM", 457, 467], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 434, 442], ["SARS-CoV", "SPECIES", 248, 256], ["SARS-CoV", "SPECIES", 457, 465], ["this study", "TEST", 23, 33], ["acute cerebrovascular diseases (ischemic stroke", "PROBLEM", 88, 135], ["intracranial hemorrhage", "PROBLEM", 137, 160], ["subarachnoid hemorrhage", "PROBLEM", 171, 194], ["cerebral venous thrombosis", "PROBLEM", 200, 226], ["SARS", "PROBLEM", 248, 252], ["CoV", "TEST", 253, 256], ["a large population", "PROBLEM", 262, 280], ["the current study", "TEST", 337, 354], ["cerebrovascular events", "PROBLEM", 408, 430], ["SARS", "PROBLEM", 457, 461], ["other viral infections", "PROBLEM", 495, 517], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["cerebrovascular diseases", "OBSERVATION", 94, 118], ["ischemic", "OBSERVATION_MODIFIER", 120, 128], ["stroke", "OBSERVATION", 129, 135], ["intracranial", "ANATOMY", 137, 149], ["hemorrhage", "OBSERVATION", 150, 160], ["subarachnoid", "OBSERVATION_MODIFIER", 171, 183], ["hemorrhage", "OBSERVATION", 184, 194], ["cerebral venous", "ANATOMY", 200, 215], ["thrombosis", "OBSERVATION", 216, 226], ["large", "OBSERVATION_MODIFIER", 264, 269], ["population", "OBSERVATION", 270, 280], ["increased", "OBSERVATION_MODIFIER", 390, 399], ["cerebrovascular events", "OBSERVATION", 408, 430], ["viral", "OBSERVATION_MODIFIER", 501, 506], ["infections", "OBSERVATION", 507, 517]]], ["The evidence also indicates that dependency on a ventilator and the presence of ischemic heart disease are predictive of cerebrovascular complications.", [["heart", "ANATOMY", 89, 94], ["cerebrovascular", "ANATOMY", 121, 136], ["ischemic heart disease", "DISEASE", 80, 102], ["cerebrovascular complications", "DISEASE", 121, 150], ["heart", "ORGAN", 89, 94], ["cerebrovascular", "ANATOMICAL_SYSTEM", 121, 136], ["a ventilator", "TREATMENT", 47, 59], ["ischemic heart disease", "PROBLEM", 80, 102], ["cerebrovascular complications", "PROBLEM", 121, 150], ["dependency", "OBSERVATION_MODIFIER", 33, 43], ["ischemic", "OBSERVATION_MODIFIER", 80, 88], ["heart", "ANATOMY", 89, 94], ["disease", "OBSERVATION", 95, 102], ["cerebrovascular complications", "OBSERVATION", 121, 150]]], ["Therefore clinicians and nurses should be monitoring critically ill patients for symptoms of acute stroke.", [["critically ill", "DISEASE", 53, 67], ["acute stroke", "DISEASE", 93, 105], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["symptoms", "PROBLEM", 81, 89], ["acute stroke", "PROBLEM", 93, 105], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["stroke", "OBSERVATION", 99, 105]]], ["More studies are needed to describe the etiologies of cerebrovascular diseases among this patient cohort and define effective prevention strategies. stroke patients.", [["cerebrovascular", "ANATOMY", 54, 69], ["cerebrovascular diseases", "DISEASE", 54, 78], ["stroke", "DISEASE", 149, 155], ["cerebrovascular", "ANATOMICAL_SYSTEM", 54, 69], ["patient", "ORGANISM", 90, 97], ["patients", "ORGANISM", 156, 164], ["patient", "SPECIES", 90, 97], ["patients", "SPECIES", 156, 164], ["cerebrovascular diseases", "PROBLEM", 54, 78], ["effective prevention strategies", "TREATMENT", 116, 147], ["stroke", "PROBLEM", 149, 155], ["cerebrovascular", "ANATOMY", 54, 69], ["diseases", "OBSERVATION", 70, 78]]], ["The age, sex, comorbidities, and laboratory findings were requested for the stroke patients and study population.", [["stroke", "DISEASE", 76, 82], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["laboratory findings", "TEST", 33, 52], ["study population", "TEST", 96, 112]]], ["For stroke patients, we also obtained additional data including the onset of stroke and SARS-CoV-2, chest CT scan findings, a need for mechanical ventilation, details of neurological investigations, and localization of the event, National Institute of Health Stroke Scale (NIHSS), and acute management and outcomes.OutcomesThe primary goal of this study was to estimate the risk of stroke among hospitalized SARS-CoV-2 patients.", [["stroke", "DISEASE", 4, 10], ["stroke", "DISEASE", 77, 83], ["SARS", "DISEASE", 88, 92], ["Stroke", "DISEASE", 259, 265], ["stroke", "DISEASE", 382, 388], ["SARS", "DISEASE", 408, 412], ["patients", "ORGANISM", 11, 19], ["SARS-CoV", "ORGANISM", 408, 416], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 419, 427], ["SARS-CoV", "SPECIES", 408, 416], ["stroke", "PROBLEM", 77, 83], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["chest CT scan findings", "TEST", 100, 122], ["mechanical ventilation", "TREATMENT", 135, 157], ["neurological investigations", "TEST", 170, 197], ["acute management", "TREATMENT", 285, 301], ["this study", "TEST", 343, 353], ["stroke", "PROBLEM", 382, 388], ["stroke", "OBSERVATION", 77, 83], ["chest", "ANATOMY", 100, 105], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["stroke", "OBSERVATION", 382, 388]]], ["Data from the centres that were unable to provide information on hospitalized patients were not used for the calculation of risk estimate.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["We also compared the baseline characteristics, comorbidities, and laboratory findings among stroke cases and a subset of the study population and investigated the parameters with higher predictive value for stroke occurrence.Statistical analysisDescriptive statistics were used to summarize the data.", [["stroke", "DISEASE", 92, 98], ["stroke", "DISEASE", 207, 213], ["comorbidities", "PROBLEM", 47, 60], ["the study population", "TEST", 121, 141], ["the parameters", "TEST", 159, 173], ["stroke occurrence", "PROBLEM", 207, 224]]], ["Demographic data, comorbidities, and laboratory findings were reported as medians (interquartile range [IQR]), mean (standard deviations [SD]), and under stratified categories when possible.", [["comorbidities", "PROBLEM", 18, 31], ["mean", "TEST", 111, 115]]], ["Categorical variables were reported as absolute frequencies and percentages.", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 64, 75]]], ["The data which were provided on a qualitative scale rather than quantitative value (such as C-reactive protein-CRP) or equivalents of the requested items (such as glomerular filtration rates instead of creatinine) were excluded from the analyses.", [["glomerular", "ANATOMY", 163, 173], ["creatinine", "CHEMICAL", 202, 212], ["creatinine", "CHEMICAL", 202, 212], ["C-reactive protein-CRP", "GENE_OR_GENE_PRODUCT", 92, 114], ["glomerular", "TISSUE", 163, 173], ["creatinine", "SIMPLE_CHEMICAL", 202, 212], ["C-reactive protein", "PROTEIN", 92, 110], ["CRP", "PROTEIN", 111, 114], ["The data", "TEST", 0, 8], ["a qualitative scale", "TEST", 32, 51], ["quantitative value", "TEST", 64, 82], ["C-reactive protein", "TEST", 92, 110], ["CRP", "TEST", 111, 114], ["glomerular filtration rates", "TREATMENT", 163, 190], ["creatinine", "TEST", 202, 212], ["the analyses", "TEST", 233, 245]]], ["The comparison between categorical variables was conducted with the Pearson chi-square test, while the differences among continuous variables were assessed by independent t-test.", [["the Pearson chi-square test", "TEST", 64, 91], ["independent t-test", "TEST", 159, 177]]], ["Bivariate logistic regression was used to determine the parameters with predictive outcome value.", [["Bivariate logistic regression", "PROBLEM", 0, 29]]], ["All tests were performed using IBM SPSS Statistics version 26 [42] and p<0.05 was considered statistically significant.Statistical analysisWe used the Risk of Bias in Exposure Studies (ROBINS-E) tool [43] to assess the quality of the data received from each center.", [["All tests", "TEST", 0, 9], ["Statistics version", "TEST", 40, 58], ["Exposure Studies", "TEST", 167, 183]]], ["We evaluated the potential bias on time-varying confounding (cases: the time window between the infection and stroke, potential of capturing late-onset strokes; study population: follow-up and reporting consistency); selection of study participants (cases: influence of outcomes on inclusion, local investigators' judgement on possibility of causality/coincidence for selective reporting of cases, automated data extraction and natural language processing or manual chart review; study population: SARS-CoV-2 hospitalization criteria); verification of exposure/diagnosis (defining the confirmed SARS-CoV-2 based on imaging, symptoms, and PCR); missing data (cases: data to confirmed the diagnosis, stroke imaging pattern, and localization; study population: high level summary data on hospitalized patients); measurement of outcomes (awareness of the local investigators of all strokes admitted in the center, consistent definition when referring to stroke); and measurement of reporting results (cases: reporting all strokes irrespective of management outcome, study population: reporting of all hospitalized SARS-CoV-2 patients).", [["infection", "DISEASE", 96, 105], ["stroke", "DISEASE", 110, 116], ["strokes", "DISEASE", 152, 159], ["stroke", "DISEASE", 698, 704], ["strokes", "DISEASE", 878, 885], ["stroke", "DISEASE", 950, 956], ["strokes", "DISEASE", 1018, 1025], ["SARS", "DISEASE", 1110, 1114], ["patients", "ORGANISM", 798, 806], ["patients", "ORGANISM", 1121, 1129], ["participants", "SPECIES", 236, 248], ["patients", "SPECIES", 798, 806], ["patients", "SPECIES", 1121, 1129], ["the infection", "PROBLEM", 92, 105], ["stroke", "PROBLEM", 110, 116], ["late-onset strokes", "PROBLEM", 141, 159], ["automated data extraction", "TREATMENT", 398, 423], ["SARS", "PROBLEM", 498, 502], ["SARS", "PROBLEM", 595, 599], ["CoV", "TEST", 600, 603], ["imaging", "TEST", 615, 622], ["symptoms", "PROBLEM", 624, 632], ["PCR", "TEST", 638, 641], ["stroke imaging pattern", "TEST", 698, 720], ["all strokes", "PROBLEM", 874, 885], ["all strokes", "PROBLEM", 1014, 1025], ["infection", "OBSERVATION", 96, 105]]], ["The summary of the outcomes was presented as a percentage of the centres with no information, low, medium, or high risk of bias under each category.Statistical analysisHeterogeneity among study levels was assessed with the Cochran Q test (x2 test for heterogeneity).", [["Statistical analysis", "TEST", 148, 168], ["study levels", "TEST", 188, 200], ["the Cochran Q test", "TEST", 219, 237], ["heterogeneity", "PROBLEM", 251, 264]]], ["The proportion of total heterogeneity to total variability was quantified by I 2 and its 95% confidence interval (CI).", [["total heterogeneity to total variability", "PROBLEM", 18, 58], ["CI", "TEST", 114, 116], ["total", "OBSERVATION_MODIFIER", 18, 23], ["heterogeneity", "OBSERVATION", 24, 37], ["total variability", "OBSERVATION", 41, 58]]], ["The Q-test with p<0.1 or an I 2 statistic greater than 50% was considered statistically significant [44] .", [["The Q-test", "TEST", 0, 10], ["an I 2 statistic", "TEST", 25, 41]]], ["We visualized subsequent stroke risk (95% CIs) following SARS-CoV-2 infection by forest plots.", [["stroke", "DISEASE", 25, 31], ["infection", "DISEASE", 68, 77], ["subsequent stroke risk", "PROBLEM", 14, 36], ["SARS", "PROBLEM", 57, 61], ["CoV-2 infection", "PROBLEM", 62, 77], ["stroke", "OBSERVATION_MODIFIER", 25, 31], ["infection", "OBSERVATION", 68, 77]]], ["To better present the possible risk difference among centres, we conducted meta-analyses under five different levels: 1) Regions (states/districts) in each country, 2) Countries grouped by continent, 3) Data limited to countries with higher health expenditures, 4) Removal of the centres with the highest and lowest risk estimation, 5) Type of data for study population (individual versus summary level).", [["Removal of the centres", "TREATMENT", 265, 287], ["study population", "TEST", 353, 369]]], ["One center in the United States (New York-2) provided the patient-level data by automated data extraction and natural language processing from their electronic health records system.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["automated data extraction", "TREATMENT", 80, 105]]], ["The investigator in that center was not able to perform a manual chart review of the stroke patients to further validate the findings.", [["stroke", "DISEASE", 85, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["a manual chart review", "TEST", 56, 77]]], ["We did not include the centres that could not provide an accurate total number of strokes (numerator) or study population (denominator) for risk calculations.", [["strokes", "DISEASE", 82, 89], ["strokes", "PROBLEM", 82, 89], ["risk calculations", "TEST", 140, 157], ["strokes", "OBSERVATION", 82, 89]]], ["To minimize the impact of the low denominator [46] , we did not include the regions with fewer than 20 hospitalized patients in the meta-analyses.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124]]], ["We used random-effects models with double arcsine transformations and DerSimonian-Laird estimator in all meta-analyses.", [["random-effects models", "TREATMENT", 8, 29], ["double arcsine transformations", "TREATMENT", 35, 65], ["DerSimonian-Laird estimator", "TREATMENT", 70, 97]]], ["The meta-analyses were performed using the R version 3.5.0 and metafor [47] package.Role of the funding sourceThere was no funding source for this study.ResultsWe received data from 26,175 hospitalized SARS-CoV-2 patients from 99 tertiary centres in 65 regions in 11 countries (Supplemental Fig. 1, page 19) .", [["SARS", "DISEASE", 202, 206], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 202, 210], ["The meta-analyses", "TEST", 0, 17], ["the R version", "TREATMENT", 39, 52], ["this study", "TEST", 142, 152], ["CoV", "TEST", 207, 210], ["no", "UNCERTAINTY", 120, 122], ["funding", "OBSERVATION", 123, 130]]], ["A total of 8376 patients were excluded from this study (available study population but unverified stroke cases: 6287; partial reports of stroke patients: 2022; study population less than 20 individuals: 50; no data available on study population: 17; Supplemental Table 3 , page 17).", [["stroke", "DISEASE", 98, 104], ["stroke", "DISEASE", 137, 143], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 144, 152], ["this study", "TEST", 44, 54], ["study population", "TEST", 66, 82], ["study population", "TEST", 160, 176], ["study population", "TEST", 228, 244]]], ["The study included 17,799 SARS-CoV-2 infected patients-156 patients with stroke.", [["SARS-CoV-2 infected", "DISEASE", 26, 45], ["stroke", "DISEASE", 73, 79], ["SARS-CoV-2", "ORGANISM", 26, 36], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 26, 34], ["The study", "TEST", 0, 9], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["stroke", "PROBLEM", 73, 79], ["stroke", "OBSERVATION", 73, 79]]], ["Table 1 presents the comorbidities and laboratory results among the patients with stroke and a subset of non-stroke patients with available detailed data.", [["stroke", "DISEASE", 82, 88], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 116, 124], ["the comorbidities", "PROBLEM", 17, 34], ["stroke", "PROBLEM", 82, 88]]], ["Among the 156 stroke patients, 123 (79%) presented with acute ischaemic stroke, 27 (17%) with intracerebral/subarachnoid hemorrhage, and 6 (4%) with cerebral venous or sinus thrombosis (Table 2) .", [["intracerebral", "ANATOMY", 94, 107], ["subarachnoid", "ANATOMY", 108, 120], ["cerebral venous", "ANATOMY", 149, 164], ["sinus", "ANATOMY", 168, 173], ["stroke", "DISEASE", 14, 20], ["acute ischaemic stroke", "DISEASE", 56, 78], ["intracerebral/subarachnoid hemorrhage", "DISEASE", 94, 131], ["cerebral venous or sinus thrombosis", "DISEASE", 149, 184], ["patients", "ORGANISM", 21, 29], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 149, 164], ["sinus", "MULTI-TISSUE_STRUCTURE", 168, 173], ["patients", "SPECIES", 21, 29], ["acute ischaemic stroke", "PROBLEM", 56, 78], ["intracerebral/subarachnoid hemorrhage", "PROBLEM", 94, 131], ["cerebral venous or sinus thrombosis", "PROBLEM", 149, 184], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["ischaemic", "OBSERVATION_MODIFIER", 62, 71], ["stroke", "OBSERVATION", 72, 78], ["intracerebral", "ANATOMY", 94, 107], ["subarachnoid", "ANATOMY", 108, 120], ["hemorrhage", "OBSERVATION", 121, 131], ["cerebral venous", "ANATOMY", 149, 164], ["sinus", "ANATOMY", 168, 173], ["thrombosis", "OBSERVATION", 174, 184]]], ["We observed mean age of 68.6 (13.9) years among patients with ischaemic stroke, 62.", [["ischaemic stroke", "DISEASE", 62, 78], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["ischaemic stroke", "PROBLEM", 62, 78], ["ischaemic", "OBSERVATION_MODIFIER", 62, 71], ["stroke", "OBSERVATION", 72, 78]]], ["When considering all the available data after quality and risk of bias assessment, the risk of subsequent stroke in the infected patients with SARS-Cov-2 is 156/17,799 (0.9%, non-weighted simple pooled analysis).", [["stroke", "DISEASE", 106, 112], ["infected", "DISEASE", 120, 128], ["SARS", "DISEASE", 143, 147], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["bias assessment", "TEST", 66, 81], ["subsequent stroke", "PROBLEM", 95, 112], ["SARS", "PROBLEM", 143, 147], ["Cov", "TEST", 148, 151], ["non-weighted simple pooled analysis", "TEST", 175, 210], ["stroke", "OBSERVATION", 106, 112], ["infected", "OBSERVATION_MODIFIER", 120, 128]]], ["A meta-analysis of data from 43 regions (Fig. 1) suggests an overall stroke risk of 0.5% [95% CI, 0.3%\u00c00.7%].", [["stroke", "DISEASE", 69, 75], ["A meta-analysis of data", "TEST", 0, 23], ["an overall stroke risk", "PROBLEM", 58, 80], ["CI", "TEST", 94, 96], ["overall", "OBSERVATION_MODIFIER", 61, 68], ["stroke", "OBSERVATION", 69, 75]]], ["When grouping the centres by continent, the risk of subsequent stroke is 1.2% [95% CI, 0.9%\u00c01.6%] in North America, 0.5% [95% CI, 0.1%\u00c01.1%] in Europe, 0.3% [95% CI, 0.0%\u00c00.9%] in Asia, and 0.0% in Oceania (Fig. 2 ).", [["stroke", "DISEASE", 63, 69], ["subsequent stroke", "PROBLEM", 52, 69], ["CI", "TEST", 83, 85], ["CI", "TEST", 126, 128], ["Europe", "TEST", 144, 150], ["CI", "TEST", 162, 164], ["Asia", "TEST", 180, 184]]], ["To control for possible unseen heterogeneity among countries with higher and lower health expenditures in terms of the diagnosis or quality of care, we repeated the analysis by including only 27 regions with higher health expenditures (Fig. 3) .", [["unseen heterogeneity", "PROBLEM", 24, 44], ["the analysis", "TEST", 161, 173]]], ["The overall stroke risk among these 27 regions is 0.7% [95% CI, 0.2%\u00c01.6%].", [["stroke", "DISEASE", 12, 18], ["CI", "TEST", 60, 62], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["stroke", "OBSERVATION", 12, 18]]], ["The repeated meta-analysis after removing the centres with the highest and lowest calculated risk suggests a comparable stroke risk of 0.6% [95% CI, 0.5%\u00c00.8%] (Supplemental Figure 8, page 29) .", [["stroke", "DISEASE", 120, 126], ["The repeated meta-analysis", "TEST", 0, 26], ["a comparable stroke risk", "PROBLEM", 107, 131], ["CI", "TEST", 145, 147]]], ["Grouping the regions based on the received data type resulted in the risk of 0.6% [0.0%\u00c01.7%] for regions that provided the individual level data for all the study population, and 0.5% [0.2%\u00c00.7%] for regions that either presented summary level data or could provide individual level data for only a subset of the study population (Supplemental Figure 9 , page 30).", [["the individual level data", "TEST", 120, 145], ["the study population", "TEST", 154, 174], ["individual level data", "TEST", 267, 288]]], ["All analyses were conducted under low heterogeneity among study levels (I 2 <50%).", [["All analyses", "TEST", 0, 12], ["study levels", "TEST", 58, 70]]], ["When comparing patients with and without a subsequent stroke, there were significant differences in age, needs for mechanical ventilation, hypertension, ischaemic heart disease, prior stroke or transient ischaemic attack, platelets counts, white blood cells, neutrophils and lymphocytes counts, and C-reactive protein (CRP) between the two groups (all p<0.01; Table 1 ).", [["heart", "ANATOMY", 163, 168], ["platelets", "ANATOMY", 222, 231], ["white blood cells", "ANATOMY", 240, 257], ["neutrophils", "ANATOMY", 259, 270], ["lymphocytes", "ANATOMY", 275, 286], ["stroke", "DISEASE", 54, 60], ["hypertension", "DISEASE", 139, 151], ["ischaemic heart disease", "DISEASE", 153, 176], ["stroke", "DISEASE", 184, 190], ["patients", "ORGANISM", 15, 23], ["heart", "ORGAN", 163, 168], ["platelets", "CELL", 222, 231], ["white blood cells", "CELL", 240, 257], ["neutrophils", "CELL", 259, 270], ["lymphocytes", "CELL", 275, 286], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 299, 317], ["CRP", "GENE_OR_GENE_PRODUCT", 319, 322], ["platelets", "CELL_TYPE", 222, 231], ["white blood cells", "CELL_TYPE", 240, 257], ["neutrophils", "CELL_TYPE", 259, 270], ["lymphocytes", "CELL_TYPE", 275, 286], ["C-reactive protein", "PROTEIN", 299, 317], ["CRP", "PROTEIN", 319, 322], ["patients", "SPECIES", 15, 23], ["a subsequent stroke", "PROBLEM", 41, 60], ["mechanical ventilation", "TREATMENT", 115, 137], ["hypertension", "PROBLEM", 139, 151], ["ischaemic heart disease", "PROBLEM", 153, 176], ["prior stroke", "PROBLEM", 178, 190], ["transient ischaemic attack", "PROBLEM", 194, 220], ["platelets counts", "TEST", 222, 238], ["white blood cells", "TEST", 240, 257], ["neutrophils", "TEST", 259, 270], ["lymphocytes counts", "TEST", 275, 293], ["C", "TEST", 299, 300], ["CRP", "TEST", 319, 322], ["stroke", "OBSERVATION", 54, 60], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["hypertension", "OBSERVATION", 139, 151], ["ischaemic", "OBSERVATION_MODIFIER", 153, 162], ["heart", "ANATOMY", 163, 168], ["disease", "OBSERVATION", 169, 176], ["stroke", "OBSERVATION", 184, 190], ["transient", "OBSERVATION_MODIFIER", 194, 203], ["ischaemic", "OBSERVATION_MODIFIER", 204, 213], ["lymphocytes counts", "OBSERVATION", 275, 293], ["reactive protein", "OBSERVATION", 301, 317]]], ["Binary logistic regression (Hosmer and Lemeshow Test p: 0.550 and Nagelkerke R Square: 0.152) suggested that mechanical ventilation (OR: 1.9, 95% CI:1.1\u00c03.5, p = 0.028), and the presence of ischaemic heart disease (OR: 2.5, 95% CI: 1.4\u00c04.7, p = 0.006) are independent predictors of stroke.", [["heart", "ANATOMY", 200, 205], ["ischaemic heart disease", "DISEASE", 190, 213], ["stroke", "DISEASE", 282, 288], ["heart", "ORGAN", 200, 205], ["Binary logistic regression", "PROBLEM", 0, 26], ["mechanical ventilation", "TREATMENT", 109, 131], ["CI", "TEST", 146, 148], ["p", "TEST", 158, 159], ["ischaemic heart disease", "PROBLEM", 190, 213], ["CI", "TEST", 228, 230], ["p", "TEST", 241, 242], ["stroke", "PROBLEM", 282, 288], ["mechanical ventilation", "OBSERVATION", 109, 131], ["ischaemic", "OBSERVATION_MODIFIER", 190, 199], ["heart", "ANATOMY", 200, 205], ["disease", "OBSERVATION", 206, 213], ["stroke", "OBSERVATION", 282, 288]]], ["When we repeated the analysis after excluding the need for ventilation (given the limited number of patients on a ventilator), ischaemic heart disease remained the only independent predictor of stroke.DiscussionThe results of this multi-national study on hospitalized patients with SARS-CoV-2 infection indicated an overall stroke risk of 0.5% (pooled risk: 0.9%).", [["heart", "ANATOMY", 137, 142], ["ischaemic heart disease", "DISEASE", 127, 150], ["stroke", "DISEASE", 194, 200], ["SARS-CoV-2 infection", "DISEASE", 282, 302], ["stroke", "DISEASE", 324, 330], ["patients", "ORGANISM", 100, 108], ["heart", "ORGAN", 137, 142], ["patients", "ORGANISM", 268, 276], ["SARS-CoV-2", "ORGANISM", 282, 292], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 268, 276], ["the analysis", "TEST", 17, 29], ["ventilation", "TREATMENT", 59, 70], ["a ventilator", "TREATMENT", 112, 124], ["ischaemic heart disease", "PROBLEM", 127, 150], ["stroke", "PROBLEM", 194, 200], ["this multi-national study", "TEST", 226, 251], ["SARS", "PROBLEM", 282, 286], ["CoV", "TEST", 287, 290], ["2 infection", "PROBLEM", 291, 302], ["an overall stroke risk", "PROBLEM", 313, 335], ["heart", "ANATOMY", 137, 142], ["disease", "OBSERVATION", 143, 150], ["stroke", "OBSERVATION", 194, 200], ["overall", "OBSERVATION_MODIFIER", 316, 323], ["stroke", "OBSERVATION", 324, 330]]], ["This frequency was obtained after a careful quality and heterogeneity assessment of the data.", [["heterogeneity assessment", "TEST", 56, 80], ["the data", "TEST", 84, 92]]], ["The results of regression models suggest that the need for mechanical ventilation and a history of ischaemic heart disease are the independent predictors of stroke among SARS-CoV-2 hospitalized patients.DiscussionSince the onset of the pandemic, a large population across the globe have been diagnosed with SARS-CoV-2 and several had associated neurological symptoms [11,48\u00c050] .", [["heart", "ANATOMY", 109, 114], ["neurological", "ANATOMY", 345, 357], ["ischaemic heart disease", "DISEASE", 99, 122], ["stroke", "DISEASE", 157, 163], ["SARS", "DISEASE", 170, 174], ["neurological symptoms", "DISEASE", 345, 366], ["heart", "ORGAN", 109, 114], ["SARS-CoV-2", "ORGANISM", 170, 180], ["patients", "ORGANISM", 194, 202], ["globe", "ORGAN", 276, 281], ["patients", "SPECIES", 194, 202], ["SARS-CoV", "SPECIES", 170, 178], ["SARS-CoV", "SPECIES", 307, 315], ["regression models", "TEST", 15, 32], ["mechanical ventilation", "TREATMENT", 59, 81], ["ischaemic heart disease", "PROBLEM", 99, 122], ["stroke", "PROBLEM", 157, 163], ["the pandemic", "PROBLEM", 232, 244], ["a large population across the globe", "PROBLEM", 246, 281], ["SARS", "PROBLEM", 307, 311], ["CoV", "TEST", 312, 315], ["associated neurological symptoms", "PROBLEM", 334, 366], ["ischaemic", "OBSERVATION_MODIFIER", 99, 108], ["heart", "ANATOMY", 109, 114], ["disease", "OBSERVATION", 115, 122], ["large", "OBSERVATION_MODIFIER", 248, 253], ["population", "OBSERVATION", 254, 264], ["globe", "ANATOMY", 276, 281]]], ["Recently, there has been increasing attention on the vascular complications of SARS-CoV-2, and different pathophysiologic mechanisms have been proposed to underpin such events; among them, one can mention vasoconstriction and increased blood pressure through an imbalance of Angiotensin-Converting Enzyme (ACE) and ACE-2 activation, immunemediated mechanisms and overexpression of the cytokines, vasculitis, and neurological consequences secondary to hypoxemia or hypotension [3, 7, 8, 10, 51] .", [["vascular", "ANATOMY", 53, 61], ["blood", "ANATOMY", 236, 241], ["neurological", "ANATOMY", 412, 424], ["SARS", "DISEASE", 79, 83], ["Angiotensin", "CHEMICAL", 275, 286], ["vasculitis", "DISEASE", 396, 406], ["neurological consequences", "DISEASE", 412, 437], ["hypoxemia", "DISEASE", 451, 460], ["hypotension", "DISEASE", 464, 475], ["vascular", "MULTI-TISSUE_STRUCTURE", 53, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["Angiotensin-Converting Enzyme", "GENE_OR_GENE_PRODUCT", 275, 304], ["ACE", "GENE_OR_GENE_PRODUCT", 306, 309], ["ACE-2", "GENE_OR_GENE_PRODUCT", 315, 320], ["ACE", "PROTEIN", 306, 309], ["cytokines", "PROTEIN", 385, 394], ["SARS-CoV", "SPECIES", 79, 87], ["the vascular complications", "PROBLEM", 49, 75], ["SARS", "PROBLEM", 79, 83], ["CoV", "TEST", 84, 87], ["vasoconstriction", "PROBLEM", 205, 221], ["increased blood pressure", "PROBLEM", 226, 250], ["Angiotensin", "TREATMENT", 275, 286], ["Converting Enzyme (ACE)", "TREATMENT", 287, 310], ["ACE-2 activation", "TREATMENT", 315, 331], ["immunemediated mechanisms", "PROBLEM", 333, 358], ["the cytokines", "PROBLEM", 381, 394], ["vasculitis", "PROBLEM", 396, 406], ["neurological consequences", "PROBLEM", 412, 437], ["hypoxemia", "PROBLEM", 451, 460], ["hypotension", "PROBLEM", 464, 475], ["increasing", "OBSERVATION_MODIFIER", 25, 35], ["vascular", "ANATOMY", 53, 61], ["complications", "OBSERVATION", 62, 75], ["increased", "OBSERVATION_MODIFIER", 226, 235], ["blood pressure", "OBSERVATION", 236, 250], ["vasculitis", "OBSERVATION", 396, 406], ["hypoxemia", "OBSERVATION", 451, 460], ["hypotension", "OBSERVATION", 464, 475]]], ["Increased proinflammatory biomarkers [52, 53] , and COVID-19-associated coagulopathy, characterized by increased fibrinogen/fibrinogen degradation products and D-dimer levels [12\u00c014] were also reported in patients with SARS-CoV-2 infection.", [["coagulopathy", "DISEASE", 72, 84], ["SARS-CoV-2 infection", "DISEASE", 219, 239], ["COVID-19", "GENE_OR_GENE_PRODUCT", 52, 60], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 113, 123], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 124, 134], ["D-dimer", "GENE_OR_GENE_PRODUCT", 160, 167], ["patients", "ORGANISM", 205, 213], ["SARS-CoV-2", "ORGANISM", 219, 229], ["fibrinogen", "PROTEIN", 113, 123], ["fibrinogen degradation products", "PROTEIN", 124, 155], ["patients", "SPECIES", 205, 213], ["Increased proinflammatory biomarkers", "TEST", 0, 36], ["COVID", "TEST", 52, 57], ["coagulopathy", "PROBLEM", 72, 84], ["increased fibrinogen/fibrinogen degradation products", "PROBLEM", 103, 155], ["D-dimer levels", "TEST", 160, 174], ["SARS", "PROBLEM", 219, 223], ["CoV-2 infection", "PROBLEM", 224, 239], ["proinflammatory", "OBSERVATION_MODIFIER", 10, 25], ["coagulopathy", "OBSERVATION", 72, 84], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["fibrinogen", "OBSERVATION", 113, 123], ["infection", "OBSERVATION", 230, 239]]], ["Further reports supported higher thrombotic complications such as ischaemic stroke, systemic arterial embolism, and venous thromboembolism in SARS-CoV-2 infected patients [54, 55] .DiscussionTo date, several series of strokes in patients with SARS-CoV-2 diagnoses have been reported [3, 4, 56] .", [["arterial", "ANATOMY", 93, 101], ["venous", "ANATOMY", 116, 122], ["thrombotic complications", "DISEASE", 33, 57], ["ischaemic stroke", "DISEASE", 66, 82], ["systemic arterial embolism", "DISEASE", 84, 110], ["venous thromboembolism", "DISEASE", 116, 138], ["SARS-CoV-2 infected", "DISEASE", 142, 161], ["strokes", "DISEASE", 218, 225], ["SARS", "DISEASE", 243, 247], ["arterial", "MULTI-TISSUE_STRUCTURE", 93, 101], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 122], ["SARS-CoV-2", "ORGANISM", 142, 152], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 229, 237], ["SARS-CoV", "SPECIES", 142, 150], ["higher thrombotic complications", "PROBLEM", 26, 57], ["ischaemic stroke", "PROBLEM", 66, 82], ["systemic arterial embolism", "PROBLEM", 84, 110], ["venous thromboembolism", "PROBLEM", 116, 138], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150], ["strokes", "PROBLEM", 218, 225], ["SARS", "PROBLEM", 243, 247], ["higher", "OBSERVATION_MODIFIER", 26, 32], ["thrombotic", "OBSERVATION_MODIFIER", 33, 43], ["complications", "OBSERVATION", 44, 57], ["ischaemic", "OBSERVATION_MODIFIER", 66, 75], ["stroke", "OBSERVATION", 76, 82], ["systemic arterial", "ANATOMY", 84, 101], ["embolism", "OBSERVATION", 102, 110], ["venous", "ANATOMY", 116, 122], ["thromboembolism", "OBSERVATION", 123, 138], ["strokes", "OBSERVATION", 218, 225]]], ["However, to our knowledge, no prior study has determined the rate of these complications at a multinational level.", [["prior study", "TEST", 30, 41], ["these complications", "PROBLEM", 69, 88], ["complications", "OBSERVATION", 75, 88]]], ["A temporal relationship and increased risk of stroke have been reported in association with different respiratory viral infections [15\u00c023].", [["stroke", "DISEASE", 46, 52], ["respiratory viral infections", "DISEASE", 102, 130], ["A temporal relationship", "PROBLEM", 0, 23], ["stroke", "PROBLEM", 46, 52], ["different respiratory viral infections", "PROBLEM", 92, 130], ["temporal", "OBSERVATION_MODIFIER", 2, 10], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["stroke", "OBSERVATION", 46, 52], ["viral infections", "OBSERVATION", 114, 130]]], ["A population-based study in the United Kingdom (UK) on 2874 patients demonstrated an increased number of the first-ever stroke within two (ischaemic stroke) to four weeks (haemorrhagic stroke) after seasonal influenza peak [15] .", [["stroke", "DISEASE", 120, 126], ["ischaemic stroke", "DISEASE", 139, 155], ["haemorrhagic stroke", "DISEASE", 172, 191], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["A population-based study", "TEST", 0, 24], ["haemorrhagic stroke", "PROBLEM", 172, 191], ["seasonal influenza peak", "PROBLEM", 199, 222], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["number", "OBSERVATION_MODIFIER", 95, 101], ["haemorrhagic", "OBSERVATION_MODIFIER", 172, 184], ["stroke", "OBSERVATION", 185, 191]]], ["Another population study from the UK on 22,400 individuals reported an increased risk of vascular events following lower respiratory or urinary tract infections, with an age-adjusted incidence ratio of 3.2 within the first three days, which decreased to 1.33 within three months post-infection [16] .", [["vascular", "ANATOMY", 89, 97], ["lower respiratory", "ANATOMY", 115, 132], ["urinary tract", "ANATOMY", 136, 149], ["lower respiratory or urinary tract infections", "DISEASE", 115, 160], ["individuals", "ORGANISM", 47, 58], ["vascular", "MULTI-TISSUE_STRUCTURE", 89, 97], ["urinary tract", "ORGANISM_SUBDIVISION", 136, 149], ["Another population study", "TEST", 0, 24], ["vascular events", "PROBLEM", 89, 104], ["lower respiratory or urinary tract infections", "PROBLEM", 115, 160], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["vascular", "ANATOMY", 89, 97], ["lower", "ANATOMY_MODIFIER", 115, 120], ["respiratory", "ANATOMY", 121, 132], ["urinary tract", "ANATOMY", 136, 149], ["infections", "OBSERVATION", 150, 160]]], ["In California, a study of about 37,000 hospitalized ischaemic stroke patients suggested a significant risk of stroke in patients with prior influenza-like illnesses, with odds ratios (OR) of 2.9 in 15 days, decreasing to 1.7 within 365 days post-infection [17] .", [["ischaemic stroke", "DISEASE", 52, 68], ["stroke", "DISEASE", 110, 116], ["influenza-like illnesses", "DISEASE", 140, 164], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 120, 128], ["a study", "TEST", 15, 22], ["ischaemic stroke", "PROBLEM", 52, 68], ["stroke", "PROBLEM", 110, 116], ["prior influenza-like illnesses", "PROBLEM", 134, 164], ["odds ratios", "TEST", 171, 182], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["stroke", "OBSERVATION", 110, 116], ["influenza", "OBSERVATION", 140, 149]]], ["Based on this study, stroke triggered by influenza-like infections are more likely to occur in patients who are younger than 45 years old (OR: 9.28, in comparison to OR: 2.71 in 45\u00c065 years old, and OR: 2.65 in patients older than 65).", [["stroke", "DISEASE", 21, 27], ["influenza-like infections", "DISEASE", 41, 66], ["influenza", "ORGANISM", 41, 50], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 211, 219], ["this study", "TEST", 9, 19], ["stroke", "PROBLEM", 21, 27], ["influenza", "PROBLEM", 41, 50], ["infections", "PROBLEM", 56, 66], ["stroke", "OBSERVATION", 21, 27], ["influenza", "OBSERVATION", 41, 50], ["infections", "OBSERVATION", 56, 66]]], ["A recent meta-analysis showed that influenza vaccination might be associated with a lower risk of ischaemic stroke events [57] .", [["influenza", "DISEASE", 35, 44], ["ischaemic stroke", "DISEASE", 98, 114], ["A recent meta-analysis", "TEST", 0, 22], ["influenza vaccination", "PROBLEM", 35, 56], ["ischaemic stroke events", "PROBLEM", 98, 121], ["influenza", "OBSERVATION", 35, 44], ["ischaemic", "OBSERVATION_MODIFIER", 98, 107], ["stroke", "OBSERVATION", 108, 114]]], ["Despite this, the overall risk of subsequent stroke seems to be less than 1%.", [["stroke", "DISEASE", 45, 51], ["subsequent stroke", "PROBLEM", 34, 51], ["stroke", "OBSERVATION", 45, 51]]], ["In another study of over 102,500 patients with a diagnosis of influenza, stroke or TIA incidence rates were reported to be 0.052, 0.035, 0.029 at 1, 3, and 6 months after influenza [19] .", [["influenza", "DISEASE", 62, 71], ["stroke", "DISEASE", 73, 79], ["TIA", "DISEASE", 83, 86], ["influenza", "DISEASE", 171, 180], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["influenza", "PROBLEM", 62, 71], ["stroke", "PROBLEM", 73, 79], ["TIA incidence rates", "PROBLEM", 83, 102], ["influenza", "PROBLEM", 171, 180], ["influenza", "OBSERVATION", 62, 71]]], ["Likewise, the United States National Readmissions Database reports on over 46,000 patients hospitalized for influenza indicated that strokes are infrequent (0.3%) causes of 30-day readmission [18] .DiscussionStrokes were also reported among patients infected with b-coronaviruses such as severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome coronavirus (MERS-CoV) [20\u00c023].", [["influenza", "DISEASE", 108, 117], ["strokes", "DISEASE", 133, 140], ["acute respiratory syndrome", "DISEASE", 295, 321], ["SARS", "DISEASE", 323, 327], ["Middle East respiratory syndrome coronavirus", "DISEASE", 332, 376], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 241, 249], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 332, 376], ["MERS-CoV", "ORGANISM", 378, 386], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 241, 249], ["Middle East respiratory syndrome coronavirus", "SPECIES", 332, 376], ["MERS-CoV", "SPECIES", 378, 386], ["influenza", "PROBLEM", 108, 117], ["strokes", "PROBLEM", 133, 140], ["b-coronaviruses", "TREATMENT", 264, 279], ["severe acute respiratory syndrome", "PROBLEM", 288, 321], ["SARS)", "PROBLEM", 323, 328], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 332, 376], ["strokes", "OBSERVATION", 133, 140], ["severe", "OBSERVATION_MODIFIER", 288, 294], ["acute", "OBSERVATION_MODIFIER", 295, 300], ["respiratory syndrome", "OBSERVATION", 301, 321], ["Middle", "ANATOMY_MODIFIER", 332, 338], ["respiratory syndrome", "OBSERVATION", 344, 364]]], ["Five (2%) patients infected with SARS in Singapore developed large artery cerebral ischemia, among them three had no known stroke risk factor [20] .", [["artery cerebral", "ANATOMY", 67, 82], ["SARS", "DISEASE", 33, 37], ["artery cerebral ischemia", "DISEASE", 67, 91], ["stroke", "DISEASE", 123, 129], ["patients", "ORGANISM", 10, 18], ["artery cerebral", "MULTI-TISSUE_STRUCTURE", 67, 82], ["patients", "SPECIES", 10, 18], ["SARS", "PROBLEM", 33, 37], ["large artery cerebral ischemia", "PROBLEM", 61, 91], ["known stroke risk factor", "PROBLEM", 117, 141], ["infected", "OBSERVATION", 19, 27], ["large", "OBSERVATION_MODIFIER", 61, 66], ["artery cerebral", "ANATOMY", 67, 82], ["ischemia", "OBSERVATION", 83, 91]]], ["Acute myocardial infarction and disseminated intravascular coagulation (three patients), and generalized hypotension (four patients) preceded the ischaemic stroke event.", [["myocardial", "ANATOMY", 6, 16], ["intravascular", "ANATOMY", 45, 58], ["myocardial infarction", "DISEASE", 6, 27], ["disseminated intravascular coagulation", "DISEASE", 32, 70], ["hypotension", "DISEASE", 105, 116], ["ischaemic stroke", "DISEASE", 146, 162], ["myocardial", "MULTI-TISSUE_STRUCTURE", 6, 16], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 123, 131], ["Acute myocardial infarction", "PROBLEM", 0, 27], ["disseminated intravascular coagulation", "PROBLEM", 32, 70], ["generalized hypotension", "PROBLEM", 93, 116], ["the ischaemic stroke event", "PROBLEM", 142, 168], ["myocardial", "ANATOMY", 6, 16], ["infarction", "OBSERVATION", 17, 27], ["disseminated", "OBSERVATION_MODIFIER", 32, 44], ["intravascular coagulation", "OBSERVATION", 45, 70], ["generalized", "OBSERVATION_MODIFIER", 93, 104], ["hypotension", "OBSERVATION", 105, 116], ["ischaemic", "OBSERVATION_MODIFIER", 146, 155], ["stroke", "OBSERVATION", 156, 162]]], ["Bilateral anterior cerebral artery stroke (a diabetic and hypertensive 57-year old man) [21] , frontal lobes intracerebral hemorrhage (a diabetic 34-year old woman) [22] , and frontal hematoma and subarachnoid hemorrhage extending to ventricles that resulted in subfalcine herniation (a diabetic 42-year old woman, with history of nephrectomy) [23] were reported in association with MERS-CoV infection.", [["anterior cerebral artery", "ANATOMY", 10, 34], ["frontal lobes", "ANATOMY", 95, 108], ["frontal hematoma", "ANATOMY", 176, 192], ["subarachnoid", "ANATOMY", 197, 209], ["ventricles", "ANATOMY", 234, 244], ["anterior cerebral artery stroke", "DISEASE", 10, 41], ["diabetic", "DISEASE", 45, 53], ["hypertensive", "DISEASE", 58, 70], ["intracerebral hemorrhage", "DISEASE", 109, 133], ["diabetic", "DISEASE", 137, 145], ["frontal hematoma", "DISEASE", 176, 192], ["subarachnoid hemorrhage", "DISEASE", 197, 220], ["subfalcine herniation", "DISEASE", 262, 283], ["diabetic", "DISEASE", 287, 295], ["MERS-CoV infection", "DISEASE", 383, 401], ["anterior cerebral artery", "MULTI-TISSUE_STRUCTURE", 10, 34], ["man", "ORGANISM", 83, 86], ["frontal lobes", "MULTI-TISSUE_STRUCTURE", 95, 108], ["woman", "ORGANISM", 158, 163], ["frontal hematoma", "PATHOLOGICAL_FORMATION", 176, 192], ["ventricles", "MULTI-TISSUE_STRUCTURE", 234, 244], ["woman", "ORGANISM", 308, 313], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 383, 391], ["man", "SPECIES", 83, 86], ["woman", "SPECIES", 158, 163], ["woman", "SPECIES", 308, 313], ["MERS-CoV", "SPECIES", 383, 391], ["Bilateral anterior cerebral artery stroke", "PROBLEM", 0, 41], ["a diabetic", "PROBLEM", 43, 53], ["frontal lobes intracerebral hemorrhage", "PROBLEM", 95, 133], ["frontal hematoma", "PROBLEM", 176, 192], ["subarachnoid hemorrhage", "PROBLEM", 197, 220], ["subfalcine herniation", "PROBLEM", 262, 283], ["nephrectomy", "TREATMENT", 331, 342], ["CoV infection", "PROBLEM", 388, 401], ["anterior cerebral artery", "ANATOMY", 10, 34], ["stroke", "OBSERVATION", 35, 41], ["diabetic", "OBSERVATION_MODIFIER", 45, 53], ["frontal lobes", "ANATOMY", 95, 108], ["intracerebral", "ANATOMY", 109, 122], ["hemorrhage", "OBSERVATION", 123, 133], ["frontal", "ANATOMY", 176, 183], ["hematoma", "OBSERVATION", 184, 192], ["subarachnoid", "ANATOMY", 197, 209], ["hemorrhage", "OBSERVATION", 210, 220], ["ventricles", "ANATOMY", 234, 244], ["subfalcine", "OBSERVATION_MODIFIER", 262, 272], ["herniation", "OBSERVATION", 273, 283], ["diabetic", "OBSERVATION_MODIFIER", 287, 295], ["nephrectomy", "OBSERVATION", 331, 342], ["CoV", "ANATOMY", 388, 391], ["infection", "OBSERVATION", 392, 401]]], ["To the best of our knowledge, the literature is limited to small case series, and no population-based rate assumption has been provided for these viral infections.DiscussionAlthough an increasing number of reports on neurological symptoms have been published since the onset of the SARS-CoV-2 outbreak, confirmed cases of cerebrovascular events in association with SARS-CoV-2 are limited.", [["neurological", "ANATOMY", 217, 229], ["cerebrovascular", "ANATOMY", 322, 337], ["viral infections", "DISEASE", 146, 162], ["SARS", "DISEASE", 282, 286], ["cerebrovascular events", "DISEASE", 322, 344], ["SARS", "DISEASE", 365, 369], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 322, 337], ["SARS-CoV", "SPECIES", 365, 373], ["small case series", "PROBLEM", 59, 76], ["these viral infections", "PROBLEM", 140, 162], ["neurological symptoms", "PROBLEM", 217, 238], ["the SARS", "PROBLEM", 278, 286], ["cerebrovascular events", "PROBLEM", 322, 344], ["SARS", "PROBLEM", 365, 369], ["CoV", "TEST", 370, 373], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["infections", "OBSERVATION", 152, 162], ["increasing", "OBSERVATION_MODIFIER", 185, 195], ["cerebrovascular", "ANATOMY", 322, 337]]], ["Zhang et al. described three Chinese patients who experienced multiple cerebral infarctions [4] .", [["cerebral", "ANATOMY", 71, 79], ["cerebral infarctions", "DISEASE", 71, 91], ["patients", "ORGANISM", 37, 45], ["cerebral", "ORGAN", 71, 79], ["patients", "SPECIES", 37, 45], ["multiple cerebral infarctions", "PROBLEM", 62, 91], ["cerebral", "ANATOMY", 71, 79], ["infarctions", "OBSERVATION", 80, 91]]], ["All of these patients were in critical conditions, significant coagulopathy, and antiphospholipid antibodies (positive anticardiolipin IgA, anti\u00c0b2glycoprotein I IgA and IgG).", [["coagulopathy", "DISEASE", 63, 75], ["antiphospholipid antibodies", "DISEASE", 81, 108], ["patients", "ORGANISM", 13, 21], ["antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 81, 108], ["anticardiolipin IgA", "GENE_OR_GENE_PRODUCT", 119, 138], ["anti\u00c0b2glycoprotein I IgA", "GENE_OR_GENE_PRODUCT", 140, 165], ["IgG", "GENE_OR_GENE_PRODUCT", 170, 173], ["antiphospholipid antibodies", "PROTEIN", 81, 108], ["positive anticardiolipin IgA", "PROTEIN", 110, 138], ["anti\u00c0b2glycoprotein I", "PROTEIN", 140, 161], ["IgA", "PROTEIN", 162, 165], ["IgG", "PROTEIN", 170, 173], ["patients", "SPECIES", 13, 21], ["significant coagulopathy", "PROBLEM", 51, 75], ["antiphospholipid antibodies", "TEST", 81, 108], ["anticardiolipin IgA", "TEST", 119, 138], ["anti\u00c0b2glycoprotein", "TEST", 140, 159], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["coagulopathy", "OBSERVATION", 63, 75], ["antiphospholipid antibodies", "OBSERVATION", 81, 108]]], ["In another case series from China, 13 out of 221 patients (6%) had strokes: large vessel stroke in five, small vessel stroke in three, cardioembolic stroke in three, and two patients were complicated with cerebral venous thrombosis and cerebral hemorrhage [3] .", [["vessel", "ANATOMY", 82, 88], ["vessel", "ANATOMY", 111, 117], ["cerebral venous", "ANATOMY", 205, 220], ["cerebral", "ANATOMY", 236, 244], ["strokes", "DISEASE", 67, 74], ["vessel stroke", "DISEASE", 82, 95], ["vessel stroke", "DISEASE", 111, 124], ["cardioembolic stroke", "DISEASE", 135, 155], ["cerebral venous thrombosis", "DISEASE", 205, 231], ["cerebral hemorrhage", "DISEASE", 236, 255], ["patients", "ORGANISM", 49, 57], ["vessel", "MULTI-TISSUE_STRUCTURE", 82, 88], ["vessel", "MULTI-TISSUE_STRUCTURE", 111, 117], ["patients", "ORGANISM", 174, 182], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 205, 220], ["cerebral", "ORGAN", 236, 244], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 174, 182], ["strokes", "PROBLEM", 67, 74], ["large vessel stroke", "PROBLEM", 76, 95], ["small vessel stroke", "PROBLEM", 105, 124], ["cardioembolic stroke", "PROBLEM", 135, 155], ["cerebral venous thrombosis", "PROBLEM", 205, 231], ["cerebral hemorrhage", "PROBLEM", 236, 255], ["strokes", "OBSERVATION", 67, 74], ["large", "OBSERVATION_MODIFIER", 76, 81], ["vessel", "ANATOMY", 82, 88], ["stroke", "OBSERVATION", 89, 95], ["small", "OBSERVATION_MODIFIER", 105, 110], ["vessel", "ANATOMY", 111, 117], ["stroke", "OBSERVATION", 118, 124], ["cardioembolic", "OBSERVATION_MODIFIER", 135, 148], ["stroke", "OBSERVATION", 149, 155], ["cerebral venous", "ANATOMY", 205, 220], ["thrombosis", "OBSERVATION", 221, 231], ["cerebral", "ANATOMY", 236, 244], ["hemorrhage", "OBSERVATION", 245, 255]]], ["In a series of six patients from the UK, all patients had large vessel occlusion (three in multiple vascular territories) with elevated D-dimer levels, among whom the stroke was the primary presentation of SARS-CoV-2 in one patient.", [["vessel", "ANATOMY", 64, 70], ["vascular", "ANATOMY", 100, 108], ["vessel occlusion", "DISEASE", 64, 80], ["stroke", "DISEASE", 167, 173], ["SARS", "DISEASE", 206, 210], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 45, 53], ["vessel", "MULTI-TISSUE_STRUCTURE", 64, 70], ["vascular", "MULTI-TISSUE_STRUCTURE", 100, 108], ["D-dimer", "GENE_OR_GENE_PRODUCT", 136, 143], ["patient", "ORGANISM", 224, 231], ["D-dimer", "PROTEIN", 136, 143], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 45, 53], ["patient", "SPECIES", 224, 231], ["large vessel occlusion", "PROBLEM", 58, 80], ["elevated D-dimer levels", "PROBLEM", 127, 150], ["the stroke", "PROBLEM", 163, 173], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["large", "OBSERVATION_MODIFIER", 58, 63], ["vessel", "ANATOMY", 64, 70], ["occlusion", "OBSERVATION", 71, 80], ["multiple", "ANATOMY_MODIFIER", 91, 99], ["vascular", "ANATOMY", 100, 108], ["territories", "ANATOMY_MODIFIER", 109, 120], ["elevated", "OBSERVATION", 127, 135], ["stroke", "OBSERVATION", 167, 173]]], ["Five patients had positive lupus anticoagulants, but only one had medium titter antiphospholipid IgM and IgG antibodies.", [["lupus anticoagulants", "DISEASE", 27, 47], ["patients", "ORGANISM", 5, 13], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 105, 119], ["medium titter antiphospholipid IgM", "PROTEIN", 66, 100], ["IgG antibodies", "PROTEIN", 105, 119], ["patients", "SPECIES", 5, 13], ["positive lupus anticoagulants", "PROBLEM", 18, 47], ["antiphospholipid IgM", "TEST", 80, 100], ["IgG antibodies", "TEST", 105, 119], ["positive", "OBSERVATION_MODIFIER", 18, 26], ["lupus anticoagulants", "OBSERVATION", 27, 47]]], ["All patients in this series were over 50 years old and had moderate to severe SARS-CoV-2 infection [5] .", [["SARS-CoV-2 infection", "DISEASE", 78, 98], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["moderate to severe SARS", "PROBLEM", 59, 82], ["CoV-2 infection", "PROBLEM", 83, 98], ["moderate", "OBSERVATION_MODIFIER", 59, 67], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["SARS", "OBSERVATION", 78, 82]]], ["In a case series from New York City, five patients, younger than 50 years old with a positive test for SARS-CoV-2, developed largevessel stroke [6] .", [["SARS", "DISEASE", 103, 107], ["largevessel stroke", "DISEASE", 125, 143], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 103, 111], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["largevessel stroke", "PROBLEM", 125, 143], ["stroke", "OBSERVATION", 137, 143]]], ["Three of these patients had prior comorbidities-39 years old with hypertension and dyslipidaemia, 44 years old with diabetes mellitus, and 49 years old with diabetes and prior stroke.", [["hypertension", "DISEASE", 66, 78], ["dyslipidaemia", "DISEASE", 83, 96], ["diabetes mellitus", "DISEASE", 116, 133], ["diabetes", "DISEASE", 157, 165], ["stroke", "DISEASE", 176, 182], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["prior comorbidities", "PROBLEM", 28, 47], ["hypertension", "PROBLEM", 66, 78], ["dyslipidaemia", "PROBLEM", 83, 96], ["diabetes mellitus", "PROBLEM", 116, 133], ["diabetes", "PROBLEM", 157, 165], ["prior stroke", "PROBLEM", 170, 182], ["hypertension", "OBSERVATION", 66, 78], ["dyslipidaemia", "OBSERVATION", 83, 96], ["diabetes", "OBSERVATION", 157, 165], ["stroke", "OBSERVATION", 176, 182]]], ["The authors stated that based on the routine admission rate of their center over the past year, the rate of young adults with large vessel stroke might be higher.", [["vessel", "ANATOMY", 132, 138], ["vessel stroke", "DISEASE", 132, 145], ["vessel", "MULTI-TISSUE_STRUCTURE", 132, 138], ["large vessel stroke", "PROBLEM", 126, 145], ["large", "OBSERVATION_MODIFIER", 126, 131], ["vessel", "ANATOMY", 132, 138], ["stroke", "OBSERVATION", 139, 145], ["higher", "OBSERVATION_MODIFIER", 155, 161]]], ["Unfortunately, the authors provided no information regarding the total hospitalized patients with SARS-CoV-2 for further risk calculation.DiscussionIt is worth mentioning that most of the reported SARS-CoV-2 infected patients with stroke had critical conditions.", [["SARS", "DISEASE", 98, 102], ["SARS-CoV-2 infected", "DISEASE", 197, 216], ["stroke", "DISEASE", 231, 237], ["patients", "ORGANISM", 84, 92], ["SARS-CoV-2", "ORGANISM", 197, 207], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 217, 225], ["further risk calculation", "TEST", 113, 137], ["stroke", "PROBLEM", 231, 237]]], ["In this study, the patients with stroke were more likely on a ventilator (36.5% versus 14.0%) and had ischaemic heart disease (29.8% versus 12.1%).", [["heart", "ANATOMY", 112, 117], ["stroke", "DISEASE", 33, 39], ["ischaemic heart disease", "DISEASE", 102, 125], ["patients", "ORGANISM", 19, 27], ["heart", "ORGAN", 112, 117], ["patients", "SPECIES", 19, 27], ["this study", "TEST", 3, 13], ["stroke", "PROBLEM", 33, 39], ["a ventilator", "TREATMENT", 60, 72], ["ischaemic heart disease", "PROBLEM", 102, 125], ["stroke", "OBSERVATION", 33, 39], ["ischaemic", "OBSERVATION_MODIFIER", 102, 111], ["heart", "ANATOMY", 112, 117], ["disease", "OBSERVATION", 118, 125]]], ["Patients who receive invasive mechanical ventilation are more likely to have elevated inflammatory markers, comorbidities, and the need for vasopressor and ionotropic agents [58] .", [["Patients", "ORGANISM", 0, 8], ["inflammatory markers", "PROTEIN", 86, 106], ["Patients", "SPECIES", 0, 8], ["invasive mechanical ventilation", "TREATMENT", 21, 52], ["elevated inflammatory markers", "PROBLEM", 77, 106], ["comorbidities", "PROBLEM", 108, 121], ["vasopressor", "TREATMENT", 140, 151], ["ionotropic agents", "TREATMENT", 156, 173], ["elevated", "OBSERVATION_MODIFIER", 77, 85], ["inflammatory", "OBSERVATION", 86, 98]]], ["Inflammation, coagulation disorder, and infection in critically ill patients may also favor a stroke [59] .", [["Inflammation", "DISEASE", 0, 12], ["coagulation disorder", "DISEASE", 14, 34], ["infection", "DISEASE", 40, 49], ["critically ill", "DISEASE", 53, 67], ["stroke", "DISEASE", 94, 100], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Inflammation", "PROBLEM", 0, 12], ["coagulation disorder", "PROBLEM", 14, 34], ["infection", "PROBLEM", 40, 49], ["a stroke", "PROBLEM", 92, 100], ["coagulation disorder", "OBSERVATION", 14, 34], ["infection", "OBSERVATION", 40, 49], ["stroke", "OBSERVATION", 94, 100]]], ["About 0.5% of patients hospitalized with sepsis experience stroke within one year [24] .", [["sepsis", "DISEASE", 41, 47], ["stroke", "DISEASE", 59, 65], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["sepsis experience stroke", "PROBLEM", 41, 65], ["sepsis", "OBSERVATION", 41, 47]]], ["Sepsis can put patients at higher risks of ischaemic (OR>28) or haemorrhagic strokes (OR>12) through the first two weeks; the risk would remain high even for up to one year [60] .", [["Sepsis", "DISEASE", 0, 6], ["ischaemic", "DISEASE", 43, 52], ["strokes", "DISEASE", 77, 84], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["Sepsis", "PROBLEM", 0, 6], ["ischaemic", "PROBLEM", 43, 52], ["haemorrhagic strokes", "PROBLEM", 64, 84], ["ischaemic", "OBSERVATION_MODIFIER", 43, 52], ["haemorrhagic", "OBSERVATION_MODIFIER", 64, 76], ["strokes", "OBSERVATION", 77, 84]]], ["A variety of mechanisms can induce coagulopathy in sepsis [25, 26] .", [["coagulopathy", "DISEASE", 35, 47], ["sepsis", "DISEASE", 51, 57], ["coagulopathy", "PROBLEM", 35, 47], ["sepsis", "PROBLEM", 51, 57], ["coagulopathy", "OBSERVATION", 35, 47], ["sepsis", "OBSERVATION", 51, 57]]], ["In addition, about 6% of patients with severe sepsis experience new-onset of atrial fibrillation, which can put them at a greater risk of in-hospital stroke (2.6%) and in-hospital mortality (56%) [27] .", [["atrial", "ANATOMY", 77, 83], ["sepsis", "DISEASE", 46, 52], ["atrial fibrillation", "DISEASE", 77, 96], ["stroke", "DISEASE", 150, 156], ["patients", "ORGANISM", 25, 33], ["atrial", "MULTI-TISSUE_STRUCTURE", 77, 83], ["patients", "SPECIES", 25, 33], ["severe sepsis", "PROBLEM", 39, 52], ["atrial fibrillation", "PROBLEM", 77, 96], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["sepsis", "OBSERVATION", 46, 52], ["atrial", "ANATOMY", 77, 83], ["fibrillation", "OBSERVATION", 84, 96]]], ["New-onset atrial fibrillation is not limited to sepsis and can occur up to 8% of the ICU admissions, leading to an increased length of stay, mortality, and poor outcomes [61] .DiscussionThe authors communicated with different centres in several countries to increase the representativeness of this study.", [["atrial", "ANATOMY", 10, 16], ["atrial fibrillation", "DISEASE", 10, 29], ["sepsis", "DISEASE", 48, 54], ["atrial", "MULTI-TISSUE_STRUCTURE", 10, 16], ["New-onset atrial fibrillation", "PROBLEM", 0, 29], ["sepsis", "PROBLEM", 48, 54], ["this study", "TEST", 293, 303], ["atrial", "ANATOMY", 10, 16], ["fibrillation", "OBSERVATION", 17, 29], ["not limited to", "UNCERTAINTY", 33, 47], ["sepsis", "OBSERVATION", 48, 54], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["length", "OBSERVATION_MODIFIER", 125, 131]]], ["However, due to the sensitive nature of the SARS-CoV-2 outbreak, the high load of patients, and lack of electronic health records and resources to extract data, or lack of priority, the recruited data were limited to 99 centres from 11 countries.", [["SARS", "DISEASE", 44, 48], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["the SARS", "PROBLEM", 40, 48], ["extract data", "TEST", 147, 159]]], ["We had to exclude 25% of patients from the analyses due to the unavailability of validated data.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["the analyses", "TEST", 39, 51]]], ["The above missingness may have introduced selection-bias and affected the generalizability of the results or weaken the conclusion that can be drawn about the phenotype and mechanisms of stroke in SARS-CoV-2.", [["stroke", "DISEASE", 187, 193], ["SARS", "DISEASE", 197, 201], ["SARS-CoV", "SPECIES", 197, 205], ["the phenotype", "PROBLEM", 155, 168], ["stroke", "PROBLEM", 187, 193], ["CoV", "TEST", 202, 205], ["stroke", "OBSERVATION", 187, 193]]], ["Nevertheless, we did not observe any significant heterogeneity in our subgroup meta-and sensitivity analyses.DiscussionIn our study, the overall estimated risk in the meta-analysis of all centres was 0.5%.", [["our subgroup meta", "TEST", 66, 83], ["our study", "TEST", 122, 131], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["heterogeneity", "OBSERVATION", 49, 62]]], ["This risk would be comparable to the reported incidence of stroke following influenza [18, 19] .", [["stroke", "DISEASE", 59, 65], ["influenza", "DISEASE", 76, 85], ["stroke", "PROBLEM", 59, 65], ["influenza", "PROBLEM", 76, 85], ["stroke", "OBSERVATION", 59, 65]]], ["When we conducted the meta-analyses by continent, we observed a subsequent stroke risk of 0.7\u00c01.2% in North America, 0.5% in Europe, and 0.3% in Asia.", [["stroke", "DISEASE", 75, 81], ["a subsequent stroke risk", "PROBLEM", 62, 86]]], ["This difference might be due to many factors including policy variation among different healthcare systems for the hospitalization of SARS-CoV-2 infected patients; some centres had relaxed criteria for admission of positively tested patients, while the others were overwhelmed and adopted strict criteria to hospitalize patients.", [["SARS-CoV-2 infected", "DISEASE", 134, 153], ["SARS-CoV-2", "ORGANISM", 134, 144], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 233, 241], ["patients", "ORGANISM", 320, 328], ["CoV-", "SPECIES", 139, 143], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 320, 328], ["SARS-CoV", "SPECIES", 134, 142], ["SARS", "PROBLEM", 134, 138]]], ["The other factor might be the confirmation of the SARS-CoV-2 infection.", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 61, 70], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["the SARS", "PROBLEM", 46, 54], ["CoV-2 infection", "PROBLEM", 55, 70], ["SARS", "OBSERVATION", 50, 54], ["infection", "OBSERVATION", 61, 70]]], ["Due to the low sensitivity of PCR [62, 63] , the testing interval, and also availability and capacity of testing sites, some centres considered chest CT scan in addition to the presence of symptoms indicative of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 212, 232], ["SARS-CoV-2", "ORGANISM", 212, 222], ["SARS-CoV", "SPECIES", 212, 220], ["the low sensitivity of PCR", "PROBLEM", 7, 33], ["the testing interval", "TEST", 45, 65], ["testing sites", "TEST", 105, 118], ["chest CT scan", "TEST", 144, 157], ["symptoms", "PROBLEM", 189, 197], ["SARS", "PROBLEM", 212, 216], ["CoV", "PROBLEM", 217, 220], ["2 infection", "PROBLEM", 221, 232], ["chest", "ANATOMY", 144, 149], ["SARS", "OBSERVATION", 212, 216], ["infection", "OBSERVATION", 223, 232]]], ["Nevertheless, in our study, the stroke risk was estimated as 0.7% among countries with higher health expenditures which only used PCR for infection confirmation.", [["stroke", "DISEASE", 32, 38], ["infection", "DISEASE", 138, 147], ["our study", "TEST", 17, 26], ["the stroke risk", "PROBLEM", 28, 43], ["higher health expenditures", "PROBLEM", 87, 113], ["PCR", "TEST", 130, 133], ["infection confirmation", "TEST", 138, 160]]], ["This rate was similar to our overall risk estimates; pooled risk estimates of 0.9% and weighted risk of 0.5%.", [["pooled risk estimates", "TEST", 53, 74], ["weighted risk", "TEST", 87, 100]]], ["Although our study includes several countries and communities and has high generalization power for the calculated risk, we realize that the risk factors associated with stroke could have been different if the study was done at the community level; secondary to a different profile of vascular risk factors, genetic predisposition, and sociodemographic factors.DiscussionWe did not have a central adjudication in this study.", [["vascular", "ANATOMY", 285, 293], ["stroke", "DISEASE", 170, 176], ["vascular", "MULTI-TISSUE_STRUCTURE", 285, 293], ["vascular risk factors", "PROTEIN", 285, 306], ["our study", "TEST", 9, 18], ["the risk factors", "PROBLEM", 137, 153], ["stroke", "PROBLEM", 170, 176], ["the study", "TEST", 206, 215], ["a different profile of vascular risk factors", "PROBLEM", 262, 306], ["genetic predisposition", "PROBLEM", 308, 330], ["this study", "TEST", 413, 423], ["vascular", "ANATOMY", 285, 293]]], ["In addition, we realize that the clinical severity could be assessed through other parameters that could not be collected considering the high number of participating centres, the partial availability of data, and the narrow study time window.", [["the clinical severity", "PROBLEM", 29, 50]]], ["Various centres may have had a different treatment protocol based on local experience that could not be fully taken into consideration.", [["a different treatment protocol", "TREATMENT", 29, 59]]], ["Despite these possible limitations, the availability of richer clinical data or care procedures would not suggest results very different from those presented.", [["care procedures", "TREATMENT", 80, 95]]], ["At the same time, the pooled and meta-analyses for risk calculation did not require detailed clinical data.DiscussionWe made attempts to capture data from all the regional hospitals for SARS-CoV-2 infection and stroke-related readmissions; however, there is the possibility of not capturing stroke or other cerebrovascular events in the convalescence stage.", [["cerebrovascular", "ANATOMY", 307, 322], ["SARS", "DISEASE", 186, 190], ["infection", "DISEASE", 197, 206], ["stroke", "DISEASE", 211, 217], ["stroke", "DISEASE", 291, 297], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 307, 322], ["SARS-CoV", "SPECIES", 186, 194], ["risk calculation", "TEST", 51, 67], ["detailed clinical data", "TEST", 84, 106], ["SARS", "PROBLEM", 186, 190], ["CoV", "PROBLEM", 191, 194], ["2 infection", "PROBLEM", 195, 206], ["stroke", "PROBLEM", 211, 217], ["capturing stroke", "PROBLEM", 281, 297], ["other cerebrovascular events", "PROBLEM", 301, 329], ["infection", "OBSERVATION", 197, 206], ["stroke", "OBSERVATION", 291, 297], ["cerebrovascular", "ANATOMY", 307, 322]]], ["Despite our attempt to capture the whole referral region, patients' mobility among nearby regions to obtain the best medical services might have introduced bias in the risk estimation.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["We realize that the SARS-CoV-2 epidemic has affected the care-seeking behaviours of patients with neurological symptoms and has exhausted care deliveries in several health systems.", [["neurological", "ANATOMY", 98, 110], ["SARS", "DISEASE", 20, 24], ["neurological symptoms", "DISEASE", 98, 119], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["the SARS", "TEST", 16, 24], ["neurological symptoms", "PROBLEM", 98, 119]]], ["We also recognize that decreased quality of care, long wait-time for conducting neuroimaging, and rapid deterioration of SARS-CoV-2 infected patients or being on a ventilator may have led to some patients with mild stroke-like symptoms not receiving further relevant investigation and diagnosis.", [["SARS-CoV-2 infected", "DISEASE", 121, 140], ["stroke", "DISEASE", 215, 221], ["SARS-CoV-2", "ORGANISM", 121, 131], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 196, 204], ["conducting neuroimaging", "TEST", 69, 92], ["SARS", "PROBLEM", 121, 125], ["a ventilator", "TREATMENT", 162, 174], ["mild stroke", "PROBLEM", 210, 221], ["like symptoms", "PROBLEM", 222, 235], ["further relevant investigation", "TEST", 250, 280], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["mild", "OBSERVATION_MODIFIER", 210, 214], ["stroke", "OBSERVATION", 215, 221]]], ["To partially alleviate the effect of some of the limitations, we provided different levels of meta-analysis in this study.DiscussionThe results of this multi-national study on hospitalized patients with SARS-CoV-2 infection indicated an overall stroke risk of 0.5% (pooled risk: 0.9%).", [["SARS-CoV-2 infection", "DISEASE", 203, 223], ["stroke", "DISEASE", 245, 251], ["patients", "ORGANISM", 189, 197], ["SARS-CoV-2", "ORGANISM", 203, 213], ["patients", "SPECIES", 189, 197], ["this study", "TEST", 111, 121], ["this multi-national study", "TEST", 147, 172], ["SARS", "PROBLEM", 203, 207], ["CoV", "TEST", 208, 211], ["2 infection", "PROBLEM", 212, 223], ["an overall stroke risk", "PROBLEM", 234, 256], ["overall", "OBSERVATION_MODIFIER", 237, 244], ["stroke", "OBSERVATION", 245, 251]]], ["This number will be lower if all patients with SARS-CoV-2 diagnosis are considered rather than hospitalized patients.", [["SARS", "DISEASE", 47, 51], ["patients", "ORGANISM", 33, 41], ["SARS-CoV-2", "ORGANISM", 47, 57], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 108, 116], ["SARS", "PROBLEM", 47, 51]]], ["The need for mechanical ventilation and ischaemic heart disease are the independent predictors of stroke among SARS-CoV-2 patients.", [["heart", "ANATOMY", 50, 55], ["ischaemic heart disease", "DISEASE", 40, 63], ["stroke", "DISEASE", 98, 104], ["SARS", "DISEASE", 111, 115], ["heart", "ORGAN", 50, 55], ["SARS-CoV-2", "ORGANISM", 111, 121], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 111, 119], ["mechanical ventilation", "TREATMENT", 13, 35], ["ischaemic heart disease", "PROBLEM", 40, 63], ["stroke", "PROBLEM", 98, 104], ["mechanical ventilation", "OBSERVATION", 13, 35], ["ischaemic", "OBSERVATION_MODIFIER", 40, 49], ["heart", "ANATOMY", 50, 55], ["disease", "OBSERVATION", 56, 63]]]]}